{"docstore/data": {"615e526e-4034-47f5-8b7d-b4be0cdf60c0": {"__data__": {"id_": "615e526e-4034-47f5-8b7d-b4be0cdf60c0", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Second Quar ter Results\n5/5/2021\nRevenues of $49.2 billion for the Second Quarter, a 3.7 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.10 and Adjusted Diluted EPS of $2.53\nAdjusted Diluted EPS Guidance Range Raised to $8.45 to $8.60 for Fiscal 2021\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021\nsecond quarter ended March 31, 2021, revenue increased 3.7 percent year-over-year to $49.2 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.10 for the March quarter of fiscal 2021, compared to\n$4.64 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n5.4 percent to $2.53 in the fiscal second quarter.\n", "original_text": "Amerisour ceBer gen R epor ts Fiscal 2021 Second Quar ter Results\n5/5/2021\nRevenues of $49.2 billion for the Second Quarter, a 3.7 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.10 and Adjusted Diluted EPS of $2.53\nAdjusted Diluted EPS Guidance Range Raised to $8.45 to $8.60 for Fiscal 2021\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021\nsecond quarter ended March 31, 2021, revenue increased 3.7 percent year-over-year to $49.2 billion. ", "page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "984951f4-9f9e-491e-8d76-75fdf91ef9cd", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52c007cb5c3539d624c7730f22d83f96c826d282cbee21db83720bb3a0d2d157", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8364cd3e-a06d-4c67-93ff-710ce5ae78c7", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Second Quar ter Results\n5/5/2021\nRevenues of $49.2 billion for the Second Quarter, a 3.7 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.10 and Adjusted Diluted EPS of $2.53\nAdjusted Diluted EPS Guidance Range Raised to $8.45 to $8.60 for Fiscal 2021\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021\nsecond quarter ended March 31, 2021, revenue increased 3.7 percent year-over-year to $49.2 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.10 for the March quarter of fiscal 2021, compared to\n$4.64 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n5.4 percent to $2.53 in the fiscal second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021. ", "original_text": "On the basis of U.S. "}, "hash": "e6fcab50998ce2ae26c72cbb6dc4c6aead2b271db5fe98fe68cda57f6d2b2a18", "class_name": "RelatedNodeInfo"}}, "text": "Amerisour ceBer gen R epor ts Fiscal 2021 Second Quar ter Results\n5/5/2021\nRevenues of $49.2 billion for the Second Quarter, a 3.7 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.10 and Adjusted Diluted EPS of $2.53\nAdjusted Diluted EPS Guidance Range Raised to $8.45 to $8.60 for Fiscal 2021\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021\nsecond quarter ended March 31, 2021, revenue increased 3.7 percent year-over-year to $49.2 billion. ", "start_char_idx": 0, "end_char_idx": 538, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8364cd3e-a06d-4c67-93ff-710ce5ae78c7": {"__data__": {"id_": "8364cd3e-a06d-4c67-93ff-710ce5ae78c7", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Second Quar ter Results\n5/5/2021\nRevenues of $49.2 billion for the Second Quarter, a 3.7 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.10 and Adjusted Diluted EPS of $2.53\nAdjusted Diluted EPS Guidance Range Raised to $8.45 to $8.60 for Fiscal 2021\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021\nsecond quarter ended March 31, 2021, revenue increased 3.7 percent year-over-year to $49.2 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.10 for the March quarter of fiscal 2021, compared to\n$4.64 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n5.4 percent to $2.53 in the fiscal second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021. ", "original_text": "On the basis of U.S. ", "page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "984951f4-9f9e-491e-8d76-75fdf91ef9cd", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52c007cb5c3539d624c7730f22d83f96c826d282cbee21db83720bb3a0d2d157", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "615e526e-4034-47f5-8b7d-b4be0cdf60c0", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Second Quar ter Results\n5/5/2021\nRevenues of $49.2 billion for the Second Quarter, a 3.7 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.10 and Adjusted Diluted EPS of $2.53\nAdjusted Diluted EPS Guidance Range Raised to $8.45 to $8.60 for Fiscal 2021\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021\nsecond quarter ended March 31, 2021, revenue increased 3.7 percent year-over-year to $49.2 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.10 for the March quarter of fiscal 2021, compared to\n$4.64 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n5.4 percent to $2.53 in the fiscal second quarter.\n", "original_text": "Amerisour ceBer gen R epor ts Fiscal 2021 Second Quar ter Results\n5/5/2021\nRevenues of $49.2 billion for the Second Quarter, a 3.7 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.10 and Adjusted Diluted EPS of $2.53\nAdjusted Diluted EPS Guidance Range Raised to $8.45 to $8.60 for Fiscal 2021\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021\nsecond quarter ended March 31, 2021, revenue increased 3.7 percent year-over-year to $49.2 billion. ", "page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab6f887c41fe7bdad10008b392adfe724103dd8cf3ec7f74a03184ba24a11ae7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d37bb5bc-1308-470d-af3c-49339acc6100", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Second Quar ter Results\n5/5/2021\nRevenues of $49.2 billion for the Second Quarter, a 3.7 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.10 and Adjusted Diluted EPS of $2.53\nAdjusted Diluted EPS Guidance Range Raised to $8.45 to $8.60 for Fiscal 2021\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021\nsecond quarter ended March 31, 2021, revenue increased 3.7 percent year-over-year to $49.2 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.10 for the March quarter of fiscal 2021, compared to\n$4.64 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n5.4 percent to $2.53 in the fiscal second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations. ", "original_text": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.10 for the March quarter of fiscal 2021, compared to\n$4.64 in the prior year quarter. "}, "hash": "e62f00e1cac7e35f13960db4374d7e09452bea86b6f6d1d6d377df932c9664ad", "class_name": "RelatedNodeInfo"}}, "text": "On the basis of U.S. ", "start_char_idx": 538, "end_char_idx": 559, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d37bb5bc-1308-470d-af3c-49339acc6100": {"__data__": {"id_": "d37bb5bc-1308-470d-af3c-49339acc6100", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Second Quar ter Results\n5/5/2021\nRevenues of $49.2 billion for the Second Quarter, a 3.7 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.10 and Adjusted Diluted EPS of $2.53\nAdjusted Diluted EPS Guidance Range Raised to $8.45 to $8.60 for Fiscal 2021\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021\nsecond quarter ended March 31, 2021, revenue increased 3.7 percent year-over-year to $49.2 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.10 for the March quarter of fiscal 2021, compared to\n$4.64 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n5.4 percent to $2.53 in the fiscal second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations. ", "original_text": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.10 for the March quarter of fiscal 2021, compared to\n$4.64 in the prior year quarter. ", "page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "984951f4-9f9e-491e-8d76-75fdf91ef9cd", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52c007cb5c3539d624c7730f22d83f96c826d282cbee21db83720bb3a0d2d157", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8364cd3e-a06d-4c67-93ff-710ce5ae78c7", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Second Quar ter Results\n5/5/2021\nRevenues of $49.2 billion for the Second Quarter, a 3.7 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.10 and Adjusted Diluted EPS of $2.53\nAdjusted Diluted EPS Guidance Range Raised to $8.45 to $8.60 for Fiscal 2021\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021\nsecond quarter ended March 31, 2021, revenue increased 3.7 percent year-over-year to $49.2 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.10 for the March quarter of fiscal 2021, compared to\n$4.64 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n5.4 percent to $2.53 in the fiscal second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021. ", "original_text": "On the basis of U.S. ", "page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "95e80bf00c3a60070f300374bbd0c1590b4c8c2780035b4137191b2006b89b53", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "370ce6f7-51e2-40f7-bda1-7d9ddc508234", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Second Quar ter Results\n5/5/2021\nRevenues of $49.2 billion for the Second Quarter, a 3.7 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.10 and Adjusted Diluted EPS of $2.53\nAdjusted Diluted EPS Guidance Range Raised to $8.45 to $8.60 for Fiscal 2021\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021\nsecond quarter ended March 31, 2021, revenue increased 3.7 percent year-over-year to $49.2 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.10 for the March quarter of fiscal 2021, compared to\n$4.64 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n5.4 percent to $2.53 in the fiscal second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.40 to $8.60 to a range of $8.45 to $8.60, reflecting growth of 7 percent to 9 percent versus the previous fiscal year.\n", "original_text": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n5.4 percent to $2.53 in the fiscal second quarter.\n"}, "hash": "67234b0c554094d148bd19195f23fd8fedf48b60a29a694ef31b2750a3b99c6d", "class_name": "RelatedNodeInfo"}}, "text": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.10 for the March quarter of fiscal 2021, compared to\n$4.64 in the prior year quarter. ", "start_char_idx": 559, "end_char_idx": 734, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "370ce6f7-51e2-40f7-bda1-7d9ddc508234": {"__data__": {"id_": "370ce6f7-51e2-40f7-bda1-7d9ddc508234", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Second Quar ter Results\n5/5/2021\nRevenues of $49.2 billion for the Second Quarter, a 3.7 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.10 and Adjusted Diluted EPS of $2.53\nAdjusted Diluted EPS Guidance Range Raised to $8.45 to $8.60 for Fiscal 2021\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021\nsecond quarter ended March 31, 2021, revenue increased 3.7 percent year-over-year to $49.2 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.10 for the March quarter of fiscal 2021, compared to\n$4.64 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n5.4 percent to $2.53 in the fiscal second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.40 to $8.60 to a range of $8.45 to $8.60, reflecting growth of 7 percent to 9 percent versus the previous fiscal year.\n", "original_text": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n5.4 percent to $2.53 in the fiscal second quarter.\n", "page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "984951f4-9f9e-491e-8d76-75fdf91ef9cd", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52c007cb5c3539d624c7730f22d83f96c826d282cbee21db83720bb3a0d2d157", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d37bb5bc-1308-470d-af3c-49339acc6100", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Second Quar ter Results\n5/5/2021\nRevenues of $49.2 billion for the Second Quarter, a 3.7 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.10 and Adjusted Diluted EPS of $2.53\nAdjusted Diluted EPS Guidance Range Raised to $8.45 to $8.60 for Fiscal 2021\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021\nsecond quarter ended March 31, 2021, revenue increased 3.7 percent year-over-year to $49.2 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.10 for the March quarter of fiscal 2021, compared to\n$4.64 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n5.4 percent to $2.53 in the fiscal second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations. ", "original_text": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.10 for the March quarter of fiscal 2021, compared to\n$4.64 in the prior year quarter. ", "page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d543b0a2d9c36aacf4296f92879c486f6668d36b2638d7c483e8ab13456597cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96ef3d31-b9ce-4f79-ac17-4ca145075c08", "node_type": "1", "metadata": {"window": "On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.10 for the March quarter of fiscal 2021, compared to\n$4.64 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n5.4 percent to $2.53 in the fiscal second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.40 to $8.60 to a range of $8.45 to $8.60, reflecting growth of 7 percent to 9 percent versus the previous fiscal year.\n \"AmerisourceBergen continues to prove our vital role as a key pillar in the healthcare system. ", "original_text": "AmerisourceBergen is updating its outlook for fiscal year 2021. "}, "hash": "479e7057655d9d2a2f66beb0d92a0312a59e12a47c639845d637bf0bb00785a5", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n5.4 percent to $2.53 in the fiscal second quarter.\n", "start_char_idx": 734, "end_char_idx": 882, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96ef3d31-b9ce-4f79-ac17-4ca145075c08": {"__data__": {"id_": "96ef3d31-b9ce-4f79-ac17-4ca145075c08", "embedding": null, "metadata": {"window": "On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.10 for the March quarter of fiscal 2021, compared to\n$4.64 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n5.4 percent to $2.53 in the fiscal second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.40 to $8.60 to a range of $8.45 to $8.60, reflecting growth of 7 percent to 9 percent versus the previous fiscal year.\n \"AmerisourceBergen continues to prove our vital role as a key pillar in the healthcare system. ", "original_text": "AmerisourceBergen is updating its outlook for fiscal year 2021. ", "page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "984951f4-9f9e-491e-8d76-75fdf91ef9cd", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52c007cb5c3539d624c7730f22d83f96c826d282cbee21db83720bb3a0d2d157", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "370ce6f7-51e2-40f7-bda1-7d9ddc508234", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Second Quar ter Results\n5/5/2021\nRevenues of $49.2 billion for the Second Quarter, a 3.7 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.10 and Adjusted Diluted EPS of $2.53\nAdjusted Diluted EPS Guidance Range Raised to $8.45 to $8.60 for Fiscal 2021\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021\nsecond quarter ended March 31, 2021, revenue increased 3.7 percent year-over-year to $49.2 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.10 for the March quarter of fiscal 2021, compared to\n$4.64 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n5.4 percent to $2.53 in the fiscal second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.40 to $8.60 to a range of $8.45 to $8.60, reflecting growth of 7 percent to 9 percent versus the previous fiscal year.\n", "original_text": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n5.4 percent to $2.53 in the fiscal second quarter.\n", "page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ae5361bb038c80188189912923197ccd8df3a2e8200f0777c0ce689e6cdd64c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "860bc0da-9781-4300-b7b1-c67b263d008d", "node_type": "1", "metadata": {"window": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.10 for the March quarter of fiscal 2021, compared to\n$4.64 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n5.4 percent to $2.53 in the fiscal second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.40 to $8.60 to a range of $8.45 to $8.60, reflecting growth of 7 percent to 9 percent versus the previous fiscal year.\n \"AmerisourceBergen continues to prove our vital role as a key pillar in the healthcare system.  Our solid performance in the March\nquarter was fueled by our associates who continue to work diligently to provide innovative solutions for our partners to ultimately\nserve their patients,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n", "original_text": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations. "}, "hash": "f15f1245d3fc409aa5b8183ea1c54977c139c95d707f5900a3c645002315b72c", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen is updating its outlook for fiscal year 2021. ", "start_char_idx": 882, "end_char_idx": 946, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "860bc0da-9781-4300-b7b1-c67b263d008d": {"__data__": {"id_": "860bc0da-9781-4300-b7b1-c67b263d008d", "embedding": null, "metadata": {"window": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.10 for the March quarter of fiscal 2021, compared to\n$4.64 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n5.4 percent to $2.53 in the fiscal second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.40 to $8.60 to a range of $8.45 to $8.60, reflecting growth of 7 percent to 9 percent versus the previous fiscal year.\n \"AmerisourceBergen continues to prove our vital role as a key pillar in the healthcare system.  Our solid performance in the March\nquarter was fueled by our associates who continue to work diligently to provide innovative solutions for our partners to ultimately\nserve their patients,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n", "original_text": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations. ", "page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "984951f4-9f9e-491e-8d76-75fdf91ef9cd", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52c007cb5c3539d624c7730f22d83f96c826d282cbee21db83720bb3a0d2d157", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96ef3d31-b9ce-4f79-ac17-4ca145075c08", "node_type": "1", "metadata": {"window": "On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.10 for the March quarter of fiscal 2021, compared to\n$4.64 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n5.4 percent to $2.53 in the fiscal second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.40 to $8.60 to a range of $8.45 to $8.60, reflecting growth of 7 percent to 9 percent versus the previous fiscal year.\n \"AmerisourceBergen continues to prove our vital role as a key pillar in the healthcare system. ", "original_text": "AmerisourceBergen is updating its outlook for fiscal year 2021. ", "page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3f5aee829320cc4f6d12b73fba53e4f481ae39103ebde70c10dbad0b4e3d7a0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e288a38-0c12-48d6-b94e-a1a8e1e5eb1d", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n5.4 percent to $2.53 in the fiscal second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.40 to $8.60 to a range of $8.45 to $8.60, reflecting growth of 7 percent to 9 percent versus the previous fiscal year.\n \"AmerisourceBergen continues to prove our vital role as a key pillar in the healthcare system.  Our solid performance in the March\nquarter was fueled by our associates who continue to work diligently to provide innovative solutions for our partners to ultimately\nserve their patients,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n \"Driven by our purpose of being united in our responsibility to create healthier futures, we are strengthening our portfolio of\nsolutions for customers, expanding on our leadership in specialty, focusing on execution and leveraging our capabilities and\nexpertise to support pharmaceutical innovation,\" Mr. ", "original_text": "Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.40 to $8.60 to a range of $8.45 to $8.60, reflecting growth of 7 percent to 9 percent versus the previous fiscal year.\n"}, "hash": "b23c7d4838af64fc11d505d3a1b09da46a9e740d5b775c6fd44ebe36fe5c8ece", "class_name": "RelatedNodeInfo"}}, "text": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations. ", "start_char_idx": 946, "end_char_idx": 1070, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e288a38-0c12-48d6-b94e-a1a8e1e5eb1d": {"__data__": {"id_": "3e288a38-0c12-48d6-b94e-a1a8e1e5eb1d", "embedding": null, "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n5.4 percent to $2.53 in the fiscal second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.40 to $8.60 to a range of $8.45 to $8.60, reflecting growth of 7 percent to 9 percent versus the previous fiscal year.\n \"AmerisourceBergen continues to prove our vital role as a key pillar in the healthcare system.  Our solid performance in the March\nquarter was fueled by our associates who continue to work diligently to provide innovative solutions for our partners to ultimately\nserve their patients,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n \"Driven by our purpose of being united in our responsibility to create healthier futures, we are strengthening our portfolio of\nsolutions for customers, expanding on our leadership in specialty, focusing on execution and leveraging our capabilities and\nexpertise to support pharmaceutical innovation,\" Mr. ", "original_text": "Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.40 to $8.60 to a range of $8.45 to $8.60, reflecting growth of 7 percent to 9 percent versus the previous fiscal year.\n", "page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "984951f4-9f9e-491e-8d76-75fdf91ef9cd", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52c007cb5c3539d624c7730f22d83f96c826d282cbee21db83720bb3a0d2d157", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "860bc0da-9781-4300-b7b1-c67b263d008d", "node_type": "1", "metadata": {"window": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.10 for the March quarter of fiscal 2021, compared to\n$4.64 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n5.4 percent to $2.53 in the fiscal second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.40 to $8.60 to a range of $8.45 to $8.60, reflecting growth of 7 percent to 9 percent versus the previous fiscal year.\n \"AmerisourceBergen continues to prove our vital role as a key pillar in the healthcare system.  Our solid performance in the March\nquarter was fueled by our associates who continue to work diligently to provide innovative solutions for our partners to ultimately\nserve their patients,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n", "original_text": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations. ", "page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "493b823ca00aa9d28c1a0b83bad82009da27543e6ba43585abc6a67588582e12", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c3660089-e092-4b3c-96eb-2903f84f6a9c", "node_type": "1", "metadata": {"window": "AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.40 to $8.60 to a range of $8.45 to $8.60, reflecting growth of 7 percent to 9 percent versus the previous fiscal year.\n \"AmerisourceBergen continues to prove our vital role as a key pillar in the healthcare system.  Our solid performance in the March\nquarter was fueled by our associates who continue to work diligently to provide innovative solutions for our partners to ultimately\nserve their patients,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n \"Driven by our purpose of being united in our responsibility to create healthier futures, we are strengthening our portfolio of\nsolutions for customers, expanding on our leadership in specialty, focusing on execution and leveraging our capabilities and\nexpertise to support pharmaceutical innovation,\" Mr.  Collis continued. ", "original_text": "\"AmerisourceBergen continues to prove our vital role as a key pillar in the healthcare system. "}, "hash": "6965b4eac60acb3bb9327862838ff39355b05dbdeca3267bae15a06a2c04347b", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.40 to $8.60 to a range of $8.45 to $8.60, reflecting growth of 7 percent to 9 percent versus the previous fiscal year.\n", "start_char_idx": 1070, "end_char_idx": 1271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c3660089-e092-4b3c-96eb-2903f84f6a9c": {"__data__": {"id_": "c3660089-e092-4b3c-96eb-2903f84f6a9c", "embedding": null, "metadata": {"window": "AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.40 to $8.60 to a range of $8.45 to $8.60, reflecting growth of 7 percent to 9 percent versus the previous fiscal year.\n \"AmerisourceBergen continues to prove our vital role as a key pillar in the healthcare system.  Our solid performance in the March\nquarter was fueled by our associates who continue to work diligently to provide innovative solutions for our partners to ultimately\nserve their patients,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n \"Driven by our purpose of being united in our responsibility to create healthier futures, we are strengthening our portfolio of\nsolutions for customers, expanding on our leadership in specialty, focusing on execution and leveraging our capabilities and\nexpertise to support pharmaceutical innovation,\" Mr.  Collis continued. ", "original_text": "\"AmerisourceBergen continues to prove our vital role as a key pillar in the healthcare system. ", "page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "984951f4-9f9e-491e-8d76-75fdf91ef9cd", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52c007cb5c3539d624c7730f22d83f96c826d282cbee21db83720bb3a0d2d157", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e288a38-0c12-48d6-b94e-a1a8e1e5eb1d", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n5.4 percent to $2.53 in the fiscal second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.40 to $8.60 to a range of $8.45 to $8.60, reflecting growth of 7 percent to 9 percent versus the previous fiscal year.\n \"AmerisourceBergen continues to prove our vital role as a key pillar in the healthcare system.  Our solid performance in the March\nquarter was fueled by our associates who continue to work diligently to provide innovative solutions for our partners to ultimately\nserve their patients,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n \"Driven by our purpose of being united in our responsibility to create healthier futures, we are strengthening our portfolio of\nsolutions for customers, expanding on our leadership in specialty, focusing on execution and leveraging our capabilities and\nexpertise to support pharmaceutical innovation,\" Mr. ", "original_text": "Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.40 to $8.60 to a range of $8.45 to $8.60, reflecting growth of 7 percent to 9 percent versus the previous fiscal year.\n", "page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "818e2afb6f6177bb8db980df79fc1f5cee5bac51fcdeae3cf2e9e4a0167172bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca9244d7-0d5d-48d1-bcdc-3d0ba5dfd45a", "node_type": "1", "metadata": {"window": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.40 to $8.60 to a range of $8.45 to $8.60, reflecting growth of 7 percent to 9 percent versus the previous fiscal year.\n \"AmerisourceBergen continues to prove our vital role as a key pillar in the healthcare system.  Our solid performance in the March\nquarter was fueled by our associates who continue to work diligently to provide innovative solutions for our partners to ultimately\nserve their patients,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n \"Driven by our purpose of being united in our responsibility to create healthier futures, we are strengthening our portfolio of\nsolutions for customers, expanding on our leadership in specialty, focusing on execution and leveraging our capabilities and\nexpertise to support pharmaceutical innovation,\" Mr.  Collis continued.  \"AmerisourceBergen is well-positioned to deliver long-term,\nsustainable growth, supported by our diverse and inclusive teams and our investments in our people and culture.\"\n", "original_text": "Our solid performance in the March\nquarter was fueled by our associates who continue to work diligently to provide innovative solutions for our partners to ultimately\nserve their patients,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n"}, "hash": "e079c4a4b3a7cd0dde434da38c5f3b70847f33118b843c51efdfa5feedd5101a", "class_name": "RelatedNodeInfo"}}, "text": "\"AmerisourceBergen continues to prove our vital role as a key pillar in the healthcare system. ", "start_char_idx": 1271, "end_char_idx": 1366, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca9244d7-0d5d-48d1-bcdc-3d0ba5dfd45a": {"__data__": {"id_": "ca9244d7-0d5d-48d1-bcdc-3d0ba5dfd45a", "embedding": null, "metadata": {"window": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.40 to $8.60 to a range of $8.45 to $8.60, reflecting growth of 7 percent to 9 percent versus the previous fiscal year.\n \"AmerisourceBergen continues to prove our vital role as a key pillar in the healthcare system.  Our solid performance in the March\nquarter was fueled by our associates who continue to work diligently to provide innovative solutions for our partners to ultimately\nserve their patients,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n \"Driven by our purpose of being united in our responsibility to create healthier futures, we are strengthening our portfolio of\nsolutions for customers, expanding on our leadership in specialty, focusing on execution and leveraging our capabilities and\nexpertise to support pharmaceutical innovation,\" Mr.  Collis continued.  \"AmerisourceBergen is well-positioned to deliver long-term,\nsustainable growth, supported by our diverse and inclusive teams and our investments in our people and culture.\"\n", "original_text": "Our solid performance in the March\nquarter was fueled by our associates who continue to work diligently to provide innovative solutions for our partners to ultimately\nserve their patients,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n", "page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "984951f4-9f9e-491e-8d76-75fdf91ef9cd", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52c007cb5c3539d624c7730f22d83f96c826d282cbee21db83720bb3a0d2d157", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c3660089-e092-4b3c-96eb-2903f84f6a9c", "node_type": "1", "metadata": {"window": "AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.40 to $8.60 to a range of $8.45 to $8.60, reflecting growth of 7 percent to 9 percent versus the previous fiscal year.\n \"AmerisourceBergen continues to prove our vital role as a key pillar in the healthcare system.  Our solid performance in the March\nquarter was fueled by our associates who continue to work diligently to provide innovative solutions for our partners to ultimately\nserve their patients,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n \"Driven by our purpose of being united in our responsibility to create healthier futures, we are strengthening our portfolio of\nsolutions for customers, expanding on our leadership in specialty, focusing on execution and leveraging our capabilities and\nexpertise to support pharmaceutical innovation,\" Mr.  Collis continued. ", "original_text": "\"AmerisourceBergen continues to prove our vital role as a key pillar in the healthcare system. ", "page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f3b553cdf866f72fe72f5912b49c7134c555bdaa1ca6637ae218b7c9c1880814", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6b5c116-b791-460e-b7ab-12e82a98bd60", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.40 to $8.60 to a range of $8.45 to $8.60, reflecting growth of 7 percent to 9 percent versus the previous fiscal year.\n \"AmerisourceBergen continues to prove our vital role as a key pillar in the healthcare system.  Our solid performance in the March\nquarter was fueled by our associates who continue to work diligently to provide innovative solutions for our partners to ultimately\nserve their patients,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n \"Driven by our purpose of being united in our responsibility to create healthier futures, we are strengthening our portfolio of\nsolutions for customers, expanding on our leadership in specialty, focusing on execution and leveraging our capabilities and\nexpertise to support pharmaceutical innovation,\" Mr.  Collis continued.  \"AmerisourceBergen is well-positioned to deliver long-term,\nsustainable growth, supported by our diverse and inclusive teams and our investments in our people and culture.\"\n Second Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAP \u00a0Adjust ed (Non-GAAP)\nRevenue $49.2B \u00a0$49.2B\nGross Pr ofit $1.5B \u00a0$1.5B\nOperating Expenses $909M \u00a0$806M\nOperating Income $624M \u00a0$707M\nInterest Expense, Net $35M \u00a0$35M\nEffectiv e Tax Rat e 23.4% \u00a021.9%\nNet Income A ttributable t o ABC $435M \u00a0$524M\nDilut ed Earnings P er Shar e $2.10 \u00a0$2.53\n1", "original_text": "\"Driven by our purpose of being united in our responsibility to create healthier futures, we are strengthening our portfolio of\nsolutions for customers, expanding on our leadership in specialty, focusing on execution and leveraging our capabilities and\nexpertise to support pharmaceutical innovation,\" Mr. "}, "hash": "c22c64f2fba0dbea6d83ebf2541cbf9ab72b7927f430a29b536cc2333769b367", "class_name": "RelatedNodeInfo"}}, "text": "Our solid performance in the March\nquarter was fueled by our associates who continue to work diligently to provide innovative solutions for our partners to ultimately\nserve their patients,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n", "start_char_idx": 1366, "end_char_idx": 1649, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6b5c116-b791-460e-b7ab-12e82a98bd60": {"__data__": {"id_": "a6b5c116-b791-460e-b7ab-12e82a98bd60", "embedding": null, "metadata": {"window": "Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.40 to $8.60 to a range of $8.45 to $8.60, reflecting growth of 7 percent to 9 percent versus the previous fiscal year.\n \"AmerisourceBergen continues to prove our vital role as a key pillar in the healthcare system.  Our solid performance in the March\nquarter was fueled by our associates who continue to work diligently to provide innovative solutions for our partners to ultimately\nserve their patients,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n \"Driven by our purpose of being united in our responsibility to create healthier futures, we are strengthening our portfolio of\nsolutions for customers, expanding on our leadership in specialty, focusing on execution and leveraging our capabilities and\nexpertise to support pharmaceutical innovation,\" Mr.  Collis continued.  \"AmerisourceBergen is well-positioned to deliver long-term,\nsustainable growth, supported by our diverse and inclusive teams and our investments in our people and culture.\"\n Second Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAP \u00a0Adjust ed (Non-GAAP)\nRevenue $49.2B \u00a0$49.2B\nGross Pr ofit $1.5B \u00a0$1.5B\nOperating Expenses $909M \u00a0$806M\nOperating Income $624M \u00a0$707M\nInterest Expense, Net $35M \u00a0$35M\nEffectiv e Tax Rat e 23.4% \u00a021.9%\nNet Income A ttributable t o ABC $435M \u00a0$524M\nDilut ed Earnings P er Shar e $2.10 \u00a0$2.53\n1", "original_text": "\"Driven by our purpose of being united in our responsibility to create healthier futures, we are strengthening our portfolio of\nsolutions for customers, expanding on our leadership in specialty, focusing on execution and leveraging our capabilities and\nexpertise to support pharmaceutical innovation,\" Mr. ", "page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "984951f4-9f9e-491e-8d76-75fdf91ef9cd", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52c007cb5c3539d624c7730f22d83f96c826d282cbee21db83720bb3a0d2d157", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca9244d7-0d5d-48d1-bcdc-3d0ba5dfd45a", "node_type": "1", "metadata": {"window": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.40 to $8.60 to a range of $8.45 to $8.60, reflecting growth of 7 percent to 9 percent versus the previous fiscal year.\n \"AmerisourceBergen continues to prove our vital role as a key pillar in the healthcare system.  Our solid performance in the March\nquarter was fueled by our associates who continue to work diligently to provide innovative solutions for our partners to ultimately\nserve their patients,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n \"Driven by our purpose of being united in our responsibility to create healthier futures, we are strengthening our portfolio of\nsolutions for customers, expanding on our leadership in specialty, focusing on execution and leveraging our capabilities and\nexpertise to support pharmaceutical innovation,\" Mr.  Collis continued.  \"AmerisourceBergen is well-positioned to deliver long-term,\nsustainable growth, supported by our diverse and inclusive teams and our investments in our people and culture.\"\n", "original_text": "Our solid performance in the March\nquarter was fueled by our associates who continue to work diligently to provide innovative solutions for our partners to ultimately\nserve their patients,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n", "page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "749478d0969211176599167e0752f1499354687fb3578ef36260af16cd5a581a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c29c869b-f26c-4f9b-91ba-5a037472b3ab", "node_type": "1", "metadata": {"window": "\"AmerisourceBergen continues to prove our vital role as a key pillar in the healthcare system.  Our solid performance in the March\nquarter was fueled by our associates who continue to work diligently to provide innovative solutions for our partners to ultimately\nserve their patients,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n \"Driven by our purpose of being united in our responsibility to create healthier futures, we are strengthening our portfolio of\nsolutions for customers, expanding on our leadership in specialty, focusing on execution and leveraging our capabilities and\nexpertise to support pharmaceutical innovation,\" Mr.  Collis continued.  \"AmerisourceBergen is well-positioned to deliver long-term,\nsustainable growth, supported by our diverse and inclusive teams and our investments in our people and culture.\"\n Second Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAP \u00a0Adjust ed (Non-GAAP)\nRevenue $49.2B \u00a0$49.2B\nGross Pr ofit $1.5B \u00a0$1.5B\nOperating Expenses $909M \u00a0$806M\nOperating Income $624M \u00a0$707M\nInterest Expense, Net $35M \u00a0$35M\nEffectiv e Tax Rat e 23.4% \u00a021.9%\nNet Income A ttributable t o ABC $435M \u00a0$524M\nDilut ed Earnings P er Shar e $2.10 \u00a0$2.53\n1", "original_text": "Collis continued. "}, "hash": "c70519a490388906fd0c2e9399257d8d4871a6e09fc652ba1766c535321ac216", "class_name": "RelatedNodeInfo"}}, "text": "\"Driven by our purpose of being united in our responsibility to create healthier futures, we are strengthening our portfolio of\nsolutions for customers, expanding on our leadership in specialty, focusing on execution and leveraging our capabilities and\nexpertise to support pharmaceutical innovation,\" Mr. ", "start_char_idx": 1649, "end_char_idx": 1955, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c29c869b-f26c-4f9b-91ba-5a037472b3ab": {"__data__": {"id_": "c29c869b-f26c-4f9b-91ba-5a037472b3ab", "embedding": null, "metadata": {"window": "\"AmerisourceBergen continues to prove our vital role as a key pillar in the healthcare system.  Our solid performance in the March\nquarter was fueled by our associates who continue to work diligently to provide innovative solutions for our partners to ultimately\nserve their patients,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n \"Driven by our purpose of being united in our responsibility to create healthier futures, we are strengthening our portfolio of\nsolutions for customers, expanding on our leadership in specialty, focusing on execution and leveraging our capabilities and\nexpertise to support pharmaceutical innovation,\" Mr.  Collis continued.  \"AmerisourceBergen is well-positioned to deliver long-term,\nsustainable growth, supported by our diverse and inclusive teams and our investments in our people and culture.\"\n Second Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAP \u00a0Adjust ed (Non-GAAP)\nRevenue $49.2B \u00a0$49.2B\nGross Pr ofit $1.5B \u00a0$1.5B\nOperating Expenses $909M \u00a0$806M\nOperating Income $624M \u00a0$707M\nInterest Expense, Net $35M \u00a0$35M\nEffectiv e Tax Rat e 23.4% \u00a021.9%\nNet Income A ttributable t o ABC $435M \u00a0$524M\nDilut ed Earnings P er Shar e $2.10 \u00a0$2.53\n1", "original_text": "Collis continued. ", "page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "984951f4-9f9e-491e-8d76-75fdf91ef9cd", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52c007cb5c3539d624c7730f22d83f96c826d282cbee21db83720bb3a0d2d157", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6b5c116-b791-460e-b7ab-12e82a98bd60", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS guidance has been raised from the previous\nexpectation of $8.40 to $8.60 to a range of $8.45 to $8.60, reflecting growth of 7 percent to 9 percent versus the previous fiscal year.\n \"AmerisourceBergen continues to prove our vital role as a key pillar in the healthcare system.  Our solid performance in the March\nquarter was fueled by our associates who continue to work diligently to provide innovative solutions for our partners to ultimately\nserve their patients,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n \"Driven by our purpose of being united in our responsibility to create healthier futures, we are strengthening our portfolio of\nsolutions for customers, expanding on our leadership in specialty, focusing on execution and leveraging our capabilities and\nexpertise to support pharmaceutical innovation,\" Mr.  Collis continued.  \"AmerisourceBergen is well-positioned to deliver long-term,\nsustainable growth, supported by our diverse and inclusive teams and our investments in our people and culture.\"\n Second Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAP \u00a0Adjust ed (Non-GAAP)\nRevenue $49.2B \u00a0$49.2B\nGross Pr ofit $1.5B \u00a0$1.5B\nOperating Expenses $909M \u00a0$806M\nOperating Income $624M \u00a0$707M\nInterest Expense, Net $35M \u00a0$35M\nEffectiv e Tax Rat e 23.4% \u00a021.9%\nNet Income A ttributable t o ABC $435M \u00a0$524M\nDilut ed Earnings P er Shar e $2.10 \u00a0$2.53\n1", "original_text": "\"Driven by our purpose of being united in our responsibility to create healthier futures, we are strengthening our portfolio of\nsolutions for customers, expanding on our leadership in specialty, focusing on execution and leveraging our capabilities and\nexpertise to support pharmaceutical innovation,\" Mr. ", "page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7d2fc32f0b3730fa498fc849de3e1349a7f61dcf62afdcc8cf8917ca96c892ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7211ee8f-65db-4d37-b604-8157b3742dc1", "node_type": "1", "metadata": {"window": "Our solid performance in the March\nquarter was fueled by our associates who continue to work diligently to provide innovative solutions for our partners to ultimately\nserve their patients,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n \"Driven by our purpose of being united in our responsibility to create healthier futures, we are strengthening our portfolio of\nsolutions for customers, expanding on our leadership in specialty, focusing on execution and leveraging our capabilities and\nexpertise to support pharmaceutical innovation,\" Mr.  Collis continued.  \"AmerisourceBergen is well-positioned to deliver long-term,\nsustainable growth, supported by our diverse and inclusive teams and our investments in our people and culture.\"\n Second Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAP \u00a0Adjust ed (Non-GAAP)\nRevenue $49.2B \u00a0$49.2B\nGross Pr ofit $1.5B \u00a0$1.5B\nOperating Expenses $909M \u00a0$806M\nOperating Income $624M \u00a0$707M\nInterest Expense, Net $35M \u00a0$35M\nEffectiv e Tax Rat e 23.4% \u00a021.9%\nNet Income A ttributable t o ABC $435M \u00a0$524M\nDilut ed Earnings P er Shar e $2.10 \u00a0$2.53\n1", "original_text": "\"AmerisourceBergen is well-positioned to deliver long-term,\nsustainable growth, supported by our diverse and inclusive teams and our investments in our people and culture.\"\n"}, "hash": "19caef877363847bc7b7a9b8687970e542f729f48693cfe71e329000c2f56c97", "class_name": "RelatedNodeInfo"}}, "text": "Collis continued. ", "start_char_idx": 1955, "end_char_idx": 1973, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7211ee8f-65db-4d37-b604-8157b3742dc1": {"__data__": {"id_": "7211ee8f-65db-4d37-b604-8157b3742dc1", "embedding": null, "metadata": {"window": "Our solid performance in the March\nquarter was fueled by our associates who continue to work diligently to provide innovative solutions for our partners to ultimately\nserve their patients,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n \"Driven by our purpose of being united in our responsibility to create healthier futures, we are strengthening our portfolio of\nsolutions for customers, expanding on our leadership in specialty, focusing on execution and leveraging our capabilities and\nexpertise to support pharmaceutical innovation,\" Mr.  Collis continued.  \"AmerisourceBergen is well-positioned to deliver long-term,\nsustainable growth, supported by our diverse and inclusive teams and our investments in our people and culture.\"\n Second Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAP \u00a0Adjust ed (Non-GAAP)\nRevenue $49.2B \u00a0$49.2B\nGross Pr ofit $1.5B \u00a0$1.5B\nOperating Expenses $909M \u00a0$806M\nOperating Income $624M \u00a0$707M\nInterest Expense, Net $35M \u00a0$35M\nEffectiv e Tax Rat e 23.4% \u00a021.9%\nNet Income A ttributable t o ABC $435M \u00a0$524M\nDilut ed Earnings P er Shar e $2.10 \u00a0$2.53\n1", "original_text": "\"AmerisourceBergen is well-positioned to deliver long-term,\nsustainable growth, supported by our diverse and inclusive teams and our investments in our people and culture.\"\n", "page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "984951f4-9f9e-491e-8d76-75fdf91ef9cd", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52c007cb5c3539d624c7730f22d83f96c826d282cbee21db83720bb3a0d2d157", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c29c869b-f26c-4f9b-91ba-5a037472b3ab", "node_type": "1", "metadata": {"window": "\"AmerisourceBergen continues to prove our vital role as a key pillar in the healthcare system.  Our solid performance in the March\nquarter was fueled by our associates who continue to work diligently to provide innovative solutions for our partners to ultimately\nserve their patients,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n \"Driven by our purpose of being united in our responsibility to create healthier futures, we are strengthening our portfolio of\nsolutions for customers, expanding on our leadership in specialty, focusing on execution and leveraging our capabilities and\nexpertise to support pharmaceutical innovation,\" Mr.  Collis continued.  \"AmerisourceBergen is well-positioned to deliver long-term,\nsustainable growth, supported by our diverse and inclusive teams and our investments in our people and culture.\"\n Second Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAP \u00a0Adjust ed (Non-GAAP)\nRevenue $49.2B \u00a0$49.2B\nGross Pr ofit $1.5B \u00a0$1.5B\nOperating Expenses $909M \u00a0$806M\nOperating Income $624M \u00a0$707M\nInterest Expense, Net $35M \u00a0$35M\nEffectiv e Tax Rat e 23.4% \u00a021.9%\nNet Income A ttributable t o ABC $435M \u00a0$524M\nDilut ed Earnings P er Shar e $2.10 \u00a0$2.53\n1", "original_text": "Collis continued. ", "page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "48e75f7462a9aea63596224131ecf63b2addc35037e41e6d757db049a512903c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5b86314-4ab9-493c-9f03-ea0e60675613", "node_type": "1", "metadata": {"window": "\"Driven by our purpose of being united in our responsibility to create healthier futures, we are strengthening our portfolio of\nsolutions for customers, expanding on our leadership in specialty, focusing on execution and leveraging our capabilities and\nexpertise to support pharmaceutical innovation,\" Mr.  Collis continued.  \"AmerisourceBergen is well-positioned to deliver long-term,\nsustainable growth, supported by our diverse and inclusive teams and our investments in our people and culture.\"\n Second Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAP \u00a0Adjust ed (Non-GAAP)\nRevenue $49.2B \u00a0$49.2B\nGross Pr ofit $1.5B \u00a0$1.5B\nOperating Expenses $909M \u00a0$806M\nOperating Income $624M \u00a0$707M\nInterest Expense, Net $35M \u00a0$35M\nEffectiv e Tax Rat e 23.4% \u00a021.9%\nNet Income A ttributable t o ABC $435M \u00a0$524M\nDilut ed Earnings P er Shar e $2.10 \u00a0$2.53\n1", "original_text": "Second Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAP \u00a0Adjust ed (Non-GAAP)\nRevenue $49.2B \u00a0$49.2B\nGross Pr ofit $1.5B \u00a0$1.5B\nOperating Expenses $909M \u00a0$806M\nOperating Income $624M \u00a0$707M\nInterest Expense, Net $35M \u00a0$35M\nEffectiv e Tax Rat e 23.4% \u00a021.9%\nNet Income A ttributable t o ABC $435M \u00a0$524M\nDilut ed Earnings P er Shar e $2.10 \u00a0$2.53\n1"}, "hash": "a23773e57e1dc80569685b9258fb134fd2dce8a15de3ba73875844f4eb6f1e87", "class_name": "RelatedNodeInfo"}}, "text": "\"AmerisourceBergen is well-positioned to deliver long-term,\nsustainable growth, supported by our diverse and inclusive teams and our investments in our people and culture.\"\n", "start_char_idx": 1973, "end_char_idx": 2146, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5b86314-4ab9-493c-9f03-ea0e60675613": {"__data__": {"id_": "d5b86314-4ab9-493c-9f03-ea0e60675613", "embedding": null, "metadata": {"window": "\"Driven by our purpose of being united in our responsibility to create healthier futures, we are strengthening our portfolio of\nsolutions for customers, expanding on our leadership in specialty, focusing on execution and leveraging our capabilities and\nexpertise to support pharmaceutical innovation,\" Mr.  Collis continued.  \"AmerisourceBergen is well-positioned to deliver long-term,\nsustainable growth, supported by our diverse and inclusive teams and our investments in our people and culture.\"\n Second Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAP \u00a0Adjust ed (Non-GAAP)\nRevenue $49.2B \u00a0$49.2B\nGross Pr ofit $1.5B \u00a0$1.5B\nOperating Expenses $909M \u00a0$806M\nOperating Income $624M \u00a0$707M\nInterest Expense, Net $35M \u00a0$35M\nEffectiv e Tax Rat e 23.4% \u00a021.9%\nNet Income A ttributable t o ABC $435M \u00a0$524M\nDilut ed Earnings P er Shar e $2.10 \u00a0$2.53\n1", "original_text": "Second Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAP \u00a0Adjust ed (Non-GAAP)\nRevenue $49.2B \u00a0$49.2B\nGross Pr ofit $1.5B \u00a0$1.5B\nOperating Expenses $909M \u00a0$806M\nOperating Income $624M \u00a0$707M\nInterest Expense, Net $35M \u00a0$35M\nEffectiv e Tax Rat e 23.4% \u00a021.9%\nNet Income A ttributable t o ABC $435M \u00a0$524M\nDilut ed Earnings P er Shar e $2.10 \u00a0$2.53\n1", "page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "984951f4-9f9e-491e-8d76-75fdf91ef9cd", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52c007cb5c3539d624c7730f22d83f96c826d282cbee21db83720bb3a0d2d157", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7211ee8f-65db-4d37-b604-8157b3742dc1", "node_type": "1", "metadata": {"window": "Our solid performance in the March\nquarter was fueled by our associates who continue to work diligently to provide innovative solutions for our partners to ultimately\nserve their patients,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.\n \"Driven by our purpose of being united in our responsibility to create healthier futures, we are strengthening our portfolio of\nsolutions for customers, expanding on our leadership in specialty, focusing on execution and leveraging our capabilities and\nexpertise to support pharmaceutical innovation,\" Mr.  Collis continued.  \"AmerisourceBergen is well-positioned to deliver long-term,\nsustainable growth, supported by our diverse and inclusive teams and our investments in our people and culture.\"\n Second Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAP \u00a0Adjust ed (Non-GAAP)\nRevenue $49.2B \u00a0$49.2B\nGross Pr ofit $1.5B \u00a0$1.5B\nOperating Expenses $909M \u00a0$806M\nOperating Income $624M \u00a0$707M\nInterest Expense, Net $35M \u00a0$35M\nEffectiv e Tax Rat e 23.4% \u00a021.9%\nNet Income A ttributable t o ABC $435M \u00a0$524M\nDilut ed Earnings P er Shar e $2.10 \u00a0$2.53\n1", "original_text": "\"AmerisourceBergen is well-positioned to deliver long-term,\nsustainable growth, supported by our diverse and inclusive teams and our investments in our people and culture.\"\n", "page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0ef4c50392ffe0fc0d140405217db2a9acc96a1cb3f390e78840fd261b1855f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42e0a856-75dd-4309-8bdf-95450ec9f0a9", "node_type": "1", "metadata": {"window": "Dilut ed Shar es Outstanding 207M \u00a0207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2021, revenue was $49.2 billion, up 3.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 3.4 percent increase in Pharmaceutical Distribution Services revenue and an 11.5 percent\nincrease in revenue within Other.\n", "original_text": "Dilut ed Shar es Outstanding 207M \u00a0207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. "}, "hash": "c9f4057e2488f3a0a244ee96961dc3a97f5ddf8036c46d5ba9f93c9422f3efe2", "class_name": "RelatedNodeInfo"}}, "text": "Second Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAP \u00a0Adjust ed (Non-GAAP)\nRevenue $49.2B \u00a0$49.2B\nGross Pr ofit $1.5B \u00a0$1.5B\nOperating Expenses $909M \u00a0$806M\nOperating Income $624M \u00a0$707M\nInterest Expense, Net $35M \u00a0$35M\nEffectiv e Tax Rat e 23.4% \u00a021.9%\nNet Income A ttributable t o ABC $435M \u00a0$524M\nDilut ed Earnings P er Shar e $2.10 \u00a0$2.53\n1", "start_char_idx": 2146, "end_char_idx": 2495, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42e0a856-75dd-4309-8bdf-95450ec9f0a9": {"__data__": {"id_": "42e0a856-75dd-4309-8bdf-95450ec9f0a9", "embedding": null, "metadata": {"window": "Dilut ed Shar es Outstanding 207M \u00a0207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2021, revenue was $49.2 billion, up 3.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 3.4 percent increase in Pharmaceutical Distribution Services revenue and an 11.5 percent\nincrease in revenue within Other.\n", "original_text": "Dilut ed Shar es Outstanding 207M \u00a0207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff718a65d5d30c5809176e9541c648df53eaed775fecbfbf7469858524e7b88d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5b86314-4ab9-493c-9f03-ea0e60675613", "node_type": "1", "metadata": {"window": "\"Driven by our purpose of being united in our responsibility to create healthier futures, we are strengthening our portfolio of\nsolutions for customers, expanding on our leadership in specialty, focusing on execution and leveraging our capabilities and\nexpertise to support pharmaceutical innovation,\" Mr.  Collis continued.  \"AmerisourceBergen is well-positioned to deliver long-term,\nsustainable growth, supported by our diverse and inclusive teams and our investments in our people and culture.\"\n Second Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAP \u00a0Adjust ed (Non-GAAP)\nRevenue $49.2B \u00a0$49.2B\nGross Pr ofit $1.5B \u00a0$1.5B\nOperating Expenses $909M \u00a0$806M\nOperating Income $624M \u00a0$707M\nInterest Expense, Net $35M \u00a0$35M\nEffectiv e Tax Rat e 23.4% \u00a021.9%\nNet Income A ttributable t o ABC $435M \u00a0$524M\nDilut ed Earnings P er Shar e $2.10 \u00a0$2.53\n1", "original_text": "Second Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAP \u00a0Adjust ed (Non-GAAP)\nRevenue $49.2B \u00a0$49.2B\nGross Pr ofit $1.5B \u00a0$1.5B\nOperating Expenses $909M \u00a0$806M\nOperating Income $624M \u00a0$707M\nInterest Expense, Net $35M \u00a0$35M\nEffectiv e Tax Rat e 23.4% \u00a021.9%\nNet Income A ttributable t o ABC $435M \u00a0$524M\nDilut ed Earnings P er Shar e $2.10 \u00a0$2.53\n1", "page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98040c9bf1ba66817c12eafbbeaacb393bd2a9ecd6d5ed667601e3631655700f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d8f9bc6-7088-40bb-9652-f40c3e685004", "node_type": "1", "metadata": {"window": "Dilut ed Shar es Outstanding 207M \u00a0207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2021, revenue was $49.2 billion, up 3.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 3.4 percent increase in Pharmaceutical Distribution Services revenue and an 11.5 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the second quarter of fiscal 2021 was $1.5 billion, a 10.5 percent increase compared to the same\nperiod in the previous fiscal year. ", "original_text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. "}, "hash": "0b69bd11a95513e7d2054dd009cd0cfa62d4a313c592023e91532280aded6827", "class_name": "RelatedNodeInfo"}}, "text": "Dilut ed Shar es Outstanding 207M \u00a0207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "start_char_idx": 0, "end_char_idx": 161, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d8f9bc6-7088-40bb-9652-f40c3e685004": {"__data__": {"id_": "4d8f9bc6-7088-40bb-9652-f40c3e685004", "embedding": null, "metadata": {"window": "Dilut ed Shar es Outstanding 207M \u00a0207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2021, revenue was $49.2 billion, up 3.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 3.4 percent increase in Pharmaceutical Distribution Services revenue and an 11.5 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the second quarter of fiscal 2021 was $1.5 billion, a 10.5 percent increase compared to the same\nperiod in the previous fiscal year. ", "original_text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff718a65d5d30c5809176e9541c648df53eaed775fecbfbf7469858524e7b88d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42e0a856-75dd-4309-8bdf-95450ec9f0a9", "node_type": "1", "metadata": {"window": "Dilut ed Shar es Outstanding 207M \u00a0207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2021, revenue was $49.2 billion, up 3.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 3.4 percent increase in Pharmaceutical Distribution Services revenue and an 11.5 percent\nincrease in revenue within Other.\n", "original_text": "Dilut ed Shar es Outstanding 207M \u00a0207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd641dfad069af634c6934ad9e8012f9638254847bf6ce1b007c817a5f6a7726", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20112f3f-d549-4c55-93c4-df05f65e2053", "node_type": "1", "metadata": {"window": "Dilut ed Shar es Outstanding 207M \u00a0207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2021, revenue was $49.2 billion, up 3.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 3.4 percent increase in Pharmaceutical Distribution Services revenue and an 11.5 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the second quarter of fiscal 2021 was $1.5 billion, a 10.5 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by an increase in gross profit for Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year quarter, and\nan increase in gross profit for Other. ", "original_text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n"}, "hash": "077d59a5581da77e3827480a88c7e4ca8e3860715e129f57e0d6c8e68dbeba27", "class_name": "RelatedNodeInfo"}}, "text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "start_char_idx": 161, "end_char_idx": 253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20112f3f-d549-4c55-93c4-df05f65e2053": {"__data__": {"id_": "20112f3f-d549-4c55-93c4-df05f65e2053", "embedding": null, "metadata": {"window": "Dilut ed Shar es Outstanding 207M \u00a0207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2021, revenue was $49.2 billion, up 3.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 3.4 percent increase in Pharmaceutical Distribution Services revenue and an 11.5 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the second quarter of fiscal 2021 was $1.5 billion, a 10.5 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by an increase in gross profit for Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year quarter, and\nan increase in gross profit for Other. ", "original_text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff718a65d5d30c5809176e9541c648df53eaed775fecbfbf7469858524e7b88d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d8f9bc6-7088-40bb-9652-f40c3e685004", "node_type": "1", "metadata": {"window": "Dilut ed Shar es Outstanding 207M \u00a0207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2021, revenue was $49.2 billion, up 3.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 3.4 percent increase in Pharmaceutical Distribution Services revenue and an 11.5 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the second quarter of fiscal 2021 was $1.5 billion, a 10.5 percent increase compared to the same\nperiod in the previous fiscal year. ", "original_text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb391d46ad9845f5718ad6d72753d6818cf92418c72c3d5fb3ec206b23b25e16", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0e77ce5-0489-4d98-a8d7-99ad6a18011a", "node_type": "1", "metadata": {"window": "Dilut ed Shar es Outstanding 207M \u00a0207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2021, revenue was $49.2 billion, up 3.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 3.4 percent increase in Pharmaceutical Distribution Services revenue and an 11.5 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the second quarter of fiscal 2021 was $1.5 billion, a 10.5 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by an increase in gross profit for Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year quarter, and\nan increase in gross profit for Other.  Gross profit as a percentage of revenue was 3.12%, an increase of 19 basis points from\nthe prior year quarter primarily driven by an increase in sales of specialty products in Pharmaceutical Distribution Services and\ngrowth in some of the Company's higher margin businesses.\n", "original_text": "Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2021, revenue was $49.2 billion, up 3.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 3.4 percent increase in Pharmaceutical Distribution Services revenue and an 11.5 percent\nincrease in revenue within Other.\n"}, "hash": "be328d4210d04f9d507d495b28b67c4b2769874e3e4ad8e4e561397c928d11cb", "class_name": "RelatedNodeInfo"}}, "text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n", "start_char_idx": 253, "end_char_idx": 475, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0e77ce5-0489-4d98-a8d7-99ad6a18011a": {"__data__": {"id_": "f0e77ce5-0489-4d98-a8d7-99ad6a18011a", "embedding": null, "metadata": {"window": "Dilut ed Shar es Outstanding 207M \u00a0207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2021, revenue was $49.2 billion, up 3.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 3.4 percent increase in Pharmaceutical Distribution Services revenue and an 11.5 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the second quarter of fiscal 2021 was $1.5 billion, a 10.5 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by an increase in gross profit for Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year quarter, and\nan increase in gross profit for Other.  Gross profit as a percentage of revenue was 3.12%, an increase of 19 basis points from\nthe prior year quarter primarily driven by an increase in sales of specialty products in Pharmaceutical Distribution Services and\ngrowth in some of the Company's higher margin businesses.\n", "original_text": "Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2021, revenue was $49.2 billion, up 3.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 3.4 percent increase in Pharmaceutical Distribution Services revenue and an 11.5 percent\nincrease in revenue within Other.\n", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff718a65d5d30c5809176e9541c648df53eaed775fecbfbf7469858524e7b88d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20112f3f-d549-4c55-93c4-df05f65e2053", "node_type": "1", "metadata": {"window": "Dilut ed Shar es Outstanding 207M \u00a0207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2021, revenue was $49.2 billion, up 3.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 3.4 percent increase in Pharmaceutical Distribution Services revenue and an 11.5 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the second quarter of fiscal 2021 was $1.5 billion, a 10.5 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by an increase in gross profit for Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year quarter, and\nan increase in gross profit for Other. ", "original_text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "778a1aca58e5a9e50273883deb08836b7cababb5df43d671d30dbdbbd65f2588", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "475059ba-f952-40dd-8a92-c4cd62ac7574", "node_type": "1", "metadata": {"window": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2021, revenue was $49.2 billion, up 3.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 3.4 percent increase in Pharmaceutical Distribution Services revenue and an 11.5 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the second quarter of fiscal 2021 was $1.5 billion, a 10.5 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by an increase in gross profit for Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year quarter, and\nan increase in gross profit for Other.  Gross profit as a percentage of revenue was 3.12%, an increase of 19 basis points from\nthe prior year quarter primarily driven by an increase in sales of specialty products in Pharmaceutical Distribution Services and\ngrowth in some of the Company's higher margin businesses.\n Operating Expenses:  In the second quarter of fiscal 2021, operating expenses were $909.0 million, a 15.7 percent decrease\ncompared to the same period last fiscal year. ", "original_text": "Gross Profit:  Gross profit in the second quarter of fiscal 2021 was $1.5 billion, a 10.5 percent increase compared to the same\nperiod in the previous fiscal year. "}, "hash": "abe220d9e8345c6f7308bd4af454e574edf33f8d2c97625cf6877b8eb7bdaddf", "class_name": "RelatedNodeInfo"}}, "text": "Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2021, revenue was $49.2 billion, up 3.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 3.4 percent increase in Pharmaceutical Distribution Services revenue and an 11.5 percent\nincrease in revenue within Other.\n", "start_char_idx": 475, "end_char_idx": 789, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "475059ba-f952-40dd-8a92-c4cd62ac7574": {"__data__": {"id_": "475059ba-f952-40dd-8a92-c4cd62ac7574", "embedding": null, "metadata": {"window": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2021, revenue was $49.2 billion, up 3.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 3.4 percent increase in Pharmaceutical Distribution Services revenue and an 11.5 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the second quarter of fiscal 2021 was $1.5 billion, a 10.5 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by an increase in gross profit for Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year quarter, and\nan increase in gross profit for Other.  Gross profit as a percentage of revenue was 3.12%, an increase of 19 basis points from\nthe prior year quarter primarily driven by an increase in sales of specialty products in Pharmaceutical Distribution Services and\ngrowth in some of the Company's higher margin businesses.\n Operating Expenses:  In the second quarter of fiscal 2021, operating expenses were $909.0 million, a 15.7 percent decrease\ncompared to the same period last fiscal year. ", "original_text": "Gross Profit:  Gross profit in the second quarter of fiscal 2021 was $1.5 billion, a 10.5 percent increase compared to the same\nperiod in the previous fiscal year. ", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff718a65d5d30c5809176e9541c648df53eaed775fecbfbf7469858524e7b88d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0e77ce5-0489-4d98-a8d7-99ad6a18011a", "node_type": "1", "metadata": {"window": "Dilut ed Shar es Outstanding 207M \u00a0207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2021, revenue was $49.2 billion, up 3.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 3.4 percent increase in Pharmaceutical Distribution Services revenue and an 11.5 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the second quarter of fiscal 2021 was $1.5 billion, a 10.5 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by an increase in gross profit for Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year quarter, and\nan increase in gross profit for Other.  Gross profit as a percentage of revenue was 3.12%, an increase of 19 basis points from\nthe prior year quarter primarily driven by an increase in sales of specialty products in Pharmaceutical Distribution Services and\ngrowth in some of the Company's higher margin businesses.\n", "original_text": "Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2021, revenue was $49.2 billion, up 3.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 3.4 percent increase in Pharmaceutical Distribution Services revenue and an 11.5 percent\nincrease in revenue within Other.\n", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a5c122049927f1ec89434ba451aaaf351c04a8cb25f65b019c4cac4744b3aa1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d314b52d-6551-481b-9034-4ad423b79d7b", "node_type": "1", "metadata": {"window": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2021, revenue was $49.2 billion, up 3.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 3.4 percent increase in Pharmaceutical Distribution Services revenue and an 11.5 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the second quarter of fiscal 2021 was $1.5 billion, a 10.5 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by an increase in gross profit for Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year quarter, and\nan increase in gross profit for Other.  Gross profit as a percentage of revenue was 3.12%, an increase of 19 basis points from\nthe prior year quarter primarily driven by an increase in sales of specialty products in Pharmaceutical Distribution Services and\ngrowth in some of the Company's higher margin businesses.\n Operating Expenses:  In the second quarter of fiscal 2021, operating expenses were $909.0 million, a 15.7 percent decrease\ncompared to the same period last fiscal year.  The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium assets recorded in the prior year quarter, which was partially offset by an increase in distribution,\nselling and administrative costs in the current year quarter. ", "original_text": "Gross profit was favorably impacted by an increase in gross profit for Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year quarter, and\nan increase in gross profit for Other. "}, "hash": "8de7342ef8cc4b8c244108e30bfc40035ca5ee862abaa80d92183b7f236871ff", "class_name": "RelatedNodeInfo"}}, "text": "Gross Profit:  Gross profit in the second quarter of fiscal 2021 was $1.5 billion, a 10.5 percent increase compared to the same\nperiod in the previous fiscal year. ", "start_char_idx": 789, "end_char_idx": 953, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d314b52d-6551-481b-9034-4ad423b79d7b": {"__data__": {"id_": "d314b52d-6551-481b-9034-4ad423b79d7b", "embedding": null, "metadata": {"window": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2021, revenue was $49.2 billion, up 3.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 3.4 percent increase in Pharmaceutical Distribution Services revenue and an 11.5 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the second quarter of fiscal 2021 was $1.5 billion, a 10.5 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by an increase in gross profit for Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year quarter, and\nan increase in gross profit for Other.  Gross profit as a percentage of revenue was 3.12%, an increase of 19 basis points from\nthe prior year quarter primarily driven by an increase in sales of specialty products in Pharmaceutical Distribution Services and\ngrowth in some of the Company's higher margin businesses.\n Operating Expenses:  In the second quarter of fiscal 2021, operating expenses were $909.0 million, a 15.7 percent decrease\ncompared to the same period last fiscal year.  The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium assets recorded in the prior year quarter, which was partially offset by an increase in distribution,\nselling and administrative costs in the current year quarter. ", "original_text": "Gross profit was favorably impacted by an increase in gross profit for Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year quarter, and\nan increase in gross profit for Other. ", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff718a65d5d30c5809176e9541c648df53eaed775fecbfbf7469858524e7b88d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "475059ba-f952-40dd-8a92-c4cd62ac7574", "node_type": "1", "metadata": {"window": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2021, revenue was $49.2 billion, up 3.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 3.4 percent increase in Pharmaceutical Distribution Services revenue and an 11.5 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the second quarter of fiscal 2021 was $1.5 billion, a 10.5 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by an increase in gross profit for Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year quarter, and\nan increase in gross profit for Other.  Gross profit as a percentage of revenue was 3.12%, an increase of 19 basis points from\nthe prior year quarter primarily driven by an increase in sales of specialty products in Pharmaceutical Distribution Services and\ngrowth in some of the Company's higher margin businesses.\n Operating Expenses:  In the second quarter of fiscal 2021, operating expenses were $909.0 million, a 15.7 percent decrease\ncompared to the same period last fiscal year. ", "original_text": "Gross Profit:  Gross profit in the second quarter of fiscal 2021 was $1.5 billion, a 10.5 percent increase compared to the same\nperiod in the previous fiscal year. ", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74a02168302e5e57a4b79e032df75a0a7ebe4fb553d04e12d15fb56d440f2107", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "270d06d4-065d-40c9-b239-2a4a6549379f", "node_type": "1", "metadata": {"window": "Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2021, revenue was $49.2 billion, up 3.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 3.4 percent increase in Pharmaceutical Distribution Services revenue and an 11.5 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the second quarter of fiscal 2021 was $1.5 billion, a 10.5 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by an increase in gross profit for Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year quarter, and\nan increase in gross profit for Other.  Gross profit as a percentage of revenue was 3.12%, an increase of 19 basis points from\nthe prior year quarter primarily driven by an increase in sales of specialty products in Pharmaceutical Distribution Services and\ngrowth in some of the Company's higher margin businesses.\n Operating Expenses:  In the second quarter of fiscal 2021, operating expenses were $909.0 million, a 15.7 percent decrease\ncompared to the same period last fiscal year.  The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium assets recorded in the prior year quarter, which was partially offset by an increase in distribution,\nselling and administrative costs in the current year quarter.  Operating expenses as a percentage of revenue in the fiscal 2021\nsecond quarter were 1.85 percent, compared to 2.27 percent for the same period in the previous fiscal year.\n", "original_text": "Gross profit as a percentage of revenue was 3.12%, an increase of 19 basis points from\nthe prior year quarter primarily driven by an increase in sales of specialty products in Pharmaceutical Distribution Services and\ngrowth in some of the Company's higher margin businesses.\n"}, "hash": "e81a2f064f28210446f02d7b65b87972adbfead7c833f49910107b3bc47e2233", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit was favorably impacted by an increase in gross profit for Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year quarter, and\nan increase in gross profit for Other. ", "start_char_idx": 953, "end_char_idx": 1206, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "270d06d4-065d-40c9-b239-2a4a6549379f": {"__data__": {"id_": "270d06d4-065d-40c9-b239-2a4a6549379f", "embedding": null, "metadata": {"window": "Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2021, revenue was $49.2 billion, up 3.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 3.4 percent increase in Pharmaceutical Distribution Services revenue and an 11.5 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the second quarter of fiscal 2021 was $1.5 billion, a 10.5 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by an increase in gross profit for Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year quarter, and\nan increase in gross profit for Other.  Gross profit as a percentage of revenue was 3.12%, an increase of 19 basis points from\nthe prior year quarter primarily driven by an increase in sales of specialty products in Pharmaceutical Distribution Services and\ngrowth in some of the Company's higher margin businesses.\n Operating Expenses:  In the second quarter of fiscal 2021, operating expenses were $909.0 million, a 15.7 percent decrease\ncompared to the same period last fiscal year.  The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium assets recorded in the prior year quarter, which was partially offset by an increase in distribution,\nselling and administrative costs in the current year quarter.  Operating expenses as a percentage of revenue in the fiscal 2021\nsecond quarter were 1.85 percent, compared to 2.27 percent for the same period in the previous fiscal year.\n", "original_text": "Gross profit as a percentage of revenue was 3.12%, an increase of 19 basis points from\nthe prior year quarter primarily driven by an increase in sales of specialty products in Pharmaceutical Distribution Services and\ngrowth in some of the Company's higher margin businesses.\n", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff718a65d5d30c5809176e9541c648df53eaed775fecbfbf7469858524e7b88d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d314b52d-6551-481b-9034-4ad423b79d7b", "node_type": "1", "metadata": {"window": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2021, revenue was $49.2 billion, up 3.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 3.4 percent increase in Pharmaceutical Distribution Services revenue and an 11.5 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the second quarter of fiscal 2021 was $1.5 billion, a 10.5 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by an increase in gross profit for Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year quarter, and\nan increase in gross profit for Other.  Gross profit as a percentage of revenue was 3.12%, an increase of 19 basis points from\nthe prior year quarter primarily driven by an increase in sales of specialty products in Pharmaceutical Distribution Services and\ngrowth in some of the Company's higher margin businesses.\n Operating Expenses:  In the second quarter of fiscal 2021, operating expenses were $909.0 million, a 15.7 percent decrease\ncompared to the same period last fiscal year.  The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium assets recorded in the prior year quarter, which was partially offset by an increase in distribution,\nselling and administrative costs in the current year quarter. ", "original_text": "Gross profit was favorably impacted by an increase in gross profit for Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year quarter, and\nan increase in gross profit for Other. ", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fb87f11b572639c6ebb0c2bbcaeb353d1e3167118486370883c6b997fb67655", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf6b3ca9-bafd-4f04-b8f9-38482cc4ae68", "node_type": "1", "metadata": {"window": "Gross Profit:  Gross profit in the second quarter of fiscal 2021 was $1.5 billion, a 10.5 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by an increase in gross profit for Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year quarter, and\nan increase in gross profit for Other.  Gross profit as a percentage of revenue was 3.12%, an increase of 19 basis points from\nthe prior year quarter primarily driven by an increase in sales of specialty products in Pharmaceutical Distribution Services and\ngrowth in some of the Company's higher margin businesses.\n Operating Expenses:  In the second quarter of fiscal 2021, operating expenses were $909.0 million, a 15.7 percent decrease\ncompared to the same period last fiscal year.  The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium assets recorded in the prior year quarter, which was partially offset by an increase in distribution,\nselling and administrative costs in the current year quarter.  Operating expenses as a percentage of revenue in the fiscal 2021\nsecond quarter were 1.85 percent, compared to 2.27 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2021 second quarter, operating income increased to $624.3 million from $309.5 million in the\nprior year quarter. ", "original_text": "Operating Expenses:  In the second quarter of fiscal 2021, operating expenses were $909.0 million, a 15.7 percent decrease\ncompared to the same period last fiscal year. "}, "hash": "486c43d735bdcbeb7dcfb0ef2f1c421ea8306424234b55aff3c9df1ea2355ca2", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit as a percentage of revenue was 3.12%, an increase of 19 basis points from\nthe prior year quarter primarily driven by an increase in sales of specialty products in Pharmaceutical Distribution Services and\ngrowth in some of the Company's higher margin businesses.\n", "start_char_idx": 1206, "end_char_idx": 1481, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf6b3ca9-bafd-4f04-b8f9-38482cc4ae68": {"__data__": {"id_": "bf6b3ca9-bafd-4f04-b8f9-38482cc4ae68", "embedding": null, "metadata": {"window": "Gross Profit:  Gross profit in the second quarter of fiscal 2021 was $1.5 billion, a 10.5 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by an increase in gross profit for Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year quarter, and\nan increase in gross profit for Other.  Gross profit as a percentage of revenue was 3.12%, an increase of 19 basis points from\nthe prior year quarter primarily driven by an increase in sales of specialty products in Pharmaceutical Distribution Services and\ngrowth in some of the Company's higher margin businesses.\n Operating Expenses:  In the second quarter of fiscal 2021, operating expenses were $909.0 million, a 15.7 percent decrease\ncompared to the same period last fiscal year.  The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium assets recorded in the prior year quarter, which was partially offset by an increase in distribution,\nselling and administrative costs in the current year quarter.  Operating expenses as a percentage of revenue in the fiscal 2021\nsecond quarter were 1.85 percent, compared to 2.27 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2021 second quarter, operating income increased to $624.3 million from $309.5 million in the\nprior year quarter. ", "original_text": "Operating Expenses:  In the second quarter of fiscal 2021, operating expenses were $909.0 million, a 15.7 percent decrease\ncompared to the same period last fiscal year. ", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff718a65d5d30c5809176e9541c648df53eaed775fecbfbf7469858524e7b88d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "270d06d4-065d-40c9-b239-2a4a6549379f", "node_type": "1", "metadata": {"window": "Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2021, revenue was $49.2 billion, up 3.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 3.4 percent increase in Pharmaceutical Distribution Services revenue and an 11.5 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the second quarter of fiscal 2021 was $1.5 billion, a 10.5 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by an increase in gross profit for Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year quarter, and\nan increase in gross profit for Other.  Gross profit as a percentage of revenue was 3.12%, an increase of 19 basis points from\nthe prior year quarter primarily driven by an increase in sales of specialty products in Pharmaceutical Distribution Services and\ngrowth in some of the Company's higher margin businesses.\n Operating Expenses:  In the second quarter of fiscal 2021, operating expenses were $909.0 million, a 15.7 percent decrease\ncompared to the same period last fiscal year.  The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium assets recorded in the prior year quarter, which was partially offset by an increase in distribution,\nselling and administrative costs in the current year quarter.  Operating expenses as a percentage of revenue in the fiscal 2021\nsecond quarter were 1.85 percent, compared to 2.27 percent for the same period in the previous fiscal year.\n", "original_text": "Gross profit as a percentage of revenue was 3.12%, an increase of 19 basis points from\nthe prior year quarter primarily driven by an increase in sales of specialty products in Pharmaceutical Distribution Services and\ngrowth in some of the Company's higher margin businesses.\n", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc794833157b9b085d12138c91743ff2d2b8888f6fb6295fa169c996270e7de5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a64fe025-50d6-44a8-afec-deb3500c3bcf", "node_type": "1", "metadata": {"window": "Gross profit was favorably impacted by an increase in gross profit for Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year quarter, and\nan increase in gross profit for Other.  Gross profit as a percentage of revenue was 3.12%, an increase of 19 basis points from\nthe prior year quarter primarily driven by an increase in sales of specialty products in Pharmaceutical Distribution Services and\ngrowth in some of the Company's higher margin businesses.\n Operating Expenses:  In the second quarter of fiscal 2021, operating expenses were $909.0 million, a 15.7 percent decrease\ncompared to the same period last fiscal year.  The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium assets recorded in the prior year quarter, which was partially offset by an increase in distribution,\nselling and administrative costs in the current year quarter.  Operating expenses as a percentage of revenue in the fiscal 2021\nsecond quarter were 1.85 percent, compared to 2.27 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2021 second quarter, operating income increased to $624.3 million from $309.5 million in the\nprior year quarter.  Operating income as a percentage of revenue was 1.27 percent in the second quarter of fiscal 2021,\ncompared to 0.65 percent for the same period in the previous fiscal year due to the increase in gross profit and decrease in\noperating expenses.\n", "original_text": "The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium assets recorded in the prior year quarter, which was partially offset by an increase in distribution,\nselling and administrative costs in the current year quarter. "}, "hash": "5b19617e79e00d4ab5f3c62763380fd93dc10546a7073e2d90d8420bef9ccd82", "class_name": "RelatedNodeInfo"}}, "text": "Operating Expenses:  In the second quarter of fiscal 2021, operating expenses were $909.0 million, a 15.7 percent decrease\ncompared to the same period last fiscal year. ", "start_char_idx": 1481, "end_char_idx": 1650, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a64fe025-50d6-44a8-afec-deb3500c3bcf": {"__data__": {"id_": "a64fe025-50d6-44a8-afec-deb3500c3bcf", "embedding": null, "metadata": {"window": "Gross profit was favorably impacted by an increase in gross profit for Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year quarter, and\nan increase in gross profit for Other.  Gross profit as a percentage of revenue was 3.12%, an increase of 19 basis points from\nthe prior year quarter primarily driven by an increase in sales of specialty products in Pharmaceutical Distribution Services and\ngrowth in some of the Company's higher margin businesses.\n Operating Expenses:  In the second quarter of fiscal 2021, operating expenses were $909.0 million, a 15.7 percent decrease\ncompared to the same period last fiscal year.  The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium assets recorded in the prior year quarter, which was partially offset by an increase in distribution,\nselling and administrative costs in the current year quarter.  Operating expenses as a percentage of revenue in the fiscal 2021\nsecond quarter were 1.85 percent, compared to 2.27 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2021 second quarter, operating income increased to $624.3 million from $309.5 million in the\nprior year quarter.  Operating income as a percentage of revenue was 1.27 percent in the second quarter of fiscal 2021,\ncompared to 0.65 percent for the same period in the previous fiscal year due to the increase in gross profit and decrease in\noperating expenses.\n", "original_text": "The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium assets recorded in the prior year quarter, which was partially offset by an increase in distribution,\nselling and administrative costs in the current year quarter. ", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff718a65d5d30c5809176e9541c648df53eaed775fecbfbf7469858524e7b88d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf6b3ca9-bafd-4f04-b8f9-38482cc4ae68", "node_type": "1", "metadata": {"window": "Gross Profit:  Gross profit in the second quarter of fiscal 2021 was $1.5 billion, a 10.5 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by an increase in gross profit for Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year quarter, and\nan increase in gross profit for Other.  Gross profit as a percentage of revenue was 3.12%, an increase of 19 basis points from\nthe prior year quarter primarily driven by an increase in sales of specialty products in Pharmaceutical Distribution Services and\ngrowth in some of the Company's higher margin businesses.\n Operating Expenses:  In the second quarter of fiscal 2021, operating expenses were $909.0 million, a 15.7 percent decrease\ncompared to the same period last fiscal year.  The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium assets recorded in the prior year quarter, which was partially offset by an increase in distribution,\nselling and administrative costs in the current year quarter.  Operating expenses as a percentage of revenue in the fiscal 2021\nsecond quarter were 1.85 percent, compared to 2.27 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2021 second quarter, operating income increased to $624.3 million from $309.5 million in the\nprior year quarter. ", "original_text": "Operating Expenses:  In the second quarter of fiscal 2021, operating expenses were $909.0 million, a 15.7 percent decrease\ncompared to the same period last fiscal year. ", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "439b0c33d463d6b7e33e9936d4cf2ade26bc46e7f1350ad37ef104f4b9003a8e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7f1cae9-4b4e-4837-92dd-c59437d173eb", "node_type": "1", "metadata": {"window": "Gross profit as a percentage of revenue was 3.12%, an increase of 19 basis points from\nthe prior year quarter primarily driven by an increase in sales of specialty products in Pharmaceutical Distribution Services and\ngrowth in some of the Company's higher margin businesses.\n Operating Expenses:  In the second quarter of fiscal 2021, operating expenses were $909.0 million, a 15.7 percent decrease\ncompared to the same period last fiscal year.  The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium assets recorded in the prior year quarter, which was partially offset by an increase in distribution,\nselling and administrative costs in the current year quarter.  Operating expenses as a percentage of revenue in the fiscal 2021\nsecond quarter were 1.85 percent, compared to 2.27 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2021 second quarter, operating income increased to $624.3 million from $309.5 million in the\nprior year quarter.  Operating income as a percentage of revenue was 1.27 percent in the second quarter of fiscal 2021,\ncompared to 0.65 percent for the same period in the previous fiscal year due to the increase in gross profit and decrease in\noperating expenses.\n Interest Expense, Net:  In the fiscal 2021 second quarter, net interest expense of $34.5 million was up 0.3 percent versus the\nprior year quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates, which\nwas largely offset by lower interest expense.\n", "original_text": "Operating expenses as a percentage of revenue in the fiscal 2021\nsecond quarter were 1.85 percent, compared to 2.27 percent for the same period in the previous fiscal year.\n"}, "hash": "4344628fb45c09dd69b2f8571f805337a896f989fdc82a95a139320592602225", "class_name": "RelatedNodeInfo"}}, "text": "The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium assets recorded in the prior year quarter, which was partially offset by an increase in distribution,\nselling and administrative costs in the current year quarter. ", "start_char_idx": 1650, "end_char_idx": 1914, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7f1cae9-4b4e-4837-92dd-c59437d173eb": {"__data__": {"id_": "c7f1cae9-4b4e-4837-92dd-c59437d173eb", "embedding": null, "metadata": {"window": "Gross profit as a percentage of revenue was 3.12%, an increase of 19 basis points from\nthe prior year quarter primarily driven by an increase in sales of specialty products in Pharmaceutical Distribution Services and\ngrowth in some of the Company's higher margin businesses.\n Operating Expenses:  In the second quarter of fiscal 2021, operating expenses were $909.0 million, a 15.7 percent decrease\ncompared to the same period last fiscal year.  The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium assets recorded in the prior year quarter, which was partially offset by an increase in distribution,\nselling and administrative costs in the current year quarter.  Operating expenses as a percentage of revenue in the fiscal 2021\nsecond quarter were 1.85 percent, compared to 2.27 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2021 second quarter, operating income increased to $624.3 million from $309.5 million in the\nprior year quarter.  Operating income as a percentage of revenue was 1.27 percent in the second quarter of fiscal 2021,\ncompared to 0.65 percent for the same period in the previous fiscal year due to the increase in gross profit and decrease in\noperating expenses.\n Interest Expense, Net:  In the fiscal 2021 second quarter, net interest expense of $34.5 million was up 0.3 percent versus the\nprior year quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates, which\nwas largely offset by lower interest expense.\n", "original_text": "Operating expenses as a percentage of revenue in the fiscal 2021\nsecond quarter were 1.85 percent, compared to 2.27 percent for the same period in the previous fiscal year.\n", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff718a65d5d30c5809176e9541c648df53eaed775fecbfbf7469858524e7b88d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a64fe025-50d6-44a8-afec-deb3500c3bcf", "node_type": "1", "metadata": {"window": "Gross profit was favorably impacted by an increase in gross profit for Pharmaceutical\nDistribution Services, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year quarter, and\nan increase in gross profit for Other.  Gross profit as a percentage of revenue was 3.12%, an increase of 19 basis points from\nthe prior year quarter primarily driven by an increase in sales of specialty products in Pharmaceutical Distribution Services and\ngrowth in some of the Company's higher margin businesses.\n Operating Expenses:  In the second quarter of fiscal 2021, operating expenses were $909.0 million, a 15.7 percent decrease\ncompared to the same period last fiscal year.  The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium assets recorded in the prior year quarter, which was partially offset by an increase in distribution,\nselling and administrative costs in the current year quarter.  Operating expenses as a percentage of revenue in the fiscal 2021\nsecond quarter were 1.85 percent, compared to 2.27 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2021 second quarter, operating income increased to $624.3 million from $309.5 million in the\nprior year quarter.  Operating income as a percentage of revenue was 1.27 percent in the second quarter of fiscal 2021,\ncompared to 0.65 percent for the same period in the previous fiscal year due to the increase in gross profit and decrease in\noperating expenses.\n", "original_text": "The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium assets recorded in the prior year quarter, which was partially offset by an increase in distribution,\nselling and administrative costs in the current year quarter. ", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e48e1e7e5cc8ae7509e2275175aa5de1515c1ccab71618bb69c37ad21f95919b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "705543bb-e966-4ed4-96f1-d78b72720351", "node_type": "1", "metadata": {"window": "Operating Expenses:  In the second quarter of fiscal 2021, operating expenses were $909.0 million, a 15.7 percent decrease\ncompared to the same period last fiscal year.  The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium assets recorded in the prior year quarter, which was partially offset by an increase in distribution,\nselling and administrative costs in the current year quarter.  Operating expenses as a percentage of revenue in the fiscal 2021\nsecond quarter were 1.85 percent, compared to 2.27 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2021 second quarter, operating income increased to $624.3 million from $309.5 million in the\nprior year quarter.  Operating income as a percentage of revenue was 1.27 percent in the second quarter of fiscal 2021,\ncompared to 0.65 percent for the same period in the previous fiscal year due to the increase in gross profit and decrease in\noperating expenses.\n Interest Expense, Net:  In the fiscal 2021 second quarter, net interest expense of $34.5 million was up 0.3 percent versus the\nprior year quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates, which\nwas largely offset by lower interest expense.\n Effective Tax Rate:  The effective tax rate was 23.4 percent for the second quarter of fiscal 2021 compared to (251.6) percent in\nthe prior year quarter which was favorably impacted by tax benefits related to the Company's decision to permanently exit\nthe PharMEDium compounding business in January 2020.\n", "original_text": "Operating Income:  In the fiscal 2021 second quarter, operating income increased to $624.3 million from $309.5 million in the\nprior year quarter. "}, "hash": "3c103d970c365509d17931da5031bb438b1800d7532bed8ca53ff8636484aa9f", "class_name": "RelatedNodeInfo"}}, "text": "Operating expenses as a percentage of revenue in the fiscal 2021\nsecond quarter were 1.85 percent, compared to 2.27 percent for the same period in the previous fiscal year.\n", "start_char_idx": 1914, "end_char_idx": 2087, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "705543bb-e966-4ed4-96f1-d78b72720351": {"__data__": {"id_": "705543bb-e966-4ed4-96f1-d78b72720351", "embedding": null, "metadata": {"window": "Operating Expenses:  In the second quarter of fiscal 2021, operating expenses were $909.0 million, a 15.7 percent decrease\ncompared to the same period last fiscal year.  The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium assets recorded in the prior year quarter, which was partially offset by an increase in distribution,\nselling and administrative costs in the current year quarter.  Operating expenses as a percentage of revenue in the fiscal 2021\nsecond quarter were 1.85 percent, compared to 2.27 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2021 second quarter, operating income increased to $624.3 million from $309.5 million in the\nprior year quarter.  Operating income as a percentage of revenue was 1.27 percent in the second quarter of fiscal 2021,\ncompared to 0.65 percent for the same period in the previous fiscal year due to the increase in gross profit and decrease in\noperating expenses.\n Interest Expense, Net:  In the fiscal 2021 second quarter, net interest expense of $34.5 million was up 0.3 percent versus the\nprior year quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates, which\nwas largely offset by lower interest expense.\n Effective Tax Rate:  The effective tax rate was 23.4 percent for the second quarter of fiscal 2021 compared to (251.6) percent in\nthe prior year quarter which was favorably impacted by tax benefits related to the Company's decision to permanently exit\nthe PharMEDium compounding business in January 2020.\n", "original_text": "Operating Income:  In the fiscal 2021 second quarter, operating income increased to $624.3 million from $309.5 million in the\nprior year quarter. ", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff718a65d5d30c5809176e9541c648df53eaed775fecbfbf7469858524e7b88d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7f1cae9-4b4e-4837-92dd-c59437d173eb", "node_type": "1", "metadata": {"window": "Gross profit as a percentage of revenue was 3.12%, an increase of 19 basis points from\nthe prior year quarter primarily driven by an increase in sales of specialty products in Pharmaceutical Distribution Services and\ngrowth in some of the Company's higher margin businesses.\n Operating Expenses:  In the second quarter of fiscal 2021, operating expenses were $909.0 million, a 15.7 percent decrease\ncompared to the same period last fiscal year.  The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium assets recorded in the prior year quarter, which was partially offset by an increase in distribution,\nselling and administrative costs in the current year quarter.  Operating expenses as a percentage of revenue in the fiscal 2021\nsecond quarter were 1.85 percent, compared to 2.27 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2021 second quarter, operating income increased to $624.3 million from $309.5 million in the\nprior year quarter.  Operating income as a percentage of revenue was 1.27 percent in the second quarter of fiscal 2021,\ncompared to 0.65 percent for the same period in the previous fiscal year due to the increase in gross profit and decrease in\noperating expenses.\n Interest Expense, Net:  In the fiscal 2021 second quarter, net interest expense of $34.5 million was up 0.3 percent versus the\nprior year quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates, which\nwas largely offset by lower interest expense.\n", "original_text": "Operating expenses as a percentage of revenue in the fiscal 2021\nsecond quarter were 1.85 percent, compared to 2.27 percent for the same period in the previous fiscal year.\n", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0902fb9a37f0d84b789a24e7fa47b53dbd9fc7d49363747e591a90da1d99edb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "236f7dfd-aeb4-4828-aeb9-ed8a447fc688", "node_type": "1", "metadata": {"window": "The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium assets recorded in the prior year quarter, which was partially offset by an increase in distribution,\nselling and administrative costs in the current year quarter.  Operating expenses as a percentage of revenue in the fiscal 2021\nsecond quarter were 1.85 percent, compared to 2.27 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2021 second quarter, operating income increased to $624.3 million from $309.5 million in the\nprior year quarter.  Operating income as a percentage of revenue was 1.27 percent in the second quarter of fiscal 2021,\ncompared to 0.65 percent for the same period in the previous fiscal year due to the increase in gross profit and decrease in\noperating expenses.\n Interest Expense, Net:  In the fiscal 2021 second quarter, net interest expense of $34.5 million was up 0.3 percent versus the\nprior year quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates, which\nwas largely offset by lower interest expense.\n Effective Tax Rate:  The effective tax rate was 23.4 percent for the second quarter of fiscal 2021 compared to (251.6) percent in\nthe prior year quarter which was favorably impacted by tax benefits related to the Company's decision to permanently exit\nthe PharMEDium compounding business in January 2020.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.10 in the second quarter of fiscal 2021 compared to $4.64 in\nthe previous fiscal year\u2019s second quarter. ", "original_text": "Operating income as a percentage of revenue was 1.27 percent in the second quarter of fiscal 2021,\ncompared to 0.65 percent for the same period in the previous fiscal year due to the increase in gross profit and decrease in\noperating expenses.\n"}, "hash": "de69ef009e213edbf062fb06a381b0a3e5c2ef65d1eed6f77cf25c2a9420c6fa", "class_name": "RelatedNodeInfo"}}, "text": "Operating Income:  In the fiscal 2021 second quarter, operating income increased to $624.3 million from $309.5 million in the\nprior year quarter. ", "start_char_idx": 2087, "end_char_idx": 2233, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "236f7dfd-aeb4-4828-aeb9-ed8a447fc688": {"__data__": {"id_": "236f7dfd-aeb4-4828-aeb9-ed8a447fc688", "embedding": null, "metadata": {"window": "The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium assets recorded in the prior year quarter, which was partially offset by an increase in distribution,\nselling and administrative costs in the current year quarter.  Operating expenses as a percentage of revenue in the fiscal 2021\nsecond quarter were 1.85 percent, compared to 2.27 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2021 second quarter, operating income increased to $624.3 million from $309.5 million in the\nprior year quarter.  Operating income as a percentage of revenue was 1.27 percent in the second quarter of fiscal 2021,\ncompared to 0.65 percent for the same period in the previous fiscal year due to the increase in gross profit and decrease in\noperating expenses.\n Interest Expense, Net:  In the fiscal 2021 second quarter, net interest expense of $34.5 million was up 0.3 percent versus the\nprior year quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates, which\nwas largely offset by lower interest expense.\n Effective Tax Rate:  The effective tax rate was 23.4 percent for the second quarter of fiscal 2021 compared to (251.6) percent in\nthe prior year quarter which was favorably impacted by tax benefits related to the Company's decision to permanently exit\nthe PharMEDium compounding business in January 2020.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.10 in the second quarter of fiscal 2021 compared to $4.64 in\nthe previous fiscal year\u2019s second quarter. ", "original_text": "Operating income as a percentage of revenue was 1.27 percent in the second quarter of fiscal 2021,\ncompared to 0.65 percent for the same period in the previous fiscal year due to the increase in gross profit and decrease in\noperating expenses.\n", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff718a65d5d30c5809176e9541c648df53eaed775fecbfbf7469858524e7b88d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "705543bb-e966-4ed4-96f1-d78b72720351", "node_type": "1", "metadata": {"window": "Operating Expenses:  In the second quarter of fiscal 2021, operating expenses were $909.0 million, a 15.7 percent decrease\ncompared to the same period last fiscal year.  The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium assets recorded in the prior year quarter, which was partially offset by an increase in distribution,\nselling and administrative costs in the current year quarter.  Operating expenses as a percentage of revenue in the fiscal 2021\nsecond quarter were 1.85 percent, compared to 2.27 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2021 second quarter, operating income increased to $624.3 million from $309.5 million in the\nprior year quarter.  Operating income as a percentage of revenue was 1.27 percent in the second quarter of fiscal 2021,\ncompared to 0.65 percent for the same period in the previous fiscal year due to the increase in gross profit and decrease in\noperating expenses.\n Interest Expense, Net:  In the fiscal 2021 second quarter, net interest expense of $34.5 million was up 0.3 percent versus the\nprior year quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates, which\nwas largely offset by lower interest expense.\n Effective Tax Rate:  The effective tax rate was 23.4 percent for the second quarter of fiscal 2021 compared to (251.6) percent in\nthe prior year quarter which was favorably impacted by tax benefits related to the Company's decision to permanently exit\nthe PharMEDium compounding business in January 2020.\n", "original_text": "Operating Income:  In the fiscal 2021 second quarter, operating income increased to $624.3 million from $309.5 million in the\nprior year quarter. ", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e3408b3f05da3f08d4e2e092d10e78831ab49d9fe4858109c4e3398b29a5a1bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2560f576-0c69-4ec5-9620-bbf5e392e5f8", "node_type": "1", "metadata": {"window": "Operating expenses as a percentage of revenue in the fiscal 2021\nsecond quarter were 1.85 percent, compared to 2.27 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2021 second quarter, operating income increased to $624.3 million from $309.5 million in the\nprior year quarter.  Operating income as a percentage of revenue was 1.27 percent in the second quarter of fiscal 2021,\ncompared to 0.65 percent for the same period in the previous fiscal year due to the increase in gross profit and decrease in\noperating expenses.\n Interest Expense, Net:  In the fiscal 2021 second quarter, net interest expense of $34.5 million was up 0.3 percent versus the\nprior year quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates, which\nwas largely offset by lower interest expense.\n Effective Tax Rate:  The effective tax rate was 23.4 percent for the second quarter of fiscal 2021 compared to (251.6) percent in\nthe prior year quarter which was favorably impacted by tax benefits related to the Company's decision to permanently exit\nthe PharMEDium compounding business in January 2020.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.10 in the second quarter of fiscal 2021 compared to $4.64 in\nthe previous fiscal year\u2019s second quarter.  The decrease was primarily due to discrete tax benefits recognized in the prior year\nperiod.\n", "original_text": "Interest Expense, Net:  In the fiscal 2021 second quarter, net interest expense of $34.5 million was up 0.3 percent versus the\nprior year quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates, which\nwas largely offset by lower interest expense.\n"}, "hash": "7e7d5b3d3eb97ce7f12662b81c6d2125cf70765cf8c903283049a22797f4f673", "class_name": "RelatedNodeInfo"}}, "text": "Operating income as a percentage of revenue was 1.27 percent in the second quarter of fiscal 2021,\ncompared to 0.65 percent for the same period in the previous fiscal year due to the increase in gross profit and decrease in\noperating expenses.\n", "start_char_idx": 2233, "end_char_idx": 2477, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2560f576-0c69-4ec5-9620-bbf5e392e5f8": {"__data__": {"id_": "2560f576-0c69-4ec5-9620-bbf5e392e5f8", "embedding": null, "metadata": {"window": "Operating expenses as a percentage of revenue in the fiscal 2021\nsecond quarter were 1.85 percent, compared to 2.27 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2021 second quarter, operating income increased to $624.3 million from $309.5 million in the\nprior year quarter.  Operating income as a percentage of revenue was 1.27 percent in the second quarter of fiscal 2021,\ncompared to 0.65 percent for the same period in the previous fiscal year due to the increase in gross profit and decrease in\noperating expenses.\n Interest Expense, Net:  In the fiscal 2021 second quarter, net interest expense of $34.5 million was up 0.3 percent versus the\nprior year quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates, which\nwas largely offset by lower interest expense.\n Effective Tax Rate:  The effective tax rate was 23.4 percent for the second quarter of fiscal 2021 compared to (251.6) percent in\nthe prior year quarter which was favorably impacted by tax benefits related to the Company's decision to permanently exit\nthe PharMEDium compounding business in January 2020.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.10 in the second quarter of fiscal 2021 compared to $4.64 in\nthe previous fiscal year\u2019s second quarter.  The decrease was primarily due to discrete tax benefits recognized in the prior year\nperiod.\n", "original_text": "Interest Expense, Net:  In the fiscal 2021 second quarter, net interest expense of $34.5 million was up 0.3 percent versus the\nprior year quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates, which\nwas largely offset by lower interest expense.\n", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff718a65d5d30c5809176e9541c648df53eaed775fecbfbf7469858524e7b88d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "236f7dfd-aeb4-4828-aeb9-ed8a447fc688", "node_type": "1", "metadata": {"window": "The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium assets recorded in the prior year quarter, which was partially offset by an increase in distribution,\nselling and administrative costs in the current year quarter.  Operating expenses as a percentage of revenue in the fiscal 2021\nsecond quarter were 1.85 percent, compared to 2.27 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2021 second quarter, operating income increased to $624.3 million from $309.5 million in the\nprior year quarter.  Operating income as a percentage of revenue was 1.27 percent in the second quarter of fiscal 2021,\ncompared to 0.65 percent for the same period in the previous fiscal year due to the increase in gross profit and decrease in\noperating expenses.\n Interest Expense, Net:  In the fiscal 2021 second quarter, net interest expense of $34.5 million was up 0.3 percent versus the\nprior year quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates, which\nwas largely offset by lower interest expense.\n Effective Tax Rate:  The effective tax rate was 23.4 percent for the second quarter of fiscal 2021 compared to (251.6) percent in\nthe prior year quarter which was favorably impacted by tax benefits related to the Company's decision to permanently exit\nthe PharMEDium compounding business in January 2020.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.10 in the second quarter of fiscal 2021 compared to $4.64 in\nthe previous fiscal year\u2019s second quarter. ", "original_text": "Operating income as a percentage of revenue was 1.27 percent in the second quarter of fiscal 2021,\ncompared to 0.65 percent for the same period in the previous fiscal year due to the increase in gross profit and decrease in\noperating expenses.\n", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32f3a91cbb6d4fc8ad70ad5d4e470cbd9c0c263aedb76a2fa228745e2df60074", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3637fd8f-bab8-4b7f-87ce-1c278da938bf", "node_type": "1", "metadata": {"window": "Operating Income:  In the fiscal 2021 second quarter, operating income increased to $624.3 million from $309.5 million in the\nprior year quarter.  Operating income as a percentage of revenue was 1.27 percent in the second quarter of fiscal 2021,\ncompared to 0.65 percent for the same period in the previous fiscal year due to the increase in gross profit and decrease in\noperating expenses.\n Interest Expense, Net:  In the fiscal 2021 second quarter, net interest expense of $34.5 million was up 0.3 percent versus the\nprior year quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates, which\nwas largely offset by lower interest expense.\n Effective Tax Rate:  The effective tax rate was 23.4 percent for the second quarter of fiscal 2021 compared to (251.6) percent in\nthe prior year quarter which was favorably impacted by tax benefits related to the Company's decision to permanently exit\nthe PharMEDium compounding business in January 2020.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.10 in the second quarter of fiscal 2021 compared to $4.64 in\nthe previous fiscal year\u2019s second quarter.  The decrease was primarily due to discrete tax benefits recognized in the prior year\nperiod.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2021 were 207.3\nmillion, a 0.1 percent increase versus the prior fiscal year second quarter.\n", "original_text": "Effective Tax Rate:  The effective tax rate was 23.4 percent for the second quarter of fiscal 2021 compared to (251.6) percent in\nthe prior year quarter which was favorably impacted by tax benefits related to the Company's decision to permanently exit\nthe PharMEDium compounding business in January 2020.\n"}, "hash": "df065100365050db52901ee01994a2fb55998a15d1ac10cac21b76c801c701ce", "class_name": "RelatedNodeInfo"}}, "text": "Interest Expense, Net:  In the fiscal 2021 second quarter, net interest expense of $34.5 million was up 0.3 percent versus the\nprior year quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates, which\nwas largely offset by lower interest expense.\n", "start_char_idx": 2477, "end_char_idx": 2777, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3637fd8f-bab8-4b7f-87ce-1c278da938bf": {"__data__": {"id_": "3637fd8f-bab8-4b7f-87ce-1c278da938bf", "embedding": null, "metadata": {"window": "Operating Income:  In the fiscal 2021 second quarter, operating income increased to $624.3 million from $309.5 million in the\nprior year quarter.  Operating income as a percentage of revenue was 1.27 percent in the second quarter of fiscal 2021,\ncompared to 0.65 percent for the same period in the previous fiscal year due to the increase in gross profit and decrease in\noperating expenses.\n Interest Expense, Net:  In the fiscal 2021 second quarter, net interest expense of $34.5 million was up 0.3 percent versus the\nprior year quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates, which\nwas largely offset by lower interest expense.\n Effective Tax Rate:  The effective tax rate was 23.4 percent for the second quarter of fiscal 2021 compared to (251.6) percent in\nthe prior year quarter which was favorably impacted by tax benefits related to the Company's decision to permanently exit\nthe PharMEDium compounding business in January 2020.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.10 in the second quarter of fiscal 2021 compared to $4.64 in\nthe previous fiscal year\u2019s second quarter.  The decrease was primarily due to discrete tax benefits recognized in the prior year\nperiod.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2021 were 207.3\nmillion, a 0.1 percent increase versus the prior fiscal year second quarter.\n", "original_text": "Effective Tax Rate:  The effective tax rate was 23.4 percent for the second quarter of fiscal 2021 compared to (251.6) percent in\nthe prior year quarter which was favorably impacted by tax benefits related to the Company's decision to permanently exit\nthe PharMEDium compounding business in January 2020.\n", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff718a65d5d30c5809176e9541c648df53eaed775fecbfbf7469858524e7b88d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2560f576-0c69-4ec5-9620-bbf5e392e5f8", "node_type": "1", "metadata": {"window": "Operating expenses as a percentage of revenue in the fiscal 2021\nsecond quarter were 1.85 percent, compared to 2.27 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2021 second quarter, operating income increased to $624.3 million from $309.5 million in the\nprior year quarter.  Operating income as a percentage of revenue was 1.27 percent in the second quarter of fiscal 2021,\ncompared to 0.65 percent for the same period in the previous fiscal year due to the increase in gross profit and decrease in\noperating expenses.\n Interest Expense, Net:  In the fiscal 2021 second quarter, net interest expense of $34.5 million was up 0.3 percent versus the\nprior year quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates, which\nwas largely offset by lower interest expense.\n Effective Tax Rate:  The effective tax rate was 23.4 percent for the second quarter of fiscal 2021 compared to (251.6) percent in\nthe prior year quarter which was favorably impacted by tax benefits related to the Company's decision to permanently exit\nthe PharMEDium compounding business in January 2020.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.10 in the second quarter of fiscal 2021 compared to $4.64 in\nthe previous fiscal year\u2019s second quarter.  The decrease was primarily due to discrete tax benefits recognized in the prior year\nperiod.\n", "original_text": "Interest Expense, Net:  In the fiscal 2021 second quarter, net interest expense of $34.5 million was up 0.3 percent versus the\nprior year quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates, which\nwas largely offset by lower interest expense.\n", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "46ab8c764345a8a71ee7a0a3b7b2b1ec4e281855354cbbd8c6d7ade4ad3099e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "abbb2155-1714-439e-9387-2802d9f30b96", "node_type": "1", "metadata": {"window": "Operating income as a percentage of revenue was 1.27 percent in the second quarter of fiscal 2021,\ncompared to 0.65 percent for the same period in the previous fiscal year due to the increase in gross profit and decrease in\noperating expenses.\n Interest Expense, Net:  In the fiscal 2021 second quarter, net interest expense of $34.5 million was up 0.3 percent versus the\nprior year quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates, which\nwas largely offset by lower interest expense.\n Effective Tax Rate:  The effective tax rate was 23.4 percent for the second quarter of fiscal 2021 compared to (251.6) percent in\nthe prior year quarter which was favorably impacted by tax benefits related to the Company's decision to permanently exit\nthe PharMEDium compounding business in January 2020.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.10 in the second quarter of fiscal 2021 compared to $4.64 in\nthe previous fiscal year\u2019s second quarter.  The decrease was primarily due to discrete tax benefits recognized in the prior year\nperiod.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2021 were 207.3\nmillion, a 0.1 percent increase versus the prior fiscal year second quarter.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $2.10 in the second quarter of fiscal 2021 compared to $4.64 in\nthe previous fiscal year\u2019s second quarter. "}, "hash": "34fe09758c48574667d4870a82bc762b4966436671bd2dca37f96bf4cecfcf42", "class_name": "RelatedNodeInfo"}}, "text": "Effective Tax Rate:  The effective tax rate was 23.4 percent for the second quarter of fiscal 2021 compared to (251.6) percent in\nthe prior year quarter which was favorably impacted by tax benefits related to the Company's decision to permanently exit\nthe PharMEDium compounding business in January 2020.\n", "start_char_idx": 2777, "end_char_idx": 3082, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "abbb2155-1714-439e-9387-2802d9f30b96": {"__data__": {"id_": "abbb2155-1714-439e-9387-2802d9f30b96", "embedding": null, "metadata": {"window": "Operating income as a percentage of revenue was 1.27 percent in the second quarter of fiscal 2021,\ncompared to 0.65 percent for the same period in the previous fiscal year due to the increase in gross profit and decrease in\noperating expenses.\n Interest Expense, Net:  In the fiscal 2021 second quarter, net interest expense of $34.5 million was up 0.3 percent versus the\nprior year quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates, which\nwas largely offset by lower interest expense.\n Effective Tax Rate:  The effective tax rate was 23.4 percent for the second quarter of fiscal 2021 compared to (251.6) percent in\nthe prior year quarter which was favorably impacted by tax benefits related to the Company's decision to permanently exit\nthe PharMEDium compounding business in January 2020.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.10 in the second quarter of fiscal 2021 compared to $4.64 in\nthe previous fiscal year\u2019s second quarter.  The decrease was primarily due to discrete tax benefits recognized in the prior year\nperiod.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2021 were 207.3\nmillion, a 0.1 percent increase versus the prior fiscal year second quarter.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $2.10 in the second quarter of fiscal 2021 compared to $4.64 in\nthe previous fiscal year\u2019s second quarter. ", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff718a65d5d30c5809176e9541c648df53eaed775fecbfbf7469858524e7b88d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3637fd8f-bab8-4b7f-87ce-1c278da938bf", "node_type": "1", "metadata": {"window": "Operating Income:  In the fiscal 2021 second quarter, operating income increased to $624.3 million from $309.5 million in the\nprior year quarter.  Operating income as a percentage of revenue was 1.27 percent in the second quarter of fiscal 2021,\ncompared to 0.65 percent for the same period in the previous fiscal year due to the increase in gross profit and decrease in\noperating expenses.\n Interest Expense, Net:  In the fiscal 2021 second quarter, net interest expense of $34.5 million was up 0.3 percent versus the\nprior year quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates, which\nwas largely offset by lower interest expense.\n Effective Tax Rate:  The effective tax rate was 23.4 percent for the second quarter of fiscal 2021 compared to (251.6) percent in\nthe prior year quarter which was favorably impacted by tax benefits related to the Company's decision to permanently exit\nthe PharMEDium compounding business in January 2020.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.10 in the second quarter of fiscal 2021 compared to $4.64 in\nthe previous fiscal year\u2019s second quarter.  The decrease was primarily due to discrete tax benefits recognized in the prior year\nperiod.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2021 were 207.3\nmillion, a 0.1 percent increase versus the prior fiscal year second quarter.\n", "original_text": "Effective Tax Rate:  The effective tax rate was 23.4 percent for the second quarter of fiscal 2021 compared to (251.6) percent in\nthe prior year quarter which was favorably impacted by tax benefits related to the Company's decision to permanently exit\nthe PharMEDium compounding business in January 2020.\n", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1f257f7c70bbd49f9f51d1204dfcf3a7f01541f21804c535e54030573722d58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ddb9fc65-93d1-4efb-b0a3-0710fc0b59cc", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  In the fiscal 2021 second quarter, net interest expense of $34.5 million was up 0.3 percent versus the\nprior year quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates, which\nwas largely offset by lower interest expense.\n Effective Tax Rate:  The effective tax rate was 23.4 percent for the second quarter of fiscal 2021 compared to (251.6) percent in\nthe prior year quarter which was favorably impacted by tax benefits related to the Company's decision to permanently exit\nthe PharMEDium compounding business in January 2020.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.10 in the second quarter of fiscal 2021 compared to $4.64 in\nthe previous fiscal year\u2019s second quarter.  The decrease was primarily due to discrete tax benefits recognized in the prior year\nperiod.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2021 were 207.3\nmillion, a 0.1 percent increase versus the prior fiscal year second quarter.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2021, revenue was\n$49.2 billion, up 3.7 percent compared to the same quarter in the previous fiscal year, reflecting a 3.4 percent increase in\nPharmaceutical Distribution Services revenue and an 11.5 percent increase in revenue within Other.\n", "original_text": "The decrease was primarily due to discrete tax benefits recognized in the prior year\nperiod.\n"}, "hash": "7531615c41614aa1cf007b4b0b0a9fbcaecd298ec58fa2daf7c0bca3685cea0c", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Earnings Per Share:  Diluted earnings per share was $2.10 in the second quarter of fiscal 2021 compared to $4.64 in\nthe previous fiscal year\u2019s second quarter. ", "start_char_idx": 3082, "end_char_idx": 3249, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ddb9fc65-93d1-4efb-b0a3-0710fc0b59cc": {"__data__": {"id_": "ddb9fc65-93d1-4efb-b0a3-0710fc0b59cc", "embedding": null, "metadata": {"window": "Interest Expense, Net:  In the fiscal 2021 second quarter, net interest expense of $34.5 million was up 0.3 percent versus the\nprior year quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates, which\nwas largely offset by lower interest expense.\n Effective Tax Rate:  The effective tax rate was 23.4 percent for the second quarter of fiscal 2021 compared to (251.6) percent in\nthe prior year quarter which was favorably impacted by tax benefits related to the Company's decision to permanently exit\nthe PharMEDium compounding business in January 2020.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.10 in the second quarter of fiscal 2021 compared to $4.64 in\nthe previous fiscal year\u2019s second quarter.  The decrease was primarily due to discrete tax benefits recognized in the prior year\nperiod.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2021 were 207.3\nmillion, a 0.1 percent increase versus the prior fiscal year second quarter.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2021, revenue was\n$49.2 billion, up 3.7 percent compared to the same quarter in the previous fiscal year, reflecting a 3.4 percent increase in\nPharmaceutical Distribution Services revenue and an 11.5 percent increase in revenue within Other.\n", "original_text": "The decrease was primarily due to discrete tax benefits recognized in the prior year\nperiod.\n", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff718a65d5d30c5809176e9541c648df53eaed775fecbfbf7469858524e7b88d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "abbb2155-1714-439e-9387-2802d9f30b96", "node_type": "1", "metadata": {"window": "Operating income as a percentage of revenue was 1.27 percent in the second quarter of fiscal 2021,\ncompared to 0.65 percent for the same period in the previous fiscal year due to the increase in gross profit and decrease in\noperating expenses.\n Interest Expense, Net:  In the fiscal 2021 second quarter, net interest expense of $34.5 million was up 0.3 percent versus the\nprior year quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates, which\nwas largely offset by lower interest expense.\n Effective Tax Rate:  The effective tax rate was 23.4 percent for the second quarter of fiscal 2021 compared to (251.6) percent in\nthe prior year quarter which was favorably impacted by tax benefits related to the Company's decision to permanently exit\nthe PharMEDium compounding business in January 2020.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.10 in the second quarter of fiscal 2021 compared to $4.64 in\nthe previous fiscal year\u2019s second quarter.  The decrease was primarily due to discrete tax benefits recognized in the prior year\nperiod.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2021 were 207.3\nmillion, a 0.1 percent increase versus the prior fiscal year second quarter.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $2.10 in the second quarter of fiscal 2021 compared to $4.64 in\nthe previous fiscal year\u2019s second quarter. ", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff63aefa65bf641ab2d72f624e3e6ccca807f9d47d07d698067429169ed20666", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4554a903-2bdc-485b-bde0-b36489e8f032", "node_type": "1", "metadata": {"window": "Effective Tax Rate:  The effective tax rate was 23.4 percent for the second quarter of fiscal 2021 compared to (251.6) percent in\nthe prior year quarter which was favorably impacted by tax benefits related to the Company's decision to permanently exit\nthe PharMEDium compounding business in January 2020.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.10 in the second quarter of fiscal 2021 compared to $4.64 in\nthe previous fiscal year\u2019s second quarter.  The decrease was primarily due to discrete tax benefits recognized in the prior year\nperiod.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2021 were 207.3\nmillion, a 0.1 percent increase versus the prior fiscal year second quarter.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2021, revenue was\n$49.2 billion, up 3.7 percent compared to the same quarter in the previous fiscal year, reflecting a 3.4 percent increase in\nPharmaceutical Distribution Services revenue and an 11.5 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 second quarter was $1.5 billion, which was up 6.7 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther. ", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2021 were 207.3\nmillion, a 0.1 percent increase versus the prior fiscal year second quarter.\n"}, "hash": "530c434a80fc7ebb35e4bc4eb6f3473fa7d9393f5b03ad676cf715d67d8c8415", "class_name": "RelatedNodeInfo"}}, "text": "The decrease was primarily due to discrete tax benefits recognized in the prior year\nperiod.\n", "start_char_idx": 3249, "end_char_idx": 3342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4554a903-2bdc-485b-bde0-b36489e8f032": {"__data__": {"id_": "4554a903-2bdc-485b-bde0-b36489e8f032", "embedding": null, "metadata": {"window": "Effective Tax Rate:  The effective tax rate was 23.4 percent for the second quarter of fiscal 2021 compared to (251.6) percent in\nthe prior year quarter which was favorably impacted by tax benefits related to the Company's decision to permanently exit\nthe PharMEDium compounding business in January 2020.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.10 in the second quarter of fiscal 2021 compared to $4.64 in\nthe previous fiscal year\u2019s second quarter.  The decrease was primarily due to discrete tax benefits recognized in the prior year\nperiod.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2021 were 207.3\nmillion, a 0.1 percent increase versus the prior fiscal year second quarter.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2021, revenue was\n$49.2 billion, up 3.7 percent compared to the same quarter in the previous fiscal year, reflecting a 3.4 percent increase in\nPharmaceutical Distribution Services revenue and an 11.5 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 second quarter was $1.5 billion, which was up 6.7 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther. ", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2021 were 207.3\nmillion, a 0.1 percent increase versus the prior fiscal year second quarter.\n", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff718a65d5d30c5809176e9541c648df53eaed775fecbfbf7469858524e7b88d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ddb9fc65-93d1-4efb-b0a3-0710fc0b59cc", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  In the fiscal 2021 second quarter, net interest expense of $34.5 million was up 0.3 percent versus the\nprior year quarter due to a decrease in interest income resulting primarily from a decline in investment interest rates, which\nwas largely offset by lower interest expense.\n Effective Tax Rate:  The effective tax rate was 23.4 percent for the second quarter of fiscal 2021 compared to (251.6) percent in\nthe prior year quarter which was favorably impacted by tax benefits related to the Company's decision to permanently exit\nthe PharMEDium compounding business in January 2020.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.10 in the second quarter of fiscal 2021 compared to $4.64 in\nthe previous fiscal year\u2019s second quarter.  The decrease was primarily due to discrete tax benefits recognized in the prior year\nperiod.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2021 were 207.3\nmillion, a 0.1 percent increase versus the prior fiscal year second quarter.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2021, revenue was\n$49.2 billion, up 3.7 percent compared to the same quarter in the previous fiscal year, reflecting a 3.4 percent increase in\nPharmaceutical Distribution Services revenue and an 11.5 percent increase in revenue within Other.\n", "original_text": "The decrease was primarily due to discrete tax benefits recognized in the prior year\nperiod.\n", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd21f2ebb3d3df07efb632cf7b11d3deac24c615dbfd61c86a1a9f3958cf1119", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7f3e227-30f6-4d09-8469-4c97553e1c7a", "node_type": "1", "metadata": {"window": "Diluted Earnings Per Share:  Diluted earnings per share was $2.10 in the second quarter of fiscal 2021 compared to $4.64 in\nthe previous fiscal year\u2019s second quarter.  The decrease was primarily due to discrete tax benefits recognized in the prior year\nperiod.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2021 were 207.3\nmillion, a 0.1 percent increase versus the prior fiscal year second quarter.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2021, revenue was\n$49.2 billion, up 3.7 percent compared to the same quarter in the previous fiscal year, reflecting a 3.4 percent increase in\nPharmaceutical Distribution Services revenue and an 11.5 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 second quarter was $1.5 billion, which was up 6.7 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther.  Adjusted gross profit as a percentage of revenue was 3.08 percent in the fiscal 2021 second quarter, an increase of 9\nbasis points when compared to the prior year quarter primarily driven by an increase in sales of specialty products in\nPharmaceutical Distribution Services and growth in some of the Company's higher margin businesses.\n", "original_text": "Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. "}, "hash": "ab1e88a0f71b719c2747719742de64cb5645ac7cb5c8a2feb5b19069d615d407", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2021 were 207.3\nmillion, a 0.1 percent increase versus the prior fiscal year second quarter.\n", "start_char_idx": 3342, "end_char_idx": 3541, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7f3e227-30f6-4d09-8469-4c97553e1c7a": {"__data__": {"id_": "f7f3e227-30f6-4d09-8469-4c97553e1c7a", "embedding": null, "metadata": {"window": "Diluted Earnings Per Share:  Diluted earnings per share was $2.10 in the second quarter of fiscal 2021 compared to $4.64 in\nthe previous fiscal year\u2019s second quarter.  The decrease was primarily due to discrete tax benefits recognized in the prior year\nperiod.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2021 were 207.3\nmillion, a 0.1 percent increase versus the prior fiscal year second quarter.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2021, revenue was\n$49.2 billion, up 3.7 percent compared to the same quarter in the previous fiscal year, reflecting a 3.4 percent increase in\nPharmaceutical Distribution Services revenue and an 11.5 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 second quarter was $1.5 billion, which was up 6.7 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther.  Adjusted gross profit as a percentage of revenue was 3.08 percent in the fiscal 2021 second quarter, an increase of 9\nbasis points when compared to the prior year quarter primarily driven by an increase in sales of specialty products in\nPharmaceutical Distribution Services and growth in some of the Company's higher margin businesses.\n", "original_text": "Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff718a65d5d30c5809176e9541c648df53eaed775fecbfbf7469858524e7b88d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4554a903-2bdc-485b-bde0-b36489e8f032", "node_type": "1", "metadata": {"window": "Effective Tax Rate:  The effective tax rate was 23.4 percent for the second quarter of fiscal 2021 compared to (251.6) percent in\nthe prior year quarter which was favorably impacted by tax benefits related to the Company's decision to permanently exit\nthe PharMEDium compounding business in January 2020.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.10 in the second quarter of fiscal 2021 compared to $4.64 in\nthe previous fiscal year\u2019s second quarter.  The decrease was primarily due to discrete tax benefits recognized in the prior year\nperiod.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2021 were 207.3\nmillion, a 0.1 percent increase versus the prior fiscal year second quarter.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2021, revenue was\n$49.2 billion, up 3.7 percent compared to the same quarter in the previous fiscal year, reflecting a 3.4 percent increase in\nPharmaceutical Distribution Services revenue and an 11.5 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 second quarter was $1.5 billion, which was up 6.7 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther. ", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2021 were 207.3\nmillion, a 0.1 percent increase versus the prior fiscal year second quarter.\n", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28767a61f605a972442c50a06a39f3f85a576181e2bfdf03dfee6f32cc038fd6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13086de3-a80b-4f83-bd0c-dd05b695d7ac", "node_type": "1", "metadata": {"window": "The decrease was primarily due to discrete tax benefits recognized in the prior year\nperiod.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2021 were 207.3\nmillion, a 0.1 percent increase versus the prior fiscal year second quarter.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2021, revenue was\n$49.2 billion, up 3.7 percent compared to the same quarter in the previous fiscal year, reflecting a 3.4 percent increase in\nPharmaceutical Distribution Services revenue and an 11.5 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 second quarter was $1.5 billion, which was up 6.7 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther.  Adjusted gross profit as a percentage of revenue was 3.08 percent in the fiscal 2021 second quarter, an increase of 9\nbasis points when compared to the prior year quarter primarily driven by an increase in sales of specialty products in\nPharmaceutical Distribution Services and growth in some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2021, adjusted operating expenses were $805.9 million, an\nincrease of 8.1 percent compared to the same period in the previous fiscal year due to higher distribution, selling, and\nadministrative expenses primarily due to an increase in payroll-related operating costs to support the Company's current and\n2", "original_text": "In the second quarter of fiscal 2021, revenue was\n$49.2 billion, up 3.7 percent compared to the same quarter in the previous fiscal year, reflecting a 3.4 percent increase in\nPharmaceutical Distribution Services revenue and an 11.5 percent increase in revenue within Other.\n"}, "hash": "9dd5140d67299ebd0459dde42c6b464d79b50d35632ebaf301ffd6766925baed", "class_name": "RelatedNodeInfo"}}, "text": "Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "start_char_idx": 3541, "end_char_idx": 3659, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13086de3-a80b-4f83-bd0c-dd05b695d7ac": {"__data__": {"id_": "13086de3-a80b-4f83-bd0c-dd05b695d7ac", "embedding": null, "metadata": {"window": "The decrease was primarily due to discrete tax benefits recognized in the prior year\nperiod.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2021 were 207.3\nmillion, a 0.1 percent increase versus the prior fiscal year second quarter.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2021, revenue was\n$49.2 billion, up 3.7 percent compared to the same quarter in the previous fiscal year, reflecting a 3.4 percent increase in\nPharmaceutical Distribution Services revenue and an 11.5 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 second quarter was $1.5 billion, which was up 6.7 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther.  Adjusted gross profit as a percentage of revenue was 3.08 percent in the fiscal 2021 second quarter, an increase of 9\nbasis points when compared to the prior year quarter primarily driven by an increase in sales of specialty products in\nPharmaceutical Distribution Services and growth in some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2021, adjusted operating expenses were $805.9 million, an\nincrease of 8.1 percent compared to the same period in the previous fiscal year due to higher distribution, selling, and\nadministrative expenses primarily due to an increase in payroll-related operating costs to support the Company's current and\n2", "original_text": "In the second quarter of fiscal 2021, revenue was\n$49.2 billion, up 3.7 percent compared to the same quarter in the previous fiscal year, reflecting a 3.4 percent increase in\nPharmaceutical Distribution Services revenue and an 11.5 percent increase in revenue within Other.\n", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff718a65d5d30c5809176e9541c648df53eaed775fecbfbf7469858524e7b88d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7f3e227-30f6-4d09-8469-4c97553e1c7a", "node_type": "1", "metadata": {"window": "Diluted Earnings Per Share:  Diluted earnings per share was $2.10 in the second quarter of fiscal 2021 compared to $4.64 in\nthe previous fiscal year\u2019s second quarter.  The decrease was primarily due to discrete tax benefits recognized in the prior year\nperiod.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2021 were 207.3\nmillion, a 0.1 percent increase versus the prior fiscal year second quarter.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2021, revenue was\n$49.2 billion, up 3.7 percent compared to the same quarter in the previous fiscal year, reflecting a 3.4 percent increase in\nPharmaceutical Distribution Services revenue and an 11.5 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 second quarter was $1.5 billion, which was up 6.7 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther.  Adjusted gross profit as a percentage of revenue was 3.08 percent in the fiscal 2021 second quarter, an increase of 9\nbasis points when compared to the prior year quarter primarily driven by an increase in sales of specialty products in\nPharmaceutical Distribution Services and growth in some of the Company's higher margin businesses.\n", "original_text": "Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "97ff1c494c66aa8c28f2bf5a69b0f838f8dfb6e52ba6f5ff4d5704d0720c39bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33fb28e9-bca7-4ea2-bbca-25ca1dcd67f8", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2021 were 207.3\nmillion, a 0.1 percent increase versus the prior fiscal year second quarter.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2021, revenue was\n$49.2 billion, up 3.7 percent compared to the same quarter in the previous fiscal year, reflecting a 3.4 percent increase in\nPharmaceutical Distribution Services revenue and an 11.5 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 second quarter was $1.5 billion, which was up 6.7 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther.  Adjusted gross profit as a percentage of revenue was 3.08 percent in the fiscal 2021 second quarter, an increase of 9\nbasis points when compared to the prior year quarter primarily driven by an increase in sales of specialty products in\nPharmaceutical Distribution Services and growth in some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2021, adjusted operating expenses were $805.9 million, an\nincrease of 8.1 percent compared to the same period in the previous fiscal year due to higher distribution, selling, and\nadministrative expenses primarily due to an increase in payroll-related operating costs to support the Company's current and\n2", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 second quarter was $1.5 billion, which was up 6.7 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther. "}, "hash": "9e2c54d41718b02ff36af14dff78c6d411d43226e3297faf5ae87b219a2b81bb", "class_name": "RelatedNodeInfo"}}, "text": "In the second quarter of fiscal 2021, revenue was\n$49.2 billion, up 3.7 percent compared to the same quarter in the previous fiscal year, reflecting a 3.4 percent increase in\nPharmaceutical Distribution Services revenue and an 11.5 percent increase in revenue within Other.\n", "start_char_idx": 3659, "end_char_idx": 3933, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33fb28e9-bca7-4ea2-bbca-25ca1dcd67f8": {"__data__": {"id_": "33fb28e9-bca7-4ea2-bbca-25ca1dcd67f8", "embedding": null, "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2021 were 207.3\nmillion, a 0.1 percent increase versus the prior fiscal year second quarter.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2021, revenue was\n$49.2 billion, up 3.7 percent compared to the same quarter in the previous fiscal year, reflecting a 3.4 percent increase in\nPharmaceutical Distribution Services revenue and an 11.5 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 second quarter was $1.5 billion, which was up 6.7 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther.  Adjusted gross profit as a percentage of revenue was 3.08 percent in the fiscal 2021 second quarter, an increase of 9\nbasis points when compared to the prior year quarter primarily driven by an increase in sales of specialty products in\nPharmaceutical Distribution Services and growth in some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2021, adjusted operating expenses were $805.9 million, an\nincrease of 8.1 percent compared to the same period in the previous fiscal year due to higher distribution, selling, and\nadministrative expenses primarily due to an increase in payroll-related operating costs to support the Company's current and\n2", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 second quarter was $1.5 billion, which was up 6.7 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther. ", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff718a65d5d30c5809176e9541c648df53eaed775fecbfbf7469858524e7b88d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13086de3-a80b-4f83-bd0c-dd05b695d7ac", "node_type": "1", "metadata": {"window": "The decrease was primarily due to discrete tax benefits recognized in the prior year\nperiod.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2021 were 207.3\nmillion, a 0.1 percent increase versus the prior fiscal year second quarter.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2021, revenue was\n$49.2 billion, up 3.7 percent compared to the same quarter in the previous fiscal year, reflecting a 3.4 percent increase in\nPharmaceutical Distribution Services revenue and an 11.5 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 second quarter was $1.5 billion, which was up 6.7 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther.  Adjusted gross profit as a percentage of revenue was 3.08 percent in the fiscal 2021 second quarter, an increase of 9\nbasis points when compared to the prior year quarter primarily driven by an increase in sales of specialty products in\nPharmaceutical Distribution Services and growth in some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2021, adjusted operating expenses were $805.9 million, an\nincrease of 8.1 percent compared to the same period in the previous fiscal year due to higher distribution, selling, and\nadministrative expenses primarily due to an increase in payroll-related operating costs to support the Company's current and\n2", "original_text": "In the second quarter of fiscal 2021, revenue was\n$49.2 billion, up 3.7 percent compared to the same quarter in the previous fiscal year, reflecting a 3.4 percent increase in\nPharmaceutical Distribution Services revenue and an 11.5 percent increase in revenue within Other.\n", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3e4fb476f5af50e7154cdfdb1f8672814db4b4666c2436f8e1388ada4f481d0e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a943171c-022e-4a8c-8ef8-28339374733a", "node_type": "1", "metadata": {"window": "Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2021, revenue was\n$49.2 billion, up 3.7 percent compared to the same quarter in the previous fiscal year, reflecting a 3.4 percent increase in\nPharmaceutical Distribution Services revenue and an 11.5 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 second quarter was $1.5 billion, which was up 6.7 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther.  Adjusted gross profit as a percentage of revenue was 3.08 percent in the fiscal 2021 second quarter, an increase of 9\nbasis points when compared to the prior year quarter primarily driven by an increase in sales of specialty products in\nPharmaceutical Distribution Services and growth in some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2021, adjusted operating expenses were $805.9 million, an\nincrease of 8.1 percent compared to the same period in the previous fiscal year due to higher distribution, selling, and\nadministrative expenses primarily due to an increase in payroll-related operating costs to support the Company's current and\n2", "original_text": "Adjusted gross profit as a percentage of revenue was 3.08 percent in the fiscal 2021 second quarter, an increase of 9\nbasis points when compared to the prior year quarter primarily driven by an increase in sales of specialty products in\nPharmaceutical Distribution Services and growth in some of the Company's higher margin businesses.\n"}, "hash": "0d66f3c8bde80032ec9310ddcbf9e91119528fc60dcaf545c6908c2e0f16253d", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 second quarter was $1.5 billion, which was up 6.7 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther. ", "start_char_idx": 3933, "end_char_idx": 4189, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a943171c-022e-4a8c-8ef8-28339374733a": {"__data__": {"id_": "a943171c-022e-4a8c-8ef8-28339374733a", "embedding": null, "metadata": {"window": "Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2021, revenue was\n$49.2 billion, up 3.7 percent compared to the same quarter in the previous fiscal year, reflecting a 3.4 percent increase in\nPharmaceutical Distribution Services revenue and an 11.5 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 second quarter was $1.5 billion, which was up 6.7 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther.  Adjusted gross profit as a percentage of revenue was 3.08 percent in the fiscal 2021 second quarter, an increase of 9\nbasis points when compared to the prior year quarter primarily driven by an increase in sales of specialty products in\nPharmaceutical Distribution Services and growth in some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2021, adjusted operating expenses were $805.9 million, an\nincrease of 8.1 percent compared to the same period in the previous fiscal year due to higher distribution, selling, and\nadministrative expenses primarily due to an increase in payroll-related operating costs to support the Company's current and\n2", "original_text": "Adjusted gross profit as a percentage of revenue was 3.08 percent in the fiscal 2021 second quarter, an increase of 9\nbasis points when compared to the prior year quarter primarily driven by an increase in sales of specialty products in\nPharmaceutical Distribution Services and growth in some of the Company's higher margin businesses.\n", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff718a65d5d30c5809176e9541c648df53eaed775fecbfbf7469858524e7b88d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33fb28e9-bca7-4ea2-bbca-25ca1dcd67f8", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2021 were 207.3\nmillion, a 0.1 percent increase versus the prior fiscal year second quarter.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2021, revenue was\n$49.2 billion, up 3.7 percent compared to the same quarter in the previous fiscal year, reflecting a 3.4 percent increase in\nPharmaceutical Distribution Services revenue and an 11.5 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 second quarter was $1.5 billion, which was up 6.7 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther.  Adjusted gross profit as a percentage of revenue was 3.08 percent in the fiscal 2021 second quarter, an increase of 9\nbasis points when compared to the prior year quarter primarily driven by an increase in sales of specialty products in\nPharmaceutical Distribution Services and growth in some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2021, adjusted operating expenses were $805.9 million, an\nincrease of 8.1 percent compared to the same period in the previous fiscal year due to higher distribution, selling, and\nadministrative expenses primarily due to an increase in payroll-related operating costs to support the Company's current and\n2", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 second quarter was $1.5 billion, which was up 6.7 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther. ", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "036242570a7b864eaea32207e570b02baba5334670507dcf1193ac941bd1620e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6090f842-404c-4d00-ad65-243c60bfb10c", "node_type": "1", "metadata": {"window": "In the second quarter of fiscal 2021, revenue was\n$49.2 billion, up 3.7 percent compared to the same quarter in the previous fiscal year, reflecting a 3.4 percent increase in\nPharmaceutical Distribution Services revenue and an 11.5 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 second quarter was $1.5 billion, which was up 6.7 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther.  Adjusted gross profit as a percentage of revenue was 3.08 percent in the fiscal 2021 second quarter, an increase of 9\nbasis points when compared to the prior year quarter primarily driven by an increase in sales of specialty products in\nPharmaceutical Distribution Services and growth in some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2021, adjusted operating expenses were $805.9 million, an\nincrease of 8.1 percent compared to the same period in the previous fiscal year due to higher distribution, selling, and\nadministrative expenses primarily due to an increase in payroll-related operating costs to support the Company's current and\n2", "original_text": "Adjusted Operating Expenses:  In the second quarter of fiscal 2021, adjusted operating expenses were $805.9 million, an\nincrease of 8.1 percent compared to the same period in the previous fiscal year due to higher distribution, selling, and\nadministrative expenses primarily due to an increase in payroll-related operating costs to support the Company's current and\n2"}, "hash": "392bb69c08c4041714524069af37a85b4912dc275170827e27a02701a5bf836b", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit as a percentage of revenue was 3.08 percent in the fiscal 2021 second quarter, an increase of 9\nbasis points when compared to the prior year quarter primarily driven by an increase in sales of specialty products in\nPharmaceutical Distribution Services and growth in some of the Company's higher margin businesses.\n", "start_char_idx": 4189, "end_char_idx": 4525, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6090f842-404c-4d00-ad65-243c60bfb10c": {"__data__": {"id_": "6090f842-404c-4d00-ad65-243c60bfb10c", "embedding": null, "metadata": {"window": "In the second quarter of fiscal 2021, revenue was\n$49.2 billion, up 3.7 percent compared to the same quarter in the previous fiscal year, reflecting a 3.4 percent increase in\nPharmaceutical Distribution Services revenue and an 11.5 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 second quarter was $1.5 billion, which was up 6.7 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther.  Adjusted gross profit as a percentage of revenue was 3.08 percent in the fiscal 2021 second quarter, an increase of 9\nbasis points when compared to the prior year quarter primarily driven by an increase in sales of specialty products in\nPharmaceutical Distribution Services and growth in some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2021, adjusted operating expenses were $805.9 million, an\nincrease of 8.1 percent compared to the same period in the previous fiscal year due to higher distribution, selling, and\nadministrative expenses primarily due to an increase in payroll-related operating costs to support the Company's current and\n2", "original_text": "Adjusted Operating Expenses:  In the second quarter of fiscal 2021, adjusted operating expenses were $805.9 million, an\nincrease of 8.1 percent compared to the same period in the previous fiscal year due to higher distribution, selling, and\nadministrative expenses primarily due to an increase in payroll-related operating costs to support the Company's current and\n2", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff718a65d5d30c5809176e9541c648df53eaed775fecbfbf7469858524e7b88d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a943171c-022e-4a8c-8ef8-28339374733a", "node_type": "1", "metadata": {"window": "Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2021, revenue was\n$49.2 billion, up 3.7 percent compared to the same quarter in the previous fiscal year, reflecting a 3.4 percent increase in\nPharmaceutical Distribution Services revenue and an 11.5 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 second quarter was $1.5 billion, which was up 6.7 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther.  Adjusted gross profit as a percentage of revenue was 3.08 percent in the fiscal 2021 second quarter, an increase of 9\nbasis points when compared to the prior year quarter primarily driven by an increase in sales of specialty products in\nPharmaceutical Distribution Services and growth in some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2021, adjusted operating expenses were $805.9 million, an\nincrease of 8.1 percent compared to the same period in the previous fiscal year due to higher distribution, selling, and\nadministrative expenses primarily due to an increase in payroll-related operating costs to support the Company's current and\n2", "original_text": "Adjusted gross profit as a percentage of revenue was 3.08 percent in the fiscal 2021 second quarter, an increase of 9\nbasis points when compared to the prior year quarter primarily driven by an increase in sales of specialty products in\nPharmaceutical Distribution Services and growth in some of the Company's higher margin businesses.\n", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d848968d151095d4c9a661faf7c00f43df9fa16f5d5d30c600b0976769afdee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5df9172b-9ce6-4a36-9764-27e462fcf0a0", "node_type": "1", "metadata": {"window": "future revenue growth.  Adjusted operating expenses as a percentage of revenue in the fiscal 2021 second quarter was 1.64\npercent, an increase of 7 basis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2021 second quarter, adjusted operating income of $706.6 million increased 5.2\npercent from the prior year period due to a 4.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 13.8 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.44 percent in the fiscal 2021 second quarter, an increase of 2 basis points when compared to the prior year quarter.\n", "original_text": "future revenue growth. "}, "hash": "2285a21f5143cbc55c74c75dc7e25c62c85ff060845dd7eec52a23764ede7638", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Operating Expenses:  In the second quarter of fiscal 2021, adjusted operating expenses were $805.9 million, an\nincrease of 8.1 percent compared to the same period in the previous fiscal year due to higher distribution, selling, and\nadministrative expenses primarily due to an increase in payroll-related operating costs to support the Company's current and\n2", "start_char_idx": 4525, "end_char_idx": 4892, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5df9172b-9ce6-4a36-9764-27e462fcf0a0": {"__data__": {"id_": "5df9172b-9ce6-4a36-9764-27e462fcf0a0", "embedding": null, "metadata": {"window": "future revenue growth.  Adjusted operating expenses as a percentage of revenue in the fiscal 2021 second quarter was 1.64\npercent, an increase of 7 basis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2021 second quarter, adjusted operating income of $706.6 million increased 5.2\npercent from the prior year period due to a 4.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 13.8 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.44 percent in the fiscal 2021 second quarter, an increase of 2 basis points when compared to the prior year quarter.\n", "original_text": "future revenue growth. ", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "faa0ff04df9e087aae368011c0247fe317130845fdc1ac00576b0aef407d1f9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6090f842-404c-4d00-ad65-243c60bfb10c", "node_type": "1", "metadata": {"window": "In the second quarter of fiscal 2021, revenue was\n$49.2 billion, up 3.7 percent compared to the same quarter in the previous fiscal year, reflecting a 3.4 percent increase in\nPharmaceutical Distribution Services revenue and an 11.5 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 second quarter was $1.5 billion, which was up 6.7 percent\ncompared to the same period in the previous year due to increases in gross profit in Pharmaceutical Distribution Services and\nOther.  Adjusted gross profit as a percentage of revenue was 3.08 percent in the fiscal 2021 second quarter, an increase of 9\nbasis points when compared to the prior year quarter primarily driven by an increase in sales of specialty products in\nPharmaceutical Distribution Services and growth in some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2021, adjusted operating expenses were $805.9 million, an\nincrease of 8.1 percent compared to the same period in the previous fiscal year due to higher distribution, selling, and\nadministrative expenses primarily due to an increase in payroll-related operating costs to support the Company's current and\n2", "original_text": "Adjusted Operating Expenses:  In the second quarter of fiscal 2021, adjusted operating expenses were $805.9 million, an\nincrease of 8.1 percent compared to the same period in the previous fiscal year due to higher distribution, selling, and\nadministrative expenses primarily due to an increase in payroll-related operating costs to support the Company's current and\n2", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bb332c9415dc7c35652a1a453f32672b6bcbca97372b143f7fbdfd1192ea4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ce7bf8d-f0b3-4e79-8df5-c697cdad114b", "node_type": "1", "metadata": {"window": "future revenue growth.  Adjusted operating expenses as a percentage of revenue in the fiscal 2021 second quarter was 1.64\npercent, an increase of 7 basis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2021 second quarter, adjusted operating income of $706.6 million increased 5.2\npercent from the prior year period due to a 4.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 13.8 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.44 percent in the fiscal 2021 second quarter, an increase of 2 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "Adjusted operating expenses as a percentage of revenue in the fiscal 2021 second quarter was 1.64\npercent, an increase of 7 basis points when compared to the prior year quarter.\n"}, "hash": "3cffc11b434c4eefb9e1796353721768a31dac83fa887003d56cb764dbbe7deb", "class_name": "RelatedNodeInfo"}}, "text": "future revenue growth. ", "start_char_idx": 0, "end_char_idx": 23, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ce7bf8d-f0b3-4e79-8df5-c697cdad114b": {"__data__": {"id_": "7ce7bf8d-f0b3-4e79-8df5-c697cdad114b", "embedding": null, "metadata": {"window": "future revenue growth.  Adjusted operating expenses as a percentage of revenue in the fiscal 2021 second quarter was 1.64\npercent, an increase of 7 basis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2021 second quarter, adjusted operating income of $706.6 million increased 5.2\npercent from the prior year period due to a 4.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 13.8 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.44 percent in the fiscal 2021 second quarter, an increase of 2 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "Adjusted operating expenses as a percentage of revenue in the fiscal 2021 second quarter was 1.64\npercent, an increase of 7 basis points when compared to the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "faa0ff04df9e087aae368011c0247fe317130845fdc1ac00576b0aef407d1f9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5df9172b-9ce6-4a36-9764-27e462fcf0a0", "node_type": "1", "metadata": {"window": "future revenue growth.  Adjusted operating expenses as a percentage of revenue in the fiscal 2021 second quarter was 1.64\npercent, an increase of 7 basis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2021 second quarter, adjusted operating income of $706.6 million increased 5.2\npercent from the prior year period due to a 4.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 13.8 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.44 percent in the fiscal 2021 second quarter, an increase of 2 basis points when compared to the prior year quarter.\n", "original_text": "future revenue growth. ", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5cc994e6ee6374c3d950065feaef0773e846afc87a70ad46b4c0874033a45b30", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb6ae3dd-7ffb-43a6-8a0a-9464303f0588", "node_type": "1", "metadata": {"window": "future revenue growth.  Adjusted operating expenses as a percentage of revenue in the fiscal 2021 second quarter was 1.64\npercent, an increase of 7 basis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2021 second quarter, adjusted operating income of $706.6 million increased 5.2\npercent from the prior year period due to a 4.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 13.8 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.44 percent in the fiscal 2021 second quarter, an increase of 2 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 second\nquarter, net interest expense of $34.5 million was up 0.3 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates, which was largely offset by lower interest expense.\n", "original_text": "Adjusted Operating Income:  In the fiscal 2021 second quarter, adjusted operating income of $706.6 million increased 5.2\npercent from the prior year period due to a 4.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 13.8 percent increase in operating income within Other. "}, "hash": "3e9ca66c73484acf55bdf98f908e151c1fede0dc7034dfff551dc615ae895de0", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expenses as a percentage of revenue in the fiscal 2021 second quarter was 1.64\npercent, an increase of 7 basis points when compared to the prior year quarter.\n", "start_char_idx": 23, "end_char_idx": 201, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb6ae3dd-7ffb-43a6-8a0a-9464303f0588": {"__data__": {"id_": "cb6ae3dd-7ffb-43a6-8a0a-9464303f0588", "embedding": null, "metadata": {"window": "future revenue growth.  Adjusted operating expenses as a percentage of revenue in the fiscal 2021 second quarter was 1.64\npercent, an increase of 7 basis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2021 second quarter, adjusted operating income of $706.6 million increased 5.2\npercent from the prior year period due to a 4.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 13.8 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.44 percent in the fiscal 2021 second quarter, an increase of 2 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 second\nquarter, net interest expense of $34.5 million was up 0.3 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates, which was largely offset by lower interest expense.\n", "original_text": "Adjusted Operating Income:  In the fiscal 2021 second quarter, adjusted operating income of $706.6 million increased 5.2\npercent from the prior year period due to a 4.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 13.8 percent increase in operating income within Other. ", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "faa0ff04df9e087aae368011c0247fe317130845fdc1ac00576b0aef407d1f9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ce7bf8d-f0b3-4e79-8df5-c697cdad114b", "node_type": "1", "metadata": {"window": "future revenue growth.  Adjusted operating expenses as a percentage of revenue in the fiscal 2021 second quarter was 1.64\npercent, an increase of 7 basis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2021 second quarter, adjusted operating income of $706.6 million increased 5.2\npercent from the prior year period due to a 4.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 13.8 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.44 percent in the fiscal 2021 second quarter, an increase of 2 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "Adjusted operating expenses as a percentage of revenue in the fiscal 2021 second quarter was 1.64\npercent, an increase of 7 basis points when compared to the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1b8a0eb44c93c6dc4d7fa7a6e9be7c2fadc43ca416c83af36d2dd3653a768098", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77a6936f-715b-4932-87ad-e8713d0f5e96", "node_type": "1", "metadata": {"window": "future revenue growth.  Adjusted operating expenses as a percentage of revenue in the fiscal 2021 second quarter was 1.64\npercent, an increase of 7 basis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2021 second quarter, adjusted operating income of $706.6 million increased 5.2\npercent from the prior year period due to a 4.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 13.8 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.44 percent in the fiscal 2021 second quarter, an increase of 2 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 second\nquarter, net interest expense of $34.5 million was up 0.3 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates, which was largely offset by lower interest expense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.9 percent for the second quarter of fiscal 2021 compared\nto 21.5 percent in the prior year quarter.\n", "original_text": "Adjusted operating income as a percentage of revenue was\n1.44 percent in the fiscal 2021 second quarter, an increase of 2 basis points when compared to the prior year quarter.\n"}, "hash": "57a7fb10da5c0788d76f1a9ac72379ddde1a15b940f45b8022f7b7048fd32667", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Operating Income:  In the fiscal 2021 second quarter, adjusted operating income of $706.6 million increased 5.2\npercent from the prior year period due to a 4.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 13.8 percent increase in operating income within Other. ", "start_char_idx": 201, "end_char_idx": 507, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77a6936f-715b-4932-87ad-e8713d0f5e96": {"__data__": {"id_": "77a6936f-715b-4932-87ad-e8713d0f5e96", "embedding": null, "metadata": {"window": "future revenue growth.  Adjusted operating expenses as a percentage of revenue in the fiscal 2021 second quarter was 1.64\npercent, an increase of 7 basis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2021 second quarter, adjusted operating income of $706.6 million increased 5.2\npercent from the prior year period due to a 4.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 13.8 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.44 percent in the fiscal 2021 second quarter, an increase of 2 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 second\nquarter, net interest expense of $34.5 million was up 0.3 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates, which was largely offset by lower interest expense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.9 percent for the second quarter of fiscal 2021 compared\nto 21.5 percent in the prior year quarter.\n", "original_text": "Adjusted operating income as a percentage of revenue was\n1.44 percent in the fiscal 2021 second quarter, an increase of 2 basis points when compared to the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "faa0ff04df9e087aae368011c0247fe317130845fdc1ac00576b0aef407d1f9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb6ae3dd-7ffb-43a6-8a0a-9464303f0588", "node_type": "1", "metadata": {"window": "future revenue growth.  Adjusted operating expenses as a percentage of revenue in the fiscal 2021 second quarter was 1.64\npercent, an increase of 7 basis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2021 second quarter, adjusted operating income of $706.6 million increased 5.2\npercent from the prior year period due to a 4.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 13.8 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.44 percent in the fiscal 2021 second quarter, an increase of 2 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 second\nquarter, net interest expense of $34.5 million was up 0.3 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates, which was largely offset by lower interest expense.\n", "original_text": "Adjusted Operating Income:  In the fiscal 2021 second quarter, adjusted operating income of $706.6 million increased 5.2\npercent from the prior year period due to a 4.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 13.8 percent increase in operating income within Other. ", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "97e2b0b05701eb448b400eb71adab0b2e8849f3c4270de3f048a83f049d15d0d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2bc7e13c-c269-4f07-a99a-5e89a0cca435", "node_type": "1", "metadata": {"window": "Adjusted operating expenses as a percentage of revenue in the fiscal 2021 second quarter was 1.64\npercent, an increase of 7 basis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2021 second quarter, adjusted operating income of $706.6 million increased 5.2\npercent from the prior year period due to a 4.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 13.8 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.44 percent in the fiscal 2021 second quarter, an increase of 2 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 second\nquarter, net interest expense of $34.5 million was up 0.3 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates, which was largely offset by lower interest expense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.9 percent for the second quarter of fiscal 2021 compared\nto 21.5 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.4 percent to $2.53 in the second quarter of\nfiscal 2021 compared to $2.40 in the previous fiscal year\u2019s second quarter, driven by the increase in adjusted operating\nincome.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. "}, "hash": "b0eaff39fcbe64d13492a472c4271e7b0c8812b2de9adcd9579a18119c8606b7", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income as a percentage of revenue was\n1.44 percent in the fiscal 2021 second quarter, an increase of 2 basis points when compared to the prior year quarter.\n", "start_char_idx": 507, "end_char_idx": 683, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2bc7e13c-c269-4f07-a99a-5e89a0cca435": {"__data__": {"id_": "2bc7e13c-c269-4f07-a99a-5e89a0cca435", "embedding": null, "metadata": {"window": "Adjusted operating expenses as a percentage of revenue in the fiscal 2021 second quarter was 1.64\npercent, an increase of 7 basis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2021 second quarter, adjusted operating income of $706.6 million increased 5.2\npercent from the prior year period due to a 4.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 13.8 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.44 percent in the fiscal 2021 second quarter, an increase of 2 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 second\nquarter, net interest expense of $34.5 million was up 0.3 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates, which was largely offset by lower interest expense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.9 percent for the second quarter of fiscal 2021 compared\nto 21.5 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.4 percent to $2.53 in the second quarter of\nfiscal 2021 compared to $2.40 in the previous fiscal year\u2019s second quarter, driven by the increase in adjusted operating\nincome.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "faa0ff04df9e087aae368011c0247fe317130845fdc1ac00576b0aef407d1f9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77a6936f-715b-4932-87ad-e8713d0f5e96", "node_type": "1", "metadata": {"window": "future revenue growth.  Adjusted operating expenses as a percentage of revenue in the fiscal 2021 second quarter was 1.64\npercent, an increase of 7 basis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2021 second quarter, adjusted operating income of $706.6 million increased 5.2\npercent from the prior year period due to a 4.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 13.8 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.44 percent in the fiscal 2021 second quarter, an increase of 2 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 second\nquarter, net interest expense of $34.5 million was up 0.3 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates, which was largely offset by lower interest expense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.9 percent for the second quarter of fiscal 2021 compared\nto 21.5 percent in the prior year quarter.\n", "original_text": "Adjusted operating income as a percentage of revenue was\n1.44 percent in the fiscal 2021 second quarter, an increase of 2 basis points when compared to the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "df080dc374939ab3daf0b188ad373f76d21b7dc6c1964fac05c2e02dc2317b4c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9592d990-403c-4072-9a27-26144a56f307", "node_type": "1", "metadata": {"window": "Adjusted Operating Income:  In the fiscal 2021 second quarter, adjusted operating income of $706.6 million increased 5.2\npercent from the prior year period due to a 4.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 13.8 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.44 percent in the fiscal 2021 second quarter, an increase of 2 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 second\nquarter, net interest expense of $34.5 million was up 0.3 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates, which was largely offset by lower interest expense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.9 percent for the second quarter of fiscal 2021 compared\nto 21.5 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.4 percent to $2.53 in the second quarter of\nfiscal 2021 compared to $2.40 in the previous fiscal year\u2019s second quarter, driven by the increase in adjusted operating\nincome.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "In the fiscal 2021 second\nquarter, net interest expense of $34.5 million was up 0.3 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates, which was largely offset by lower interest expense.\n"}, "hash": "ec6e72781de210a4e5d0dcef5082933ff93cc5ea5cf032e1095e97206e1a61a2", "class_name": "RelatedNodeInfo"}}, "text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "start_char_idx": 683, "end_char_idx": 782, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9592d990-403c-4072-9a27-26144a56f307": {"__data__": {"id_": "9592d990-403c-4072-9a27-26144a56f307", "embedding": null, "metadata": {"window": "Adjusted Operating Income:  In the fiscal 2021 second quarter, adjusted operating income of $706.6 million increased 5.2\npercent from the prior year period due to a 4.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 13.8 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.44 percent in the fiscal 2021 second quarter, an increase of 2 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 second\nquarter, net interest expense of $34.5 million was up 0.3 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates, which was largely offset by lower interest expense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.9 percent for the second quarter of fiscal 2021 compared\nto 21.5 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.4 percent to $2.53 in the second quarter of\nfiscal 2021 compared to $2.40 in the previous fiscal year\u2019s second quarter, driven by the increase in adjusted operating\nincome.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "In the fiscal 2021 second\nquarter, net interest expense of $34.5 million was up 0.3 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates, which was largely offset by lower interest expense.\n", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "faa0ff04df9e087aae368011c0247fe317130845fdc1ac00576b0aef407d1f9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2bc7e13c-c269-4f07-a99a-5e89a0cca435", "node_type": "1", "metadata": {"window": "Adjusted operating expenses as a percentage of revenue in the fiscal 2021 second quarter was 1.64\npercent, an increase of 7 basis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2021 second quarter, adjusted operating income of $706.6 million increased 5.2\npercent from the prior year period due to a 4.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 13.8 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.44 percent in the fiscal 2021 second quarter, an increase of 2 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 second\nquarter, net interest expense of $34.5 million was up 0.3 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates, which was largely offset by lower interest expense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.9 percent for the second quarter of fiscal 2021 compared\nto 21.5 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.4 percent to $2.53 in the second quarter of\nfiscal 2021 compared to $2.40 in the previous fiscal year\u2019s second quarter, driven by the increase in adjusted operating\nincome.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3eb5a96f5f48a998f039d567aa56c771d637e305c39e2635ebe50e8598804141", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44015e49-9a4c-46bc-9342-55f80b54639f", "node_type": "1", "metadata": {"window": "Adjusted operating income as a percentage of revenue was\n1.44 percent in the fiscal 2021 second quarter, an increase of 2 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 second\nquarter, net interest expense of $34.5 million was up 0.3 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates, which was largely offset by lower interest expense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.9 percent for the second quarter of fiscal 2021 compared\nto 21.5 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.4 percent to $2.53 in the second quarter of\nfiscal 2021 compared to $2.40 in the previous fiscal year\u2019s second quarter, driven by the increase in adjusted operating\nincome.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2021 were 207.3 million, a 0.1 percent increase versus\nthe prior fiscal year second quarter.\n", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.9 percent for the second quarter of fiscal 2021 compared\nto 21.5 percent in the prior year quarter.\n"}, "hash": "2dba78a2b8532b2a16937b933325ae382359a533213481b09f9d284e22d638a6", "class_name": "RelatedNodeInfo"}}, "text": "In the fiscal 2021 second\nquarter, net interest expense of $34.5 million was up 0.3 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates, which was largely offset by lower interest expense.\n", "start_char_idx": 782, "end_char_idx": 1058, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44015e49-9a4c-46bc-9342-55f80b54639f": {"__data__": {"id_": "44015e49-9a4c-46bc-9342-55f80b54639f", "embedding": null, "metadata": {"window": "Adjusted operating income as a percentage of revenue was\n1.44 percent in the fiscal 2021 second quarter, an increase of 2 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 second\nquarter, net interest expense of $34.5 million was up 0.3 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates, which was largely offset by lower interest expense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.9 percent for the second quarter of fiscal 2021 compared\nto 21.5 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.4 percent to $2.53 in the second quarter of\nfiscal 2021 compared to $2.40 in the previous fiscal year\u2019s second quarter, driven by the increase in adjusted operating\nincome.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2021 were 207.3 million, a 0.1 percent increase versus\nthe prior fiscal year second quarter.\n", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.9 percent for the second quarter of fiscal 2021 compared\nto 21.5 percent in the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "faa0ff04df9e087aae368011c0247fe317130845fdc1ac00576b0aef407d1f9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9592d990-403c-4072-9a27-26144a56f307", "node_type": "1", "metadata": {"window": "Adjusted Operating Income:  In the fiscal 2021 second quarter, adjusted operating income of $706.6 million increased 5.2\npercent from the prior year period due to a 4.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 13.8 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.44 percent in the fiscal 2021 second quarter, an increase of 2 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 second\nquarter, net interest expense of $34.5 million was up 0.3 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates, which was largely offset by lower interest expense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.9 percent for the second quarter of fiscal 2021 compared\nto 21.5 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.4 percent to $2.53 in the second quarter of\nfiscal 2021 compared to $2.40 in the previous fiscal year\u2019s second quarter, driven by the increase in adjusted operating\nincome.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "In the fiscal 2021 second\nquarter, net interest expense of $34.5 million was up 0.3 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates, which was largely offset by lower interest expense.\n", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d05b23ca40191bf0ab012e8f7f43179fbb8e2de527b3f8c603dcaafaea94ccf5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9cee156b-4b92-4e30-85ff-8c356021b279", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 second\nquarter, net interest expense of $34.5 million was up 0.3 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates, which was largely offset by lower interest expense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.9 percent for the second quarter of fiscal 2021 compared\nto 21.5 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.4 percent to $2.53 in the second quarter of\nfiscal 2021 compared to $2.40 in the previous fiscal year\u2019s second quarter, driven by the increase in adjusted operating\nincome.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2021 were 207.3 million, a 0.1 percent increase versus\nthe prior fiscal year second quarter.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation. ", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.4 percent to $2.53 in the second quarter of\nfiscal 2021 compared to $2.40 in the previous fiscal year\u2019s second quarter, driven by the increase in adjusted operating\nincome.\n"}, "hash": "2adaf9da7ac5724fdfbc6984a6d219295858a9af0746441a32491827f5a5208b", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.9 percent for the second quarter of fiscal 2021 compared\nto 21.5 percent in the prior year quarter.\n", "start_char_idx": 1058, "end_char_idx": 1227, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9cee156b-4b92-4e30-85ff-8c356021b279": {"__data__": {"id_": "9cee156b-4b92-4e30-85ff-8c356021b279", "embedding": null, "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 second\nquarter, net interest expense of $34.5 million was up 0.3 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates, which was largely offset by lower interest expense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.9 percent for the second quarter of fiscal 2021 compared\nto 21.5 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.4 percent to $2.53 in the second quarter of\nfiscal 2021 compared to $2.40 in the previous fiscal year\u2019s second quarter, driven by the increase in adjusted operating\nincome.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2021 were 207.3 million, a 0.1 percent increase versus\nthe prior fiscal year second quarter.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation. ", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.4 percent to $2.53 in the second quarter of\nfiscal 2021 compared to $2.40 in the previous fiscal year\u2019s second quarter, driven by the increase in adjusted operating\nincome.\n", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "faa0ff04df9e087aae368011c0247fe317130845fdc1ac00576b0aef407d1f9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44015e49-9a4c-46bc-9342-55f80b54639f", "node_type": "1", "metadata": {"window": "Adjusted operating income as a percentage of revenue was\n1.44 percent in the fiscal 2021 second quarter, an increase of 2 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 second\nquarter, net interest expense of $34.5 million was up 0.3 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates, which was largely offset by lower interest expense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.9 percent for the second quarter of fiscal 2021 compared\nto 21.5 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.4 percent to $2.53 in the second quarter of\nfiscal 2021 compared to $2.40 in the previous fiscal year\u2019s second quarter, driven by the increase in adjusted operating\nincome.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2021 were 207.3 million, a 0.1 percent increase versus\nthe prior fiscal year second quarter.\n", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.9 percent for the second quarter of fiscal 2021 compared\nto 21.5 percent in the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4b063d7c899b5e89c1b0d1e2c4e0b5bebf54c101abb790749a63ddaa1280b054", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6f1373d-d38b-49e0-8bae-9d01da611d13", "node_type": "1", "metadata": {"window": "In the fiscal 2021 second\nquarter, net interest expense of $34.5 million was up 0.3 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates, which was largely offset by lower interest expense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.9 percent for the second quarter of fiscal 2021 compared\nto 21.5 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.4 percent to $2.53 in the second quarter of\nfiscal 2021 compared to $2.40 in the previous fiscal year\u2019s second quarter, driven by the increase in adjusted operating\nincome.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2021 were 207.3 million, a 0.1 percent increase versus\nthe prior fiscal year second quarter.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. "}, "hash": "5a63b1d446ea1bee329a1cda8f2d648fd4265f286f99a2c9d6a4eda42384dc5c", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.4 percent to $2.53 in the second quarter of\nfiscal 2021 compared to $2.40 in the previous fiscal year\u2019s second quarter, driven by the increase in adjusted operating\nincome.\n", "start_char_idx": 1227, "end_char_idx": 1483, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6f1373d-d38b-49e0-8bae-9d01da611d13": {"__data__": {"id_": "a6f1373d-d38b-49e0-8bae-9d01da611d13", "embedding": null, "metadata": {"window": "In the fiscal 2021 second\nquarter, net interest expense of $34.5 million was up 0.3 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates, which was largely offset by lower interest expense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.9 percent for the second quarter of fiscal 2021 compared\nto 21.5 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.4 percent to $2.53 in the second quarter of\nfiscal 2021 compared to $2.40 in the previous fiscal year\u2019s second quarter, driven by the increase in adjusted operating\nincome.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2021 were 207.3 million, a 0.1 percent increase versus\nthe prior fiscal year second quarter.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "faa0ff04df9e087aae368011c0247fe317130845fdc1ac00576b0aef407d1f9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9cee156b-4b92-4e30-85ff-8c356021b279", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 second\nquarter, net interest expense of $34.5 million was up 0.3 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates, which was largely offset by lower interest expense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.9 percent for the second quarter of fiscal 2021 compared\nto 21.5 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.4 percent to $2.53 in the second quarter of\nfiscal 2021 compared to $2.40 in the previous fiscal year\u2019s second quarter, driven by the increase in adjusted operating\nincome.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2021 were 207.3 million, a 0.1 percent increase versus\nthe prior fiscal year second quarter.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation. ", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.4 percent to $2.53 in the second quarter of\nfiscal 2021 compared to $2.40 in the previous fiscal year\u2019s second quarter, driven by the increase in adjusted operating\nincome.\n", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28df473d0349b23e84891b8794773a18dd89a135fa7a8630fd7ae0a14cdac4e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c79e544a-1bb0-4a7a-9f46-cf0fec48bbe4", "node_type": "1", "metadata": {"window": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.9 percent for the second quarter of fiscal 2021 compared\nto 21.5 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.4 percent to $2.53 in the second quarter of\nfiscal 2021 compared to $2.40 in the previous fiscal year\u2019s second quarter, driven by the increase in adjusted operating\nincome.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2021 were 207.3 million, a 0.1 percent increase versus\nthe prior fiscal year second quarter.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.1 billion, an increase of 3.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments. ", "original_text": "Diluted\nweighted average shares outstanding for the second quarter of fiscal 2021 were 207.3 million, a 0.1 percent increase versus\nthe prior fiscal year second quarter.\n"}, "hash": "a6baf7f30028a645ded95623f59d6715752df27be2a7fc5c6b3924f18224bb03", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "start_char_idx": 1483, "end_char_idx": 1593, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c79e544a-1bb0-4a7a-9f46-cf0fec48bbe4": {"__data__": {"id_": "c79e544a-1bb0-4a7a-9f46-cf0fec48bbe4", "embedding": null, "metadata": {"window": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.9 percent for the second quarter of fiscal 2021 compared\nto 21.5 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.4 percent to $2.53 in the second quarter of\nfiscal 2021 compared to $2.40 in the previous fiscal year\u2019s second quarter, driven by the increase in adjusted operating\nincome.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2021 were 207.3 million, a 0.1 percent increase versus\nthe prior fiscal year second quarter.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.1 billion, an increase of 3.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments. ", "original_text": "Diluted\nweighted average shares outstanding for the second quarter of fiscal 2021 were 207.3 million, a 0.1 percent increase versus\nthe prior fiscal year second quarter.\n", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "faa0ff04df9e087aae368011c0247fe317130845fdc1ac00576b0aef407d1f9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6f1373d-d38b-49e0-8bae-9d01da611d13", "node_type": "1", "metadata": {"window": "In the fiscal 2021 second\nquarter, net interest expense of $34.5 million was up 0.3 percent versus the prior year quarter due to a decrease in interest\nincome resulting primarily from a decline in investment interest rates, which was largely offset by lower interest expense.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.9 percent for the second quarter of fiscal 2021 compared\nto 21.5 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.4 percent to $2.53 in the second quarter of\nfiscal 2021 compared to $2.40 in the previous fiscal year\u2019s second quarter, driven by the increase in adjusted operating\nincome.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2021 were 207.3 million, a 0.1 percent increase versus\nthe prior fiscal year second quarter.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f5027f5a064c3495ffb8ec4ea84d60979ee71d3e0580a57f7db4673cb2f4fef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8761f8c8-aec9-4d20-9a11-899d2e5ff9f8", "node_type": "1", "metadata": {"window": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.4 percent to $2.53 in the second quarter of\nfiscal 2021 compared to $2.40 in the previous fiscal year\u2019s second quarter, driven by the increase in adjusted operating\nincome.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2021 were 207.3 million, a 0.1 percent increase versus\nthe prior fiscal year second quarter.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.1 billion, an increase of 3.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments.  Segment operating income of\n$589.0 million in the second quarter of fiscal 2021 was up 4.6 percent compared to the same period in the previous fiscal year,\nprimarily due to the growth in sales of specialty products.\n", "original_text": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation. "}, "hash": "a6acdb3a4edf2eed4903aa81f19500ec63aa263d10edd4525728cef6304e7eee", "class_name": "RelatedNodeInfo"}}, "text": "Diluted\nweighted average shares outstanding for the second quarter of fiscal 2021 were 207.3 million, a 0.1 percent increase versus\nthe prior fiscal year second quarter.\n", "start_char_idx": 1593, "end_char_idx": 1763, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8761f8c8-aec9-4d20-9a11-899d2e5ff9f8": {"__data__": {"id_": "8761f8c8-aec9-4d20-9a11-899d2e5ff9f8", "embedding": null, "metadata": {"window": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.4 percent to $2.53 in the second quarter of\nfiscal 2021 compared to $2.40 in the previous fiscal year\u2019s second quarter, driven by the increase in adjusted operating\nincome.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2021 were 207.3 million, a 0.1 percent increase versus\nthe prior fiscal year second quarter.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.1 billion, an increase of 3.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments.  Segment operating income of\n$589.0 million in the second quarter of fiscal 2021 was up 4.6 percent compared to the same period in the previous fiscal year,\nprimarily due to the growth in sales of specialty products.\n", "original_text": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation. ", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "faa0ff04df9e087aae368011c0247fe317130845fdc1ac00576b0aef407d1f9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c79e544a-1bb0-4a7a-9f46-cf0fec48bbe4", "node_type": "1", "metadata": {"window": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.9 percent for the second quarter of fiscal 2021 compared\nto 21.5 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.4 percent to $2.53 in the second quarter of\nfiscal 2021 compared to $2.40 in the previous fiscal year\u2019s second quarter, driven by the increase in adjusted operating\nincome.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2021 were 207.3 million, a 0.1 percent increase versus\nthe prior fiscal year second quarter.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.1 billion, an increase of 3.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments. ", "original_text": "Diluted\nweighted average shares outstanding for the second quarter of fiscal 2021 were 207.3 million, a 0.1 percent increase versus\nthe prior fiscal year second quarter.\n", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b753125df10a3ba174685b79013b6bfa3f1d06623e4776a3e4ad7887a8020975", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e0bd691-4f91-49e8-a349-7b0407a9b431", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2021 were 207.3 million, a 0.1 percent increase versus\nthe prior fiscal year second quarter.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.1 billion, an increase of 3.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments.  Segment operating income of\n$589.0 million in the second quarter of fiscal 2021 was up 4.6 percent compared to the same period in the previous fiscal year,\nprimarily due to the growth in sales of specialty products.\n Other\nRevenue in Other was $2.1 billion in the second quarter of fiscal 2021, an increase of 11.5 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier. ", "original_text": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n"}, "hash": "bc21fa99e3fd73ae02a205b6b6c9a0d61487a8a92559f895ab81d40d75be7d79", "class_name": "RelatedNodeInfo"}}, "text": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation. ", "start_char_idx": 1763, "end_char_idx": 2095, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e0bd691-4f91-49e8-a349-7b0407a9b431": {"__data__": {"id_": "6e0bd691-4f91-49e8-a349-7b0407a9b431", "embedding": null, "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2021 were 207.3 million, a 0.1 percent increase versus\nthe prior fiscal year second quarter.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.1 billion, an increase of 3.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments.  Segment operating income of\n$589.0 million in the second quarter of fiscal 2021 was up 4.6 percent compared to the same period in the previous fiscal year,\nprimarily due to the growth in sales of specialty products.\n Other\nRevenue in Other was $2.1 billion in the second quarter of fiscal 2021, an increase of 11.5 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier. ", "original_text": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "faa0ff04df9e087aae368011c0247fe317130845fdc1ac00576b0aef407d1f9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8761f8c8-aec9-4d20-9a11-899d2e5ff9f8", "node_type": "1", "metadata": {"window": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 5.4 percent to $2.53 in the second quarter of\nfiscal 2021 compared to $2.40 in the previous fiscal year\u2019s second quarter, driven by the increase in adjusted operating\nincome.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2021 were 207.3 million, a 0.1 percent increase versus\nthe prior fiscal year second quarter.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.1 billion, an increase of 3.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments.  Segment operating income of\n$589.0 million in the second quarter of fiscal 2021 was up 4.6 percent compared to the same period in the previous fiscal year,\nprimarily due to the growth in sales of specialty products.\n", "original_text": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation. ", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2f6bbb3b07aab3da53f5f893191fcea7ed37ca4ac6ba162d706d0a45af4cd756", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "551f5751-93b3-49c2-91b6-f6129cff2c8b", "node_type": "1", "metadata": {"window": "Diluted\nweighted average shares outstanding for the second quarter of fiscal 2021 were 207.3 million, a 0.1 percent increase versus\nthe prior fiscal year second quarter.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.1 billion, an increase of 3.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments.  Segment operating income of\n$589.0 million in the second quarter of fiscal 2021 was up 4.6 percent compared to the same period in the previous fiscal year,\nprimarily due to the growth in sales of specialty products.\n Other\nRevenue in Other was $2.1 billion in the second quarter of fiscal 2021, an increase of 11.5 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other\nincreased 13.8 percent to $123.2 million in the second quarter of fiscal 2021 due to the strong performance of World Courier and\nMWI.\n", "original_text": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.1 billion, an increase of 3.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments. "}, "hash": "5abaec84a8e387f0cd1a8b8fd24ab1c308ba8413de4985a37aa269f179b28988", "class_name": "RelatedNodeInfo"}}, "text": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n", "start_char_idx": 2095, "end_char_idx": 2300, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "551f5751-93b3-49c2-91b6-f6129cff2c8b": {"__data__": {"id_": "551f5751-93b3-49c2-91b6-f6129cff2c8b", "embedding": null, "metadata": {"window": "Diluted\nweighted average shares outstanding for the second quarter of fiscal 2021 were 207.3 million, a 0.1 percent increase versus\nthe prior fiscal year second quarter.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.1 billion, an increase of 3.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments.  Segment operating income of\n$589.0 million in the second quarter of fiscal 2021 was up 4.6 percent compared to the same period in the previous fiscal year,\nprimarily due to the growth in sales of specialty products.\n Other\nRevenue in Other was $2.1 billion in the second quarter of fiscal 2021, an increase of 11.5 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other\nincreased 13.8 percent to $123.2 million in the second quarter of fiscal 2021 due to the strong performance of World Courier and\nMWI.\n", "original_text": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.1 billion, an increase of 3.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments. ", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "faa0ff04df9e087aae368011c0247fe317130845fdc1ac00576b0aef407d1f9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e0bd691-4f91-49e8-a349-7b0407a9b431", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2021 were 207.3 million, a 0.1 percent increase versus\nthe prior fiscal year second quarter.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.1 billion, an increase of 3.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments.  Segment operating income of\n$589.0 million in the second quarter of fiscal 2021 was up 4.6 percent compared to the same period in the previous fiscal year,\nprimarily due to the growth in sales of specialty products.\n Other\nRevenue in Other was $2.1 billion in the second quarter of fiscal 2021, an increase of 11.5 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier. ", "original_text": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d470002384cd41d171271fe8d50aa53bf9761091ea0f7b1376ee1880c8fa0a63", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee719b7d-7363-40bd-aeca-f21557ddd20b", "node_type": "1", "metadata": {"window": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.1 billion, an increase of 3.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments.  Segment operating income of\n$589.0 million in the second quarter of fiscal 2021 was up 4.6 percent compared to the same period in the previous fiscal year,\nprimarily due to the growth in sales of specialty products.\n Other\nRevenue in Other was $2.1 billion in the second quarter of fiscal 2021, an increase of 11.5 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other\nincreased 13.8 percent to $123.2 million in the second quarter of fiscal 2021 due to the strong performance of World Courier and\nMWI.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen released its 2020 Global Sustainability Report and ESG Reporting Index, detailing the impact of its robust\nsustainability and community efforts. ", "original_text": "Segment operating income of\n$589.0 million in the second quarter of fiscal 2021 was up 4.6 percent compared to the same period in the previous fiscal year,\nprimarily due to the growth in sales of specialty products.\n"}, "hash": "ff82cf30780ebbd1b0bfea3af471b7ede4a92fd481a40087ccb3f0df1353af70", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.1 billion, an increase of 3.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments. ", "start_char_idx": 2300, "end_char_idx": 2577, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee719b7d-7363-40bd-aeca-f21557ddd20b": {"__data__": {"id_": "ee719b7d-7363-40bd-aeca-f21557ddd20b", "embedding": null, "metadata": {"window": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.1 billion, an increase of 3.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments.  Segment operating income of\n$589.0 million in the second quarter of fiscal 2021 was up 4.6 percent compared to the same period in the previous fiscal year,\nprimarily due to the growth in sales of specialty products.\n Other\nRevenue in Other was $2.1 billion in the second quarter of fiscal 2021, an increase of 11.5 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other\nincreased 13.8 percent to $123.2 million in the second quarter of fiscal 2021 due to the strong performance of World Courier and\nMWI.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen released its 2020 Global Sustainability Report and ESG Reporting Index, detailing the impact of its robust\nsustainability and community efforts. ", "original_text": "Segment operating income of\n$589.0 million in the second quarter of fiscal 2021 was up 4.6 percent compared to the same period in the previous fiscal year,\nprimarily due to the growth in sales of specialty products.\n", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "faa0ff04df9e087aae368011c0247fe317130845fdc1ac00576b0aef407d1f9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "551f5751-93b3-49c2-91b6-f6129cff2c8b", "node_type": "1", "metadata": {"window": "Diluted\nweighted average shares outstanding for the second quarter of fiscal 2021 were 207.3 million, a 0.1 percent increase versus\nthe prior fiscal year second quarter.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.1 billion, an increase of 3.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments.  Segment operating income of\n$589.0 million in the second quarter of fiscal 2021 was up 4.6 percent compared to the same period in the previous fiscal year,\nprimarily due to the growth in sales of specialty products.\n Other\nRevenue in Other was $2.1 billion in the second quarter of fiscal 2021, an increase of 11.5 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other\nincreased 13.8 percent to $123.2 million in the second quarter of fiscal 2021 due to the strong performance of World Courier and\nMWI.\n", "original_text": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.1 billion, an increase of 3.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments. ", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "056176f84bf3343b59835d6b65c510ca4889070650337a22aa4ef953f1bc8b0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd2b827a-fe1c-48f3-9c63-7e72e99b98c3", "node_type": "1", "metadata": {"window": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.1 billion, an increase of 3.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments.  Segment operating income of\n$589.0 million in the second quarter of fiscal 2021 was up 4.6 percent compared to the same period in the previous fiscal year,\nprimarily due to the growth in sales of specialty products.\n Other\nRevenue in Other was $2.1 billion in the second quarter of fiscal 2021, an increase of 11.5 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other\nincreased 13.8 percent to $123.2 million in the second quarter of fiscal 2021 due to the strong performance of World Courier and\nMWI.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen released its 2020 Global Sustainability Report and ESG Reporting Index, detailing the impact of its robust\nsustainability and community efforts.  This year, AmerisourceBergen made its report available through the launch of a new\nmicrosite, which serves as a comprehensive, interactive resource to showcase data, information and relevant assets from the\nCompany in connection with topics related to ESG. ", "original_text": "Other\nRevenue in Other was $2.1 billion in the second quarter of fiscal 2021, an increase of 11.5 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier. "}, "hash": "c20559d5d82c984b94d9823fd7db1c79737b46a1c7bafaaf7540e2a5b032b248", "class_name": "RelatedNodeInfo"}}, "text": "Segment operating income of\n$589.0 million in the second quarter of fiscal 2021 was up 4.6 percent compared to the same period in the previous fiscal year,\nprimarily due to the growth in sales of specialty products.\n", "start_char_idx": 2577, "end_char_idx": 2793, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd2b827a-fe1c-48f3-9c63-7e72e99b98c3": {"__data__": {"id_": "bd2b827a-fe1c-48f3-9c63-7e72e99b98c3", "embedding": null, "metadata": {"window": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.1 billion, an increase of 3.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments.  Segment operating income of\n$589.0 million in the second quarter of fiscal 2021 was up 4.6 percent compared to the same period in the previous fiscal year,\nprimarily due to the growth in sales of specialty products.\n Other\nRevenue in Other was $2.1 billion in the second quarter of fiscal 2021, an increase of 11.5 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other\nincreased 13.8 percent to $123.2 million in the second quarter of fiscal 2021 due to the strong performance of World Courier and\nMWI.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen released its 2020 Global Sustainability Report and ESG Reporting Index, detailing the impact of its robust\nsustainability and community efforts.  This year, AmerisourceBergen made its report available through the launch of a new\nmicrosite, which serves as a comprehensive, interactive resource to showcase data, information and relevant assets from the\nCompany in connection with topics related to ESG. ", "original_text": "Other\nRevenue in Other was $2.1 billion in the second quarter of fiscal 2021, an increase of 11.5 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier. ", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "faa0ff04df9e087aae368011c0247fe317130845fdc1ac00576b0aef407d1f9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee719b7d-7363-40bd-aeca-f21557ddd20b", "node_type": "1", "metadata": {"window": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.1 billion, an increase of 3.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments.  Segment operating income of\n$589.0 million in the second quarter of fiscal 2021 was up 4.6 percent compared to the same period in the previous fiscal year,\nprimarily due to the growth in sales of specialty products.\n Other\nRevenue in Other was $2.1 billion in the second quarter of fiscal 2021, an increase of 11.5 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other\nincreased 13.8 percent to $123.2 million in the second quarter of fiscal 2021 due to the strong performance of World Courier and\nMWI.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen released its 2020 Global Sustainability Report and ESG Reporting Index, detailing the impact of its robust\nsustainability and community efforts. ", "original_text": "Segment operating income of\n$589.0 million in the second quarter of fiscal 2021 was up 4.6 percent compared to the same period in the previous fiscal year,\nprimarily due to the growth in sales of specialty products.\n", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "814a721ae9d2bc07bf723642899d52e33a14f0691e16578824a6fa35d09100aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bdbb774f-5f3e-4728-9113-8a10f821f033", "node_type": "1", "metadata": {"window": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.1 billion, an increase of 3.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments.  Segment operating income of\n$589.0 million in the second quarter of fiscal 2021 was up 4.6 percent compared to the same period in the previous fiscal year,\nprimarily due to the growth in sales of specialty products.\n Other\nRevenue in Other was $2.1 billion in the second quarter of fiscal 2021, an increase of 11.5 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other\nincreased 13.8 percent to $123.2 million in the second quarter of fiscal 2021 due to the strong performance of World Courier and\nMWI.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen released its 2020 Global Sustainability Report and ESG Reporting Index, detailing the impact of its robust\nsustainability and community efforts.  This year, AmerisourceBergen made its report available through the launch of a new\nmicrosite, which serves as a comprehensive, interactive resource to showcase data, information and relevant assets from the\nCompany in connection with topics related to ESG.  For the third year in a row, selected information within the 2020 report\nwas assured by ERM Certification and Verification Services.\n", "original_text": "Operating income in Other\nincreased 13.8 percent to $123.2 million in the second quarter of fiscal 2021 due to the strong performance of World Courier and\nMWI.\n"}, "hash": "07c147ac32bbf7a58d7c3fabd55b0f98954ef21364e825db7c53f17291f85ec7", "class_name": "RelatedNodeInfo"}}, "text": "Other\nRevenue in Other was $2.1 billion in the second quarter of fiscal 2021, an increase of 11.5 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier. ", "start_char_idx": 2793, "end_char_idx": 3029, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bdbb774f-5f3e-4728-9113-8a10f821f033": {"__data__": {"id_": "bdbb774f-5f3e-4728-9113-8a10f821f033", "embedding": null, "metadata": {"window": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.1 billion, an increase of 3.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments.  Segment operating income of\n$589.0 million in the second quarter of fiscal 2021 was up 4.6 percent compared to the same period in the previous fiscal year,\nprimarily due to the growth in sales of specialty products.\n Other\nRevenue in Other was $2.1 billion in the second quarter of fiscal 2021, an increase of 11.5 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other\nincreased 13.8 percent to $123.2 million in the second quarter of fiscal 2021 due to the strong performance of World Courier and\nMWI.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen released its 2020 Global Sustainability Report and ESG Reporting Index, detailing the impact of its robust\nsustainability and community efforts.  This year, AmerisourceBergen made its report available through the launch of a new\nmicrosite, which serves as a comprehensive, interactive resource to showcase data, information and relevant assets from the\nCompany in connection with topics related to ESG.  For the third year in a row, selected information within the 2020 report\nwas assured by ERM Certification and Verification Services.\n", "original_text": "Operating income in Other\nincreased 13.8 percent to $123.2 million in the second quarter of fiscal 2021 due to the strong performance of World Courier and\nMWI.\n", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "faa0ff04df9e087aae368011c0247fe317130845fdc1ac00576b0aef407d1f9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd2b827a-fe1c-48f3-9c63-7e72e99b98c3", "node_type": "1", "metadata": {"window": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.1 billion, an increase of 3.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments.  Segment operating income of\n$589.0 million in the second quarter of fiscal 2021 was up 4.6 percent compared to the same period in the previous fiscal year,\nprimarily due to the growth in sales of specialty products.\n Other\nRevenue in Other was $2.1 billion in the second quarter of fiscal 2021, an increase of 11.5 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other\nincreased 13.8 percent to $123.2 million in the second quarter of fiscal 2021 due to the strong performance of World Courier and\nMWI.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen released its 2020 Global Sustainability Report and ESG Reporting Index, detailing the impact of its robust\nsustainability and community efforts.  This year, AmerisourceBergen made its report available through the launch of a new\nmicrosite, which serves as a comprehensive, interactive resource to showcase data, information and relevant assets from the\nCompany in connection with topics related to ESG. ", "original_text": "Other\nRevenue in Other was $2.1 billion in the second quarter of fiscal 2021, an increase of 11.5 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier. ", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "53337e7fe66391bdfb7157dc8d996fa0badf532e528427a6b19dcfdba87b6ecd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dee38d65-7a1f-4453-b70b-db66afa30ec8", "node_type": "1", "metadata": {"window": "Segment operating income of\n$589.0 million in the second quarter of fiscal 2021 was up 4.6 percent compared to the same period in the previous fiscal year,\nprimarily due to the growth in sales of specialty products.\n Other\nRevenue in Other was $2.1 billion in the second quarter of fiscal 2021, an increase of 11.5 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other\nincreased 13.8 percent to $123.2 million in the second quarter of fiscal 2021 due to the strong performance of World Courier and\nMWI.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen released its 2020 Global Sustainability Report and ESG Reporting Index, detailing the impact of its robust\nsustainability and community efforts.  This year, AmerisourceBergen made its report available through the launch of a new\nmicrosite, which serves as a comprehensive, interactive resource to showcase data, information and relevant assets from the\nCompany in connection with topics related to ESG.  For the third year in a row, selected information within the 2020 report\nwas assured by ERM Certification and Verification Services.\n The Anti-Defamation League (ADL) Philadelphia chapter presented the Americanism Award to Steven H. Collis, Chairman,\nPresident & CEO, and AmerisourceBergen for their commitment to fighting hate locally, across the country and the world. ", "original_text": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen released its 2020 Global Sustainability Report and ESG Reporting Index, detailing the impact of its robust\nsustainability and community efforts. "}, "hash": "7d2f7eee0c5cb54fd88ebfbfd900ed435777d0c19fd0f0abea3f32f32da81d67", "class_name": "RelatedNodeInfo"}}, "text": "Operating income in Other\nincreased 13.8 percent to $123.2 million in the second quarter of fiscal 2021 due to the strong performance of World Courier and\nMWI.\n", "start_char_idx": 3029, "end_char_idx": 3189, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dee38d65-7a1f-4453-b70b-db66afa30ec8": {"__data__": {"id_": "dee38d65-7a1f-4453-b70b-db66afa30ec8", "embedding": null, "metadata": {"window": "Segment operating income of\n$589.0 million in the second quarter of fiscal 2021 was up 4.6 percent compared to the same period in the previous fiscal year,\nprimarily due to the growth in sales of specialty products.\n Other\nRevenue in Other was $2.1 billion in the second quarter of fiscal 2021, an increase of 11.5 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other\nincreased 13.8 percent to $123.2 million in the second quarter of fiscal 2021 due to the strong performance of World Courier and\nMWI.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen released its 2020 Global Sustainability Report and ESG Reporting Index, detailing the impact of its robust\nsustainability and community efforts.  This year, AmerisourceBergen made its report available through the launch of a new\nmicrosite, which serves as a comprehensive, interactive resource to showcase data, information and relevant assets from the\nCompany in connection with topics related to ESG.  For the third year in a row, selected information within the 2020 report\nwas assured by ERM Certification and Verification Services.\n The Anti-Defamation League (ADL) Philadelphia chapter presented the Americanism Award to Steven H. Collis, Chairman,\nPresident & CEO, and AmerisourceBergen for their commitment to fighting hate locally, across the country and the world. ", "original_text": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen released its 2020 Global Sustainability Report and ESG Reporting Index, detailing the impact of its robust\nsustainability and community efforts. ", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "faa0ff04df9e087aae368011c0247fe317130845fdc1ac00576b0aef407d1f9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bdbb774f-5f3e-4728-9113-8a10f821f033", "node_type": "1", "metadata": {"window": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $47.1 billion, an increase of 3.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments.  Segment operating income of\n$589.0 million in the second quarter of fiscal 2021 was up 4.6 percent compared to the same period in the previous fiscal year,\nprimarily due to the growth in sales of specialty products.\n Other\nRevenue in Other was $2.1 billion in the second quarter of fiscal 2021, an increase of 11.5 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other\nincreased 13.8 percent to $123.2 million in the second quarter of fiscal 2021 due to the strong performance of World Courier and\nMWI.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen released its 2020 Global Sustainability Report and ESG Reporting Index, detailing the impact of its robust\nsustainability and community efforts.  This year, AmerisourceBergen made its report available through the launch of a new\nmicrosite, which serves as a comprehensive, interactive resource to showcase data, information and relevant assets from the\nCompany in connection with topics related to ESG.  For the third year in a row, selected information within the 2020 report\nwas assured by ERM Certification and Verification Services.\n", "original_text": "Operating income in Other\nincreased 13.8 percent to $123.2 million in the second quarter of fiscal 2021 due to the strong performance of World Courier and\nMWI.\n", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75d5f4c2ebd0e69225ddea5a867e34d8ce6ad971b6286b2e01834a31192d8054", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6d6bc92-9a17-4ac0-9740-d60cf91490f9", "node_type": "1", "metadata": {"window": "Other\nRevenue in Other was $2.1 billion in the second quarter of fiscal 2021, an increase of 11.5 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other\nincreased 13.8 percent to $123.2 million in the second quarter of fiscal 2021 due to the strong performance of World Courier and\nMWI.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen released its 2020 Global Sustainability Report and ESG Reporting Index, detailing the impact of its robust\nsustainability and community efforts.  This year, AmerisourceBergen made its report available through the launch of a new\nmicrosite, which serves as a comprehensive, interactive resource to showcase data, information and relevant assets from the\nCompany in connection with topics related to ESG.  For the third year in a row, selected information within the 2020 report\nwas assured by ERM Certification and Verification Services.\n The Anti-Defamation League (ADL) Philadelphia chapter presented the Americanism Award to Steven H. Collis, Chairman,\nPresident & CEO, and AmerisourceBergen for their commitment to fighting hate locally, across the country and the world.  The\nAmericanism Award has honored leaders in business, community affairs and charitable endeavors who distinguish themselves\nand their organizations through their dedication to preserving liberty and advancing the cause of human rights, respect,\ndignity and equal opportunity.\n", "original_text": "This year, AmerisourceBergen made its report available through the launch of a new\nmicrosite, which serves as a comprehensive, interactive resource to showcase data, information and relevant assets from the\nCompany in connection with topics related to ESG. "}, "hash": "5a25da0b88a7c4ba6c87ea855cd9b9092fd968705d8547bac1427fb8fd9bf7fb", "class_name": "RelatedNodeInfo"}}, "text": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen released its 2020 Global Sustainability Report and ESG Reporting Index, detailing the impact of its robust\nsustainability and community efforts. ", "start_char_idx": 3189, "end_char_idx": 3393, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6d6bc92-9a17-4ac0-9740-d60cf91490f9": {"__data__": {"id_": "b6d6bc92-9a17-4ac0-9740-d60cf91490f9", "embedding": null, "metadata": {"window": "Other\nRevenue in Other was $2.1 billion in the second quarter of fiscal 2021, an increase of 11.5 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other\nincreased 13.8 percent to $123.2 million in the second quarter of fiscal 2021 due to the strong performance of World Courier and\nMWI.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen released its 2020 Global Sustainability Report and ESG Reporting Index, detailing the impact of its robust\nsustainability and community efforts.  This year, AmerisourceBergen made its report available through the launch of a new\nmicrosite, which serves as a comprehensive, interactive resource to showcase data, information and relevant assets from the\nCompany in connection with topics related to ESG.  For the third year in a row, selected information within the 2020 report\nwas assured by ERM Certification and Verification Services.\n The Anti-Defamation League (ADL) Philadelphia chapter presented the Americanism Award to Steven H. Collis, Chairman,\nPresident & CEO, and AmerisourceBergen for their commitment to fighting hate locally, across the country and the world.  The\nAmericanism Award has honored leaders in business, community affairs and charitable endeavors who distinguish themselves\nand their organizations through their dedication to preserving liberty and advancing the cause of human rights, respect,\ndignity and equal opportunity.\n", "original_text": "This year, AmerisourceBergen made its report available through the launch of a new\nmicrosite, which serves as a comprehensive, interactive resource to showcase data, information and relevant assets from the\nCompany in connection with topics related to ESG. ", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "faa0ff04df9e087aae368011c0247fe317130845fdc1ac00576b0aef407d1f9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dee38d65-7a1f-4453-b70b-db66afa30ec8", "node_type": "1", "metadata": {"window": "Segment operating income of\n$589.0 million in the second quarter of fiscal 2021 was up 4.6 percent compared to the same period in the previous fiscal year,\nprimarily due to the growth in sales of specialty products.\n Other\nRevenue in Other was $2.1 billion in the second quarter of fiscal 2021, an increase of 11.5 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other\nincreased 13.8 percent to $123.2 million in the second quarter of fiscal 2021 due to the strong performance of World Courier and\nMWI.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen released its 2020 Global Sustainability Report and ESG Reporting Index, detailing the impact of its robust\nsustainability and community efforts.  This year, AmerisourceBergen made its report available through the launch of a new\nmicrosite, which serves as a comprehensive, interactive resource to showcase data, information and relevant assets from the\nCompany in connection with topics related to ESG.  For the third year in a row, selected information within the 2020 report\nwas assured by ERM Certification and Verification Services.\n The Anti-Defamation League (ADL) Philadelphia chapter presented the Americanism Award to Steven H. Collis, Chairman,\nPresident & CEO, and AmerisourceBergen for their commitment to fighting hate locally, across the country and the world. ", "original_text": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen released its 2020 Global Sustainability Report and ESG Reporting Index, detailing the impact of its robust\nsustainability and community efforts. ", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e473b0cc7ac8f347c857b9f24a3ec1535fb644d568a13d7baf6cd8502f6392db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a16c8ff3-1875-42e7-9817-e018833a4197", "node_type": "1", "metadata": {"window": "Operating income in Other\nincreased 13.8 percent to $123.2 million in the second quarter of fiscal 2021 due to the strong performance of World Courier and\nMWI.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen released its 2020 Global Sustainability Report and ESG Reporting Index, detailing the impact of its robust\nsustainability and community efforts.  This year, AmerisourceBergen made its report available through the launch of a new\nmicrosite, which serves as a comprehensive, interactive resource to showcase data, information and relevant assets from the\nCompany in connection with topics related to ESG.  For the third year in a row, selected information within the 2020 report\nwas assured by ERM Certification and Verification Services.\n The Anti-Defamation League (ADL) Philadelphia chapter presented the Americanism Award to Steven H. Collis, Chairman,\nPresident & CEO, and AmerisourceBergen for their commitment to fighting hate locally, across the country and the world.  The\nAmericanism Award has honored leaders in business, community affairs and charitable endeavors who distinguish themselves\nand their organizations through their dedication to preserving liberty and advancing the cause of human rights, respect,\ndignity and equal opportunity.\n The AmerisourceBergen Foundation, an independent not-for-profit charitable giving organization focused on supporting\nhealth-related causes that enrich the global community, announced a $700,000 donation to Boys & Girls Clubs of America to\n3", "original_text": "For the third year in a row, selected information within the 2020 report\nwas assured by ERM Certification and Verification Services.\n"}, "hash": "9bd0984c6f9e1dd287df659c07406e7f5f92f0aca4a1b9337b8cc5e3a3e77459", "class_name": "RelatedNodeInfo"}}, "text": "This year, AmerisourceBergen made its report available through the launch of a new\nmicrosite, which serves as a comprehensive, interactive resource to showcase data, information and relevant assets from the\nCompany in connection with topics related to ESG. ", "start_char_idx": 3393, "end_char_idx": 3650, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a16c8ff3-1875-42e7-9817-e018833a4197": {"__data__": {"id_": "a16c8ff3-1875-42e7-9817-e018833a4197", "embedding": null, "metadata": {"window": "Operating income in Other\nincreased 13.8 percent to $123.2 million in the second quarter of fiscal 2021 due to the strong performance of World Courier and\nMWI.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen released its 2020 Global Sustainability Report and ESG Reporting Index, detailing the impact of its robust\nsustainability and community efforts.  This year, AmerisourceBergen made its report available through the launch of a new\nmicrosite, which serves as a comprehensive, interactive resource to showcase data, information and relevant assets from the\nCompany in connection with topics related to ESG.  For the third year in a row, selected information within the 2020 report\nwas assured by ERM Certification and Verification Services.\n The Anti-Defamation League (ADL) Philadelphia chapter presented the Americanism Award to Steven H. Collis, Chairman,\nPresident & CEO, and AmerisourceBergen for their commitment to fighting hate locally, across the country and the world.  The\nAmericanism Award has honored leaders in business, community affairs and charitable endeavors who distinguish themselves\nand their organizations through their dedication to preserving liberty and advancing the cause of human rights, respect,\ndignity and equal opportunity.\n The AmerisourceBergen Foundation, an independent not-for-profit charitable giving organization focused on supporting\nhealth-related causes that enrich the global community, announced a $700,000 donation to Boys & Girls Clubs of America to\n3", "original_text": "For the third year in a row, selected information within the 2020 report\nwas assured by ERM Certification and Verification Services.\n", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "faa0ff04df9e087aae368011c0247fe317130845fdc1ac00576b0aef407d1f9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6d6bc92-9a17-4ac0-9740-d60cf91490f9", "node_type": "1", "metadata": {"window": "Other\nRevenue in Other was $2.1 billion in the second quarter of fiscal 2021, an increase of 11.5 percent compared to the same period in\nthe prior fiscal year due to growth at all three operating segments: MWI, ABCS, and World Courier.  Operating income in Other\nincreased 13.8 percent to $123.2 million in the second quarter of fiscal 2021 due to the strong performance of World Courier and\nMWI.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen released its 2020 Global Sustainability Report and ESG Reporting Index, detailing the impact of its robust\nsustainability and community efforts.  This year, AmerisourceBergen made its report available through the launch of a new\nmicrosite, which serves as a comprehensive, interactive resource to showcase data, information and relevant assets from the\nCompany in connection with topics related to ESG.  For the third year in a row, selected information within the 2020 report\nwas assured by ERM Certification and Verification Services.\n The Anti-Defamation League (ADL) Philadelphia chapter presented the Americanism Award to Steven H. Collis, Chairman,\nPresident & CEO, and AmerisourceBergen for their commitment to fighting hate locally, across the country and the world.  The\nAmericanism Award has honored leaders in business, community affairs and charitable endeavors who distinguish themselves\nand their organizations through their dedication to preserving liberty and advancing the cause of human rights, respect,\ndignity and equal opportunity.\n", "original_text": "This year, AmerisourceBergen made its report available through the launch of a new\nmicrosite, which serves as a comprehensive, interactive resource to showcase data, information and relevant assets from the\nCompany in connection with topics related to ESG. ", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e0f8e440a746849273a23defdd2ed63e81ba3e72421c623ab9bed3fc729170e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f421df79-0e2d-44c3-bcde-6e7cfa2b65e4", "node_type": "1", "metadata": {"window": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen released its 2020 Global Sustainability Report and ESG Reporting Index, detailing the impact of its robust\nsustainability and community efforts.  This year, AmerisourceBergen made its report available through the launch of a new\nmicrosite, which serves as a comprehensive, interactive resource to showcase data, information and relevant assets from the\nCompany in connection with topics related to ESG.  For the third year in a row, selected information within the 2020 report\nwas assured by ERM Certification and Verification Services.\n The Anti-Defamation League (ADL) Philadelphia chapter presented the Americanism Award to Steven H. Collis, Chairman,\nPresident & CEO, and AmerisourceBergen for their commitment to fighting hate locally, across the country and the world.  The\nAmericanism Award has honored leaders in business, community affairs and charitable endeavors who distinguish themselves\nand their organizations through their dedication to preserving liberty and advancing the cause of human rights, respect,\ndignity and equal opportunity.\n The AmerisourceBergen Foundation, an independent not-for-profit charitable giving organization focused on supporting\nhealth-related causes that enrich the global community, announced a $700,000 donation to Boys & Girls Clubs of America to\n3", "original_text": "The Anti-Defamation League (ADL) Philadelphia chapter presented the Americanism Award to Steven H. Collis, Chairman,\nPresident & CEO, and AmerisourceBergen for their commitment to fighting hate locally, across the country and the world. "}, "hash": "905b75dbab91b1d50f2b9c1eab27648d9c0e7eee2187515a51d15733a157f2eb", "class_name": "RelatedNodeInfo"}}, "text": "For the third year in a row, selected information within the 2020 report\nwas assured by ERM Certification and Verification Services.\n", "start_char_idx": 3650, "end_char_idx": 3783, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f421df79-0e2d-44c3-bcde-6e7cfa2b65e4": {"__data__": {"id_": "f421df79-0e2d-44c3-bcde-6e7cfa2b65e4", "embedding": null, "metadata": {"window": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen released its 2020 Global Sustainability Report and ESG Reporting Index, detailing the impact of its robust\nsustainability and community efforts.  This year, AmerisourceBergen made its report available through the launch of a new\nmicrosite, which serves as a comprehensive, interactive resource to showcase data, information and relevant assets from the\nCompany in connection with topics related to ESG.  For the third year in a row, selected information within the 2020 report\nwas assured by ERM Certification and Verification Services.\n The Anti-Defamation League (ADL) Philadelphia chapter presented the Americanism Award to Steven H. Collis, Chairman,\nPresident & CEO, and AmerisourceBergen for their commitment to fighting hate locally, across the country and the world.  The\nAmericanism Award has honored leaders in business, community affairs and charitable endeavors who distinguish themselves\nand their organizations through their dedication to preserving liberty and advancing the cause of human rights, respect,\ndignity and equal opportunity.\n The AmerisourceBergen Foundation, an independent not-for-profit charitable giving organization focused on supporting\nhealth-related causes that enrich the global community, announced a $700,000 donation to Boys & Girls Clubs of America to\n3", "original_text": "The Anti-Defamation League (ADL) Philadelphia chapter presented the Americanism Award to Steven H. Collis, Chairman,\nPresident & CEO, and AmerisourceBergen for their commitment to fighting hate locally, across the country and the world. ", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "faa0ff04df9e087aae368011c0247fe317130845fdc1ac00576b0aef407d1f9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a16c8ff3-1875-42e7-9817-e018833a4197", "node_type": "1", "metadata": {"window": "Operating income in Other\nincreased 13.8 percent to $123.2 million in the second quarter of fiscal 2021 due to the strong performance of World Courier and\nMWI.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen released its 2020 Global Sustainability Report and ESG Reporting Index, detailing the impact of its robust\nsustainability and community efforts.  This year, AmerisourceBergen made its report available through the launch of a new\nmicrosite, which serves as a comprehensive, interactive resource to showcase data, information and relevant assets from the\nCompany in connection with topics related to ESG.  For the third year in a row, selected information within the 2020 report\nwas assured by ERM Certification and Verification Services.\n The Anti-Defamation League (ADL) Philadelphia chapter presented the Americanism Award to Steven H. Collis, Chairman,\nPresident & CEO, and AmerisourceBergen for their commitment to fighting hate locally, across the country and the world.  The\nAmericanism Award has honored leaders in business, community affairs and charitable endeavors who distinguish themselves\nand their organizations through their dedication to preserving liberty and advancing the cause of human rights, respect,\ndignity and equal opportunity.\n The AmerisourceBergen Foundation, an independent not-for-profit charitable giving organization focused on supporting\nhealth-related causes that enrich the global community, announced a $700,000 donation to Boys & Girls Clubs of America to\n3", "original_text": "For the third year in a row, selected information within the 2020 report\nwas assured by ERM Certification and Verification Services.\n", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fb3f46df8aaa3a43af3c5905c517556a12fc99e994d9f8432814031570c17b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38d6ec95-8885-4e56-856b-9214b8631697", "node_type": "1", "metadata": {"window": "This year, AmerisourceBergen made its report available through the launch of a new\nmicrosite, which serves as a comprehensive, interactive resource to showcase data, information and relevant assets from the\nCompany in connection with topics related to ESG.  For the third year in a row, selected information within the 2020 report\nwas assured by ERM Certification and Verification Services.\n The Anti-Defamation League (ADL) Philadelphia chapter presented the Americanism Award to Steven H. Collis, Chairman,\nPresident & CEO, and AmerisourceBergen for their commitment to fighting hate locally, across the country and the world.  The\nAmericanism Award has honored leaders in business, community affairs and charitable endeavors who distinguish themselves\nand their organizations through their dedication to preserving liberty and advancing the cause of human rights, respect,\ndignity and equal opportunity.\n The AmerisourceBergen Foundation, an independent not-for-profit charitable giving organization focused on supporting\nhealth-related causes that enrich the global community, announced a $700,000 donation to Boys & Girls Clubs of America to\n3", "original_text": "The\nAmericanism Award has honored leaders in business, community affairs and charitable endeavors who distinguish themselves\nand their organizations through their dedication to preserving liberty and advancing the cause of human rights, respect,\ndignity and equal opportunity.\n"}, "hash": "f9db791469b0ded0e9a458b9b3f82778a316ed01a1708b0b7018c981b48bc9b2", "class_name": "RelatedNodeInfo"}}, "text": "The Anti-Defamation League (ADL) Philadelphia chapter presented the Americanism Award to Steven H. Collis, Chairman,\nPresident & CEO, and AmerisourceBergen for their commitment to fighting hate locally, across the country and the world. ", "start_char_idx": 3783, "end_char_idx": 4020, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38d6ec95-8885-4e56-856b-9214b8631697": {"__data__": {"id_": "38d6ec95-8885-4e56-856b-9214b8631697", "embedding": null, "metadata": {"window": "This year, AmerisourceBergen made its report available through the launch of a new\nmicrosite, which serves as a comprehensive, interactive resource to showcase data, information and relevant assets from the\nCompany in connection with topics related to ESG.  For the third year in a row, selected information within the 2020 report\nwas assured by ERM Certification and Verification Services.\n The Anti-Defamation League (ADL) Philadelphia chapter presented the Americanism Award to Steven H. Collis, Chairman,\nPresident & CEO, and AmerisourceBergen for their commitment to fighting hate locally, across the country and the world.  The\nAmericanism Award has honored leaders in business, community affairs and charitable endeavors who distinguish themselves\nand their organizations through their dedication to preserving liberty and advancing the cause of human rights, respect,\ndignity and equal opportunity.\n The AmerisourceBergen Foundation, an independent not-for-profit charitable giving organization focused on supporting\nhealth-related causes that enrich the global community, announced a $700,000 donation to Boys & Girls Clubs of America to\n3", "original_text": "The\nAmericanism Award has honored leaders in business, community affairs and charitable endeavors who distinguish themselves\nand their organizations through their dedication to preserving liberty and advancing the cause of human rights, respect,\ndignity and equal opportunity.\n", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "faa0ff04df9e087aae368011c0247fe317130845fdc1ac00576b0aef407d1f9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f421df79-0e2d-44c3-bcde-6e7cfa2b65e4", "node_type": "1", "metadata": {"window": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen released its 2020 Global Sustainability Report and ESG Reporting Index, detailing the impact of its robust\nsustainability and community efforts.  This year, AmerisourceBergen made its report available through the launch of a new\nmicrosite, which serves as a comprehensive, interactive resource to showcase data, information and relevant assets from the\nCompany in connection with topics related to ESG.  For the third year in a row, selected information within the 2020 report\nwas assured by ERM Certification and Verification Services.\n The Anti-Defamation League (ADL) Philadelphia chapter presented the Americanism Award to Steven H. Collis, Chairman,\nPresident & CEO, and AmerisourceBergen for their commitment to fighting hate locally, across the country and the world.  The\nAmericanism Award has honored leaders in business, community affairs and charitable endeavors who distinguish themselves\nand their organizations through their dedication to preserving liberty and advancing the cause of human rights, respect,\ndignity and equal opportunity.\n The AmerisourceBergen Foundation, an independent not-for-profit charitable giving organization focused on supporting\nhealth-related causes that enrich the global community, announced a $700,000 donation to Boys & Girls Clubs of America to\n3", "original_text": "The Anti-Defamation League (ADL) Philadelphia chapter presented the Americanism Award to Steven H. Collis, Chairman,\nPresident & CEO, and AmerisourceBergen for their commitment to fighting hate locally, across the country and the world. ", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88e913d519678be0438141423088b8c185366c1fe2867a7a32ae2f73132fe343", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f217a0da-3c0e-4e2f-93a1-93b82c08361f", "node_type": "1", "metadata": {"window": "For the third year in a row, selected information within the 2020 report\nwas assured by ERM Certification and Verification Services.\n The Anti-Defamation League (ADL) Philadelphia chapter presented the Americanism Award to Steven H. Collis, Chairman,\nPresident & CEO, and AmerisourceBergen for their commitment to fighting hate locally, across the country and the world.  The\nAmericanism Award has honored leaders in business, community affairs and charitable endeavors who distinguish themselves\nand their organizations through their dedication to preserving liberty and advancing the cause of human rights, respect,\ndignity and equal opportunity.\n The AmerisourceBergen Foundation, an independent not-for-profit charitable giving organization focused on supporting\nhealth-related causes that enrich the global community, announced a $700,000 donation to Boys & Girls Clubs of America to\n3", "original_text": "The AmerisourceBergen Foundation, an independent not-for-profit charitable giving organization focused on supporting\nhealth-related causes that enrich the global community, announced a $700,000 donation to Boys & Girls Clubs of America to\n3"}, "hash": "d91ea3d304e563daaa9e07a639f36caaf826a73d851bd96971fdf5fba8d3d83b", "class_name": "RelatedNodeInfo"}}, "text": "The\nAmericanism Award has honored leaders in business, community affairs and charitable endeavors who distinguish themselves\nand their organizations through their dedication to preserving liberty and advancing the cause of human rights, respect,\ndignity and equal opportunity.\n", "start_char_idx": 4020, "end_char_idx": 4297, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f217a0da-3c0e-4e2f-93a1-93b82c08361f": {"__data__": {"id_": "f217a0da-3c0e-4e2f-93a1-93b82c08361f", "embedding": null, "metadata": {"window": "For the third year in a row, selected information within the 2020 report\nwas assured by ERM Certification and Verification Services.\n The Anti-Defamation League (ADL) Philadelphia chapter presented the Americanism Award to Steven H. Collis, Chairman,\nPresident & CEO, and AmerisourceBergen for their commitment to fighting hate locally, across the country and the world.  The\nAmericanism Award has honored leaders in business, community affairs and charitable endeavors who distinguish themselves\nand their organizations through their dedication to preserving liberty and advancing the cause of human rights, respect,\ndignity and equal opportunity.\n The AmerisourceBergen Foundation, an independent not-for-profit charitable giving organization focused on supporting\nhealth-related causes that enrich the global community, announced a $700,000 donation to Boys & Girls Clubs of America to\n3", "original_text": "The AmerisourceBergen Foundation, an independent not-for-profit charitable giving organization focused on supporting\nhealth-related causes that enrich the global community, announced a $700,000 donation to Boys & Girls Clubs of America to\n3", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "faa0ff04df9e087aae368011c0247fe317130845fdc1ac00576b0aef407d1f9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38d6ec95-8885-4e56-856b-9214b8631697", "node_type": "1", "metadata": {"window": "This year, AmerisourceBergen made its report available through the launch of a new\nmicrosite, which serves as a comprehensive, interactive resource to showcase data, information and relevant assets from the\nCompany in connection with topics related to ESG.  For the third year in a row, selected information within the 2020 report\nwas assured by ERM Certification and Verification Services.\n The Anti-Defamation League (ADL) Philadelphia chapter presented the Americanism Award to Steven H. Collis, Chairman,\nPresident & CEO, and AmerisourceBergen for their commitment to fighting hate locally, across the country and the world.  The\nAmericanism Award has honored leaders in business, community affairs and charitable endeavors who distinguish themselves\nand their organizations through their dedication to preserving liberty and advancing the cause of human rights, respect,\ndignity and equal opportunity.\n The AmerisourceBergen Foundation, an independent not-for-profit charitable giving organization focused on supporting\nhealth-related causes that enrich the global community, announced a $700,000 donation to Boys & Girls Clubs of America to\n3", "original_text": "The\nAmericanism Award has honored leaders in business, community affairs and charitable endeavors who distinguish themselves\nand their organizations through their dedication to preserving liberty and advancing the cause of human rights, respect,\ndignity and equal opportunity.\n", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6cc0545b99a751b72733b19def5ea8d5c0c955035c48dc800c3baca02560d48a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2f55977-b190-4192-8c2a-295da12e7183", "node_type": "1", "metadata": {"window": "support COVID-19 vaccine education and awareness in an effort to remove barriers to vital healthcare access.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance,\nincluding better than expected performance in our Global Commercialization Services & Animal Health group, and an incrementally\nhigher expected share count for the year. ", "original_text": "support COVID-19 vaccine education and awareness in an effort to remove barriers to vital healthcare access.\n"}, "hash": "92fdbd76139c89cf063a27ece2ba114e0bb46f4806ded67dfeadd5a20664ac6c", "class_name": "RelatedNodeInfo"}}, "text": "The AmerisourceBergen Foundation, an independent not-for-profit charitable giving organization focused on supporting\nhealth-related causes that enrich the global community, announced a $700,000 donation to Boys & Girls Clubs of America to\n3", "start_char_idx": 4297, "end_char_idx": 4537, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2f55977-b190-4192-8c2a-295da12e7183": {"__data__": {"id_": "d2f55977-b190-4192-8c2a-295da12e7183", "embedding": null, "metadata": {"window": "support COVID-19 vaccine education and awareness in an effort to remove barriers to vital healthcare access.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance,\nincluding better than expected performance in our Global Commercialization Services & Animal Health group, and an incrementally\nhigher expected share count for the year. ", "original_text": "support COVID-19 vaccine education and awareness in an effort to remove barriers to vital healthcare access.\n", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5df726b7adb4ccf71bfd420344086e5244203684a9d66dd1fe080fbe17c31c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f217a0da-3c0e-4e2f-93a1-93b82c08361f", "node_type": "1", "metadata": {"window": "For the third year in a row, selected information within the 2020 report\nwas assured by ERM Certification and Verification Services.\n The Anti-Defamation League (ADL) Philadelphia chapter presented the Americanism Award to Steven H. Collis, Chairman,\nPresident & CEO, and AmerisourceBergen for their commitment to fighting hate locally, across the country and the world.  The\nAmericanism Award has honored leaders in business, community affairs and charitable endeavors who distinguish themselves\nand their organizations through their dedication to preserving liberty and advancing the cause of human rights, respect,\ndignity and equal opportunity.\n The AmerisourceBergen Foundation, an independent not-for-profit charitable giving organization focused on supporting\nhealth-related causes that enrich the global community, announced a $700,000 donation to Boys & Girls Clubs of America to\n3", "original_text": "The AmerisourceBergen Foundation, an independent not-for-profit charitable giving organization focused on supporting\nhealth-related causes that enrich the global community, announced a $700,000 donation to Boys & Girls Clubs of America to\n3", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "03faef48333ae1ccb103fcac55af520705a27505ef750987ed3ee76cc65f7e65", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73ff4732-5744-4d9e-a491-e68bc077ff09", "node_type": "1", "metadata": {"window": "support COVID-19 vaccine education and awareness in an effort to remove barriers to vital healthcare access.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance,\nincluding better than expected performance in our Global Commercialization Services & Animal Health group, and an incrementally\nhigher expected share count for the year.  This updated financial guidance does not include any contribution from the proposed\nAlliance Healthcare acquisition and does not reflect the weighted average share count impact of the 2 million shares of\nAmerisourceBergen common stock that will be delivered at closing of the transaction. ", "original_text": "Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. "}, "hash": "2e4f0346106e1c91a42a1afb0a082ddfdf2c565e1e8b4671cd2f09bc54354a18", "class_name": "RelatedNodeInfo"}}, "text": "support COVID-19 vaccine education and awareness in an effort to remove barriers to vital healthcare access.\n", "start_char_idx": 0, "end_char_idx": 109, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73ff4732-5744-4d9e-a491-e68bc077ff09": {"__data__": {"id_": "73ff4732-5744-4d9e-a491-e68bc077ff09", "embedding": null, "metadata": {"window": "support COVID-19 vaccine education and awareness in an effort to remove barriers to vital healthcare access.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance,\nincluding better than expected performance in our Global Commercialization Services & Animal Health group, and an incrementally\nhigher expected share count for the year.  This updated financial guidance does not include any contribution from the proposed\nAlliance Healthcare acquisition and does not reflect the weighted average share count impact of the 2 million shares of\nAmerisourceBergen common stock that will be delivered at closing of the transaction. ", "original_text": "Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5df726b7adb4ccf71bfd420344086e5244203684a9d66dd1fe080fbe17c31c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2f55977-b190-4192-8c2a-295da12e7183", "node_type": "1", "metadata": {"window": "support COVID-19 vaccine education and awareness in an effort to remove barriers to vital healthcare access.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance,\nincluding better than expected performance in our Global Commercialization Services & Animal Health group, and an incrementally\nhigher expected share count for the year. ", "original_text": "support COVID-19 vaccine education and awareness in an effort to remove barriers to vital healthcare access.\n", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "05325de3066849e59015ec571f0903244fd4ff38646030b6e5b7ea126557a4c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3aa54655-290d-46bd-ac5d-01e65e76dd8a", "node_type": "1", "metadata": {"window": "support COVID-19 vaccine education and awareness in an effort to remove barriers to vital healthcare access.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance,\nincluding better than expected performance in our Global Commercialization Services & Animal Health group, and an incrementally\nhigher expected share count for the year.  This updated financial guidance does not include any contribution from the proposed\nAlliance Healthcare acquisition and does not reflect the weighted average share count impact of the 2 million shares of\nAmerisourceBergen common stock that will be delivered at closing of the transaction.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $8.45 to $8.60, raised from the previous range of $8.40 to $8.60.\n", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n"}, "hash": "cd02ea12cff2388efe9936358226e818f04e0aec4dee0d8f0e544622430e48a1", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "start_char_idx": 109, "end_char_idx": 353, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3aa54655-290d-46bd-ac5d-01e65e76dd8a": {"__data__": {"id_": "3aa54655-290d-46bd-ac5d-01e65e76dd8a", "embedding": null, "metadata": {"window": "support COVID-19 vaccine education and awareness in an effort to remove barriers to vital healthcare access.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance,\nincluding better than expected performance in our Global Commercialization Services & Animal Health group, and an incrementally\nhigher expected share count for the year.  This updated financial guidance does not include any contribution from the proposed\nAlliance Healthcare acquisition and does not reflect the weighted average share count impact of the 2 million shares of\nAmerisourceBergen common stock that will be delivered at closing of the transaction.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $8.45 to $8.60, raised from the previous range of $8.40 to $8.60.\n", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5df726b7adb4ccf71bfd420344086e5244203684a9d66dd1fe080fbe17c31c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73ff4732-5744-4d9e-a491-e68bc077ff09", "node_type": "1", "metadata": {"window": "support COVID-19 vaccine education and awareness in an effort to remove barriers to vital healthcare access.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance,\nincluding better than expected performance in our Global Commercialization Services & Animal Health group, and an incrementally\nhigher expected share count for the year.  This updated financial guidance does not include any contribution from the proposed\nAlliance Healthcare acquisition and does not reflect the weighted average share count impact of the 2 million shares of\nAmerisourceBergen common stock that will be delivered at closing of the transaction. ", "original_text": "Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f291dcee9051e42eebc01c3b01d22fbb1164f4c3be0de7e90d53ee1045470768", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00fdab8c-f721-4967-a282-2f0cd0abe3e9", "node_type": "1", "metadata": {"window": "support COVID-19 vaccine education and awareness in an effort to remove barriers to vital healthcare access.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance,\nincluding better than expected performance in our Global Commercialization Services & Animal Health group, and an incrementally\nhigher expected share count for the year.  This updated financial guidance does not include any contribution from the proposed\nAlliance Healthcare acquisition and does not reflect the weighted average share count impact of the 2 million shares of\nAmerisourceBergen common stock that will be delivered at closing of the transaction.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $8.45 to $8.60, raised from the previous range of $8.40 to $8.60.\n Additional expectations now include:\nAdjusted operating expense growth in the high-single digit percent range, narrowed from the mid- to high-single digit\npercent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income growth in\nthe low-double digit percent range, up from the mid- to high-single digit percent range;\nWeighted average shares to be between 207 million and 208 million, raised from the previous expectation of approximately\n207 million for the fiscal year.\n", "original_text": "Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance,\nincluding better than expected performance in our Global Commercialization Services & Animal Health group, and an incrementally\nhigher expected share count for the year. "}, "hash": "84ce7bbe6e880b976f7f48633d0ba4ab08ec8472ed4aafcf53c6402a9ef574df", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "start_char_idx": 353, "end_char_idx": 485, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00fdab8c-f721-4967-a282-2f0cd0abe3e9": {"__data__": {"id_": "00fdab8c-f721-4967-a282-2f0cd0abe3e9", "embedding": null, "metadata": {"window": "support COVID-19 vaccine education and awareness in an effort to remove barriers to vital healthcare access.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance,\nincluding better than expected performance in our Global Commercialization Services & Animal Health group, and an incrementally\nhigher expected share count for the year.  This updated financial guidance does not include any contribution from the proposed\nAlliance Healthcare acquisition and does not reflect the weighted average share count impact of the 2 million shares of\nAmerisourceBergen common stock that will be delivered at closing of the transaction.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $8.45 to $8.60, raised from the previous range of $8.40 to $8.60.\n Additional expectations now include:\nAdjusted operating expense growth in the high-single digit percent range, narrowed from the mid- to high-single digit\npercent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income growth in\nthe low-double digit percent range, up from the mid- to high-single digit percent range;\nWeighted average shares to be between 207 million and 208 million, raised from the previous expectation of approximately\n207 million for the fiscal year.\n", "original_text": "Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance,\nincluding better than expected performance in our Global Commercialization Services & Animal Health group, and an incrementally\nhigher expected share count for the year. ", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5df726b7adb4ccf71bfd420344086e5244203684a9d66dd1fe080fbe17c31c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3aa54655-290d-46bd-ac5d-01e65e76dd8a", "node_type": "1", "metadata": {"window": "support COVID-19 vaccine education and awareness in an effort to remove barriers to vital healthcare access.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance,\nincluding better than expected performance in our Global Commercialization Services & Animal Health group, and an incrementally\nhigher expected share count for the year.  This updated financial guidance does not include any contribution from the proposed\nAlliance Healthcare acquisition and does not reflect the weighted average share count impact of the 2 million shares of\nAmerisourceBergen common stock that will be delivered at closing of the transaction.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $8.45 to $8.60, raised from the previous range of $8.40 to $8.60.\n", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d1030d2dce9a23de710d6c25473dac3056f52304913cc1515182c5eddc1d415", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "413fa278-a10d-4015-9ecf-7d25b95dbc69", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance,\nincluding better than expected performance in our Global Commercialization Services & Animal Health group, and an incrementally\nhigher expected share count for the year.  This updated financial guidance does not include any contribution from the proposed\nAlliance Healthcare acquisition and does not reflect the weighted average share count impact of the 2 million shares of\nAmerisourceBergen common stock that will be delivered at closing of the transaction.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $8.45 to $8.60, raised from the previous range of $8.40 to $8.60.\n Additional expectations now include:\nAdjusted operating expense growth in the high-single digit percent range, narrowed from the mid- to high-single digit\npercent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income growth in\nthe low-double digit percent range, up from the mid- to high-single digit percent range;\nWeighted average shares to be between 207 million and 208 million, raised from the previous expectation of approximately\n207 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n", "original_text": "This updated financial guidance does not include any contribution from the proposed\nAlliance Healthcare acquisition and does not reflect the weighted average share count impact of the 2 million shares of\nAmerisourceBergen common stock that will be delivered at closing of the transaction. "}, "hash": "050e041a0660b027cd43f7f3a1f8ca572cb98b0dadb4e60a9ad743999c22dc4b", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance,\nincluding better than expected performance in our Global Commercialization Services & Animal Health group, and an incrementally\nhigher expected share count for the year. ", "start_char_idx": 485, "end_char_idx": 844, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "413fa278-a10d-4015-9ecf-7d25b95dbc69": {"__data__": {"id_": "413fa278-a10d-4015-9ecf-7d25b95dbc69", "embedding": null, "metadata": {"window": "Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance,\nincluding better than expected performance in our Global Commercialization Services & Animal Health group, and an incrementally\nhigher expected share count for the year.  This updated financial guidance does not include any contribution from the proposed\nAlliance Healthcare acquisition and does not reflect the weighted average share count impact of the 2 million shares of\nAmerisourceBergen common stock that will be delivered at closing of the transaction.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $8.45 to $8.60, raised from the previous range of $8.40 to $8.60.\n Additional expectations now include:\nAdjusted operating expense growth in the high-single digit percent range, narrowed from the mid- to high-single digit\npercent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income growth in\nthe low-double digit percent range, up from the mid- to high-single digit percent range;\nWeighted average shares to be between 207 million and 208 million, raised from the previous expectation of approximately\n207 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n", "original_text": "This updated financial guidance does not include any contribution from the proposed\nAlliance Healthcare acquisition and does not reflect the weighted average share count impact of the 2 million shares of\nAmerisourceBergen common stock that will be delivered at closing of the transaction. ", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5df726b7adb4ccf71bfd420344086e5244203684a9d66dd1fe080fbe17c31c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00fdab8c-f721-4967-a282-2f0cd0abe3e9", "node_type": "1", "metadata": {"window": "support COVID-19 vaccine education and awareness in an effort to remove barriers to vital healthcare access.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance,\nincluding better than expected performance in our Global Commercialization Services & Animal Health group, and an incrementally\nhigher expected share count for the year.  This updated financial guidance does not include any contribution from the proposed\nAlliance Healthcare acquisition and does not reflect the weighted average share count impact of the 2 million shares of\nAmerisourceBergen common stock that will be delivered at closing of the transaction.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $8.45 to $8.60, raised from the previous range of $8.40 to $8.60.\n Additional expectations now include:\nAdjusted operating expense growth in the high-single digit percent range, narrowed from the mid- to high-single digit\npercent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income growth in\nthe low-double digit percent range, up from the mid- to high-single digit percent range;\nWeighted average shares to be between 207 million and 208 million, raised from the previous expectation of approximately\n207 million for the fiscal year.\n", "original_text": "Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance,\nincluding better than expected performance in our Global Commercialization Services & Animal Health group, and an incrementally\nhigher expected share count for the year. ", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a1c1317c8894d28cb823ccd46f94fce4a62c457dcb23946b3eab673355274a95", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "12d23d64-13aa-42fa-a483-c7b32d4e1ddf", "node_type": "1", "metadata": {"window": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance,\nincluding better than expected performance in our Global Commercialization Services & Animal Health group, and an incrementally\nhigher expected share count for the year.  This updated financial guidance does not include any contribution from the proposed\nAlliance Healthcare acquisition and does not reflect the weighted average share count impact of the 2 million shares of\nAmerisourceBergen common stock that will be delivered at closing of the transaction.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $8.45 to $8.60, raised from the previous range of $8.40 to $8.60.\n Additional expectations now include:\nAdjusted operating expense growth in the high-single digit percent range, narrowed from the mid- to high-single digit\npercent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income growth in\nthe low-double digit percent range, up from the mid- to high-single digit percent range;\nWeighted average shares to be between 207 million and 208 million, raised from the previous expectation of approximately\n207 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable June 1, 2021, to\nstockholders of record at the close of business on May 17, 2021.\n", "original_text": "The Company now expects:\nAdjusted Diluted EPS to be in the range of $8.45 to $8.60, raised from the previous range of $8.40 to $8.60.\n"}, "hash": "bd99b61f5fecb48c5f0a48b1c5c13a387a75239f23f26f49225fe131422dbab7", "class_name": "RelatedNodeInfo"}}, "text": "This updated financial guidance does not include any contribution from the proposed\nAlliance Healthcare acquisition and does not reflect the weighted average share count impact of the 2 million shares of\nAmerisourceBergen common stock that will be delivered at closing of the transaction. ", "start_char_idx": 844, "end_char_idx": 1133, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "12d23d64-13aa-42fa-a483-c7b32d4e1ddf": {"__data__": {"id_": "12d23d64-13aa-42fa-a483-c7b32d4e1ddf", "embedding": null, "metadata": {"window": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance,\nincluding better than expected performance in our Global Commercialization Services & Animal Health group, and an incrementally\nhigher expected share count for the year.  This updated financial guidance does not include any contribution from the proposed\nAlliance Healthcare acquisition and does not reflect the weighted average share count impact of the 2 million shares of\nAmerisourceBergen common stock that will be delivered at closing of the transaction.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $8.45 to $8.60, raised from the previous range of $8.40 to $8.60.\n Additional expectations now include:\nAdjusted operating expense growth in the high-single digit percent range, narrowed from the mid- to high-single digit\npercent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income growth in\nthe low-double digit percent range, up from the mid- to high-single digit percent range;\nWeighted average shares to be between 207 million and 208 million, raised from the previous expectation of approximately\n207 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable June 1, 2021, to\nstockholders of record at the close of business on May 17, 2021.\n", "original_text": "The Company now expects:\nAdjusted Diluted EPS to be in the range of $8.45 to $8.60, raised from the previous range of $8.40 to $8.60.\n", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5df726b7adb4ccf71bfd420344086e5244203684a9d66dd1fe080fbe17c31c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "413fa278-a10d-4015-9ecf-7d25b95dbc69", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance,\nincluding better than expected performance in our Global Commercialization Services & Animal Health group, and an incrementally\nhigher expected share count for the year.  This updated financial guidance does not include any contribution from the proposed\nAlliance Healthcare acquisition and does not reflect the weighted average share count impact of the 2 million shares of\nAmerisourceBergen common stock that will be delivered at closing of the transaction.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $8.45 to $8.60, raised from the previous range of $8.40 to $8.60.\n Additional expectations now include:\nAdjusted operating expense growth in the high-single digit percent range, narrowed from the mid- to high-single digit\npercent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income growth in\nthe low-double digit percent range, up from the mid- to high-single digit percent range;\nWeighted average shares to be between 207 million and 208 million, raised from the previous expectation of approximately\n207 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n", "original_text": "This updated financial guidance does not include any contribution from the proposed\nAlliance Healthcare acquisition and does not reflect the weighted average share count impact of the 2 million shares of\nAmerisourceBergen common stock that will be delivered at closing of the transaction. ", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "844cc8aa6c1307e01ac24c27185fabf0ca1e5e7e4ab7c3e4c6874deba4a6198e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8258d42c-1a2b-46be-abb7-1313c058ee08", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance,\nincluding better than expected performance in our Global Commercialization Services & Animal Health group, and an incrementally\nhigher expected share count for the year.  This updated financial guidance does not include any contribution from the proposed\nAlliance Healthcare acquisition and does not reflect the weighted average share count impact of the 2 million shares of\nAmerisourceBergen common stock that will be delivered at closing of the transaction.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $8.45 to $8.60, raised from the previous range of $8.40 to $8.60.\n Additional expectations now include:\nAdjusted operating expense growth in the high-single digit percent range, narrowed from the mid- to high-single digit\npercent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income growth in\nthe low-double digit percent range, up from the mid- to high-single digit percent range;\nWeighted average shares to be between 207 million and 208 million, raised from the previous expectation of approximately\n207 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable June 1, 2021, to\nstockholders of record at the close of business on May 17, 2021.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "original_text": "Additional expectations now include:\nAdjusted operating expense growth in the high-single digit percent range, narrowed from the mid- to high-single digit\npercent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income growth in\nthe low-double digit percent range, up from the mid- to high-single digit percent range;\nWeighted average shares to be between 207 million and 208 million, raised from the previous expectation of approximately\n207 million for the fiscal year.\n"}, "hash": "07beba2d00552073620a6f790e8ffb8d98901290ff56306367d2b93ea1ebca85", "class_name": "RelatedNodeInfo"}}, "text": "The Company now expects:\nAdjusted Diluted EPS to be in the range of $8.45 to $8.60, raised from the previous range of $8.40 to $8.60.\n", "start_char_idx": 1133, "end_char_idx": 1267, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8258d42c-1a2b-46be-abb7-1313c058ee08": {"__data__": {"id_": "8258d42c-1a2b-46be-abb7-1313c058ee08", "embedding": null, "metadata": {"window": "Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance,\nincluding better than expected performance in our Global Commercialization Services & Animal Health group, and an incrementally\nhigher expected share count for the year.  This updated financial guidance does not include any contribution from the proposed\nAlliance Healthcare acquisition and does not reflect the weighted average share count impact of the 2 million shares of\nAmerisourceBergen common stock that will be delivered at closing of the transaction.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $8.45 to $8.60, raised from the previous range of $8.40 to $8.60.\n Additional expectations now include:\nAdjusted operating expense growth in the high-single digit percent range, narrowed from the mid- to high-single digit\npercent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income growth in\nthe low-double digit percent range, up from the mid- to high-single digit percent range;\nWeighted average shares to be between 207 million and 208 million, raised from the previous expectation of approximately\n207 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable June 1, 2021, to\nstockholders of record at the close of business on May 17, 2021.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "original_text": "Additional expectations now include:\nAdjusted operating expense growth in the high-single digit percent range, narrowed from the mid- to high-single digit\npercent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income growth in\nthe low-double digit percent range, up from the mid- to high-single digit percent range;\nWeighted average shares to be between 207 million and 208 million, raised from the previous expectation of approximately\n207 million for the fiscal year.\n", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5df726b7adb4ccf71bfd420344086e5244203684a9d66dd1fe080fbe17c31c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "12d23d64-13aa-42fa-a483-c7b32d4e1ddf", "node_type": "1", "metadata": {"window": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance,\nincluding better than expected performance in our Global Commercialization Services & Animal Health group, and an incrementally\nhigher expected share count for the year.  This updated financial guidance does not include any contribution from the proposed\nAlliance Healthcare acquisition and does not reflect the weighted average share count impact of the 2 million shares of\nAmerisourceBergen common stock that will be delivered at closing of the transaction.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $8.45 to $8.60, raised from the previous range of $8.40 to $8.60.\n Additional expectations now include:\nAdjusted operating expense growth in the high-single digit percent range, narrowed from the mid- to high-single digit\npercent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income growth in\nthe low-double digit percent range, up from the mid- to high-single digit percent range;\nWeighted average shares to be between 207 million and 208 million, raised from the previous expectation of approximately\n207 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable June 1, 2021, to\nstockholders of record at the close of business on May 17, 2021.\n", "original_text": "The Company now expects:\nAdjusted Diluted EPS to be in the range of $8.45 to $8.60, raised from the previous range of $8.40 to $8.60.\n", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "558b64d71852049e177f72334a19de23a01209abb2a88611663d6d54f119282f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da16ce54-eee0-4fa5-836d-a6169e3faf01", "node_type": "1", "metadata": {"window": "This updated financial guidance does not include any contribution from the proposed\nAlliance Healthcare acquisition and does not reflect the weighted average share count impact of the 2 million shares of\nAmerisourceBergen common stock that will be delivered at closing of the transaction.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $8.45 to $8.60, raised from the previous range of $8.40 to $8.60.\n Additional expectations now include:\nAdjusted operating expense growth in the high-single digit percent range, narrowed from the mid- to high-single digit\npercent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income growth in\nthe low-double digit percent range, up from the mid- to high-single digit percent range;\nWeighted average shares to be between 207 million and 208 million, raised from the previous expectation of approximately\n207 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable June 1, 2021, to\nstockholders of record at the close of business on May 17, 2021.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 5, 2021. ", "original_text": "All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n"}, "hash": "bd87505f852420a0b1d5dc33e0c32c4e1e4577c6c628414ad2af9db578eed035", "class_name": "RelatedNodeInfo"}}, "text": "Additional expectations now include:\nAdjusted operating expense growth in the high-single digit percent range, narrowed from the mid- to high-single digit\npercent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income growth in\nthe low-double digit percent range, up from the mid- to high-single digit percent range;\nWeighted average shares to be between 207 million and 208 million, raised from the previous expectation of approximately\n207 million for the fiscal year.\n", "start_char_idx": 1267, "end_char_idx": 1802, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da16ce54-eee0-4fa5-836d-a6169e3faf01": {"__data__": {"id_": "da16ce54-eee0-4fa5-836d-a6169e3faf01", "embedding": null, "metadata": {"window": "This updated financial guidance does not include any contribution from the proposed\nAlliance Healthcare acquisition and does not reflect the weighted average share count impact of the 2 million shares of\nAmerisourceBergen common stock that will be delivered at closing of the transaction.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $8.45 to $8.60, raised from the previous range of $8.40 to $8.60.\n Additional expectations now include:\nAdjusted operating expense growth in the high-single digit percent range, narrowed from the mid- to high-single digit\npercent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income growth in\nthe low-double digit percent range, up from the mid- to high-single digit percent range;\nWeighted average shares to be between 207 million and 208 million, raised from the previous expectation of approximately\n207 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable June 1, 2021, to\nstockholders of record at the close of business on May 17, 2021.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 5, 2021. ", "original_text": "All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5df726b7adb4ccf71bfd420344086e5244203684a9d66dd1fe080fbe17c31c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8258d42c-1a2b-46be-abb7-1313c058ee08", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance,\nincluding better than expected performance in our Global Commercialization Services & Animal Health group, and an incrementally\nhigher expected share count for the year.  This updated financial guidance does not include any contribution from the proposed\nAlliance Healthcare acquisition and does not reflect the weighted average share count impact of the 2 million shares of\nAmerisourceBergen common stock that will be delivered at closing of the transaction.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $8.45 to $8.60, raised from the previous range of $8.40 to $8.60.\n Additional expectations now include:\nAdjusted operating expense growth in the high-single digit percent range, narrowed from the mid- to high-single digit\npercent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income growth in\nthe low-double digit percent range, up from the mid- to high-single digit percent range;\nWeighted average shares to be between 207 million and 208 million, raised from the previous expectation of approximately\n207 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable June 1, 2021, to\nstockholders of record at the close of business on May 17, 2021.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "original_text": "Additional expectations now include:\nAdjusted operating expense growth in the high-single digit percent range, narrowed from the mid- to high-single digit\npercent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income growth in\nthe low-double digit percent range, up from the mid- to high-single digit percent range;\nWeighted average shares to be between 207 million and 208 million, raised from the previous expectation of approximately\n207 million for the fiscal year.\n", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b27471237870b45cf3ec8c2fae84ccec28f26c531304ab931c8aa54545d20ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ec6a258-c1d8-439a-9eb4-5567fb414a16", "node_type": "1", "metadata": {"window": "The Company now expects:\nAdjusted Diluted EPS to be in the range of $8.45 to $8.60, raised from the previous range of $8.40 to $8.60.\n Additional expectations now include:\nAdjusted operating expense growth in the high-single digit percent range, narrowed from the mid- to high-single digit\npercent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income growth in\nthe low-double digit percent range, up from the mid- to high-single digit percent range;\nWeighted average shares to be between 207 million and 208 million, raised from the previous expectation of approximately\n207 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable June 1, 2021, to\nstockholders of record at the close of business on May 17, 2021.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 5, 2021.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com . ", "original_text": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable June 1, 2021, to\nstockholders of record at the close of business on May 17, 2021.\n"}, "hash": "97e1e9d809692f36c0d0e36e749a2d60c6593a426e191f98a0403268674bc0d5", "class_name": "RelatedNodeInfo"}}, "text": "All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n", "start_char_idx": 1802, "end_char_idx": 1930, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ec6a258-c1d8-439a-9eb4-5567fb414a16": {"__data__": {"id_": "8ec6a258-c1d8-439a-9eb4-5567fb414a16", "embedding": null, "metadata": {"window": "The Company now expects:\nAdjusted Diluted EPS to be in the range of $8.45 to $8.60, raised from the previous range of $8.40 to $8.60.\n Additional expectations now include:\nAdjusted operating expense growth in the high-single digit percent range, narrowed from the mid- to high-single digit\npercent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income growth in\nthe low-double digit percent range, up from the mid- to high-single digit percent range;\nWeighted average shares to be between 207 million and 208 million, raised from the previous expectation of approximately\n207 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable June 1, 2021, to\nstockholders of record at the close of business on May 17, 2021.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 5, 2021.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com . ", "original_text": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable June 1, 2021, to\nstockholders of record at the close of business on May 17, 2021.\n", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5df726b7adb4ccf71bfd420344086e5244203684a9d66dd1fe080fbe17c31c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da16ce54-eee0-4fa5-836d-a6169e3faf01", "node_type": "1", "metadata": {"window": "This updated financial guidance does not include any contribution from the proposed\nAlliance Healthcare acquisition and does not reflect the weighted average share count impact of the 2 million shares of\nAmerisourceBergen common stock that will be delivered at closing of the transaction.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $8.45 to $8.60, raised from the previous range of $8.40 to $8.60.\n Additional expectations now include:\nAdjusted operating expense growth in the high-single digit percent range, narrowed from the mid- to high-single digit\npercent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income growth in\nthe low-double digit percent range, up from the mid- to high-single digit percent range;\nWeighted average shares to be between 207 million and 208 million, raised from the previous expectation of approximately\n207 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable June 1, 2021, to\nstockholders of record at the close of business on May 17, 2021.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 5, 2021. ", "original_text": "All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0da2d9cff57b0114996320501aeef14ef6ed339c9ad4f7fbd159466547a3cfe5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26e4a0bb-0eb3-4c66-9233-819f1718915e", "node_type": "1", "metadata": {"window": "Additional expectations now include:\nAdjusted operating expense growth in the high-single digit percent range, narrowed from the mid- to high-single digit\npercent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income growth in\nthe low-double digit percent range, up from the mid- to high-single digit percent range;\nWeighted average shares to be between 207 million and 208 million, raised from the previous expectation of approximately\n207 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable June 1, 2021, to\nstockholders of record at the close of business on May 17, 2021.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 5, 2021.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694. ", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. "}, "hash": "8ed821c88f128fad1407701fe6e0b6aadbe8049940572076239211603678af9c", "class_name": "RelatedNodeInfo"}}, "text": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable June 1, 2021, to\nstockholders of record at the close of business on May 17, 2021.\n", "start_char_idx": 1930, "end_char_idx": 2136, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "26e4a0bb-0eb3-4c66-9233-819f1718915e": {"__data__": {"id_": "26e4a0bb-0eb3-4c66-9233-819f1718915e", "embedding": null, "metadata": {"window": "Additional expectations now include:\nAdjusted operating expense growth in the high-single digit percent range, narrowed from the mid- to high-single digit\npercent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income growth in\nthe low-double digit percent range, up from the mid- to high-single digit percent range;\nWeighted average shares to be between 207 million and 208 million, raised from the previous expectation of approximately\n207 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable June 1, 2021, to\nstockholders of record at the close of business on May 17, 2021.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 5, 2021.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694. ", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5df726b7adb4ccf71bfd420344086e5244203684a9d66dd1fe080fbe17c31c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ec6a258-c1d8-439a-9eb4-5567fb414a16", "node_type": "1", "metadata": {"window": "The Company now expects:\nAdjusted Diluted EPS to be in the range of $8.45 to $8.60, raised from the previous range of $8.40 to $8.60.\n Additional expectations now include:\nAdjusted operating expense growth in the high-single digit percent range, narrowed from the mid- to high-single digit\npercent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income growth in\nthe low-double digit percent range, up from the mid- to high-single digit percent range;\nWeighted average shares to be between 207 million and 208 million, raised from the previous expectation of approximately\n207 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable June 1, 2021, to\nstockholders of record at the close of business on May 17, 2021.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 5, 2021.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com . ", "original_text": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable June 1, 2021, to\nstockholders of record at the close of business on May 17, 2021.\n", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c8b2558f938588541f21d7c1e71ebf9e0754f6431554728f4157ab5068ceec76", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6114f95-2428-4716-af68-3dac6e1025e4", "node_type": "1", "metadata": {"window": "All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable June 1, 2021, to\nstockholders of record at the close of business on May 17, 2021.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 5, 2021.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282. ", "original_text": "ET on May 5, 2021. "}, "hash": "58f3c935ff18c0838197a8f16862aad9f8bf8aeaba16a514de0fa30a00b331fe", "class_name": "RelatedNodeInfo"}}, "text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "start_char_idx": 2136, "end_char_idx": 2251, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6114f95-2428-4716-af68-3dac6e1025e4": {"__data__": {"id_": "d6114f95-2428-4716-af68-3dac6e1025e4", "embedding": null, "metadata": {"window": "All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable June 1, 2021, to\nstockholders of record at the close of business on May 17, 2021.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 5, 2021.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282. ", "original_text": "ET on May 5, 2021. ", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5df726b7adb4ccf71bfd420344086e5244203684a9d66dd1fe080fbe17c31c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26e4a0bb-0eb3-4c66-9233-819f1718915e", "node_type": "1", "metadata": {"window": "Additional expectations now include:\nAdjusted operating expense growth in the high-single digit percent range, narrowed from the mid- to high-single digit\npercent range;\nOther, which is comprised of our Global Commercialization Services & Animal Health businesses, operating income growth in\nthe low-double digit percent range, up from the mid- to high-single digit percent range;\nWeighted average shares to be between 207 million and 208 million, raised from the previous expectation of approximately\n207 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable June 1, 2021, to\nstockholders of record at the close of business on May 17, 2021.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 5, 2021.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694. ", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3f18c695f520e122b02f3c7c2285c7b55aff4e5659bf6b2a52330c209ce64d2c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "754f07a6-e2e8-4cd5-a6e1-2e610c7cf1ce", "node_type": "1", "metadata": {"window": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable June 1, 2021, to\nstockholders of record at the close of business on May 17, 2021.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 5, 2021.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired. ", "original_text": "A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com . "}, "hash": "acff117c8d451c851fc02988f174bdada8da555f2a6188594a7a28a4a556b589", "class_name": "RelatedNodeInfo"}}, "text": "ET on May 5, 2021. ", "start_char_idx": 2251, "end_char_idx": 2270, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "754f07a6-e2e8-4cd5-a6e1-2e610c7cf1ce": {"__data__": {"id_": "754f07a6-e2e8-4cd5-a6e1-2e610c7cf1ce", "embedding": null, "metadata": {"window": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable June 1, 2021, to\nstockholders of record at the close of business on May 17, 2021.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 5, 2021.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired. ", "original_text": "A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com . ", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5df726b7adb4ccf71bfd420344086e5244203684a9d66dd1fe080fbe17c31c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6114f95-2428-4716-af68-3dac6e1025e4", "node_type": "1", "metadata": {"window": "All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable June 1, 2021, to\nstockholders of record at the close of business on May 17, 2021.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 5, 2021.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282. ", "original_text": "ET on May 5, 2021. ", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f93f8f21f8b34cef822aa222052417dfa25138b00a56dc552d69531d44b875bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2c527e5-6ac1-42e8-90d5-dae5db56a479", "node_type": "1", "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 5, 2021.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . ", "original_text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694. "}, "hash": "99962e72f941ce5c8a3221bce068626623963674e48b06a231b4f80f40fc1072", "class_name": "RelatedNodeInfo"}}, "text": "A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com . ", "start_char_idx": 2270, "end_char_idx": 2387, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2c527e5-6ac1-42e8-90d5-dae5db56a479": {"__data__": {"id_": "c2c527e5-6ac1-42e8-90d5-dae5db56a479", "embedding": null, "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 5, 2021.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . ", "original_text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694. ", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5df726b7adb4ccf71bfd420344086e5244203684a9d66dd1fe080fbe17c31c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "754f07a6-e2e8-4cd5-a6e1-2e610c7cf1ce", "node_type": "1", "metadata": {"window": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable June 1, 2021, to\nstockholders of record at the close of business on May 17, 2021.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 5, 2021.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired. ", "original_text": "A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com . ", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d21289d873bb1e4d7a95c6098a5dd0c749494b46ce8227c7cfc453bbe21e1b77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0fc38fa0-6d4d-4b62-8647-133a4322a55a", "node_type": "1", "metadata": {"window": "ET on May 5, 2021.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "original_text": "From outside the United States, dial +1 (412) 317-5282. "}, "hash": "03e201b6454a8290dbf39bddf94d21356f1f3849a1f685ee0eee9d5dcef3411b", "class_name": "RelatedNodeInfo"}}, "text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694. ", "start_char_idx": 2387, "end_char_idx": 2626, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0fc38fa0-6d4d-4b62-8647-133a4322a55a": {"__data__": {"id_": "0fc38fa0-6d4d-4b62-8647-133a4322a55a", "embedding": null, "metadata": {"window": "ET on May 5, 2021.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "original_text": "From outside the United States, dial +1 (412) 317-5282. ", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5df726b7adb4ccf71bfd420344086e5244203684a9d66dd1fe080fbe17c31c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2c527e5-6ac1-42e8-90d5-dae5db56a479", "node_type": "1", "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 5, 2021.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . ", "original_text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694. ", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a704a797e4a7f2e422ebe0ed40dd3fbdce8a08cf78c980f22ec1867d66c7403", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7add16e-5246-4bdb-adae-372257c50e47", "node_type": "1", "metadata": {"window": "A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "No access code is\nrequired. "}, "hash": "6a37f6d8b4a06bc0ec2521afca572cd0fe24a8caa1329c332e294dc0b9ed10b5", "class_name": "RelatedNodeInfo"}}, "text": "From outside the United States, dial +1 (412) 317-5282. ", "start_char_idx": 2626, "end_char_idx": 2682, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7add16e-5246-4bdb-adae-372257c50e47": {"__data__": {"id_": "a7add16e-5246-4bdb-adae-372257c50e47", "embedding": null, "metadata": {"window": "A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "No access code is\nrequired. ", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5df726b7adb4ccf71bfd420344086e5244203684a9d66dd1fe080fbe17c31c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0fc38fa0-6d4d-4b62-8647-133a4322a55a", "node_type": "1", "metadata": {"window": "ET on May 5, 2021.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "original_text": "From outside the United States, dial +1 (412) 317-5282. ", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "41a9dc43e73fd47d94006fdfbe960cf87b3a1b951fde8b5323fe7d7a5ec5c40d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11a9555d-4b1b-44a7-bad0-82ce154449f0", "node_type": "1", "metadata": {"window": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . "}, "hash": "c8ebaa055d627d00b7ff9e142184196236c96c3a5a483769d01d10eb9efc4b86", "class_name": "RelatedNodeInfo"}}, "text": "No access code is\nrequired. ", "start_char_idx": 2682, "end_char_idx": 2710, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11a9555d-4b1b-44a7-bad0-82ce154449f0": {"__data__": {"id_": "11a9555d-4b1b-44a7-bad0-82ce154449f0", "embedding": null, "metadata": {"window": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . ", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5df726b7adb4ccf71bfd420344086e5244203684a9d66dd1fe080fbe17c31c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7add16e-5246-4bdb-adae-372257c50e47", "node_type": "1", "metadata": {"window": "A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "No access code is\nrequired. ", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6fbabea6292d5440b1a7bdf08a07817d8b7fb789e42f95f81b607ca7db3d92f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b05cf9c-3454-4a49-ae5c-94896e9eb185", "node_type": "1", "metadata": {"window": "From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n"}, "hash": "977e52b469423f96d46f5da5cce93b4e56c7a608fe5b6815a463b36b0c95f305", "class_name": "RelatedNodeInfo"}}, "text": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . ", "start_char_idx": 2710, "end_char_idx": 2807, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b05cf9c-3454-4a49-ae5c-94896e9eb185": {"__data__": {"id_": "6b05cf9c-3454-4a49-ae5c-94896e9eb185", "embedding": null, "metadata": {"window": "From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5df726b7adb4ccf71bfd420344086e5244203684a9d66dd1fe080fbe17c31c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11a9555d-4b1b-44a7-bad0-82ce154449f0", "node_type": "1", "metadata": {"window": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . ", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2f68d77eb226568a70c8f06b586ecdf0efeace738e42d019e0551eb78fcad76c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b9c733e-08e6-4c28-9fee-ea22f52a3352", "node_type": "1", "metadata": {"window": "No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529. ", "original_text": "Replays of the call will be made available via telephone and webcast. "}, "hash": "a785338c29e966735e941039c52688d2834afbc610b23b145bbdf354a4b80e19", "class_name": "RelatedNodeInfo"}}, "text": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "start_char_idx": 2807, "end_char_idx": 2930, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b9c733e-08e6-4c28-9fee-ea22f52a3352": {"__data__": {"id_": "7b9c733e-08e6-4c28-9fee-ea22f52a3352", "embedding": null, "metadata": {"window": "No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529. ", "original_text": "Replays of the call will be made available via telephone and webcast. ", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5df726b7adb4ccf71bfd420344086e5244203684a9d66dd1fe080fbe17c31c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b05cf9c-3454-4a49-ae5c-94896e9eb185", "node_type": "1", "metadata": {"window": "From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e909a484a45753680ce5edb2183dd6e5caaaede57ea05ff6459d3731407ff8f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f3c75b5-41bf-4b55-a43d-2ea33f0da549", "node_type": "1", "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. "}, "hash": "dfa62d043018eabe2b73c0f5a741fd437ad6219af065d177bfeef0d158127e1c", "class_name": "RelatedNodeInfo"}}, "text": "Replays of the call will be made available via telephone and webcast. ", "start_char_idx": 2930, "end_char_idx": 3000, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f3c75b5-41bf-4b55-a43d-2ea33f0da549": {"__data__": {"id_": "9f3c75b5-41bf-4b55-a43d-2ea33f0da549", "embedding": null, "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5df726b7adb4ccf71bfd420344086e5244203684a9d66dd1fe080fbe17c31c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b9c733e-08e6-4c28-9fee-ea22f52a3352", "node_type": "1", "metadata": {"window": "No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529. ", "original_text": "Replays of the call will be made available via telephone and webcast. ", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1753209da4c5812f759e6e711c8aea9e0ebc4d47dc49a315c3b3760fe91ed9b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "612574e8-985f-4c76-91fc-2cd0bcfe1ffb", "node_type": "1", "metadata": {"window": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088. ", "original_text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. "}, "hash": "ed68e8fd717353b7f09af06aefbedf950b43b4b04274a32f1c1af039221032fd", "class_name": "RelatedNodeInfo"}}, "text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "start_char_idx": 3000, "end_char_idx": 3170, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "612574e8-985f-4c76-91fc-2cd0bcfe1ffb": {"__data__": {"id_": "612574e8-985f-4c76-91fc-2cd0bcfe1ffb", "embedding": null, "metadata": {"window": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088. ", "original_text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5df726b7adb4ccf71bfd420344086e5244203684a9d66dd1fe080fbe17c31c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f3c75b5-41bf-4b55-a43d-2ea33f0da549", "node_type": "1", "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "647c31178cc784b05cbfeb5564476616f66efc6dab35f74593643147d82567c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f8eb318-f0ab-496b-8d43-2bbb3a3c5097", "node_type": "1", "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10153917.\n", "original_text": "To access the telephone replay from within the U.S., dial (877) 344-7529. "}, "hash": "9cb06f7ddac23561ea59c52e7c8cbabf59216d3cd45f018a83bac8037b1c8542", "class_name": "RelatedNodeInfo"}}, "text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "start_char_idx": 3170, "end_char_idx": 3312, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f8eb318-f0ab-496b-8d43-2bbb3a3c5097": {"__data__": {"id_": "8f8eb318-f0ab-496b-8d43-2bbb3a3c5097", "embedding": null, "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10153917.\n", "original_text": "To access the telephone replay from within the U.S., dial (877) 344-7529. ", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5df726b7adb4ccf71bfd420344086e5244203684a9d66dd1fe080fbe17c31c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "612574e8-985f-4c76-91fc-2cd0bcfe1ffb", "node_type": "1", "metadata": {"window": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088. ", "original_text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6435737cb80270edbf05cf0d2759dadfa6d116e85027763c4c406ae1d0e5612e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4266fc77-443c-4479-885e-87d47df5823e", "node_type": "1", "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10153917.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "original_text": "From Canada, dial +1 (855) 669-9658. "}, "hash": "603d115b740fcee3e02e7b6d9253547d5dd3652a4ae54bc8bd5182be55af3d23", "class_name": "RelatedNodeInfo"}}, "text": "To access the telephone replay from within the U.S., dial (877) 344-7529. ", "start_char_idx": 3312, "end_char_idx": 3386, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4266fc77-443c-4479-885e-87d47df5823e": {"__data__": {"id_": "4266fc77-443c-4479-885e-87d47df5823e", "embedding": null, "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10153917.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "original_text": "From Canada, dial +1 (855) 669-9658. ", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5df726b7adb4ccf71bfd420344086e5244203684a9d66dd1fe080fbe17c31c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f8eb318-f0ab-496b-8d43-2bbb3a3c5097", "node_type": "1", "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10153917.\n", "original_text": "To access the telephone replay from within the U.S., dial (877) 344-7529. ", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c59c39247cf12bec9756b6ad0ff585972f811241f56cf8ca9e43260dd55b0ce0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d8fd312-1b67-4f22-93fc-57bfd3c263db", "node_type": "1", "metadata": {"window": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10153917.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\n4", "original_text": "From outside\nthe United States and Canada, dial +1 (412) 317-0088. "}, "hash": "3bb1590ca68db0e47a2d760ed973fee999ea4328283e67eb511340e0687d7fa3", "class_name": "RelatedNodeInfo"}}, "text": "From Canada, dial +1 (855) 669-9658. ", "start_char_idx": 3386, "end_char_idx": 3423, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d8fd312-1b67-4f22-93fc-57bfd3c263db": {"__data__": {"id_": "5d8fd312-1b67-4f22-93fc-57bfd3c263db", "embedding": null, "metadata": {"window": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10153917.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\n4", "original_text": "From outside\nthe United States and Canada, dial +1 (412) 317-0088. ", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5df726b7adb4ccf71bfd420344086e5244203684a9d66dd1fe080fbe17c31c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4266fc77-443c-4479-885e-87d47df5823e", "node_type": "1", "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10153917.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "original_text": "From Canada, dial +1 (855) 669-9658. ", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "53e07eab273bfa491696b7aa9ea138c83800fd1ba031597e3aea47015a651649", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d576f0a6-c780-4e0e-97f1-1eba01ee8206", "node_type": "1", "metadata": {"window": "To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10153917.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\n4", "original_text": "The access code for the replay is 10153917.\n"}, "hash": "f36606da7aba94c2318e3a2562c6a3290679045939c3362dbd5c460112e6c6ce", "class_name": "RelatedNodeInfo"}}, "text": "From outside\nthe United States and Canada, dial +1 (412) 317-0088. ", "start_char_idx": 3423, "end_char_idx": 3490, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d576f0a6-c780-4e0e-97f1-1eba01ee8206": {"__data__": {"id_": "d576f0a6-c780-4e0e-97f1-1eba01ee8206", "embedding": null, "metadata": {"window": "To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10153917.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\n4", "original_text": "The access code for the replay is 10153917.\n", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5df726b7adb4ccf71bfd420344086e5244203684a9d66dd1fe080fbe17c31c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d8fd312-1b67-4f22-93fc-57bfd3c263db", "node_type": "1", "metadata": {"window": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10153917.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\n4", "original_text": "From outside\nthe United States and Canada, dial +1 (412) 317-0088. ", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa357a995541d50558405da8ee656f11b7dbeabeaa744f246a1c7c09bdc1ccc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd08d2ef-2b11-47d1-86a3-414e093e93bc", "node_type": "1", "metadata": {"window": "From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10153917.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\n4", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. "}, "hash": "5d2e5d6df5d6f508b93e22650cda7d3fb933c5d337401fb34baba8b07edf9b91", "class_name": "RelatedNodeInfo"}}, "text": "The access code for the replay is 10153917.\n", "start_char_idx": 3490, "end_char_idx": 3534, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd08d2ef-2b11-47d1-86a3-414e093e93bc": {"__data__": {"id_": "bd08d2ef-2b11-47d1-86a3-414e093e93bc", "embedding": null, "metadata": {"window": "From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10153917.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\n4", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5df726b7adb4ccf71bfd420344086e5244203684a9d66dd1fe080fbe17c31c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d576f0a6-c780-4e0e-97f1-1eba01ee8206", "node_type": "1", "metadata": {"window": "To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10153917.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\n4", "original_text": "The access code for the replay is 10153917.\n", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e0e39be8f109fda1fc23606bb78b49043386b9af9909f14a46cc27d03b8cb12", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbee68b9-1f5a-4c85-9db7-bb9f0ca9b9f2", "node_type": "1", "metadata": {"window": "From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10153917.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\n4", "original_text": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\n4"}, "hash": "c7e143fbcda3a66177034462241f5aa58738220c9d853a85efa55b65d49215a4", "class_name": "RelatedNodeInfo"}}, "text": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "start_char_idx": 3534, "end_char_idx": 3747, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbee68b9-1f5a-4c85-9db7-bb9f0ca9b9f2": {"__data__": {"id_": "dbee68b9-1f5a-4c85-9db7-bb9f0ca9b9f2", "embedding": null, "metadata": {"window": "From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10153917.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\n4", "original_text": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\n4", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5df726b7adb4ccf71bfd420344086e5244203684a9d66dd1fe080fbe17c31c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd08d2ef-2b11-47d1-86a3-414e093e93bc", "node_type": "1", "metadata": {"window": "From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10153917.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\n4", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d8f24cefe95e0f0e3a3744f8338d81aff7501f95a6cdd99696c6d8b5a98c5fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7d3c56b-d11b-4c72-b23f-45802d12c629", "node_type": "1", "metadata": {"window": "and reliability for human and animal health.  Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n", "original_text": "and reliability for human and animal health. "}, "hash": "bf3c003b90aadc8aedb80b3de42ee37c6114f16059bc69e003a1acebffeff912", "class_name": "RelatedNodeInfo"}}, "text": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\n4", "start_char_idx": 3747, "end_char_idx": 3938, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7d3c56b-d11b-4c72-b23f-45802d12c629": {"__data__": {"id_": "a7d3c56b-d11b-4c72-b23f-45802d12c629", "embedding": null, "metadata": {"window": "and reliability for human and animal health.  Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n", "original_text": "and reliability for human and animal health. ", "page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c0bb4e5-b04e-460e-86a6-b70620fb2591", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82a3f1ffd92df8b289e5ce4affe786eee100bbba675ff2f61b17262fcbac15e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbee68b9-1f5a-4c85-9db7-bb9f0ca9b9f2", "node_type": "1", "metadata": {"window": "From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10153917.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\n4", "original_text": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\n4", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2a1ad16eaad1e5392de539192008131d7ebb166dcca90fc222ad8ec8401167f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9e0f246-1c0c-46c2-8f0a-d88d5e0c6e3e", "node_type": "1", "metadata": {"window": "and reliability for human and animal health.  Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\"). ", "original_text": "Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. "}, "hash": "8718a51195957af38d96db76453ab53e418a8ed16b33f9b193fb63b7c98a3e44", "class_name": "RelatedNodeInfo"}}, "text": "and reliability for human and animal health. ", "start_char_idx": 0, "end_char_idx": 45, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9e0f246-1c0c-46c2-8f0a-d88d5e0c6e3e": {"__data__": {"id_": "a9e0f246-1c0c-46c2-8f0a-d88d5e0c6e3e", "embedding": null, "metadata": {"window": "and reliability for human and animal health.  Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\"). ", "original_text": "Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c0bb4e5-b04e-460e-86a6-b70620fb2591", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82a3f1ffd92df8b289e5ce4affe786eee100bbba675ff2f61b17262fcbac15e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7d3c56b-d11b-4c72-b23f-45802d12c629", "node_type": "1", "metadata": {"window": "and reliability for human and animal health.  Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n", "original_text": "and reliability for human and animal health. ", "page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "56b1865a41a1dd772da459b1ee2546358c4c8cfaec633b9838236ac4e312c063", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4e0d1b3-9c49-42ea-a0e4-36dd093b49be", "node_type": "1", "metadata": {"window": "and reliability for human and animal health.  Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements. ", "original_text": "AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue. "}, "hash": "d02ab230232f935408faaeb7a786acddacfaff76062313d05face49e5beaacfc", "class_name": "RelatedNodeInfo"}}, "text": "Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "start_char_idx": 45, "end_char_idx": 160, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4e0d1b3-9c49-42ea-a0e4-36dd093b49be": {"__data__": {"id_": "b4e0d1b3-9c49-42ea-a0e4-36dd093b49be", "embedding": null, "metadata": {"window": "and reliability for human and animal health.  Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements. ", "original_text": "AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue. ", "page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c0bb4e5-b04e-460e-86a6-b70620fb2591", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82a3f1ffd92df8b289e5ce4affe786eee100bbba675ff2f61b17262fcbac15e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9e0f246-1c0c-46c2-8f0a-d88d5e0c6e3e", "node_type": "1", "metadata": {"window": "and reliability for human and animal health.  Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\"). ", "original_text": "Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "151c7890e206a7f6cfa70c2acbf8a4481cf49fa91a3d9c76df5c1e7d5185c058", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf70412e-87ff-4d4d-98b6-0cc2825be1cd", "node_type": "1", "metadata": {"window": "and reliability for human and animal health.  Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. ", "original_text": "Learn more at investor.amerisourcebergen.com .\n"}, "hash": "0e1d8ae65eeddca1d084606003cd172f866519e86b9175650b77fdf185c332c3", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue. ", "start_char_idx": 160, "end_char_idx": 258, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf70412e-87ff-4d4d-98b6-0cc2825be1cd": {"__data__": {"id_": "bf70412e-87ff-4d4d-98b6-0cc2825be1cd", "embedding": null, "metadata": {"window": "and reliability for human and animal health.  Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. ", "original_text": "Learn more at investor.amerisourcebergen.com .\n", "page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c0bb4e5-b04e-460e-86a6-b70620fb2591", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82a3f1ffd92df8b289e5ce4affe786eee100bbba675ff2f61b17262fcbac15e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4e0d1b3-9c49-42ea-a0e4-36dd093b49be", "node_type": "1", "metadata": {"window": "and reliability for human and animal health.  Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements. ", "original_text": "AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue. ", "page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d99666c3774da8e305496977af7bc8f662d38a3d44f3f090db413c0224f2f58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67be2197-1743-4a59-86f1-343ae8e8ee22", "node_type": "1", "metadata": {"window": "Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated. ", "original_text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\"). "}, "hash": "6f98e9bee15dab2ee6049d8a9ea0c48e21e5843fe8e7ff92b135387be84b1e6d", "class_name": "RelatedNodeInfo"}}, "text": "Learn more at investor.amerisourcebergen.com .\n", "start_char_idx": 258, "end_char_idx": 305, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67be2197-1743-4a59-86f1-343ae8e8ee22": {"__data__": {"id_": "67be2197-1743-4a59-86f1-343ae8e8ee22", "embedding": null, "metadata": {"window": "Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated. ", "original_text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\"). ", "page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c0bb4e5-b04e-460e-86a6-b70620fb2591", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82a3f1ffd92df8b289e5ce4affe786eee100bbba675ff2f61b17262fcbac15e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf70412e-87ff-4d4d-98b6-0cc2825be1cd", "node_type": "1", "metadata": {"window": "and reliability for human and animal health.  Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. ", "original_text": "Learn more at investor.amerisourcebergen.com .\n", "page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebb0fd7cd646cd2557781de7d6c15dfb262256b9724bce3a73e99c8acb2b6753", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25413cb1-4f95-4ed4-8dbf-fca73b3203a8", "node_type": "1", "metadata": {"window": "AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the Company\u2019s ability to consummate the proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s\nAlliance Healthcare businesses and related strategic transactions; the regulatory approvals required for the proposed acquisition and\nrelated strategic transactions not being obtained on the terms expected or on the anticipated schedule or at all; the integration of\nthe Alliance Healthcare business into the Company being more difficult, time consuming or costly than expected; the Company\u2019s or\nAlliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating performance and results; the effects of\ndisruption from the proposed acquisition and related strategic transactions on the respective businesses of the Company and\nAlliance Healthcare and the fact that the announcement or pendency of the proposed acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the proposed acquisition of the Alliance Healthcare businesses and related strategic\ntransactions, that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the\nanticipated synergies related thereto or to capture the anticipated synergies within the expected time period; risks associated with\nthe strategic, long-term relationship between Walgreens Boots Alliance, Inc. ", "original_text": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements. "}, "hash": "d64060707a5bce504adf499d26f895ab45e5d4349265161c34c90f209d08bd1f", "class_name": "RelatedNodeInfo"}}, "text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\"). ", "start_char_idx": 305, "end_char_idx": 652, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25413cb1-4f95-4ed4-8dbf-fca73b3203a8": {"__data__": {"id_": "25413cb1-4f95-4ed4-8dbf-fca73b3203a8", "embedding": null, "metadata": {"window": "AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the Company\u2019s ability to consummate the proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s\nAlliance Healthcare businesses and related strategic transactions; the regulatory approvals required for the proposed acquisition and\nrelated strategic transactions not being obtained on the terms expected or on the anticipated schedule or at all; the integration of\nthe Alliance Healthcare business into the Company being more difficult, time consuming or costly than expected; the Company\u2019s or\nAlliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating performance and results; the effects of\ndisruption from the proposed acquisition and related strategic transactions on the respective businesses of the Company and\nAlliance Healthcare and the fact that the announcement or pendency of the proposed acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the proposed acquisition of the Alliance Healthcare businesses and related strategic\ntransactions, that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the\nanticipated synergies related thereto or to capture the anticipated synergies within the expected time period; risks associated with\nthe strategic, long-term relationship between Walgreens Boots Alliance, Inc. ", "original_text": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements. ", "page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c0bb4e5-b04e-460e-86a6-b70620fb2591", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82a3f1ffd92df8b289e5ce4affe786eee100bbba675ff2f61b17262fcbac15e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67be2197-1743-4a59-86f1-343ae8e8ee22", "node_type": "1", "metadata": {"window": "Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated. ", "original_text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\"). ", "page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c10de0e81b8b05e91baaa7c3d4a5ca72fa78368c430381d25583760a37b026c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4560d255-65ba-4df9-9201-cebcf74cd8c6", "node_type": "1", "metadata": {"window": "Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the Company\u2019s ability to consummate the proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s\nAlliance Healthcare businesses and related strategic transactions; the regulatory approvals required for the proposed acquisition and\nrelated strategic transactions not being obtained on the terms expected or on the anticipated schedule or at all; the integration of\nthe Alliance Healthcare business into the Company being more difficult, time consuming or costly than expected; the Company\u2019s or\nAlliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating performance and results; the effects of\ndisruption from the proposed acquisition and related strategic transactions on the respective businesses of the Company and\nAlliance Healthcare and the fact that the announcement or pendency of the proposed acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the proposed acquisition of the Alliance Healthcare businesses and related strategic\ntransactions, that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the\nanticipated synergies related thereto or to capture the anticipated synergies within the expected time period; risks associated with\nthe strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; managing foreign expansion,\nincluding non-compliance with the U.S. ", "original_text": "These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. "}, "hash": "034d6a1953ff003a09431ad57d3faef92f65c43824509f596268897c18a0f687", "class_name": "RelatedNodeInfo"}}, "text": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements. ", "start_char_idx": 652, "end_char_idx": 1001, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4560d255-65ba-4df9-9201-cebcf74cd8c6": {"__data__": {"id_": "4560d255-65ba-4df9-9201-cebcf74cd8c6", "embedding": null, "metadata": {"window": "Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the Company\u2019s ability to consummate the proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s\nAlliance Healthcare businesses and related strategic transactions; the regulatory approvals required for the proposed acquisition and\nrelated strategic transactions not being obtained on the terms expected or on the anticipated schedule or at all; the integration of\nthe Alliance Healthcare business into the Company being more difficult, time consuming or costly than expected; the Company\u2019s or\nAlliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating performance and results; the effects of\ndisruption from the proposed acquisition and related strategic transactions on the respective businesses of the Company and\nAlliance Healthcare and the fact that the announcement or pendency of the proposed acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the proposed acquisition of the Alliance Healthcare businesses and related strategic\ntransactions, that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the\nanticipated synergies related thereto or to capture the anticipated synergies within the expected time period; risks associated with\nthe strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; managing foreign expansion,\nincluding non-compliance with the U.S. ", "original_text": "These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. ", "page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c0bb4e5-b04e-460e-86a6-b70620fb2591", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82a3f1ffd92df8b289e5ce4affe786eee100bbba675ff2f61b17262fcbac15e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25413cb1-4f95-4ed4-8dbf-fca73b3203a8", "node_type": "1", "metadata": {"window": "AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the Company\u2019s ability to consummate the proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s\nAlliance Healthcare businesses and related strategic transactions; the regulatory approvals required for the proposed acquisition and\nrelated strategic transactions not being obtained on the terms expected or on the anticipated schedule or at all; the integration of\nthe Alliance Healthcare business into the Company being more difficult, time consuming or costly than expected; the Company\u2019s or\nAlliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating performance and results; the effects of\ndisruption from the proposed acquisition and related strategic transactions on the respective businesses of the Company and\nAlliance Healthcare and the fact that the announcement or pendency of the proposed acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the proposed acquisition of the Alliance Healthcare businesses and related strategic\ntransactions, that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the\nanticipated synergies related thereto or to capture the anticipated synergies within the expected time period; risks associated with\nthe strategic, long-term relationship between Walgreens Boots Alliance, Inc. ", "original_text": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements. ", "page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c8d3a063293cf6225abb5922ee697c4927dfc67ba34ea3abf1d28cd773fb1da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "afa6e91b-b340-4bf0-9bf2-cebacb94ab08", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the Company\u2019s ability to consummate the proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s\nAlliance Healthcare businesses and related strategic transactions; the regulatory approvals required for the proposed acquisition and\nrelated strategic transactions not being obtained on the terms expected or on the anticipated schedule or at all; the integration of\nthe Alliance Healthcare business into the Company being more difficult, time consuming or costly than expected; the Company\u2019s or\nAlliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating performance and results; the effects of\ndisruption from the proposed acquisition and related strategic transactions on the respective businesses of the Company and\nAlliance Healthcare and the fact that the announcement or pendency of the proposed acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the proposed acquisition of the Alliance Healthcare businesses and related strategic\ntransactions, that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the\nanticipated synergies related thereto or to capture the anticipated synergies within the expected time period; risks associated with\nthe strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; managing foreign expansion,\nincluding non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and\nregulations; financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the\nCompany's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events, such as additional pandemics, that\naffect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments with\nrespect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and complete divestitures; the\ndisruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest\nrate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other\neconomic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.\n", "original_text": "These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated. "}, "hash": "c301a978dbaa025f02215c629e7b98896dd4365ffa1509db5cbf08d1221ae6f4", "class_name": "RelatedNodeInfo"}}, "text": "These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. ", "start_char_idx": 1001, "end_char_idx": 1163, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "afa6e91b-b340-4bf0-9bf2-cebacb94ab08": {"__data__": {"id_": "afa6e91b-b340-4bf0-9bf2-cebacb94ab08", "embedding": null, "metadata": {"window": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the Company\u2019s ability to consummate the proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s\nAlliance Healthcare businesses and related strategic transactions; the regulatory approvals required for the proposed acquisition and\nrelated strategic transactions not being obtained on the terms expected or on the anticipated schedule or at all; the integration of\nthe Alliance Healthcare business into the Company being more difficult, time consuming or costly than expected; the Company\u2019s or\nAlliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating performance and results; the effects of\ndisruption from the proposed acquisition and related strategic transactions on the respective businesses of the Company and\nAlliance Healthcare and the fact that the announcement or pendency of the proposed acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the proposed acquisition of the Alliance Healthcare businesses and related strategic\ntransactions, that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the\nanticipated synergies related thereto or to capture the anticipated synergies within the expected time period; risks associated with\nthe strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; managing foreign expansion,\nincluding non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and\nregulations; financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the\nCompany's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events, such as additional pandemics, that\naffect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments with\nrespect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and complete divestitures; the\ndisruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest\nrate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other\neconomic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.\n", "original_text": "These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated. ", "page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c0bb4e5-b04e-460e-86a6-b70620fb2591", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82a3f1ffd92df8b289e5ce4affe786eee100bbba675ff2f61b17262fcbac15e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4560d255-65ba-4df9-9201-cebcf74cd8c6", "node_type": "1", "metadata": {"window": "Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the Company\u2019s ability to consummate the proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s\nAlliance Healthcare businesses and related strategic transactions; the regulatory approvals required for the proposed acquisition and\nrelated strategic transactions not being obtained on the terms expected or on the anticipated schedule or at all; the integration of\nthe Alliance Healthcare business into the Company being more difficult, time consuming or costly than expected; the Company\u2019s or\nAlliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating performance and results; the effects of\ndisruption from the proposed acquisition and related strategic transactions on the respective businesses of the Company and\nAlliance Healthcare and the fact that the announcement or pendency of the proposed acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the proposed acquisition of the Alliance Healthcare businesses and related strategic\ntransactions, that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the\nanticipated synergies related thereto or to capture the anticipated synergies within the expected time period; risks associated with\nthe strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; managing foreign expansion,\nincluding non-compliance with the U.S. ", "original_text": "These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. ", "page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a0161cfc76c0b58155795d3a2d4cecb1711a354c4ceb03f0fd9e799c3905539", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a470d7c-e68d-4349-9afb-593c34d8aed1", "node_type": "1", "metadata": {"window": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the Company\u2019s ability to consummate the proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s\nAlliance Healthcare businesses and related strategic transactions; the regulatory approvals required for the proposed acquisition and\nrelated strategic transactions not being obtained on the terms expected or on the anticipated schedule or at all; the integration of\nthe Alliance Healthcare business into the Company being more difficult, time consuming or costly than expected; the Company\u2019s or\nAlliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating performance and results; the effects of\ndisruption from the proposed acquisition and related strategic transactions on the respective businesses of the Company and\nAlliance Healthcare and the fact that the announcement or pendency of the proposed acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the proposed acquisition of the Alliance Healthcare businesses and related strategic\ntransactions, that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the\nanticipated synergies related thereto or to capture the anticipated synergies within the expected time period; risks associated with\nthe strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; managing foreign expansion,\nincluding non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and\nregulations; financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the\nCompany's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events, such as additional pandemics, that\naffect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments with\nrespect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and complete divestitures; the\ndisruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest\nrate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other\neconomic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act. ", "original_text": "Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the Company\u2019s ability to consummate the proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s\nAlliance Healthcare businesses and related strategic transactions; the regulatory approvals required for the proposed acquisition and\nrelated strategic transactions not being obtained on the terms expected or on the anticipated schedule or at all; the integration of\nthe Alliance Healthcare business into the Company being more difficult, time consuming or costly than expected; the Company\u2019s or\nAlliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating performance and results; the effects of\ndisruption from the proposed acquisition and related strategic transactions on the respective businesses of the Company and\nAlliance Healthcare and the fact that the announcement or pendency of the proposed acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the proposed acquisition of the Alliance Healthcare businesses and related strategic\ntransactions, that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the\nanticipated synergies related thereto or to capture the anticipated synergies within the expected time period; risks associated with\nthe strategic, long-term relationship between Walgreens Boots Alliance, Inc. "}, "hash": "6bb012af8ee9cf111cfe3d10d4016487c991c51221f7b80bd53a989c46dd83dc", "class_name": "RelatedNodeInfo"}}, "text": "These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated. ", "start_char_idx": 1163, "end_char_idx": 1362, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a470d7c-e68d-4349-9afb-593c34d8aed1": {"__data__": {"id_": "1a470d7c-e68d-4349-9afb-593c34d8aed1", "embedding": null, "metadata": {"window": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the Company\u2019s ability to consummate the proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s\nAlliance Healthcare businesses and related strategic transactions; the regulatory approvals required for the proposed acquisition and\nrelated strategic transactions not being obtained on the terms expected or on the anticipated schedule or at all; the integration of\nthe Alliance Healthcare business into the Company being more difficult, time consuming or costly than expected; the Company\u2019s or\nAlliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating performance and results; the effects of\ndisruption from the proposed acquisition and related strategic transactions on the respective businesses of the Company and\nAlliance Healthcare and the fact that the announcement or pendency of the proposed acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the proposed acquisition of the Alliance Healthcare businesses and related strategic\ntransactions, that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the\nanticipated synergies related thereto or to capture the anticipated synergies within the expected time period; risks associated with\nthe strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; managing foreign expansion,\nincluding non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and\nregulations; financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the\nCompany's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events, such as additional pandemics, that\naffect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments with\nrespect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and complete divestitures; the\ndisruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest\nrate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other\neconomic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act. ", "original_text": "Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the Company\u2019s ability to consummate the proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s\nAlliance Healthcare businesses and related strategic transactions; the regulatory approvals required for the proposed acquisition and\nrelated strategic transactions not being obtained on the terms expected or on the anticipated schedule or at all; the integration of\nthe Alliance Healthcare business into the Company being more difficult, time consuming or costly than expected; the Company\u2019s or\nAlliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating performance and results; the effects of\ndisruption from the proposed acquisition and related strategic transactions on the respective businesses of the Company and\nAlliance Healthcare and the fact that the announcement or pendency of the proposed acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the proposed acquisition of the Alliance Healthcare businesses and related strategic\ntransactions, that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the\nanticipated synergies related thereto or to capture the anticipated synergies within the expected time period; risks associated with\nthe strategic, long-term relationship between Walgreens Boots Alliance, Inc. ", "page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c0bb4e5-b04e-460e-86a6-b70620fb2591", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82a3f1ffd92df8b289e5ce4affe786eee100bbba675ff2f61b17262fcbac15e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "afa6e91b-b340-4bf0-9bf2-cebacb94ab08", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the Company\u2019s ability to consummate the proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s\nAlliance Healthcare businesses and related strategic transactions; the regulatory approvals required for the proposed acquisition and\nrelated strategic transactions not being obtained on the terms expected or on the anticipated schedule or at all; the integration of\nthe Alliance Healthcare business into the Company being more difficult, time consuming or costly than expected; the Company\u2019s or\nAlliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating performance and results; the effects of\ndisruption from the proposed acquisition and related strategic transactions on the respective businesses of the Company and\nAlliance Healthcare and the fact that the announcement or pendency of the proposed acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the proposed acquisition of the Alliance Healthcare businesses and related strategic\ntransactions, that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the\nanticipated synergies related thereto or to capture the anticipated synergies within the expected time period; risks associated with\nthe strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; managing foreign expansion,\nincluding non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and\nregulations; financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the\nCompany's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events, such as additional pandemics, that\naffect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments with\nrespect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and complete divestitures; the\ndisruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest\nrate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other\neconomic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.\n", "original_text": "These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated. ", "page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1c6a044e9af9a105dee4c445f9711d693fb260366fafc9d23e05ce53f6582a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "afac8dce-f45f-4f63-bb9a-c10c006acaea", "node_type": "1", "metadata": {"window": "These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the Company\u2019s ability to consummate the proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s\nAlliance Healthcare businesses and related strategic transactions; the regulatory approvals required for the proposed acquisition and\nrelated strategic transactions not being obtained on the terms expected or on the anticipated schedule or at all; the integration of\nthe Alliance Healthcare business into the Company being more difficult, time consuming or costly than expected; the Company\u2019s or\nAlliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating performance and results; the effects of\ndisruption from the proposed acquisition and related strategic transactions on the respective businesses of the Company and\nAlliance Healthcare and the fact that the announcement or pendency of the proposed acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the proposed acquisition of the Alliance Healthcare businesses and related strategic\ntransactions, that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the\nanticipated synergies related thereto or to capture the anticipated synergies within the expected time period; risks associated with\nthe strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; managing foreign expansion,\nincluding non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and\nregulations; financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the\nCompany's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events, such as additional pandemics, that\naffect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments with\nrespect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and complete divestitures; the\ndisruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest\nrate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other\neconomic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\n5", "original_text": "and the Company, including with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; managing foreign expansion,\nincluding non-compliance with the U.S. "}, "hash": "16ff44f63cb7d39883a1fed1d905ab10d29618f491e504892dd03f286985f4f7", "class_name": "RelatedNodeInfo"}}, "text": "Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the Company\u2019s ability to consummate the proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s\nAlliance Healthcare businesses and related strategic transactions; the regulatory approvals required for the proposed acquisition and\nrelated strategic transactions not being obtained on the terms expected or on the anticipated schedule or at all; the integration of\nthe Alliance Healthcare business into the Company being more difficult, time consuming or costly than expected; the Company\u2019s or\nAlliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating performance and results; the effects of\ndisruption from the proposed acquisition and related strategic transactions on the respective businesses of the Company and\nAlliance Healthcare and the fact that the announcement or pendency of the proposed acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the proposed acquisition of the Alliance Healthcare businesses and related strategic\ntransactions, that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the\nanticipated synergies related thereto or to capture the anticipated synergies within the expected time period; risks associated with\nthe strategic, long-term relationship between Walgreens Boots Alliance, Inc. ", "start_char_idx": 1362, "end_char_idx": 4742, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "afac8dce-f45f-4f63-bb9a-c10c006acaea": {"__data__": {"id_": "afac8dce-f45f-4f63-bb9a-c10c006acaea", "embedding": null, "metadata": {"window": "These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the Company\u2019s ability to consummate the proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s\nAlliance Healthcare businesses and related strategic transactions; the regulatory approvals required for the proposed acquisition and\nrelated strategic transactions not being obtained on the terms expected or on the anticipated schedule or at all; the integration of\nthe Alliance Healthcare business into the Company being more difficult, time consuming or costly than expected; the Company\u2019s or\nAlliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating performance and results; the effects of\ndisruption from the proposed acquisition and related strategic transactions on the respective businesses of the Company and\nAlliance Healthcare and the fact that the announcement or pendency of the proposed acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the proposed acquisition of the Alliance Healthcare businesses and related strategic\ntransactions, that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the\nanticipated synergies related thereto or to capture the anticipated synergies within the expected time period; risks associated with\nthe strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; managing foreign expansion,\nincluding non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and\nregulations; financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the\nCompany's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events, such as additional pandemics, that\naffect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments with\nrespect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and complete divestitures; the\ndisruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest\nrate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other\neconomic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\n5", "original_text": "and the Company, including with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; managing foreign expansion,\nincluding non-compliance with the U.S. ", "page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c0bb4e5-b04e-460e-86a6-b70620fb2591", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82a3f1ffd92df8b289e5ce4affe786eee100bbba675ff2f61b17262fcbac15e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a470d7c-e68d-4349-9afb-593c34d8aed1", "node_type": "1", "metadata": {"window": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the Company\u2019s ability to consummate the proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s\nAlliance Healthcare businesses and related strategic transactions; the regulatory approvals required for the proposed acquisition and\nrelated strategic transactions not being obtained on the terms expected or on the anticipated schedule or at all; the integration of\nthe Alliance Healthcare business into the Company being more difficult, time consuming or costly than expected; the Company\u2019s or\nAlliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating performance and results; the effects of\ndisruption from the proposed acquisition and related strategic transactions on the respective businesses of the Company and\nAlliance Healthcare and the fact that the announcement or pendency of the proposed acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the proposed acquisition of the Alliance Healthcare businesses and related strategic\ntransactions, that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the\nanticipated synergies related thereto or to capture the anticipated synergies within the expected time period; risks associated with\nthe strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; managing foreign expansion,\nincluding non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and\nregulations; financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the\nCompany's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events, such as additional pandemics, that\naffect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments with\nrespect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and complete divestitures; the\ndisruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest\nrate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other\neconomic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act. ", "original_text": "Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the Company\u2019s ability to consummate the proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s\nAlliance Healthcare businesses and related strategic transactions; the regulatory approvals required for the proposed acquisition and\nrelated strategic transactions not being obtained on the terms expected or on the anticipated schedule or at all; the integration of\nthe Alliance Healthcare business into the Company being more difficult, time consuming or costly than expected; the Company\u2019s or\nAlliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating performance and results; the effects of\ndisruption from the proposed acquisition and related strategic transactions on the respective businesses of the Company and\nAlliance Healthcare and the fact that the announcement or pendency of the proposed acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the proposed acquisition of the Alliance Healthcare businesses and related strategic\ntransactions, that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the\nanticipated synergies related thereto or to capture the anticipated synergies within the expected time period; risks associated with\nthe strategic, long-term relationship between Walgreens Boots Alliance, Inc. ", "page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0deb3a8d3df943bf89c787a575ce336d4e9ca8b9ff1ff42b87a88847abaf4ed7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6d110ae-49c2-43a3-b35b-90f16a299b17", "node_type": "1", "metadata": {"window": "These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the Company\u2019s ability to consummate the proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s\nAlliance Healthcare businesses and related strategic transactions; the regulatory approvals required for the proposed acquisition and\nrelated strategic transactions not being obtained on the terms expected or on the anticipated schedule or at all; the integration of\nthe Alliance Healthcare business into the Company being more difficult, time consuming or costly than expected; the Company\u2019s or\nAlliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating performance and results; the effects of\ndisruption from the proposed acquisition and related strategic transactions on the respective businesses of the Company and\nAlliance Healthcare and the fact that the announcement or pendency of the proposed acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the proposed acquisition of the Alliance Healthcare businesses and related strategic\ntransactions, that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the\nanticipated synergies related thereto or to capture the anticipated synergies within the expected time period; risks associated with\nthe strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; managing foreign expansion,\nincluding non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and\nregulations; financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the\nCompany's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events, such as additional pandemics, that\naffect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments with\nrespect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and complete divestitures; the\ndisruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest\nrate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other\neconomic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\n5", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and\nregulations; financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the\nCompany's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events, such as additional pandemics, that\naffect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments with\nrespect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and complete divestitures; the\ndisruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest\nrate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other\neconomic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.\n"}, "hash": "e0215c1944940e063c4805f1dd6ab876378d03c3007abad442d1990ad9d39a1d", "class_name": "RelatedNodeInfo"}}, "text": "and the Company, including with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; managing foreign expansion,\nincluding non-compliance with the U.S. ", "start_char_idx": 4742, "end_char_idx": 4953, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6d110ae-49c2-43a3-b35b-90f16a299b17": {"__data__": {"id_": "c6d110ae-49c2-43a3-b35b-90f16a299b17", "embedding": null, "metadata": {"window": "These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the Company\u2019s ability to consummate the proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s\nAlliance Healthcare businesses and related strategic transactions; the regulatory approvals required for the proposed acquisition and\nrelated strategic transactions not being obtained on the terms expected or on the anticipated schedule or at all; the integration of\nthe Alliance Healthcare business into the Company being more difficult, time consuming or costly than expected; the Company\u2019s or\nAlliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating performance and results; the effects of\ndisruption from the proposed acquisition and related strategic transactions on the respective businesses of the Company and\nAlliance Healthcare and the fact that the announcement or pendency of the proposed acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the proposed acquisition of the Alliance Healthcare businesses and related strategic\ntransactions, that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the\nanticipated synergies related thereto or to capture the anticipated synergies within the expected time period; risks associated with\nthe strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; managing foreign expansion,\nincluding non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and\nregulations; financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the\nCompany's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events, such as additional pandemics, that\naffect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments with\nrespect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and complete divestitures; the\ndisruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest\nrate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other\neconomic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\n5", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and\nregulations; financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the\nCompany's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events, such as additional pandemics, that\naffect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments with\nrespect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and complete divestitures; the\ndisruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest\nrate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other\neconomic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.\n", "page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c0bb4e5-b04e-460e-86a6-b70620fb2591", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82a3f1ffd92df8b289e5ce4affe786eee100bbba675ff2f61b17262fcbac15e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "afac8dce-f45f-4f63-bb9a-c10c006acaea", "node_type": "1", "metadata": {"window": "These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the Company\u2019s ability to consummate the proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s\nAlliance Healthcare businesses and related strategic transactions; the regulatory approvals required for the proposed acquisition and\nrelated strategic transactions not being obtained on the terms expected or on the anticipated schedule or at all; the integration of\nthe Alliance Healthcare business into the Company being more difficult, time consuming or costly than expected; the Company\u2019s or\nAlliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating performance and results; the effects of\ndisruption from the proposed acquisition and related strategic transactions on the respective businesses of the Company and\nAlliance Healthcare and the fact that the announcement or pendency of the proposed acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the proposed acquisition of the Alliance Healthcare businesses and related strategic\ntransactions, that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the\nanticipated synergies related thereto or to capture the anticipated synergies within the expected time period; risks associated with\nthe strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; managing foreign expansion,\nincluding non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and\nregulations; financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the\nCompany's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events, such as additional pandemics, that\naffect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments with\nrespect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and complete divestitures; the\ndisruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest\nrate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other\neconomic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\n5", "original_text": "and the Company, including with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; managing foreign expansion,\nincluding non-compliance with the U.S. ", "page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80d55212443305c9f8ca82631a6e9608e23906a0fbabf85e0465e7dc0cf3b3d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b21417bb-2de0-48e8-b01c-3b6c1b05cf73", "node_type": "1", "metadata": {"window": "Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the Company\u2019s ability to consummate the proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s\nAlliance Healthcare businesses and related strategic transactions; the regulatory approvals required for the proposed acquisition and\nrelated strategic transactions not being obtained on the terms expected or on the anticipated schedule or at all; the integration of\nthe Alliance Healthcare business into the Company being more difficult, time consuming or costly than expected; the Company\u2019s or\nAlliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating performance and results; the effects of\ndisruption from the proposed acquisition and related strategic transactions on the respective businesses of the Company and\nAlliance Healthcare and the fact that the announcement or pendency of the proposed acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the proposed acquisition of the Alliance Healthcare businesses and related strategic\ntransactions, that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the\nanticipated synergies related thereto or to capture the anticipated synergies within the expected time period; risks associated with\nthe strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; managing foreign expansion,\nincluding non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and\nregulations; financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the\nCompany's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events, such as additional pandemics, that\naffect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments with\nrespect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and complete divestitures; the\ndisruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest\nrate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other\neconomic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\n5", "original_text": "Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act. "}, "hash": "e7b8fc4a5b4bf60c86739c8138775fc4e6b2962335b9c7ac05c8b5f0fab80452", "class_name": "RelatedNodeInfo"}}, "text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and\nregulations; financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the\nCompany's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events, such as additional pandemics, that\naffect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments with\nrespect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and complete divestitures; the\ndisruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest\nrate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other\neconomic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.\n", "start_char_idx": 4953, "end_char_idx": 6609, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b21417bb-2de0-48e8-b01c-3b6c1b05cf73": {"__data__": {"id_": "b21417bb-2de0-48e8-b01c-3b6c1b05cf73", "embedding": null, "metadata": {"window": "Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the Company\u2019s ability to consummate the proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s\nAlliance Healthcare businesses and related strategic transactions; the regulatory approvals required for the proposed acquisition and\nrelated strategic transactions not being obtained on the terms expected or on the anticipated schedule or at all; the integration of\nthe Alliance Healthcare business into the Company being more difficult, time consuming or costly than expected; the Company\u2019s or\nAlliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating performance and results; the effects of\ndisruption from the proposed acquisition and related strategic transactions on the respective businesses of the Company and\nAlliance Healthcare and the fact that the announcement or pendency of the proposed acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the proposed acquisition of the Alliance Healthcare businesses and related strategic\ntransactions, that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the\nanticipated synergies related thereto or to capture the anticipated synergies within the expected time period; risks associated with\nthe strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; managing foreign expansion,\nincluding non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and\nregulations; financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the\nCompany's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events, such as additional pandemics, that\naffect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments with\nrespect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and complete divestitures; the\ndisruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest\nrate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other\neconomic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\n5", "original_text": "Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act. ", "page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c0bb4e5-b04e-460e-86a6-b70620fb2591", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82a3f1ffd92df8b289e5ce4affe786eee100bbba675ff2f61b17262fcbac15e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6d110ae-49c2-43a3-b35b-90f16a299b17", "node_type": "1", "metadata": {"window": "These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the Company\u2019s ability to consummate the proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s\nAlliance Healthcare businesses and related strategic transactions; the regulatory approvals required for the proposed acquisition and\nrelated strategic transactions not being obtained on the terms expected or on the anticipated schedule or at all; the integration of\nthe Alliance Healthcare business into the Company being more difficult, time consuming or costly than expected; the Company\u2019s or\nAlliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating performance and results; the effects of\ndisruption from the proposed acquisition and related strategic transactions on the respective businesses of the Company and\nAlliance Healthcare and the fact that the announcement or pendency of the proposed acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the proposed acquisition of the Alliance Healthcare businesses and related strategic\ntransactions, that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the\nanticipated synergies related thereto or to capture the anticipated synergies within the expected time period; risks associated with\nthe strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; managing foreign expansion,\nincluding non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and\nregulations; financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the\nCompany's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events, such as additional pandemics, that\naffect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments with\nrespect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and complete divestitures; the\ndisruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest\nrate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other\neconomic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\n5", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and\nregulations; financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the\nCompany's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events, such as additional pandemics, that\naffect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments with\nrespect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and complete divestitures; the\ndisruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest\nrate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other\neconomic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.\n", "page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "291b9440831893941fad0f31695f35554e936520ce2b519bfc216e913072a136", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bcd2b4ba-04cc-4ea8-8ce3-9558c0787be0", "node_type": "1", "metadata": {"window": "and the Company, including with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; managing foreign expansion,\nincluding non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and\nregulations; financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the\nCompany's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events, such as additional pandemics, that\naffect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments with\nrespect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and complete divestitures; the\ndisruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest\nrate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other\neconomic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\n5", "original_text": "The Company undertakes no obligation to publicly update or revise any forward-looking statements,\n5"}, "hash": "95fbabb2aa42959a17fce1b39f262e994f22042ada4d3db8ec803dd26bfed09c", "class_name": "RelatedNodeInfo"}}, "text": "Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act. ", "start_char_idx": 6609, "end_char_idx": 7024, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bcd2b4ba-04cc-4ea8-8ce3-9558c0787be0": {"__data__": {"id_": "bcd2b4ba-04cc-4ea8-8ce3-9558c0787be0", "embedding": null, "metadata": {"window": "and the Company, including with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; managing foreign expansion,\nincluding non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and\nregulations; financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the\nCompany's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events, such as additional pandemics, that\naffect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments with\nrespect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and complete divestitures; the\ndisruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest\nrate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other\neconomic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\n5", "original_text": "The Company undertakes no obligation to publicly update or revise any forward-looking statements,\n5", "page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c0bb4e5-b04e-460e-86a6-b70620fb2591", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82a3f1ffd92df8b289e5ce4affe786eee100bbba675ff2f61b17262fcbac15e9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b21417bb-2de0-48e8-b01c-3b6c1b05cf73", "node_type": "1", "metadata": {"window": "Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the Company\u2019s ability to consummate the proposed acquisition of Walgreens Boots Alliance, Inc.\u2019s\nAlliance Healthcare businesses and related strategic transactions; the regulatory approvals required for the proposed acquisition and\nrelated strategic transactions not being obtained on the terms expected or on the anticipated schedule or at all; the integration of\nthe Alliance Healthcare business into the Company being more difficult, time consuming or costly than expected; the Company\u2019s or\nAlliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating performance and results; the effects of\ndisruption from the proposed acquisition and related strategic transactions on the respective businesses of the Company and\nAlliance Healthcare and the fact that the announcement or pendency of the proposed acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the proposed acquisition of the Alliance Healthcare businesses and related strategic\ntransactions, that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the\nanticipated synergies related thereto or to capture the anticipated synergies within the expected time period; risks associated with\nthe strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; managing foreign expansion,\nincluding non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and\nregulations; financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the\nCompany's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events, such as additional pandemics, that\naffect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments with\nrespect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and complete divestitures; the\ndisruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest\nrate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other\neconomic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\n5", "original_text": "Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act. ", "page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "60319b0c8f4051864756563d1562289d41e107adf8b61614bb7858e1f1f11713", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50b95348-3bfc-4da7-85ff-d4760e6e95da", "node_type": "1", "metadata": {"window": "except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nMarch 31, 2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$49,154,171 \u00a0\u00a0\u00a0 \u00a0$47,417,639 \u00a0\u00a0\u00a0 \u00a03.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a047,620,790 \u00a0\u00a0\u00a0 \u00a046,029,532 \u00a0\u00a0\u00a0 \u00a03.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,533,381 \u00a0\u00a03.12 %\u00a01,388,107 \u00a0\u00a02.93 %\u00a010.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0730,081 \u00a0\u00a01.49 %\u00a0693,413 \u00a0\u00a01.46 %\u00a05.3 %\nDepreciation and amortization \u00a0100,797 \u00a0\u00a00.21 %\u00a093,795 \u00a0\u00a00.20 %\u00a07.5 %\nEmployee severance, litigation, and other 3 \u00a078,156 \u00a0\u00a0\u00a0 \u00a067,732 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0223,652 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0909,034 \u00a0\u00a01.85 %\u00a01,078,592 \u00a0\u00a02.27 %\u00a0(15.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0624,347 \u00a0\u00a01.27 %\u00a0309,515 \u00a0\u00a00.65 %\u00a0101.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 4 \u00a023,310 \u00a0\u00a0\u00a0 \u00a0(1,109 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a034,526 \u00a0\u00a0\u00a0 \u00a034,421 \u00a0\u00a0\u00a0 \u00a00.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0566,511 \u00a0\u00a01.15 %\u00a0276,203 \u00a0\u00a00.58 %\u00a0105.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0132,506 \u00a0\u00a0\u00a0 \u00a0(694,908 )\u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "except as required by the federal securities laws.\n"}, "hash": "0ae0c4a1cca8426b54ff91abd9819102998322984aee7821d2258ff36da9a77c", "class_name": "RelatedNodeInfo"}}, "text": "The Company undertakes no obligation to publicly update or revise any forward-looking statements,\n5", "start_char_idx": 7024, "end_char_idx": 7123, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50b95348-3bfc-4da7-85ff-d4760e6e95da": {"__data__": {"id_": "50b95348-3bfc-4da7-85ff-d4760e6e95da", "embedding": null, "metadata": {"window": "except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nMarch 31, 2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$49,154,171 \u00a0\u00a0\u00a0 \u00a0$47,417,639 \u00a0\u00a0\u00a0 \u00a03.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a047,620,790 \u00a0\u00a0\u00a0 \u00a046,029,532 \u00a0\u00a0\u00a0 \u00a03.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,533,381 \u00a0\u00a03.12 %\u00a01,388,107 \u00a0\u00a02.93 %\u00a010.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0730,081 \u00a0\u00a01.49 %\u00a0693,413 \u00a0\u00a01.46 %\u00a05.3 %\nDepreciation and amortization \u00a0100,797 \u00a0\u00a00.21 %\u00a093,795 \u00a0\u00a00.20 %\u00a07.5 %\nEmployee severance, litigation, and other 3 \u00a078,156 \u00a0\u00a0\u00a0 \u00a067,732 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0223,652 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0909,034 \u00a0\u00a01.85 %\u00a01,078,592 \u00a0\u00a02.27 %\u00a0(15.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0624,347 \u00a0\u00a01.27 %\u00a0309,515 \u00a0\u00a00.65 %\u00a0101.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 4 \u00a023,310 \u00a0\u00a0\u00a0 \u00a0(1,109 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a034,526 \u00a0\u00a0\u00a0 \u00a034,421 \u00a0\u00a0\u00a0 \u00a00.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0566,511 \u00a0\u00a01.15 %\u00a0276,203 \u00a0\u00a00.58 %\u00a0105.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0132,506 \u00a0\u00a0\u00a0 \u00a0(694,908 )\u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "except as required by the federal securities laws.\n", "page_label": "6", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0851a017-3b2c-4844-8e95-7505a16132d0", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c20ffca81f3db469896bea0f3feb89528c8e9f3979d646255582b1beaca243bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bcd2b4ba-04cc-4ea8-8ce3-9558c0787be0", "node_type": "1", "metadata": {"window": "and the Company, including with respect to the\npharmaceutical distribution agreement and/or the global generic purchasing services arrangement; managing foreign expansion,\nincluding non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and\nregulations; financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the\nCompany's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation\nand the international transfer of personal data; natural disasters or other unexpected events, such as additional pandemics, that\naffect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments with\nrespect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and complete divestitures; the\ndisruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest\nrate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other\neconomic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\n5", "original_text": "The Company undertakes no obligation to publicly update or revise any forward-looking statements,\n5", "page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a9c439e8117d8257653388d0c7e2235edeecc3a3ad844733fbfb533a5299758a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "807c2296-5361-4d23-89a2-353814dbdae1", "node_type": "1", "metadata": {"window": "except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nMarch 31, 2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$49,154,171 \u00a0\u00a0\u00a0 \u00a0$47,417,639 \u00a0\u00a0\u00a0 \u00a03.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a047,620,790 \u00a0\u00a0\u00a0 \u00a046,029,532 \u00a0\u00a0\u00a0 \u00a03.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,533,381 \u00a0\u00a03.12 %\u00a01,388,107 \u00a0\u00a02.93 %\u00a010.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0730,081 \u00a0\u00a01.49 %\u00a0693,413 \u00a0\u00a01.46 %\u00a05.3 %\nDepreciation and amortization \u00a0100,797 \u00a0\u00a00.21 %\u00a093,795 \u00a0\u00a00.20 %\u00a07.5 %\nEmployee severance, litigation, and other 3 \u00a078,156 \u00a0\u00a0\u00a0 \u00a067,732 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0223,652 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0909,034 \u00a0\u00a01.85 %\u00a01,078,592 \u00a0\u00a02.27 %\u00a0(15.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0624,347 \u00a0\u00a01.27 %\u00a0309,515 \u00a0\u00a00.65 %\u00a0101.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 4 \u00a023,310 \u00a0\u00a0\u00a0 \u00a0(1,109 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a034,526 \u00a0\u00a0\u00a0 \u00a034,421 \u00a0\u00a0\u00a0 \u00a00.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0566,511 \u00a0\u00a01.15 %\u00a0276,203 \u00a0\u00a00.58 %\u00a0105.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0132,506 \u00a0\u00a0\u00a0 \u00a0(694,908 )\u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nMarch 31, 2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$49,154,171 \u00a0\u00a0\u00a0 \u00a0$47,417,639 \u00a0\u00a0\u00a0 \u00a03.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a047,620,790 \u00a0\u00a0\u00a0 \u00a046,029,532 \u00a0\u00a0\u00a0 \u00a03.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,533,381 \u00a0\u00a03.12 %\u00a01,388,107 \u00a0\u00a02.93 %\u00a010.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0730,081 \u00a0\u00a01.49 %\u00a0693,413 \u00a0\u00a01.46 %\u00a05.3 %\nDepreciation and amortization \u00a0100,797 \u00a0\u00a00.21 %\u00a093,795 \u00a0\u00a00.20 %\u00a07.5 %\nEmployee severance, litigation, and other 3 \u00a078,156 \u00a0\u00a0\u00a0 \u00a067,732 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0223,652 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0909,034 \u00a0\u00a01.85 %\u00a01,078,592 \u00a0\u00a02.27 %\u00a0(15.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0624,347 \u00a0\u00a01.27 %\u00a0309,515 \u00a0\u00a00.65 %\u00a0101.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 4 \u00a023,310 \u00a0\u00a0\u00a0 \u00a0(1,109 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a034,526 \u00a0\u00a0\u00a0 \u00a034,421 \u00a0\u00a0\u00a0 \u00a00.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0566,511 \u00a0\u00a01.15 %\u00a0276,203 \u00a0\u00a00.58 %\u00a0105.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0132,506 \u00a0\u00a0\u00a0 \u00a0(694,908 )\u00a0\u00a0 \u00a0\u00a0\n6"}, "hash": "7b9c5381bd6e50313aa5488ba58d9a0c73d7ebc791732e713242e2c168149acc", "class_name": "RelatedNodeInfo"}}, "text": "except as required by the federal securities laws.\n", "start_char_idx": 0, "end_char_idx": 51, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "807c2296-5361-4d23-89a2-353814dbdae1": {"__data__": {"id_": "807c2296-5361-4d23-89a2-353814dbdae1", "embedding": null, "metadata": {"window": "except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nMarch 31, 2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$49,154,171 \u00a0\u00a0\u00a0 \u00a0$47,417,639 \u00a0\u00a0\u00a0 \u00a03.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a047,620,790 \u00a0\u00a0\u00a0 \u00a046,029,532 \u00a0\u00a0\u00a0 \u00a03.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,533,381 \u00a0\u00a03.12 %\u00a01,388,107 \u00a0\u00a02.93 %\u00a010.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0730,081 \u00a0\u00a01.49 %\u00a0693,413 \u00a0\u00a01.46 %\u00a05.3 %\nDepreciation and amortization \u00a0100,797 \u00a0\u00a00.21 %\u00a093,795 \u00a0\u00a00.20 %\u00a07.5 %\nEmployee severance, litigation, and other 3 \u00a078,156 \u00a0\u00a0\u00a0 \u00a067,732 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0223,652 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0909,034 \u00a0\u00a01.85 %\u00a01,078,592 \u00a0\u00a02.27 %\u00a0(15.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0624,347 \u00a0\u00a01.27 %\u00a0309,515 \u00a0\u00a00.65 %\u00a0101.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 4 \u00a023,310 \u00a0\u00a0\u00a0 \u00a0(1,109 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a034,526 \u00a0\u00a0\u00a0 \u00a034,421 \u00a0\u00a0\u00a0 \u00a00.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0566,511 \u00a0\u00a01.15 %\u00a0276,203 \u00a0\u00a00.58 %\u00a0105.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0132,506 \u00a0\u00a0\u00a0 \u00a0(694,908 )\u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nMarch 31, 2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$49,154,171 \u00a0\u00a0\u00a0 \u00a0$47,417,639 \u00a0\u00a0\u00a0 \u00a03.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a047,620,790 \u00a0\u00a0\u00a0 \u00a046,029,532 \u00a0\u00a0\u00a0 \u00a03.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,533,381 \u00a0\u00a03.12 %\u00a01,388,107 \u00a0\u00a02.93 %\u00a010.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0730,081 \u00a0\u00a01.49 %\u00a0693,413 \u00a0\u00a01.46 %\u00a05.3 %\nDepreciation and amortization \u00a0100,797 \u00a0\u00a00.21 %\u00a093,795 \u00a0\u00a00.20 %\u00a07.5 %\nEmployee severance, litigation, and other 3 \u00a078,156 \u00a0\u00a0\u00a0 \u00a067,732 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0223,652 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0909,034 \u00a0\u00a01.85 %\u00a01,078,592 \u00a0\u00a02.27 %\u00a0(15.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0624,347 \u00a0\u00a01.27 %\u00a0309,515 \u00a0\u00a00.65 %\u00a0101.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 4 \u00a023,310 \u00a0\u00a0\u00a0 \u00a0(1,109 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a034,526 \u00a0\u00a0\u00a0 \u00a034,421 \u00a0\u00a0\u00a0 \u00a00.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0566,511 \u00a0\u00a01.15 %\u00a0276,203 \u00a0\u00a00.58 %\u00a0105.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0132,506 \u00a0\u00a0\u00a0 \u00a0(694,908 )\u00a0\u00a0 \u00a0\u00a0\n6", "page_label": "6", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0851a017-3b2c-4844-8e95-7505a16132d0", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c20ffca81f3db469896bea0f3feb89528c8e9f3979d646255582b1beaca243bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50b95348-3bfc-4da7-85ff-d4760e6e95da", "node_type": "1", "metadata": {"window": "except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nMarch 31, 2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$49,154,171 \u00a0\u00a0\u00a0 \u00a0$47,417,639 \u00a0\u00a0\u00a0 \u00a03.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a047,620,790 \u00a0\u00a0\u00a0 \u00a046,029,532 \u00a0\u00a0\u00a0 \u00a03.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,533,381 \u00a0\u00a03.12 %\u00a01,388,107 \u00a0\u00a02.93 %\u00a010.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0730,081 \u00a0\u00a01.49 %\u00a0693,413 \u00a0\u00a01.46 %\u00a05.3 %\nDepreciation and amortization \u00a0100,797 \u00a0\u00a00.21 %\u00a093,795 \u00a0\u00a00.20 %\u00a07.5 %\nEmployee severance, litigation, and other 3 \u00a078,156 \u00a0\u00a0\u00a0 \u00a067,732 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0223,652 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0909,034 \u00a0\u00a01.85 %\u00a01,078,592 \u00a0\u00a02.27 %\u00a0(15.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0624,347 \u00a0\u00a01.27 %\u00a0309,515 \u00a0\u00a00.65 %\u00a0101.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 4 \u00a023,310 \u00a0\u00a0\u00a0 \u00a0(1,109 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a034,526 \u00a0\u00a0\u00a0 \u00a034,421 \u00a0\u00a0\u00a0 \u00a00.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0566,511 \u00a0\u00a01.15 %\u00a0276,203 \u00a0\u00a00.58 %\u00a0105.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0132,506 \u00a0\u00a0\u00a0 \u00a0(694,908 )\u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "except as required by the federal securities laws.\n", "page_label": "6", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4072223025e9229ad10269df2755a8e5fc792c38c671b89182cc9ee56f770e6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7fd435b8-1dc8-4d0f-bb70-ef0daa8dbbcd", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0434,005 \u00a0\u00a00.88 %\u00a0971,111 \u00a0\u00a02.05 %\u00a0(55.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a01,262 \u00a0\u00a0\u00a0 \u00a0(10,834 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$435,267 \u00a0\u00a00.89 %\u00a0$960,277 \u00a0\u00a02.03 %\u00a0(54.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.12 \u00a0\u00a0\u00a0 \u00a0$4.68 \u00a0\u00a0\u00a0 \u00a0(54.7 )%\nDiluted \u00a0$2.10 \u00a0\u00a0\u00a0 \u00a0$4.64 \u00a0\u00a0\u00a0 \u00a0(54.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,916 \u00a0\u00a0\u00a0 \u00a0205,370 \u00a0\u00a0\u00a0 \u00a0(0.2 )%\nDiluted \u00a0207,315 \u00a0\u00a0\u00a0 \u00a0207,062 \u00a0\u00a0\u00a0 \u00a00.1 %\n________________________________________\n1Includes a $20.9 million LIFO credit in the three months ended March 31, 2021.  Includes a $23.9 million LIFO expense, a $0.1\nmillion gain from antitrust litigation settlements, and $5.0 million of PharMEDium shutdown costs in the three months ended\nMarch 31, 2020.\n\u00a0\u00a0\n 2Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $24.9 million of legal fees in connection with opioid lawsuits and investigations, and\n$36.2 million of other costs in connection with acquisition-related deal and integration costs, business transformation efforts,\nand other restructuring initiatives in the three months ended March 31, 2021. ", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0434,005 \u00a0\u00a00.88 %\u00a0971,111 \u00a0\u00a02.05 %\u00a0(55.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a01,262 \u00a0\u00a0\u00a0 \u00a0(10,834 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$435,267 \u00a0\u00a00.89 %\u00a0$960,277 \u00a0\u00a02.03 %\u00a0(54.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.12 \u00a0\u00a0\u00a0 \u00a0$4.68 \u00a0\u00a0\u00a0 \u00a0(54.7 )%\nDiluted \u00a0$2.10 \u00a0\u00a0\u00a0 \u00a0$4.64 \u00a0\u00a0\u00a0 \u00a0(54.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,916 \u00a0\u00a0\u00a0 \u00a0205,370 \u00a0\u00a0\u00a0 \u00a0(0.2 )%\nDiluted \u00a0207,315 \u00a0\u00a0\u00a0 \u00a0207,062 \u00a0\u00a0\u00a0 \u00a00.1 %\n________________________________________\n1Includes a $20.9 million LIFO credit in the three months ended March 31, 2021. "}, "hash": "83a2314fbd3a9f93ee91358cceeaa6fbe7c32cfcf484ec34135e38188d2bb4a1", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nMarch 31, 2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$49,154,171 \u00a0\u00a0\u00a0 \u00a0$47,417,639 \u00a0\u00a0\u00a0 \u00a03.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a047,620,790 \u00a0\u00a0\u00a0 \u00a046,029,532 \u00a0\u00a0\u00a0 \u00a03.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,533,381 \u00a0\u00a03.12 %\u00a01,388,107 \u00a0\u00a02.93 %\u00a010.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0730,081 \u00a0\u00a01.49 %\u00a0693,413 \u00a0\u00a01.46 %\u00a05.3 %\nDepreciation and amortization \u00a0100,797 \u00a0\u00a00.21 %\u00a093,795 \u00a0\u00a00.20 %\u00a07.5 %\nEmployee severance, litigation, and other 3 \u00a078,156 \u00a0\u00a0\u00a0 \u00a067,732 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0223,652 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0909,034 \u00a0\u00a01.85 %\u00a01,078,592 \u00a0\u00a02.27 %\u00a0(15.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0624,347 \u00a0\u00a01.27 %\u00a0309,515 \u00a0\u00a00.65 %\u00a0101.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 4 \u00a023,310 \u00a0\u00a0\u00a0 \u00a0(1,109 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a034,526 \u00a0\u00a0\u00a0 \u00a034,421 \u00a0\u00a0\u00a0 \u00a00.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0566,511 \u00a0\u00a01.15 %\u00a0276,203 \u00a0\u00a00.58 %\u00a0105.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0132,506 \u00a0\u00a0\u00a0 \u00a0(694,908 )\u00a0\u00a0 \u00a0\u00a0\n6", "start_char_idx": 51, "end_char_idx": 1242, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7fd435b8-1dc8-4d0f-bb70-ef0daa8dbbcd": {"__data__": {"id_": "7fd435b8-1dc8-4d0f-bb70-ef0daa8dbbcd", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0434,005 \u00a0\u00a00.88 %\u00a0971,111 \u00a0\u00a02.05 %\u00a0(55.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a01,262 \u00a0\u00a0\u00a0 \u00a0(10,834 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$435,267 \u00a0\u00a00.89 %\u00a0$960,277 \u00a0\u00a02.03 %\u00a0(54.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.12 \u00a0\u00a0\u00a0 \u00a0$4.68 \u00a0\u00a0\u00a0 \u00a0(54.7 )%\nDiluted \u00a0$2.10 \u00a0\u00a0\u00a0 \u00a0$4.64 \u00a0\u00a0\u00a0 \u00a0(54.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,916 \u00a0\u00a0\u00a0 \u00a0205,370 \u00a0\u00a0\u00a0 \u00a0(0.2 )%\nDiluted \u00a0207,315 \u00a0\u00a0\u00a0 \u00a0207,062 \u00a0\u00a0\u00a0 \u00a00.1 %\n________________________________________\n1Includes a $20.9 million LIFO credit in the three months ended March 31, 2021.  Includes a $23.9 million LIFO expense, a $0.1\nmillion gain from antitrust litigation settlements, and $5.0 million of PharMEDium shutdown costs in the three months ended\nMarch 31, 2020.\n\u00a0\u00a0\n 2Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $24.9 million of legal fees in connection with opioid lawsuits and investigations, and\n$36.2 million of other costs in connection with acquisition-related deal and integration costs, business transformation efforts,\nand other restructuring initiatives in the three months ended March 31, 2021. ", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0434,005 \u00a0\u00a00.88 %\u00a0971,111 \u00a0\u00a02.05 %\u00a0(55.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a01,262 \u00a0\u00a0\u00a0 \u00a0(10,834 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$435,267 \u00a0\u00a00.89 %\u00a0$960,277 \u00a0\u00a02.03 %\u00a0(54.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.12 \u00a0\u00a0\u00a0 \u00a0$4.68 \u00a0\u00a0\u00a0 \u00a0(54.7 )%\nDiluted \u00a0$2.10 \u00a0\u00a0\u00a0 \u00a0$4.64 \u00a0\u00a0\u00a0 \u00a0(54.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,916 \u00a0\u00a0\u00a0 \u00a0205,370 \u00a0\u00a0\u00a0 \u00a0(0.2 )%\nDiluted \u00a0207,315 \u00a0\u00a0\u00a0 \u00a0207,062 \u00a0\u00a0\u00a0 \u00a00.1 %\n________________________________________\n1Includes a $20.9 million LIFO credit in the three months ended March 31, 2021. ", "page_label": "7", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff0cb08d-f257-46de-95f4-d4816cbc4ebe", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7400f4b36e86e64713c8acd835f45792e4026af0f84c1115c893d608dda5e141", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "807c2296-5361-4d23-89a2-353814dbdae1", "node_type": "1", "metadata": {"window": "except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nMarch 31, 2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$49,154,171 \u00a0\u00a0\u00a0 \u00a0$47,417,639 \u00a0\u00a0\u00a0 \u00a03.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a047,620,790 \u00a0\u00a0\u00a0 \u00a046,029,532 \u00a0\u00a0\u00a0 \u00a03.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,533,381 \u00a0\u00a03.12 %\u00a01,388,107 \u00a0\u00a02.93 %\u00a010.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0730,081 \u00a0\u00a01.49 %\u00a0693,413 \u00a0\u00a01.46 %\u00a05.3 %\nDepreciation and amortization \u00a0100,797 \u00a0\u00a00.21 %\u00a093,795 \u00a0\u00a00.20 %\u00a07.5 %\nEmployee severance, litigation, and other 3 \u00a078,156 \u00a0\u00a0\u00a0 \u00a067,732 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0223,652 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0909,034 \u00a0\u00a01.85 %\u00a01,078,592 \u00a0\u00a02.27 %\u00a0(15.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0624,347 \u00a0\u00a01.27 %\u00a0309,515 \u00a0\u00a00.65 %\u00a0101.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 4 \u00a023,310 \u00a0\u00a0\u00a0 \u00a0(1,109 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a034,526 \u00a0\u00a0\u00a0 \u00a034,421 \u00a0\u00a0\u00a0 \u00a00.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0566,511 \u00a0\u00a01.15 %\u00a0276,203 \u00a0\u00a00.58 %\u00a0105.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0132,506 \u00a0\u00a0\u00a0 \u00a0(694,908 )\u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nMarch 31, 2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$49,154,171 \u00a0\u00a0\u00a0 \u00a0$47,417,639 \u00a0\u00a0\u00a0 \u00a03.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a047,620,790 \u00a0\u00a0\u00a0 \u00a046,029,532 \u00a0\u00a0\u00a0 \u00a03.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,533,381 \u00a0\u00a03.12 %\u00a01,388,107 \u00a0\u00a02.93 %\u00a010.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0730,081 \u00a0\u00a01.49 %\u00a0693,413 \u00a0\u00a01.46 %\u00a05.3 %\nDepreciation and amortization \u00a0100,797 \u00a0\u00a00.21 %\u00a093,795 \u00a0\u00a00.20 %\u00a07.5 %\nEmployee severance, litigation, and other 3 \u00a078,156 \u00a0\u00a0\u00a0 \u00a067,732 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0223,652 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0909,034 \u00a0\u00a01.85 %\u00a01,078,592 \u00a0\u00a02.27 %\u00a0(15.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0624,347 \u00a0\u00a01.27 %\u00a0309,515 \u00a0\u00a00.65 %\u00a0101.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 4 \u00a023,310 \u00a0\u00a0\u00a0 \u00a0(1,109 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a034,526 \u00a0\u00a0\u00a0 \u00a034,421 \u00a0\u00a0\u00a0 \u00a00.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0566,511 \u00a0\u00a01.15 %\u00a0276,203 \u00a0\u00a00.58 %\u00a0105.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0132,506 \u00a0\u00a0\u00a0 \u00a0(694,908 )\u00a0\u00a0 \u00a0\u00a0\n6", "page_label": "6", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7bc05e48bde495ab605b2802a9d78c64b59eff9ae9591ab6ccfb9f020ec55357", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f11e0955-2151-4de3-a7f0-ed4d8ebb4728", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0434,005 \u00a0\u00a00.88 %\u00a0971,111 \u00a0\u00a02.05 %\u00a0(55.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a01,262 \u00a0\u00a0\u00a0 \u00a0(10,834 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$435,267 \u00a0\u00a00.89 %\u00a0$960,277 \u00a0\u00a02.03 %\u00a0(54.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.12 \u00a0\u00a0\u00a0 \u00a0$4.68 \u00a0\u00a0\u00a0 \u00a0(54.7 )%\nDiluted \u00a0$2.10 \u00a0\u00a0\u00a0 \u00a0$4.64 \u00a0\u00a0\u00a0 \u00a0(54.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,916 \u00a0\u00a0\u00a0 \u00a0205,370 \u00a0\u00a0\u00a0 \u00a0(0.2 )%\nDiluted \u00a0207,315 \u00a0\u00a0\u00a0 \u00a0207,062 \u00a0\u00a0\u00a0 \u00a00.1 %\n________________________________________\n1Includes a $20.9 million LIFO credit in the three months ended March 31, 2021.  Includes a $23.9 million LIFO expense, a $0.1\nmillion gain from antitrust litigation settlements, and $5.0 million of PharMEDium shutdown costs in the three months ended\nMarch 31, 2020.\n\u00a0\u00a0\n 2Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $24.9 million of legal fees in connection with opioid lawsuits and investigations, and\n$36.2 million of other costs in connection with acquisition-related deal and integration costs, business transformation efforts,\nand other restructuring initiatives in the three months ended March 31, 2021.  Includes $25.0 million of employee severance,\n$30.8 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $11.9 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the three months ended March 31, 2020.\n\u00a0\u00a0\n", "original_text": "Includes a $23.9 million LIFO expense, a $0.1\nmillion gain from antitrust litigation settlements, and $5.0 million of PharMEDium shutdown costs in the three months ended\nMarch 31, 2020.\n\u00a0\u00a0\n"}, "hash": "51ca756ad606b5f4ee9580d59b88184f3b8e7f7ac40b208cc829294c5687d79f", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0434,005 \u00a0\u00a00.88 %\u00a0971,111 \u00a0\u00a02.05 %\u00a0(55.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a01,262 \u00a0\u00a0\u00a0 \u00a0(10,834 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$435,267 \u00a0\u00a00.89 %\u00a0$960,277 \u00a0\u00a02.03 %\u00a0(54.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.12 \u00a0\u00a0\u00a0 \u00a0$4.68 \u00a0\u00a0\u00a0 \u00a0(54.7 )%\nDiluted \u00a0$2.10 \u00a0\u00a0\u00a0 \u00a0$4.64 \u00a0\u00a0\u00a0 \u00a0(54.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,916 \u00a0\u00a0\u00a0 \u00a0205,370 \u00a0\u00a0\u00a0 \u00a0(0.2 )%\nDiluted \u00a0207,315 \u00a0\u00a0\u00a0 \u00a0207,062 \u00a0\u00a0\u00a0 \u00a00.1 %\n________________________________________\n1Includes a $20.9 million LIFO credit in the three months ended March 31, 2021. ", "start_char_idx": 0, "end_char_idx": 704, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f11e0955-2151-4de3-a7f0-ed4d8ebb4728": {"__data__": {"id_": "f11e0955-2151-4de3-a7f0-ed4d8ebb4728", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0434,005 \u00a0\u00a00.88 %\u00a0971,111 \u00a0\u00a02.05 %\u00a0(55.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a01,262 \u00a0\u00a0\u00a0 \u00a0(10,834 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$435,267 \u00a0\u00a00.89 %\u00a0$960,277 \u00a0\u00a02.03 %\u00a0(54.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.12 \u00a0\u00a0\u00a0 \u00a0$4.68 \u00a0\u00a0\u00a0 \u00a0(54.7 )%\nDiluted \u00a0$2.10 \u00a0\u00a0\u00a0 \u00a0$4.64 \u00a0\u00a0\u00a0 \u00a0(54.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,916 \u00a0\u00a0\u00a0 \u00a0205,370 \u00a0\u00a0\u00a0 \u00a0(0.2 )%\nDiluted \u00a0207,315 \u00a0\u00a0\u00a0 \u00a0207,062 \u00a0\u00a0\u00a0 \u00a00.1 %\n________________________________________\n1Includes a $20.9 million LIFO credit in the three months ended March 31, 2021.  Includes a $23.9 million LIFO expense, a $0.1\nmillion gain from antitrust litigation settlements, and $5.0 million of PharMEDium shutdown costs in the three months ended\nMarch 31, 2020.\n\u00a0\u00a0\n 2Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $24.9 million of legal fees in connection with opioid lawsuits and investigations, and\n$36.2 million of other costs in connection with acquisition-related deal and integration costs, business transformation efforts,\nand other restructuring initiatives in the three months ended March 31, 2021.  Includes $25.0 million of employee severance,\n$30.8 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $11.9 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the three months ended March 31, 2020.\n\u00a0\u00a0\n", "original_text": "Includes a $23.9 million LIFO expense, a $0.1\nmillion gain from antitrust litigation settlements, and $5.0 million of PharMEDium shutdown costs in the three months ended\nMarch 31, 2020.\n\u00a0\u00a0\n", "page_label": "7", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff0cb08d-f257-46de-95f4-d4816cbc4ebe", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7400f4b36e86e64713c8acd835f45792e4026af0f84c1115c893d608dda5e141", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7fd435b8-1dc8-4d0f-bb70-ef0daa8dbbcd", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0434,005 \u00a0\u00a00.88 %\u00a0971,111 \u00a0\u00a02.05 %\u00a0(55.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a01,262 \u00a0\u00a0\u00a0 \u00a0(10,834 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$435,267 \u00a0\u00a00.89 %\u00a0$960,277 \u00a0\u00a02.03 %\u00a0(54.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.12 \u00a0\u00a0\u00a0 \u00a0$4.68 \u00a0\u00a0\u00a0 \u00a0(54.7 )%\nDiluted \u00a0$2.10 \u00a0\u00a0\u00a0 \u00a0$4.64 \u00a0\u00a0\u00a0 \u00a0(54.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,916 \u00a0\u00a0\u00a0 \u00a0205,370 \u00a0\u00a0\u00a0 \u00a0(0.2 )%\nDiluted \u00a0207,315 \u00a0\u00a0\u00a0 \u00a0207,062 \u00a0\u00a0\u00a0 \u00a00.1 %\n________________________________________\n1Includes a $20.9 million LIFO credit in the three months ended March 31, 2021.  Includes a $23.9 million LIFO expense, a $0.1\nmillion gain from antitrust litigation settlements, and $5.0 million of PharMEDium shutdown costs in the three months ended\nMarch 31, 2020.\n\u00a0\u00a0\n 2Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $24.9 million of legal fees in connection with opioid lawsuits and investigations, and\n$36.2 million of other costs in connection with acquisition-related deal and integration costs, business transformation efforts,\nand other restructuring initiatives in the three months ended March 31, 2021. ", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0434,005 \u00a0\u00a00.88 %\u00a0971,111 \u00a0\u00a02.05 %\u00a0(55.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a01,262 \u00a0\u00a0\u00a0 \u00a0(10,834 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$435,267 \u00a0\u00a00.89 %\u00a0$960,277 \u00a0\u00a02.03 %\u00a0(54.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.12 \u00a0\u00a0\u00a0 \u00a0$4.68 \u00a0\u00a0\u00a0 \u00a0(54.7 )%\nDiluted \u00a0$2.10 \u00a0\u00a0\u00a0 \u00a0$4.64 \u00a0\u00a0\u00a0 \u00a0(54.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,916 \u00a0\u00a0\u00a0 \u00a0205,370 \u00a0\u00a0\u00a0 \u00a0(0.2 )%\nDiluted \u00a0207,315 \u00a0\u00a0\u00a0 \u00a0207,062 \u00a0\u00a0\u00a0 \u00a00.1 %\n________________________________________\n1Includes a $20.9 million LIFO credit in the three months ended March 31, 2021. ", "page_label": "7", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e20fdc93dc7dbae18d3462264cc3f0ded77dbc58bd64de1d2a4a112d9ab9f337", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89938753-d4f9-4206-b8d9-8c49d34866f7", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0434,005 \u00a0\u00a00.88 %\u00a0971,111 \u00a0\u00a02.05 %\u00a0(55.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a01,262 \u00a0\u00a0\u00a0 \u00a0(10,834 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$435,267 \u00a0\u00a00.89 %\u00a0$960,277 \u00a0\u00a02.03 %\u00a0(54.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.12 \u00a0\u00a0\u00a0 \u00a0$4.68 \u00a0\u00a0\u00a0 \u00a0(54.7 )%\nDiluted \u00a0$2.10 \u00a0\u00a0\u00a0 \u00a0$4.64 \u00a0\u00a0\u00a0 \u00a0(54.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,916 \u00a0\u00a0\u00a0 \u00a0205,370 \u00a0\u00a0\u00a0 \u00a0(0.2 )%\nDiluted \u00a0207,315 \u00a0\u00a0\u00a0 \u00a0207,062 \u00a0\u00a0\u00a0 \u00a00.1 %\n________________________________________\n1Includes a $20.9 million LIFO credit in the three months ended March 31, 2021.  Includes a $23.9 million LIFO expense, a $0.1\nmillion gain from antitrust litigation settlements, and $5.0 million of PharMEDium shutdown costs in the three months ended\nMarch 31, 2020.\n\u00a0\u00a0\n 2Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $24.9 million of legal fees in connection with opioid lawsuits and investigations, and\n$36.2 million of other costs in connection with acquisition-related deal and integration costs, business transformation efforts,\nand other restructuring initiatives in the three months ended March 31, 2021.  Includes $25.0 million of employee severance,\n$30.8 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $11.9 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the three months ended March 31, 2020.\n\u00a0\u00a0\n 4Includes a $21.4 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended March 31, 2021.\n\u00a0\u00a0\n", "original_text": "2Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\u00a0\n"}, "hash": "a90da8784a4137b0c85f79804c1e68098e252a8435aabce25c78c694d8adb7a0", "class_name": "RelatedNodeInfo"}}, "text": "Includes a $23.9 million LIFO expense, a $0.1\nmillion gain from antitrust litigation settlements, and $5.0 million of PharMEDium shutdown costs in the three months ended\nMarch 31, 2020.\n\u00a0\u00a0\n", "start_char_idx": 704, "end_char_idx": 893, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89938753-d4f9-4206-b8d9-8c49d34866f7": {"__data__": {"id_": "89938753-d4f9-4206-b8d9-8c49d34866f7", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0434,005 \u00a0\u00a00.88 %\u00a0971,111 \u00a0\u00a02.05 %\u00a0(55.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a01,262 \u00a0\u00a0\u00a0 \u00a0(10,834 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$435,267 \u00a0\u00a00.89 %\u00a0$960,277 \u00a0\u00a02.03 %\u00a0(54.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.12 \u00a0\u00a0\u00a0 \u00a0$4.68 \u00a0\u00a0\u00a0 \u00a0(54.7 )%\nDiluted \u00a0$2.10 \u00a0\u00a0\u00a0 \u00a0$4.64 \u00a0\u00a0\u00a0 \u00a0(54.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,916 \u00a0\u00a0\u00a0 \u00a0205,370 \u00a0\u00a0\u00a0 \u00a0(0.2 )%\nDiluted \u00a0207,315 \u00a0\u00a0\u00a0 \u00a0207,062 \u00a0\u00a0\u00a0 \u00a00.1 %\n________________________________________\n1Includes a $20.9 million LIFO credit in the three months ended March 31, 2021.  Includes a $23.9 million LIFO expense, a $0.1\nmillion gain from antitrust litigation settlements, and $5.0 million of PharMEDium shutdown costs in the three months ended\nMarch 31, 2020.\n\u00a0\u00a0\n 2Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $24.9 million of legal fees in connection with opioid lawsuits and investigations, and\n$36.2 million of other costs in connection with acquisition-related deal and integration costs, business transformation efforts,\nand other restructuring initiatives in the three months ended March 31, 2021.  Includes $25.0 million of employee severance,\n$30.8 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $11.9 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the three months ended March 31, 2020.\n\u00a0\u00a0\n 4Includes a $21.4 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended March 31, 2021.\n\u00a0\u00a0\n", "original_text": "2Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\u00a0\n", "page_label": "7", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff0cb08d-f257-46de-95f4-d4816cbc4ebe", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7400f4b36e86e64713c8acd835f45792e4026af0f84c1115c893d608dda5e141", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f11e0955-2151-4de3-a7f0-ed4d8ebb4728", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0434,005 \u00a0\u00a00.88 %\u00a0971,111 \u00a0\u00a02.05 %\u00a0(55.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a01,262 \u00a0\u00a0\u00a0 \u00a0(10,834 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$435,267 \u00a0\u00a00.89 %\u00a0$960,277 \u00a0\u00a02.03 %\u00a0(54.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.12 \u00a0\u00a0\u00a0 \u00a0$4.68 \u00a0\u00a0\u00a0 \u00a0(54.7 )%\nDiluted \u00a0$2.10 \u00a0\u00a0\u00a0 \u00a0$4.64 \u00a0\u00a0\u00a0 \u00a0(54.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,916 \u00a0\u00a0\u00a0 \u00a0205,370 \u00a0\u00a0\u00a0 \u00a0(0.2 )%\nDiluted \u00a0207,315 \u00a0\u00a0\u00a0 \u00a0207,062 \u00a0\u00a0\u00a0 \u00a00.1 %\n________________________________________\n1Includes a $20.9 million LIFO credit in the three months ended March 31, 2021.  Includes a $23.9 million LIFO expense, a $0.1\nmillion gain from antitrust litigation settlements, and $5.0 million of PharMEDium shutdown costs in the three months ended\nMarch 31, 2020.\n\u00a0\u00a0\n 2Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $24.9 million of legal fees in connection with opioid lawsuits and investigations, and\n$36.2 million of other costs in connection with acquisition-related deal and integration costs, business transformation efforts,\nand other restructuring initiatives in the three months ended March 31, 2021.  Includes $25.0 million of employee severance,\n$30.8 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $11.9 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the three months ended March 31, 2020.\n\u00a0\u00a0\n", "original_text": "Includes a $23.9 million LIFO expense, a $0.1\nmillion gain from antitrust litigation settlements, and $5.0 million of PharMEDium shutdown costs in the three months ended\nMarch 31, 2020.\n\u00a0\u00a0\n", "page_label": "7", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc2aa3a3098355a24fc8d1019b06f57f4c0bba503b2225d88b7bff544e3bc0cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36dad163-71d6-4b73-9f53-0ff96ed72467", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0434,005 \u00a0\u00a00.88 %\u00a0971,111 \u00a0\u00a02.05 %\u00a0(55.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a01,262 \u00a0\u00a0\u00a0 \u00a0(10,834 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$435,267 \u00a0\u00a00.89 %\u00a0$960,277 \u00a0\u00a02.03 %\u00a0(54.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.12 \u00a0\u00a0\u00a0 \u00a0$4.68 \u00a0\u00a0\u00a0 \u00a0(54.7 )%\nDiluted \u00a0$2.10 \u00a0\u00a0\u00a0 \u00a0$4.64 \u00a0\u00a0\u00a0 \u00a0(54.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,916 \u00a0\u00a0\u00a0 \u00a0205,370 \u00a0\u00a0\u00a0 \u00a0(0.2 )%\nDiluted \u00a0207,315 \u00a0\u00a0\u00a0 \u00a0207,062 \u00a0\u00a0\u00a0 \u00a00.1 %\n________________________________________\n1Includes a $20.9 million LIFO credit in the three months ended March 31, 2021.  Includes a $23.9 million LIFO expense, a $0.1\nmillion gain from antitrust litigation settlements, and $5.0 million of PharMEDium shutdown costs in the three months ended\nMarch 31, 2020.\n\u00a0\u00a0\n 2Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $24.9 million of legal fees in connection with opioid lawsuits and investigations, and\n$36.2 million of other costs in connection with acquisition-related deal and integration costs, business transformation efforts,\nand other restructuring initiatives in the three months ended March 31, 2021.  Includes $25.0 million of employee severance,\n$30.8 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $11.9 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the three months ended March 31, 2020.\n\u00a0\u00a0\n 4Includes a $21.4 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended March 31, 2021.\n\u00a0\u00a0\n 5Includes $2.7 million of expense relating to Swiss tax reform in the three months ended March 31, 2021. ", "original_text": "3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $24.9 million of legal fees in connection with opioid lawsuits and investigations, and\n$36.2 million of other costs in connection with acquisition-related deal and integration costs, business transformation efforts,\nand other restructuring initiatives in the three months ended March 31, 2021. "}, "hash": "c2b3e7cb2c75331f592fbd72281b34456d09e5c490e1a024a89226e4fa01cf21", "class_name": "RelatedNodeInfo"}}, "text": "2Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\u00a0\n", "start_char_idx": 893, "end_char_idx": 1145, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36dad163-71d6-4b73-9f53-0ff96ed72467": {"__data__": {"id_": "36dad163-71d6-4b73-9f53-0ff96ed72467", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0434,005 \u00a0\u00a00.88 %\u00a0971,111 \u00a0\u00a02.05 %\u00a0(55.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a01,262 \u00a0\u00a0\u00a0 \u00a0(10,834 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$435,267 \u00a0\u00a00.89 %\u00a0$960,277 \u00a0\u00a02.03 %\u00a0(54.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.12 \u00a0\u00a0\u00a0 \u00a0$4.68 \u00a0\u00a0\u00a0 \u00a0(54.7 )%\nDiluted \u00a0$2.10 \u00a0\u00a0\u00a0 \u00a0$4.64 \u00a0\u00a0\u00a0 \u00a0(54.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,916 \u00a0\u00a0\u00a0 \u00a0205,370 \u00a0\u00a0\u00a0 \u00a0(0.2 )%\nDiluted \u00a0207,315 \u00a0\u00a0\u00a0 \u00a0207,062 \u00a0\u00a0\u00a0 \u00a00.1 %\n________________________________________\n1Includes a $20.9 million LIFO credit in the three months ended March 31, 2021.  Includes a $23.9 million LIFO expense, a $0.1\nmillion gain from antitrust litigation settlements, and $5.0 million of PharMEDium shutdown costs in the three months ended\nMarch 31, 2020.\n\u00a0\u00a0\n 2Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $24.9 million of legal fees in connection with opioid lawsuits and investigations, and\n$36.2 million of other costs in connection with acquisition-related deal and integration costs, business transformation efforts,\nand other restructuring initiatives in the three months ended March 31, 2021.  Includes $25.0 million of employee severance,\n$30.8 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $11.9 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the three months ended March 31, 2020.\n\u00a0\u00a0\n 4Includes a $21.4 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended March 31, 2021.\n\u00a0\u00a0\n 5Includes $2.7 million of expense relating to Swiss tax reform in the three months ended March 31, 2021. ", "original_text": "3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $24.9 million of legal fees in connection with opioid lawsuits and investigations, and\n$36.2 million of other costs in connection with acquisition-related deal and integration costs, business transformation efforts,\nand other restructuring initiatives in the three months ended March 31, 2021. ", "page_label": "7", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff0cb08d-f257-46de-95f4-d4816cbc4ebe", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7400f4b36e86e64713c8acd835f45792e4026af0f84c1115c893d608dda5e141", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89938753-d4f9-4206-b8d9-8c49d34866f7", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0434,005 \u00a0\u00a00.88 %\u00a0971,111 \u00a0\u00a02.05 %\u00a0(55.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a01,262 \u00a0\u00a0\u00a0 \u00a0(10,834 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$435,267 \u00a0\u00a00.89 %\u00a0$960,277 \u00a0\u00a02.03 %\u00a0(54.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.12 \u00a0\u00a0\u00a0 \u00a0$4.68 \u00a0\u00a0\u00a0 \u00a0(54.7 )%\nDiluted \u00a0$2.10 \u00a0\u00a0\u00a0 \u00a0$4.64 \u00a0\u00a0\u00a0 \u00a0(54.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,916 \u00a0\u00a0\u00a0 \u00a0205,370 \u00a0\u00a0\u00a0 \u00a0(0.2 )%\nDiluted \u00a0207,315 \u00a0\u00a0\u00a0 \u00a0207,062 \u00a0\u00a0\u00a0 \u00a00.1 %\n________________________________________\n1Includes a $20.9 million LIFO credit in the three months ended March 31, 2021.  Includes a $23.9 million LIFO expense, a $0.1\nmillion gain from antitrust litigation settlements, and $5.0 million of PharMEDium shutdown costs in the three months ended\nMarch 31, 2020.\n\u00a0\u00a0\n 2Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $24.9 million of legal fees in connection with opioid lawsuits and investigations, and\n$36.2 million of other costs in connection with acquisition-related deal and integration costs, business transformation efforts,\nand other restructuring initiatives in the three months ended March 31, 2021.  Includes $25.0 million of employee severance,\n$30.8 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $11.9 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the three months ended March 31, 2020.\n\u00a0\u00a0\n 4Includes a $21.4 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended March 31, 2021.\n\u00a0\u00a0\n", "original_text": "2Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\u00a0\n", "page_label": "7", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "59bcb80e6c9b59b914e5077e85f235130b346ed2429aefab69e025a1a6512d2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef33f21a-6112-47f9-8122-4addd28f2ab5", "node_type": "1", "metadata": {"window": "Includes a $23.9 million LIFO expense, a $0.1\nmillion gain from antitrust litigation settlements, and $5.0 million of PharMEDium shutdown costs in the three months ended\nMarch 31, 2020.\n\u00a0\u00a0\n 2Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $24.9 million of legal fees in connection with opioid lawsuits and investigations, and\n$36.2 million of other costs in connection with acquisition-related deal and integration costs, business transformation efforts,\nand other restructuring initiatives in the three months ended March 31, 2021.  Includes $25.0 million of employee severance,\n$30.8 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $11.9 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the three months ended March 31, 2020.\n\u00a0\u00a0\n 4Includes a $21.4 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended March 31, 2021.\n\u00a0\u00a0\n 5Includes $2.7 million of expense relating to Swiss tax reform in the three months ended March 31, 2021.  Includes $741.0 million\nof discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the\n7", "original_text": "Includes $25.0 million of employee severance,\n$30.8 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $11.9 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the three months ended March 31, 2020.\n\u00a0\u00a0\n"}, "hash": "0c4f0722f8a28cd3a93cf3888c19bf2552761399f56c860e3b3356c5ab1933a0", "class_name": "RelatedNodeInfo"}}, "text": "3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $24.9 million of legal fees in connection with opioid lawsuits and investigations, and\n$36.2 million of other costs in connection with acquisition-related deal and integration costs, business transformation efforts,\nand other restructuring initiatives in the three months ended March 31, 2021. ", "start_char_idx": 1145, "end_char_idx": 1610, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef33f21a-6112-47f9-8122-4addd28f2ab5": {"__data__": {"id_": "ef33f21a-6112-47f9-8122-4addd28f2ab5", "embedding": null, "metadata": {"window": "Includes a $23.9 million LIFO expense, a $0.1\nmillion gain from antitrust litigation settlements, and $5.0 million of PharMEDium shutdown costs in the three months ended\nMarch 31, 2020.\n\u00a0\u00a0\n 2Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $24.9 million of legal fees in connection with opioid lawsuits and investigations, and\n$36.2 million of other costs in connection with acquisition-related deal and integration costs, business transformation efforts,\nand other restructuring initiatives in the three months ended March 31, 2021.  Includes $25.0 million of employee severance,\n$30.8 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $11.9 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the three months ended March 31, 2020.\n\u00a0\u00a0\n 4Includes a $21.4 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended March 31, 2021.\n\u00a0\u00a0\n 5Includes $2.7 million of expense relating to Swiss tax reform in the three months ended March 31, 2021.  Includes $741.0 million\nof discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the\n7", "original_text": "Includes $25.0 million of employee severance,\n$30.8 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $11.9 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the three months ended March 31, 2020.\n\u00a0\u00a0\n", "page_label": "7", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff0cb08d-f257-46de-95f4-d4816cbc4ebe", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7400f4b36e86e64713c8acd835f45792e4026af0f84c1115c893d608dda5e141", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36dad163-71d6-4b73-9f53-0ff96ed72467", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0434,005 \u00a0\u00a00.88 %\u00a0971,111 \u00a0\u00a02.05 %\u00a0(55.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a01,262 \u00a0\u00a0\u00a0 \u00a0(10,834 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$435,267 \u00a0\u00a00.89 %\u00a0$960,277 \u00a0\u00a02.03 %\u00a0(54.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.12 \u00a0\u00a0\u00a0 \u00a0$4.68 \u00a0\u00a0\u00a0 \u00a0(54.7 )%\nDiluted \u00a0$2.10 \u00a0\u00a0\u00a0 \u00a0$4.64 \u00a0\u00a0\u00a0 \u00a0(54.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,916 \u00a0\u00a0\u00a0 \u00a0205,370 \u00a0\u00a0\u00a0 \u00a0(0.2 )%\nDiluted \u00a0207,315 \u00a0\u00a0\u00a0 \u00a0207,062 \u00a0\u00a0\u00a0 \u00a00.1 %\n________________________________________\n1Includes a $20.9 million LIFO credit in the three months ended March 31, 2021.  Includes a $23.9 million LIFO expense, a $0.1\nmillion gain from antitrust litigation settlements, and $5.0 million of PharMEDium shutdown costs in the three months ended\nMarch 31, 2020.\n\u00a0\u00a0\n 2Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $24.9 million of legal fees in connection with opioid lawsuits and investigations, and\n$36.2 million of other costs in connection with acquisition-related deal and integration costs, business transformation efforts,\nand other restructuring initiatives in the three months ended March 31, 2021.  Includes $25.0 million of employee severance,\n$30.8 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $11.9 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the three months ended March 31, 2020.\n\u00a0\u00a0\n 4Includes a $21.4 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended March 31, 2021.\n\u00a0\u00a0\n 5Includes $2.7 million of expense relating to Swiss tax reform in the three months ended March 31, 2021. ", "original_text": "3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $24.9 million of legal fees in connection with opioid lawsuits and investigations, and\n$36.2 million of other costs in connection with acquisition-related deal and integration costs, business transformation efforts,\nand other restructuring initiatives in the three months ended March 31, 2021. ", "page_label": "7", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcedb6af60b1dd054338cb8afe54ff8886cce39b583e04b756f11ecf9e3e2e89", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a31d8386-ada5-438e-8450-ee42c689a563", "node_type": "1", "metadata": {"window": "2Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $24.9 million of legal fees in connection with opioid lawsuits and investigations, and\n$36.2 million of other costs in connection with acquisition-related deal and integration costs, business transformation efforts,\nand other restructuring initiatives in the three months ended March 31, 2021.  Includes $25.0 million of employee severance,\n$30.8 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $11.9 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the three months ended March 31, 2020.\n\u00a0\u00a0\n 4Includes a $21.4 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended March 31, 2021.\n\u00a0\u00a0\n 5Includes $2.7 million of expense relating to Swiss tax reform in the three months ended March 31, 2021.  Includes $741.0 million\nof discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the\n7", "original_text": "4Includes a $21.4 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended March 31, 2021.\n\u00a0\u00a0\n"}, "hash": "4fee90367eaf81af02b4eadb4e85e62ea4aed910b85ce1898caf2109b57c7e9f", "class_name": "RelatedNodeInfo"}}, "text": "Includes $25.0 million of employee severance,\n$30.8 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $11.9 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the three months ended March 31, 2020.\n\u00a0\u00a0\n", "start_char_idx": 1610, "end_char_idx": 1981, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a31d8386-ada5-438e-8450-ee42c689a563": {"__data__": {"id_": "a31d8386-ada5-438e-8450-ee42c689a563", "embedding": null, "metadata": {"window": "2Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $24.9 million of legal fees in connection with opioid lawsuits and investigations, and\n$36.2 million of other costs in connection with acquisition-related deal and integration costs, business transformation efforts,\nand other restructuring initiatives in the three months ended March 31, 2021.  Includes $25.0 million of employee severance,\n$30.8 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $11.9 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the three months ended March 31, 2020.\n\u00a0\u00a0\n 4Includes a $21.4 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended March 31, 2021.\n\u00a0\u00a0\n 5Includes $2.7 million of expense relating to Swiss tax reform in the three months ended March 31, 2021.  Includes $741.0 million\nof discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the\n7", "original_text": "4Includes a $21.4 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended March 31, 2021.\n\u00a0\u00a0\n", "page_label": "7", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff0cb08d-f257-46de-95f4-d4816cbc4ebe", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7400f4b36e86e64713c8acd835f45792e4026af0f84c1115c893d608dda5e141", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef33f21a-6112-47f9-8122-4addd28f2ab5", "node_type": "1", "metadata": {"window": "Includes a $23.9 million LIFO expense, a $0.1\nmillion gain from antitrust litigation settlements, and $5.0 million of PharMEDium shutdown costs in the three months ended\nMarch 31, 2020.\n\u00a0\u00a0\n 2Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $24.9 million of legal fees in connection with opioid lawsuits and investigations, and\n$36.2 million of other costs in connection with acquisition-related deal and integration costs, business transformation efforts,\nand other restructuring initiatives in the three months ended March 31, 2021.  Includes $25.0 million of employee severance,\n$30.8 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $11.9 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the three months ended March 31, 2020.\n\u00a0\u00a0\n 4Includes a $21.4 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended March 31, 2021.\n\u00a0\u00a0\n 5Includes $2.7 million of expense relating to Swiss tax reform in the three months ended March 31, 2021.  Includes $741.0 million\nof discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the\n7", "original_text": "Includes $25.0 million of employee severance,\n$30.8 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $11.9 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the three months ended March 31, 2020.\n\u00a0\u00a0\n", "page_label": "7", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a9a9d129ad155a958b2372d68b66b70458d8593d9a9c268912dd2eadf4862ba7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e504a89-1cd2-454e-b6dd-623439b5a225", "node_type": "1", "metadata": {"window": "3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $24.9 million of legal fees in connection with opioid lawsuits and investigations, and\n$36.2 million of other costs in connection with acquisition-related deal and integration costs, business transformation efforts,\nand other restructuring initiatives in the three months ended March 31, 2021.  Includes $25.0 million of employee severance,\n$30.8 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $11.9 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the three months ended March 31, 2020.\n\u00a0\u00a0\n 4Includes a $21.4 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended March 31, 2021.\n\u00a0\u00a0\n 5Includes $2.7 million of expense relating to Swiss tax reform in the three months ended March 31, 2021.  Includes $741.0 million\nof discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the\n7", "original_text": "5Includes $2.7 million of expense relating to Swiss tax reform in the three months ended March 31, 2021. "}, "hash": "1a5dc274f00086502832fbe35cc99fd79721c09ea098f0b60615f9df798bde1d", "class_name": "RelatedNodeInfo"}}, "text": "4Includes a $21.4 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended March 31, 2021.\n\u00a0\u00a0\n", "start_char_idx": 1981, "end_char_idx": 2143, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e504a89-1cd2-454e-b6dd-623439b5a225": {"__data__": {"id_": "5e504a89-1cd2-454e-b6dd-623439b5a225", "embedding": null, "metadata": {"window": "3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $24.9 million of legal fees in connection with opioid lawsuits and investigations, and\n$36.2 million of other costs in connection with acquisition-related deal and integration costs, business transformation efforts,\nand other restructuring initiatives in the three months ended March 31, 2021.  Includes $25.0 million of employee severance,\n$30.8 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $11.9 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the three months ended March 31, 2020.\n\u00a0\u00a0\n 4Includes a $21.4 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended March 31, 2021.\n\u00a0\u00a0\n 5Includes $2.7 million of expense relating to Swiss tax reform in the three months ended March 31, 2021.  Includes $741.0 million\nof discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the\n7", "original_text": "5Includes $2.7 million of expense relating to Swiss tax reform in the three months ended March 31, 2021. ", "page_label": "7", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff0cb08d-f257-46de-95f4-d4816cbc4ebe", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7400f4b36e86e64713c8acd835f45792e4026af0f84c1115c893d608dda5e141", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a31d8386-ada5-438e-8450-ee42c689a563", "node_type": "1", "metadata": {"window": "2Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $24.9 million of legal fees in connection with opioid lawsuits and investigations, and\n$36.2 million of other costs in connection with acquisition-related deal and integration costs, business transformation efforts,\nand other restructuring initiatives in the three months ended March 31, 2021.  Includes $25.0 million of employee severance,\n$30.8 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $11.9 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the three months ended March 31, 2020.\n\u00a0\u00a0\n 4Includes a $21.4 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended March 31, 2021.\n\u00a0\u00a0\n 5Includes $2.7 million of expense relating to Swiss tax reform in the three months ended March 31, 2021.  Includes $741.0 million\nof discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the\n7", "original_text": "4Includes a $21.4 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended March 31, 2021.\n\u00a0\u00a0\n", "page_label": "7", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6222ab9b7536f4be349af6ff9bc2dc64a2450c5322b16401c8b666f6b65d6164", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8be24d9-a0b5-4056-936e-e0081c0d2a16", "node_type": "1", "metadata": {"window": "Includes $25.0 million of employee severance,\n$30.8 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $11.9 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the three months ended March 31, 2020.\n\u00a0\u00a0\n 4Includes a $21.4 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended March 31, 2021.\n\u00a0\u00a0\n 5Includes $2.7 million of expense relating to Swiss tax reform in the three months ended March 31, 2021.  Includes $741.0 million\nof discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the\n7", "original_text": "Includes $741.0 million\nof discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the\n7"}, "hash": "6ddb041a0ab5c3a19bf092ca8f3269c1eb81e1cbeb7f38268bcd915187d81dfb", "class_name": "RelatedNodeInfo"}}, "text": "5Includes $2.7 million of expense relating to Swiss tax reform in the three months ended March 31, 2021. ", "start_char_idx": 2143, "end_char_idx": 2248, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8be24d9-a0b5-4056-936e-e0081c0d2a16": {"__data__": {"id_": "a8be24d9-a0b5-4056-936e-e0081c0d2a16", "embedding": null, "metadata": {"window": "Includes $25.0 million of employee severance,\n$30.8 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $11.9 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the three months ended March 31, 2020.\n\u00a0\u00a0\n 4Includes a $21.4 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended March 31, 2021.\n\u00a0\u00a0\n 5Includes $2.7 million of expense relating to Swiss tax reform in the three months ended March 31, 2021.  Includes $741.0 million\nof discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the\n7", "original_text": "Includes $741.0 million\nof discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the\n7", "page_label": "7", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff0cb08d-f257-46de-95f4-d4816cbc4ebe", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7400f4b36e86e64713c8acd835f45792e4026af0f84c1115c893d608dda5e141", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e504a89-1cd2-454e-b6dd-623439b5a225", "node_type": "1", "metadata": {"window": "3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $24.9 million of legal fees in connection with opioid lawsuits and investigations, and\n$36.2 million of other costs in connection with acquisition-related deal and integration costs, business transformation efforts,\nand other restructuring initiatives in the three months ended March 31, 2021.  Includes $25.0 million of employee severance,\n$30.8 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $11.9 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the three months ended March 31, 2020.\n\u00a0\u00a0\n 4Includes a $21.4 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended March 31, 2021.\n\u00a0\u00a0\n 5Includes $2.7 million of expense relating to Swiss tax reform in the three months ended March 31, 2021.  Includes $741.0 million\nof discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the\n7", "original_text": "5Includes $2.7 million of expense relating to Swiss tax reform in the three months ended March 31, 2021. ", "page_label": "7", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb2e0ca46b5772d5f0bf13d0e1719cf1d0995ab1e466bf5ebadf3c659c31803e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a914bca4-67bb-4357-8214-9b425e7c007f", "node_type": "1", "metadata": {"window": "PharMEDium business in the three months ended March 31, 2020.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Six \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0Six \nMonths Ended \nMarch 31, 2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$101,670,727 \u00a0\u00a0\u00a0 \u00a0$95,282,381 \u00a0\u00a0\u00a0 \u00a06.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a098,685,116 \u00a0\u00a0\u00a0 \u00a092,663,060 \u00a0\u00a0\u00a0 \u00a06.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a02,985,611 \u00a0\u00a02.94 %\u00a02,619,321 \u00a0\u00a02.75 %\u00a014.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a01,465,149 \u00a0\u00a01.44 %\u00a01,379,366 \u00a0\u00a01.45 %\u00a06.2 %\nDepreciation and amortization \u00a0200,350 \u00a0\u00a00.20 %\u00a0198,310 \u00a0\u00a00.21 %\u00a01.0 %\nEmployee severance, litigation, and other 3 \u00a0148,537 \u00a0\u00a0\u00a0 \u00a0107,041 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,814,036 \u00a0\u00a01.78 %\u00a02,046,369 \u00a0\u00a02.15 %\u00a0(11.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a01,171,575 \u00a0\u00a01.15 %\u00a0572,952 \u00a0\u00a00.60 %\u00a0104.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss, net  4 \u00a09,042 \u00a0\u00a0\u00a0 \u00a01,733 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a068,140 \u00a0\u00a0\u00a0 \u00a065,428 \u00a0\u00a0\u00a0 \u00a04.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a01,094,393 \u00a0\u00a01.08 %\u00a0505,791 \u00a0\u00a00.53 %\u00a0116.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0281,681 \u00a0\u00a0\u00a0 \u00a0(651,888 )\u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "PharMEDium business in the three months ended March 31, 2020.\n"}, "hash": "6b1d7acebe3216a4885d40e65dd40bb7c367fd5ff290c74920690dec42a6fa89", "class_name": "RelatedNodeInfo"}}, "text": "Includes $741.0 million\nof discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the\n7", "start_char_idx": 2248, "end_char_idx": 2395, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a914bca4-67bb-4357-8214-9b425e7c007f": {"__data__": {"id_": "a914bca4-67bb-4357-8214-9b425e7c007f", "embedding": null, "metadata": {"window": "PharMEDium business in the three months ended March 31, 2020.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Six \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0Six \nMonths Ended \nMarch 31, 2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$101,670,727 \u00a0\u00a0\u00a0 \u00a0$95,282,381 \u00a0\u00a0\u00a0 \u00a06.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a098,685,116 \u00a0\u00a0\u00a0 \u00a092,663,060 \u00a0\u00a0\u00a0 \u00a06.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a02,985,611 \u00a0\u00a02.94 %\u00a02,619,321 \u00a0\u00a02.75 %\u00a014.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a01,465,149 \u00a0\u00a01.44 %\u00a01,379,366 \u00a0\u00a01.45 %\u00a06.2 %\nDepreciation and amortization \u00a0200,350 \u00a0\u00a00.20 %\u00a0198,310 \u00a0\u00a00.21 %\u00a01.0 %\nEmployee severance, litigation, and other 3 \u00a0148,537 \u00a0\u00a0\u00a0 \u00a0107,041 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,814,036 \u00a0\u00a01.78 %\u00a02,046,369 \u00a0\u00a02.15 %\u00a0(11.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a01,171,575 \u00a0\u00a01.15 %\u00a0572,952 \u00a0\u00a00.60 %\u00a0104.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss, net  4 \u00a09,042 \u00a0\u00a0\u00a0 \u00a01,733 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a068,140 \u00a0\u00a0\u00a0 \u00a065,428 \u00a0\u00a0\u00a0 \u00a04.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a01,094,393 \u00a0\u00a01.08 %\u00a0505,791 \u00a0\u00a00.53 %\u00a0116.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0281,681 \u00a0\u00a0\u00a0 \u00a0(651,888 )\u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "PharMEDium business in the three months ended March 31, 2020.\n", "page_label": "8", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca520586-707e-4b53-b512-5219e544df95", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c727228a89b37686e925a9f2dac3a87b121d592d92a27e620b6555b59aa188a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8be24d9-a0b5-4056-936e-e0081c0d2a16", "node_type": "1", "metadata": {"window": "Includes $25.0 million of employee severance,\n$30.8 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $11.9 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the three months ended March 31, 2020.\n\u00a0\u00a0\n 4Includes a $21.4 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the three\nmonths ended March 31, 2021.\n\u00a0\u00a0\n 5Includes $2.7 million of expense relating to Swiss tax reform in the three months ended March 31, 2021.  Includes $741.0 million\nof discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the\n7", "original_text": "Includes $741.0 million\nof discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the\n7", "page_label": "7", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00600377d7a3ba2aea53f422c1d18b6fb90fda65e9030fe7036937abf150e5c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "579b8eda-750c-4518-8511-e361b9d03d1c", "node_type": "1", "metadata": {"window": "PharMEDium business in the three months ended March 31, 2020.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Six \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0Six \nMonths Ended \nMarch 31, 2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$101,670,727 \u00a0\u00a0\u00a0 \u00a0$95,282,381 \u00a0\u00a0\u00a0 \u00a06.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a098,685,116 \u00a0\u00a0\u00a0 \u00a092,663,060 \u00a0\u00a0\u00a0 \u00a06.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a02,985,611 \u00a0\u00a02.94 %\u00a02,619,321 \u00a0\u00a02.75 %\u00a014.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a01,465,149 \u00a0\u00a01.44 %\u00a01,379,366 \u00a0\u00a01.45 %\u00a06.2 %\nDepreciation and amortization \u00a0200,350 \u00a0\u00a00.20 %\u00a0198,310 \u00a0\u00a00.21 %\u00a01.0 %\nEmployee severance, litigation, and other 3 \u00a0148,537 \u00a0\u00a0\u00a0 \u00a0107,041 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,814,036 \u00a0\u00a01.78 %\u00a02,046,369 \u00a0\u00a02.15 %\u00a0(11.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a01,171,575 \u00a0\u00a01.15 %\u00a0572,952 \u00a0\u00a00.60 %\u00a0104.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss, net  4 \u00a09,042 \u00a0\u00a0\u00a0 \u00a01,733 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a068,140 \u00a0\u00a0\u00a0 \u00a065,428 \u00a0\u00a0\u00a0 \u00a04.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a01,094,393 \u00a0\u00a01.08 %\u00a0505,791 \u00a0\u00a00.53 %\u00a0116.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0281,681 \u00a0\u00a0\u00a0 \u00a0(651,888 )\u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Six \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0Six \nMonths Ended \nMarch 31, 2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$101,670,727 \u00a0\u00a0\u00a0 \u00a0$95,282,381 \u00a0\u00a0\u00a0 \u00a06.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a098,685,116 \u00a0\u00a0\u00a0 \u00a092,663,060 \u00a0\u00a0\u00a0 \u00a06.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a02,985,611 \u00a0\u00a02.94 %\u00a02,619,321 \u00a0\u00a02.75 %\u00a014.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a01,465,149 \u00a0\u00a01.44 %\u00a01,379,366 \u00a0\u00a01.45 %\u00a06.2 %\nDepreciation and amortization \u00a0200,350 \u00a0\u00a00.20 %\u00a0198,310 \u00a0\u00a00.21 %\u00a01.0 %\nEmployee severance, litigation, and other 3 \u00a0148,537 \u00a0\u00a0\u00a0 \u00a0107,041 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,814,036 \u00a0\u00a01.78 %\u00a02,046,369 \u00a0\u00a02.15 %\u00a0(11.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a01,171,575 \u00a0\u00a01.15 %\u00a0572,952 \u00a0\u00a00.60 %\u00a0104.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss, net  4 \u00a09,042 \u00a0\u00a0\u00a0 \u00a01,733 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a068,140 \u00a0\u00a0\u00a0 \u00a065,428 \u00a0\u00a0\u00a0 \u00a04.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a01,094,393 \u00a0\u00a01.08 %\u00a0505,791 \u00a0\u00a00.53 %\u00a0116.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0281,681 \u00a0\u00a0\u00a0 \u00a0(651,888 )\u00a0\u00a0 \u00a0\u00a0\n8"}, "hash": "1392291abbba576e4a3c38ab3e7454d01919de7fdc942061b136d63b2cf19e26", "class_name": "RelatedNodeInfo"}}, "text": "PharMEDium business in the three months ended March 31, 2020.\n", "start_char_idx": 0, "end_char_idx": 62, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "579b8eda-750c-4518-8511-e361b9d03d1c": {"__data__": {"id_": "579b8eda-750c-4518-8511-e361b9d03d1c", "embedding": null, "metadata": {"window": "PharMEDium business in the three months ended March 31, 2020.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Six \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0Six \nMonths Ended \nMarch 31, 2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$101,670,727 \u00a0\u00a0\u00a0 \u00a0$95,282,381 \u00a0\u00a0\u00a0 \u00a06.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a098,685,116 \u00a0\u00a0\u00a0 \u00a092,663,060 \u00a0\u00a0\u00a0 \u00a06.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a02,985,611 \u00a0\u00a02.94 %\u00a02,619,321 \u00a0\u00a02.75 %\u00a014.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a01,465,149 \u00a0\u00a01.44 %\u00a01,379,366 \u00a0\u00a01.45 %\u00a06.2 %\nDepreciation and amortization \u00a0200,350 \u00a0\u00a00.20 %\u00a0198,310 \u00a0\u00a00.21 %\u00a01.0 %\nEmployee severance, litigation, and other 3 \u00a0148,537 \u00a0\u00a0\u00a0 \u00a0107,041 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,814,036 \u00a0\u00a01.78 %\u00a02,046,369 \u00a0\u00a02.15 %\u00a0(11.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a01,171,575 \u00a0\u00a01.15 %\u00a0572,952 \u00a0\u00a00.60 %\u00a0104.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss, net  4 \u00a09,042 \u00a0\u00a0\u00a0 \u00a01,733 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a068,140 \u00a0\u00a0\u00a0 \u00a065,428 \u00a0\u00a0\u00a0 \u00a04.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a01,094,393 \u00a0\u00a01.08 %\u00a0505,791 \u00a0\u00a00.53 %\u00a0116.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0281,681 \u00a0\u00a0\u00a0 \u00a0(651,888 )\u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Six \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0Six \nMonths Ended \nMarch 31, 2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$101,670,727 \u00a0\u00a0\u00a0 \u00a0$95,282,381 \u00a0\u00a0\u00a0 \u00a06.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a098,685,116 \u00a0\u00a0\u00a0 \u00a092,663,060 \u00a0\u00a0\u00a0 \u00a06.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a02,985,611 \u00a0\u00a02.94 %\u00a02,619,321 \u00a0\u00a02.75 %\u00a014.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a01,465,149 \u00a0\u00a01.44 %\u00a01,379,366 \u00a0\u00a01.45 %\u00a06.2 %\nDepreciation and amortization \u00a0200,350 \u00a0\u00a00.20 %\u00a0198,310 \u00a0\u00a00.21 %\u00a01.0 %\nEmployee severance, litigation, and other 3 \u00a0148,537 \u00a0\u00a0\u00a0 \u00a0107,041 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,814,036 \u00a0\u00a01.78 %\u00a02,046,369 \u00a0\u00a02.15 %\u00a0(11.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a01,171,575 \u00a0\u00a01.15 %\u00a0572,952 \u00a0\u00a00.60 %\u00a0104.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss, net  4 \u00a09,042 \u00a0\u00a0\u00a0 \u00a01,733 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a068,140 \u00a0\u00a0\u00a0 \u00a065,428 \u00a0\u00a0\u00a0 \u00a04.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a01,094,393 \u00a0\u00a01.08 %\u00a0505,791 \u00a0\u00a00.53 %\u00a0116.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0281,681 \u00a0\u00a0\u00a0 \u00a0(651,888 )\u00a0\u00a0 \u00a0\u00a0\n8", "page_label": "8", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ca520586-707e-4b53-b512-5219e544df95", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c727228a89b37686e925a9f2dac3a87b121d592d92a27e620b6555b59aa188a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a914bca4-67bb-4357-8214-9b425e7c007f", "node_type": "1", "metadata": {"window": "PharMEDium business in the three months ended March 31, 2020.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Six \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0Six \nMonths Ended \nMarch 31, 2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$101,670,727 \u00a0\u00a0\u00a0 \u00a0$95,282,381 \u00a0\u00a0\u00a0 \u00a06.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a098,685,116 \u00a0\u00a0\u00a0 \u00a092,663,060 \u00a0\u00a0\u00a0 \u00a06.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a02,985,611 \u00a0\u00a02.94 %\u00a02,619,321 \u00a0\u00a02.75 %\u00a014.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a01,465,149 \u00a0\u00a01.44 %\u00a01,379,366 \u00a0\u00a01.45 %\u00a06.2 %\nDepreciation and amortization \u00a0200,350 \u00a0\u00a00.20 %\u00a0198,310 \u00a0\u00a00.21 %\u00a01.0 %\nEmployee severance, litigation, and other 3 \u00a0148,537 \u00a0\u00a0\u00a0 \u00a0107,041 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,814,036 \u00a0\u00a01.78 %\u00a02,046,369 \u00a0\u00a02.15 %\u00a0(11.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a01,171,575 \u00a0\u00a01.15 %\u00a0572,952 \u00a0\u00a00.60 %\u00a0104.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss, net  4 \u00a09,042 \u00a0\u00a0\u00a0 \u00a01,733 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a068,140 \u00a0\u00a0\u00a0 \u00a065,428 \u00a0\u00a0\u00a0 \u00a04.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a01,094,393 \u00a0\u00a01.08 %\u00a0505,791 \u00a0\u00a00.53 %\u00a0116.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0281,681 \u00a0\u00a0\u00a0 \u00a0(651,888 )\u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "PharMEDium business in the three months ended March 31, 2020.\n", "page_label": "8", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a94044bf89fee0ed7ec24a8a910214fb8b6eacb527616a04e83885f23a6c504", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "befcbe45-89fe-4367-ab89-0dc3fe8d3d46", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0812,712 \u00a0\u00a00.80 %\u00a01,157,679 \u00a0\u00a01.21 %\u00a0(29.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(2,600 )\u00a0\u00a0 \u00a0(9,762 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$810,112 \u00a0\u00a00.80 %\u00a0$1,147,917 \u00a0\u00a01.20 %\u00a0(29.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.96 \u00a0\u00a0\u00a0 \u00a0$5.58 \u00a0\u00a0\u00a0 \u00a0(29.0 )%\nDiluted \u00a0$3.91 \u00a0\u00a0\u00a0 \u00a0$5.54 \u00a0\u00a0\u00a0 \u00a0(29.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,804 \u00a0\u00a0\u00a0 \u00a0205,693 \u00a0\u00a0\u00a0 \u00a0(0.4 )%\nDiluted \u00a0207,063 \u00a0\u00a0\u00a0 \u00a0207,293 \u00a0\u00a0\u00a0 \u00a0(0.1 )%\n________________________________________\n\u00a0\u00a0\n1Includes a $46.6 million LIFO credit in the six months ended March 31, 2021.  Includes a $37.1 million LIFO expense, an $8.5\nmillion gain from antitrust litigation settlements, and $12.1 million of PharMEDium shutdown and remediation costs in the six\nmonths ended March 31, 2020.\n\u00a0\u00a0\n 2Includes $36.5 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended\nMarch 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $56.9 million of litigation and opioid-related costs related to legal fees in connection\nwith opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0812,712 \u00a0\u00a00.80 %\u00a01,157,679 \u00a0\u00a01.21 %\u00a0(29.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(2,600 )\u00a0\u00a0 \u00a0(9,762 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$810,112 \u00a0\u00a00.80 %\u00a0$1,147,917 \u00a0\u00a01.20 %\u00a0(29.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.96 \u00a0\u00a0\u00a0 \u00a0$5.58 \u00a0\u00a0\u00a0 \u00a0(29.0 )%\nDiluted \u00a0$3.91 \u00a0\u00a0\u00a0 \u00a0$5.54 \u00a0\u00a0\u00a0 \u00a0(29.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,804 \u00a0\u00a0\u00a0 \u00a0205,693 \u00a0\u00a0\u00a0 \u00a0(0.4 )%\nDiluted \u00a0207,063 \u00a0\u00a0\u00a0 \u00a0207,293 \u00a0\u00a0\u00a0 \u00a0(0.1 )%\n________________________________________\n\u00a0\u00a0\n1Includes a $46.6 million LIFO credit in the six months ended March 31, 2021. "}, "hash": "ac11b9c90397ae2856a2da429487688835ade431bb9c0acc3d65e0d83eb45da6", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Six \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0Six \nMonths Ended \nMarch 31, 2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$101,670,727 \u00a0\u00a0\u00a0 \u00a0$95,282,381 \u00a0\u00a0\u00a0 \u00a06.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a098,685,116 \u00a0\u00a0\u00a0 \u00a092,663,060 \u00a0\u00a0\u00a0 \u00a06.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a02,985,611 \u00a0\u00a02.94 %\u00a02,619,321 \u00a0\u00a02.75 %\u00a014.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a01,465,149 \u00a0\u00a01.44 %\u00a01,379,366 \u00a0\u00a01.45 %\u00a06.2 %\nDepreciation and amortization \u00a0200,350 \u00a0\u00a00.20 %\u00a0198,310 \u00a0\u00a00.21 %\u00a01.0 %\nEmployee severance, litigation, and other 3 \u00a0148,537 \u00a0\u00a0\u00a0 \u00a0107,041 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,814,036 \u00a0\u00a01.78 %\u00a02,046,369 \u00a0\u00a02.15 %\u00a0(11.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a01,171,575 \u00a0\u00a01.15 %\u00a0572,952 \u00a0\u00a00.60 %\u00a0104.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss, net  4 \u00a09,042 \u00a0\u00a0\u00a0 \u00a01,733 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a068,140 \u00a0\u00a0\u00a0 \u00a065,428 \u00a0\u00a0\u00a0 \u00a04.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a01,094,393 \u00a0\u00a01.08 %\u00a0505,791 \u00a0\u00a00.53 %\u00a0116.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0281,681 \u00a0\u00a0\u00a0 \u00a0(651,888 )\u00a0\u00a0 \u00a0\u00a0\n8", "start_char_idx": 62, "end_char_idx": 1253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "befcbe45-89fe-4367-ab89-0dc3fe8d3d46": {"__data__": {"id_": "befcbe45-89fe-4367-ab89-0dc3fe8d3d46", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0812,712 \u00a0\u00a00.80 %\u00a01,157,679 \u00a0\u00a01.21 %\u00a0(29.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(2,600 )\u00a0\u00a0 \u00a0(9,762 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$810,112 \u00a0\u00a00.80 %\u00a0$1,147,917 \u00a0\u00a01.20 %\u00a0(29.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.96 \u00a0\u00a0\u00a0 \u00a0$5.58 \u00a0\u00a0\u00a0 \u00a0(29.0 )%\nDiluted \u00a0$3.91 \u00a0\u00a0\u00a0 \u00a0$5.54 \u00a0\u00a0\u00a0 \u00a0(29.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,804 \u00a0\u00a0\u00a0 \u00a0205,693 \u00a0\u00a0\u00a0 \u00a0(0.4 )%\nDiluted \u00a0207,063 \u00a0\u00a0\u00a0 \u00a0207,293 \u00a0\u00a0\u00a0 \u00a0(0.1 )%\n________________________________________\n\u00a0\u00a0\n1Includes a $46.6 million LIFO credit in the six months ended March 31, 2021.  Includes a $37.1 million LIFO expense, an $8.5\nmillion gain from antitrust litigation settlements, and $12.1 million of PharMEDium shutdown and remediation costs in the six\nmonths ended March 31, 2020.\n\u00a0\u00a0\n 2Includes $36.5 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended\nMarch 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $56.9 million of litigation and opioid-related costs related to legal fees in connection\nwith opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0812,712 \u00a0\u00a00.80 %\u00a01,157,679 \u00a0\u00a01.21 %\u00a0(29.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(2,600 )\u00a0\u00a0 \u00a0(9,762 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$810,112 \u00a0\u00a00.80 %\u00a0$1,147,917 \u00a0\u00a01.20 %\u00a0(29.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.96 \u00a0\u00a0\u00a0 \u00a0$5.58 \u00a0\u00a0\u00a0 \u00a0(29.0 )%\nDiluted \u00a0$3.91 \u00a0\u00a0\u00a0 \u00a0$5.54 \u00a0\u00a0\u00a0 \u00a0(29.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,804 \u00a0\u00a0\u00a0 \u00a0205,693 \u00a0\u00a0\u00a0 \u00a0(0.4 )%\nDiluted \u00a0207,063 \u00a0\u00a0\u00a0 \u00a0207,293 \u00a0\u00a0\u00a0 \u00a0(0.1 )%\n________________________________________\n\u00a0\u00a0\n1Includes a $46.6 million LIFO credit in the six months ended March 31, 2021. ", "page_label": "9", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f346ea14-bb69-427b-b23c-3ab5c70c3ac2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec757ac4ca47b8611ef4acc6723f45487b020c6742935f3a4a6ba1a6d66b76d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "579b8eda-750c-4518-8511-e361b9d03d1c", "node_type": "1", "metadata": {"window": "PharMEDium business in the three months ended March 31, 2020.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Six \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0Six \nMonths Ended \nMarch 31, 2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$101,670,727 \u00a0\u00a0\u00a0 \u00a0$95,282,381 \u00a0\u00a0\u00a0 \u00a06.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a098,685,116 \u00a0\u00a0\u00a0 \u00a092,663,060 \u00a0\u00a0\u00a0 \u00a06.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a02,985,611 \u00a0\u00a02.94 %\u00a02,619,321 \u00a0\u00a02.75 %\u00a014.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a01,465,149 \u00a0\u00a01.44 %\u00a01,379,366 \u00a0\u00a01.45 %\u00a06.2 %\nDepreciation and amortization \u00a0200,350 \u00a0\u00a00.20 %\u00a0198,310 \u00a0\u00a00.21 %\u00a01.0 %\nEmployee severance, litigation, and other 3 \u00a0148,537 \u00a0\u00a0\u00a0 \u00a0107,041 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,814,036 \u00a0\u00a01.78 %\u00a02,046,369 \u00a0\u00a02.15 %\u00a0(11.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a01,171,575 \u00a0\u00a01.15 %\u00a0572,952 \u00a0\u00a00.60 %\u00a0104.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss, net  4 \u00a09,042 \u00a0\u00a0\u00a0 \u00a01,733 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a068,140 \u00a0\u00a0\u00a0 \u00a065,428 \u00a0\u00a0\u00a0 \u00a04.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a01,094,393 \u00a0\u00a01.08 %\u00a0505,791 \u00a0\u00a00.53 %\u00a0116.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0281,681 \u00a0\u00a0\u00a0 \u00a0(651,888 )\u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Six \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0Six \nMonths Ended \nMarch 31, 2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$101,670,727 \u00a0\u00a0\u00a0 \u00a0$95,282,381 \u00a0\u00a0\u00a0 \u00a06.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a098,685,116 \u00a0\u00a0\u00a0 \u00a092,663,060 \u00a0\u00a0\u00a0 \u00a06.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a02,985,611 \u00a0\u00a02.94 %\u00a02,619,321 \u00a0\u00a02.75 %\u00a014.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a01,465,149 \u00a0\u00a01.44 %\u00a01,379,366 \u00a0\u00a01.45 %\u00a06.2 %\nDepreciation and amortization \u00a0200,350 \u00a0\u00a00.20 %\u00a0198,310 \u00a0\u00a00.21 %\u00a01.0 %\nEmployee severance, litigation, and other 3 \u00a0148,537 \u00a0\u00a0\u00a0 \u00a0107,041 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,814,036 \u00a0\u00a01.78 %\u00a02,046,369 \u00a0\u00a02.15 %\u00a0(11.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a01,171,575 \u00a0\u00a01.15 %\u00a0572,952 \u00a0\u00a00.60 %\u00a0104.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss, net  4 \u00a09,042 \u00a0\u00a0\u00a0 \u00a01,733 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a068,140 \u00a0\u00a0\u00a0 \u00a065,428 \u00a0\u00a0\u00a0 \u00a04.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a01,094,393 \u00a0\u00a01.08 %\u00a0505,791 \u00a0\u00a00.53 %\u00a0116.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0281,681 \u00a0\u00a0\u00a0 \u00a0(651,888 )\u00a0\u00a0 \u00a0\u00a0\n8", "page_label": "8", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86964fde195c5962c8fe4b09ca3d53177fbc920b7ba6525aa0de6caea9464132", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e2bef73-fa40-4241-a343-31b3b9d1d230", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0812,712 \u00a0\u00a00.80 %\u00a01,157,679 \u00a0\u00a01.21 %\u00a0(29.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(2,600 )\u00a0\u00a0 \u00a0(9,762 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$810,112 \u00a0\u00a00.80 %\u00a0$1,147,917 \u00a0\u00a01.20 %\u00a0(29.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.96 \u00a0\u00a0\u00a0 \u00a0$5.58 \u00a0\u00a0\u00a0 \u00a0(29.0 )%\nDiluted \u00a0$3.91 \u00a0\u00a0\u00a0 \u00a0$5.54 \u00a0\u00a0\u00a0 \u00a0(29.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,804 \u00a0\u00a0\u00a0 \u00a0205,693 \u00a0\u00a0\u00a0 \u00a0(0.4 )%\nDiluted \u00a0207,063 \u00a0\u00a0\u00a0 \u00a0207,293 \u00a0\u00a0\u00a0 \u00a0(0.1 )%\n________________________________________\n\u00a0\u00a0\n1Includes a $46.6 million LIFO credit in the six months ended March 31, 2021.  Includes a $37.1 million LIFO expense, an $8.5\nmillion gain from antitrust litigation settlements, and $12.1 million of PharMEDium shutdown and remediation costs in the six\nmonths ended March 31, 2020.\n\u00a0\u00a0\n 2Includes $36.5 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended\nMarch 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $56.9 million of litigation and opioid-related costs related to legal fees in connection\nwith opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.\n\u00a0\u00a0\n", "original_text": "Includes a $37.1 million LIFO expense, an $8.5\nmillion gain from antitrust litigation settlements, and $12.1 million of PharMEDium shutdown and remediation costs in the six\nmonths ended March 31, 2020.\n\u00a0\u00a0\n"}, "hash": "b35585ab83e833d663a6743960a881fad55e046052acd659237d862b7e271989", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0812,712 \u00a0\u00a00.80 %\u00a01,157,679 \u00a0\u00a01.21 %\u00a0(29.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(2,600 )\u00a0\u00a0 \u00a0(9,762 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$810,112 \u00a0\u00a00.80 %\u00a0$1,147,917 \u00a0\u00a01.20 %\u00a0(29.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.96 \u00a0\u00a0\u00a0 \u00a0$5.58 \u00a0\u00a0\u00a0 \u00a0(29.0 )%\nDiluted \u00a0$3.91 \u00a0\u00a0\u00a0 \u00a0$5.54 \u00a0\u00a0\u00a0 \u00a0(29.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,804 \u00a0\u00a0\u00a0 \u00a0205,693 \u00a0\u00a0\u00a0 \u00a0(0.4 )%\nDiluted \u00a0207,063 \u00a0\u00a0\u00a0 \u00a0207,293 \u00a0\u00a0\u00a0 \u00a0(0.1 )%\n________________________________________\n\u00a0\u00a0\n1Includes a $46.6 million LIFO credit in the six months ended March 31, 2021. ", "start_char_idx": 0, "end_char_idx": 704, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e2bef73-fa40-4241-a343-31b3b9d1d230": {"__data__": {"id_": "3e2bef73-fa40-4241-a343-31b3b9d1d230", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0812,712 \u00a0\u00a00.80 %\u00a01,157,679 \u00a0\u00a01.21 %\u00a0(29.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(2,600 )\u00a0\u00a0 \u00a0(9,762 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$810,112 \u00a0\u00a00.80 %\u00a0$1,147,917 \u00a0\u00a01.20 %\u00a0(29.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.96 \u00a0\u00a0\u00a0 \u00a0$5.58 \u00a0\u00a0\u00a0 \u00a0(29.0 )%\nDiluted \u00a0$3.91 \u00a0\u00a0\u00a0 \u00a0$5.54 \u00a0\u00a0\u00a0 \u00a0(29.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,804 \u00a0\u00a0\u00a0 \u00a0205,693 \u00a0\u00a0\u00a0 \u00a0(0.4 )%\nDiluted \u00a0207,063 \u00a0\u00a0\u00a0 \u00a0207,293 \u00a0\u00a0\u00a0 \u00a0(0.1 )%\n________________________________________\n\u00a0\u00a0\n1Includes a $46.6 million LIFO credit in the six months ended March 31, 2021.  Includes a $37.1 million LIFO expense, an $8.5\nmillion gain from antitrust litigation settlements, and $12.1 million of PharMEDium shutdown and remediation costs in the six\nmonths ended March 31, 2020.\n\u00a0\u00a0\n 2Includes $36.5 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended\nMarch 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $56.9 million of litigation and opioid-related costs related to legal fees in connection\nwith opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.\n\u00a0\u00a0\n", "original_text": "Includes a $37.1 million LIFO expense, an $8.5\nmillion gain from antitrust litigation settlements, and $12.1 million of PharMEDium shutdown and remediation costs in the six\nmonths ended March 31, 2020.\n\u00a0\u00a0\n", "page_label": "9", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f346ea14-bb69-427b-b23c-3ab5c70c3ac2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec757ac4ca47b8611ef4acc6723f45487b020c6742935f3a4a6ba1a6d66b76d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "befcbe45-89fe-4367-ab89-0dc3fe8d3d46", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0812,712 \u00a0\u00a00.80 %\u00a01,157,679 \u00a0\u00a01.21 %\u00a0(29.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(2,600 )\u00a0\u00a0 \u00a0(9,762 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$810,112 \u00a0\u00a00.80 %\u00a0$1,147,917 \u00a0\u00a01.20 %\u00a0(29.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.96 \u00a0\u00a0\u00a0 \u00a0$5.58 \u00a0\u00a0\u00a0 \u00a0(29.0 )%\nDiluted \u00a0$3.91 \u00a0\u00a0\u00a0 \u00a0$5.54 \u00a0\u00a0\u00a0 \u00a0(29.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,804 \u00a0\u00a0\u00a0 \u00a0205,693 \u00a0\u00a0\u00a0 \u00a0(0.4 )%\nDiluted \u00a0207,063 \u00a0\u00a0\u00a0 \u00a0207,293 \u00a0\u00a0\u00a0 \u00a0(0.1 )%\n________________________________________\n\u00a0\u00a0\n1Includes a $46.6 million LIFO credit in the six months ended March 31, 2021.  Includes a $37.1 million LIFO expense, an $8.5\nmillion gain from antitrust litigation settlements, and $12.1 million of PharMEDium shutdown and remediation costs in the six\nmonths ended March 31, 2020.\n\u00a0\u00a0\n 2Includes $36.5 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended\nMarch 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $56.9 million of litigation and opioid-related costs related to legal fees in connection\nwith opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0812,712 \u00a0\u00a00.80 %\u00a01,157,679 \u00a0\u00a01.21 %\u00a0(29.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(2,600 )\u00a0\u00a0 \u00a0(9,762 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$810,112 \u00a0\u00a00.80 %\u00a0$1,147,917 \u00a0\u00a01.20 %\u00a0(29.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.96 \u00a0\u00a0\u00a0 \u00a0$5.58 \u00a0\u00a0\u00a0 \u00a0(29.0 )%\nDiluted \u00a0$3.91 \u00a0\u00a0\u00a0 \u00a0$5.54 \u00a0\u00a0\u00a0 \u00a0(29.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,804 \u00a0\u00a0\u00a0 \u00a0205,693 \u00a0\u00a0\u00a0 \u00a0(0.4 )%\nDiluted \u00a0207,063 \u00a0\u00a0\u00a0 \u00a0207,293 \u00a0\u00a0\u00a0 \u00a0(0.1 )%\n________________________________________\n\u00a0\u00a0\n1Includes a $46.6 million LIFO credit in the six months ended March 31, 2021. ", "page_label": "9", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8420b0d51c1e5e1b719a786508fef1ccb6c4758b48734ca86064449b383425a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f37fec2-6431-47d8-87ad-2766dfd54fa3", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0812,712 \u00a0\u00a00.80 %\u00a01,157,679 \u00a0\u00a01.21 %\u00a0(29.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(2,600 )\u00a0\u00a0 \u00a0(9,762 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$810,112 \u00a0\u00a00.80 %\u00a0$1,147,917 \u00a0\u00a01.20 %\u00a0(29.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.96 \u00a0\u00a0\u00a0 \u00a0$5.58 \u00a0\u00a0\u00a0 \u00a0(29.0 )%\nDiluted \u00a0$3.91 \u00a0\u00a0\u00a0 \u00a0$5.54 \u00a0\u00a0\u00a0 \u00a0(29.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,804 \u00a0\u00a0\u00a0 \u00a0205,693 \u00a0\u00a0\u00a0 \u00a0(0.4 )%\nDiluted \u00a0207,063 \u00a0\u00a0\u00a0 \u00a0207,293 \u00a0\u00a0\u00a0 \u00a0(0.1 )%\n________________________________________\n\u00a0\u00a0\n1Includes a $46.6 million LIFO credit in the six months ended March 31, 2021.  Includes a $37.1 million LIFO expense, an $8.5\nmillion gain from antitrust litigation settlements, and $12.1 million of PharMEDium shutdown and remediation costs in the six\nmonths ended March 31, 2020.\n\u00a0\u00a0\n 2Includes $36.5 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended\nMarch 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $56.9 million of litigation and opioid-related costs related to legal fees in connection\nwith opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.\n\u00a0\u00a0\n 4Includes a $7.3 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the six\nmonths ended March 31, 2021.\n\u00a0\u00a0\n", "original_text": "2Includes $36.5 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended\nMarch 31, 2020.\n\u00a0\u00a0\n"}, "hash": "ed969e950aa109a6fda43a6c30a1bff0a6d802599c747c43ece9b8698293ed16", "class_name": "RelatedNodeInfo"}}, "text": "Includes a $37.1 million LIFO expense, an $8.5\nmillion gain from antitrust litigation settlements, and $12.1 million of PharMEDium shutdown and remediation costs in the six\nmonths ended March 31, 2020.\n\u00a0\u00a0\n", "start_char_idx": 704, "end_char_idx": 909, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f37fec2-6431-47d8-87ad-2766dfd54fa3": {"__data__": {"id_": "2f37fec2-6431-47d8-87ad-2766dfd54fa3", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0812,712 \u00a0\u00a00.80 %\u00a01,157,679 \u00a0\u00a01.21 %\u00a0(29.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(2,600 )\u00a0\u00a0 \u00a0(9,762 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$810,112 \u00a0\u00a00.80 %\u00a0$1,147,917 \u00a0\u00a01.20 %\u00a0(29.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.96 \u00a0\u00a0\u00a0 \u00a0$5.58 \u00a0\u00a0\u00a0 \u00a0(29.0 )%\nDiluted \u00a0$3.91 \u00a0\u00a0\u00a0 \u00a0$5.54 \u00a0\u00a0\u00a0 \u00a0(29.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,804 \u00a0\u00a0\u00a0 \u00a0205,693 \u00a0\u00a0\u00a0 \u00a0(0.4 )%\nDiluted \u00a0207,063 \u00a0\u00a0\u00a0 \u00a0207,293 \u00a0\u00a0\u00a0 \u00a0(0.1 )%\n________________________________________\n\u00a0\u00a0\n1Includes a $46.6 million LIFO credit in the six months ended March 31, 2021.  Includes a $37.1 million LIFO expense, an $8.5\nmillion gain from antitrust litigation settlements, and $12.1 million of PharMEDium shutdown and remediation costs in the six\nmonths ended March 31, 2020.\n\u00a0\u00a0\n 2Includes $36.5 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended\nMarch 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $56.9 million of litigation and opioid-related costs related to legal fees in connection\nwith opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.\n\u00a0\u00a0\n 4Includes a $7.3 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the six\nmonths ended March 31, 2021.\n\u00a0\u00a0\n", "original_text": "2Includes $36.5 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended\nMarch 31, 2020.\n\u00a0\u00a0\n", "page_label": "9", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f346ea14-bb69-427b-b23c-3ab5c70c3ac2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec757ac4ca47b8611ef4acc6723f45487b020c6742935f3a4a6ba1a6d66b76d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e2bef73-fa40-4241-a343-31b3b9d1d230", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0812,712 \u00a0\u00a00.80 %\u00a01,157,679 \u00a0\u00a01.21 %\u00a0(29.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(2,600 )\u00a0\u00a0 \u00a0(9,762 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$810,112 \u00a0\u00a00.80 %\u00a0$1,147,917 \u00a0\u00a01.20 %\u00a0(29.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.96 \u00a0\u00a0\u00a0 \u00a0$5.58 \u00a0\u00a0\u00a0 \u00a0(29.0 )%\nDiluted \u00a0$3.91 \u00a0\u00a0\u00a0 \u00a0$5.54 \u00a0\u00a0\u00a0 \u00a0(29.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,804 \u00a0\u00a0\u00a0 \u00a0205,693 \u00a0\u00a0\u00a0 \u00a0(0.4 )%\nDiluted \u00a0207,063 \u00a0\u00a0\u00a0 \u00a0207,293 \u00a0\u00a0\u00a0 \u00a0(0.1 )%\n________________________________________\n\u00a0\u00a0\n1Includes a $46.6 million LIFO credit in the six months ended March 31, 2021.  Includes a $37.1 million LIFO expense, an $8.5\nmillion gain from antitrust litigation settlements, and $12.1 million of PharMEDium shutdown and remediation costs in the six\nmonths ended March 31, 2020.\n\u00a0\u00a0\n 2Includes $36.5 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended\nMarch 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $56.9 million of litigation and opioid-related costs related to legal fees in connection\nwith opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.\n\u00a0\u00a0\n", "original_text": "Includes a $37.1 million LIFO expense, an $8.5\nmillion gain from antitrust litigation settlements, and $12.1 million of PharMEDium shutdown and remediation costs in the six\nmonths ended March 31, 2020.\n\u00a0\u00a0\n", "page_label": "9", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62ed124fb94f09889efeefcd28f08495b8c3de3979e8e3f70367876415afc37a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7cb20609-1051-4047-8921-e1866d571757", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0812,712 \u00a0\u00a00.80 %\u00a01,157,679 \u00a0\u00a01.21 %\u00a0(29.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(2,600 )\u00a0\u00a0 \u00a0(9,762 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$810,112 \u00a0\u00a00.80 %\u00a0$1,147,917 \u00a0\u00a01.20 %\u00a0(29.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.96 \u00a0\u00a0\u00a0 \u00a0$5.58 \u00a0\u00a0\u00a0 \u00a0(29.0 )%\nDiluted \u00a0$3.91 \u00a0\u00a0\u00a0 \u00a0$5.54 \u00a0\u00a0\u00a0 \u00a0(29.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,804 \u00a0\u00a0\u00a0 \u00a0205,693 \u00a0\u00a0\u00a0 \u00a0(0.4 )%\nDiluted \u00a0207,063 \u00a0\u00a0\u00a0 \u00a0207,293 \u00a0\u00a0\u00a0 \u00a0(0.1 )%\n________________________________________\n\u00a0\u00a0\n1Includes a $46.6 million LIFO credit in the six months ended March 31, 2021.  Includes a $37.1 million LIFO expense, an $8.5\nmillion gain from antitrust litigation settlements, and $12.1 million of PharMEDium shutdown and remediation costs in the six\nmonths ended March 31, 2020.\n\u00a0\u00a0\n 2Includes $36.5 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended\nMarch 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $56.9 million of litigation and opioid-related costs related to legal fees in connection\nwith opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.\n\u00a0\u00a0\n 4Includes a $7.3 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the six\nmonths ended March 31, 2021.\n\u00a0\u00a0\n 9", "original_text": "3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $56.9 million of litigation and opioid-related costs related to legal fees in connection\nwith opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n"}, "hash": "463d3c266a35c815113a919746a96291fe94c940b3ec91d7766241c6774b6534", "class_name": "RelatedNodeInfo"}}, "text": "2Includes $36.5 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended\nMarch 31, 2020.\n\u00a0\u00a0\n", "start_char_idx": 909, "end_char_idx": 1175, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7cb20609-1051-4047-8921-e1866d571757": {"__data__": {"id_": "7cb20609-1051-4047-8921-e1866d571757", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0812,712 \u00a0\u00a00.80 %\u00a01,157,679 \u00a0\u00a01.21 %\u00a0(29.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(2,600 )\u00a0\u00a0 \u00a0(9,762 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$810,112 \u00a0\u00a00.80 %\u00a0$1,147,917 \u00a0\u00a01.20 %\u00a0(29.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.96 \u00a0\u00a0\u00a0 \u00a0$5.58 \u00a0\u00a0\u00a0 \u00a0(29.0 )%\nDiluted \u00a0$3.91 \u00a0\u00a0\u00a0 \u00a0$5.54 \u00a0\u00a0\u00a0 \u00a0(29.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,804 \u00a0\u00a0\u00a0 \u00a0205,693 \u00a0\u00a0\u00a0 \u00a0(0.4 )%\nDiluted \u00a0207,063 \u00a0\u00a0\u00a0 \u00a0207,293 \u00a0\u00a0\u00a0 \u00a0(0.1 )%\n________________________________________\n\u00a0\u00a0\n1Includes a $46.6 million LIFO credit in the six months ended March 31, 2021.  Includes a $37.1 million LIFO expense, an $8.5\nmillion gain from antitrust litigation settlements, and $12.1 million of PharMEDium shutdown and remediation costs in the six\nmonths ended March 31, 2020.\n\u00a0\u00a0\n 2Includes $36.5 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended\nMarch 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $56.9 million of litigation and opioid-related costs related to legal fees in connection\nwith opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.\n\u00a0\u00a0\n 4Includes a $7.3 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the six\nmonths ended March 31, 2021.\n\u00a0\u00a0\n 9", "original_text": "3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $56.9 million of litigation and opioid-related costs related to legal fees in connection\nwith opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n", "page_label": "9", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f346ea14-bb69-427b-b23c-3ab5c70c3ac2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec757ac4ca47b8611ef4acc6723f45487b020c6742935f3a4a6ba1a6d66b76d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f37fec2-6431-47d8-87ad-2766dfd54fa3", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0812,712 \u00a0\u00a00.80 %\u00a01,157,679 \u00a0\u00a01.21 %\u00a0(29.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(2,600 )\u00a0\u00a0 \u00a0(9,762 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$810,112 \u00a0\u00a00.80 %\u00a0$1,147,917 \u00a0\u00a01.20 %\u00a0(29.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.96 \u00a0\u00a0\u00a0 \u00a0$5.58 \u00a0\u00a0\u00a0 \u00a0(29.0 )%\nDiluted \u00a0$3.91 \u00a0\u00a0\u00a0 \u00a0$5.54 \u00a0\u00a0\u00a0 \u00a0(29.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,804 \u00a0\u00a0\u00a0 \u00a0205,693 \u00a0\u00a0\u00a0 \u00a0(0.4 )%\nDiluted \u00a0207,063 \u00a0\u00a0\u00a0 \u00a0207,293 \u00a0\u00a0\u00a0 \u00a0(0.1 )%\n________________________________________\n\u00a0\u00a0\n1Includes a $46.6 million LIFO credit in the six months ended March 31, 2021.  Includes a $37.1 million LIFO expense, an $8.5\nmillion gain from antitrust litigation settlements, and $12.1 million of PharMEDium shutdown and remediation costs in the six\nmonths ended March 31, 2020.\n\u00a0\u00a0\n 2Includes $36.5 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended\nMarch 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $56.9 million of litigation and opioid-related costs related to legal fees in connection\nwith opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.\n\u00a0\u00a0\n 4Includes a $7.3 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the six\nmonths ended March 31, 2021.\n\u00a0\u00a0\n", "original_text": "2Includes $36.5 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended\nMarch 31, 2020.\n\u00a0\u00a0\n", "page_label": "9", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "257fbd0254e5efaf94125464ab3d5339a452e05d58b14f4a0002f073acf1ba46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b7e5cb5-c584-49ed-b103-5529eaf573d7", "node_type": "1", "metadata": {"window": "Includes a $37.1 million LIFO expense, an $8.5\nmillion gain from antitrust litigation settlements, and $12.1 million of PharMEDium shutdown and remediation costs in the six\nmonths ended March 31, 2020.\n\u00a0\u00a0\n 2Includes $36.5 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended\nMarch 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $56.9 million of litigation and opioid-related costs related to legal fees in connection\nwith opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.\n\u00a0\u00a0\n 4Includes a $7.3 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the six\nmonths ended March 31, 2021.\n\u00a0\u00a0\n 9", "original_text": "Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.\n\u00a0\u00a0\n"}, "hash": "216c66b93416f9c1e5d5cbf7742f3c76764eb65bd8390601b5c049df43356cb6", "class_name": "RelatedNodeInfo"}}, "text": "3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $56.9 million of litigation and opioid-related costs related to legal fees in connection\nwith opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n", "start_char_idx": 1175, "end_char_idx": 1685, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b7e5cb5-c584-49ed-b103-5529eaf573d7": {"__data__": {"id_": "1b7e5cb5-c584-49ed-b103-5529eaf573d7", "embedding": null, "metadata": {"window": "Includes a $37.1 million LIFO expense, an $8.5\nmillion gain from antitrust litigation settlements, and $12.1 million of PharMEDium shutdown and remediation costs in the six\nmonths ended March 31, 2020.\n\u00a0\u00a0\n 2Includes $36.5 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended\nMarch 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $56.9 million of litigation and opioid-related costs related to legal fees in connection\nwith opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.\n\u00a0\u00a0\n 4Includes a $7.3 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the six\nmonths ended March 31, 2021.\n\u00a0\u00a0\n 9", "original_text": "Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.\n\u00a0\u00a0\n", "page_label": "9", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f346ea14-bb69-427b-b23c-3ab5c70c3ac2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec757ac4ca47b8611ef4acc6723f45487b020c6742935f3a4a6ba1a6d66b76d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7cb20609-1051-4047-8921-e1866d571757", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0812,712 \u00a0\u00a00.80 %\u00a01,157,679 \u00a0\u00a01.21 %\u00a0(29.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(2,600 )\u00a0\u00a0 \u00a0(9,762 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$810,112 \u00a0\u00a00.80 %\u00a0$1,147,917 \u00a0\u00a01.20 %\u00a0(29.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.96 \u00a0\u00a0\u00a0 \u00a0$5.58 \u00a0\u00a0\u00a0 \u00a0(29.0 )%\nDiluted \u00a0$3.91 \u00a0\u00a0\u00a0 \u00a0$5.54 \u00a0\u00a0\u00a0 \u00a0(29.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,804 \u00a0\u00a0\u00a0 \u00a0205,693 \u00a0\u00a0\u00a0 \u00a0(0.4 )%\nDiluted \u00a0207,063 \u00a0\u00a0\u00a0 \u00a0207,293 \u00a0\u00a0\u00a0 \u00a0(0.1 )%\n________________________________________\n\u00a0\u00a0\n1Includes a $46.6 million LIFO credit in the six months ended March 31, 2021.  Includes a $37.1 million LIFO expense, an $8.5\nmillion gain from antitrust litigation settlements, and $12.1 million of PharMEDium shutdown and remediation costs in the six\nmonths ended March 31, 2020.\n\u00a0\u00a0\n 2Includes $36.5 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended\nMarch 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $56.9 million of litigation and opioid-related costs related to legal fees in connection\nwith opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.\n\u00a0\u00a0\n 4Includes a $7.3 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the six\nmonths ended March 31, 2021.\n\u00a0\u00a0\n 9", "original_text": "3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $56.9 million of litigation and opioid-related costs related to legal fees in connection\nwith opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n", "page_label": "9", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9bc933c3e05b4427c47b5c0f71d2cb8123da4fa889c16451b93d981852aaaace", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21d2fc89-a1e3-4ad2-a78a-b6f3cc6ca2a5", "node_type": "1", "metadata": {"window": "2Includes $36.5 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended\nMarch 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $56.9 million of litigation and opioid-related costs related to legal fees in connection\nwith opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.\n\u00a0\u00a0\n 4Includes a $7.3 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the six\nmonths ended March 31, 2021.\n\u00a0\u00a0\n 9", "original_text": "4Includes a $7.3 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the six\nmonths ended March 31, 2021.\n\u00a0\u00a0\n"}, "hash": "b59f46f6eb101ac70d6a06b44022db8f20e7566b3b538f22d62db3d2b75324bd", "class_name": "RelatedNodeInfo"}}, "text": "Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.\n\u00a0\u00a0\n", "start_char_idx": 1685, "end_char_idx": 2054, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21d2fc89-a1e3-4ad2-a78a-b6f3cc6ca2a5": {"__data__": {"id_": "21d2fc89-a1e3-4ad2-a78a-b6f3cc6ca2a5", "embedding": null, "metadata": {"window": "2Includes $36.5 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended\nMarch 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $56.9 million of litigation and opioid-related costs related to legal fees in connection\nwith opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.\n\u00a0\u00a0\n 4Includes a $7.3 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the six\nmonths ended March 31, 2021.\n\u00a0\u00a0\n 9", "original_text": "4Includes a $7.3 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the six\nmonths ended March 31, 2021.\n\u00a0\u00a0\n", "page_label": "9", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f346ea14-bb69-427b-b23c-3ab5c70c3ac2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec757ac4ca47b8611ef4acc6723f45487b020c6742935f3a4a6ba1a6d66b76d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b7e5cb5-c584-49ed-b103-5529eaf573d7", "node_type": "1", "metadata": {"window": "Includes a $37.1 million LIFO expense, an $8.5\nmillion gain from antitrust litigation settlements, and $12.1 million of PharMEDium shutdown and remediation costs in the six\nmonths ended March 31, 2020.\n\u00a0\u00a0\n 2Includes $36.5 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended\nMarch 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $56.9 million of litigation and opioid-related costs related to legal fees in connection\nwith opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.\n\u00a0\u00a0\n 4Includes a $7.3 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the six\nmonths ended March 31, 2021.\n\u00a0\u00a0\n 9", "original_text": "Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.\n\u00a0\u00a0\n", "page_label": "9", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00836e70e66220832cb39f9811a10d83348c49fdb706c07e8d8c3bd90cadc8da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4562fdba-7491-46b3-9eea-c9406f1da834", "node_type": "1", "metadata": {"window": "3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $56.9 million of litigation and opioid-related costs related to legal fees in connection\nwith opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.\n\u00a0\u00a0\n 4Includes a $7.3 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the six\nmonths ended March 31, 2021.\n\u00a0\u00a0\n 9", "original_text": "9"}, "hash": "02bd756ec76914ad1cfa85d77580007ef0162326b1b5ce562173ab4f8d667a20", "class_name": "RelatedNodeInfo"}}, "text": "4Includes a $7.3 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the six\nmonths ended March 31, 2021.\n\u00a0\u00a0\n", "start_char_idx": 2054, "end_char_idx": 2213, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4562fdba-7491-46b3-9eea-c9406f1da834": {"__data__": {"id_": "4562fdba-7491-46b3-9eea-c9406f1da834", "embedding": null, "metadata": {"window": "3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $56.9 million of litigation and opioid-related costs related to legal fees in connection\nwith opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.\n\u00a0\u00a0\n 4Includes a $7.3 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the six\nmonths ended March 31, 2021.\n\u00a0\u00a0\n 9", "original_text": "9", "page_label": "9", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f346ea14-bb69-427b-b23c-3ab5c70c3ac2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec757ac4ca47b8611ef4acc6723f45487b020c6742935f3a4a6ba1a6d66b76d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21d2fc89-a1e3-4ad2-a78a-b6f3cc6ca2a5", "node_type": "1", "metadata": {"window": "2Includes $36.5 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended\nMarch 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $56.9 million of litigation and opioid-related costs related to legal fees in connection\nwith opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.\n\u00a0\u00a0\n 4Includes a $7.3 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the six\nmonths ended March 31, 2021.\n\u00a0\u00a0\n 9", "original_text": "4Includes a $7.3 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the six\nmonths ended March 31, 2021.\n\u00a0\u00a0\n", "page_label": "9", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf832af15d00acfefca26c45d98c2a033b3c3e4977ec6039245f8eb2785c1ea6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37a96cc7-7ec8-4cf5-915f-c53fd1715562", "node_type": "1", "metadata": {"window": "5Includes $55.0 million of expense relating to Swiss tax reform and $20.4 million of discrete tax benefits primarily attributable to\nthe income tax deductions resulting from the permanent shutdown of the PharMEDium business in the six months ended\nMarch 31, 2021.  Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting\nfrom the permanent shutdown of the PharMEDium business in the six months ended March 31, 2020.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \n Expense \u00a0Net Loss \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\nGAAP \u00a0$1,533,381 \u00a0\u00a0$909,034 \u00a0\u00a0$624,347 \u00a0\u00a0$566,511 \u00a0\u00a0$132,506 \u00a0\u00a0$1,262 \u00a0\u00a0$435,267 \u00a0\u00a0$2.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(20,918 )\u00a0\u2014 \u00a0\u00a0(20,918 )\u00a0(20,918 )\u00a0(4,957 )\u00a0\u2014 \u00a0\u00a0(15,961 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(24,973 )\u00a024,973 \u00a0\u00a024,973 \u00a0\u00a03,302 \u00a0\u00a0(437 )\u00a021,234 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(78,156 )\u00a078,156 \u00a0\u00a078,156 \u00a0\u00a018,494 \u00a0\u00a0\u2014 \u00a0\u00a059,662 \u00a0\u00a00.29 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a021,368 \u00a0\u00a0(2,701 )\u00a0\u2014 \u00a0\u00a024,069 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP \u00a0$1,512,463 \u00a0\u00a0$805,905 \u00a0\u00a0$706,558 \u00a0\u00a0$670,090 \u00a0\u00a0$146,644 \u00a0\u00a0$825 \u00a0\u00a0$524,271 \u00a0\u00a0$2.53 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a06.7 % \u00a08.1 % \u00a05.2 % \u00a05.0 % \u00a06.9 % \u00a0\u00a0 \u00a05.4 % \u00a05.4 %\n\u00a0\n10", "original_text": "5Includes $55.0 million of expense relating to Swiss tax reform and $20.4 million of discrete tax benefits primarily attributable to\nthe income tax deductions resulting from the permanent shutdown of the PharMEDium business in the six months ended\nMarch 31, 2021. "}, "hash": "44965a7aaed2bfecd9f82eb97a92131b8a78aee7ccea823ebd4305401c8b3505", "class_name": "RelatedNodeInfo"}}, "text": "9", "start_char_idx": 54, "end_char_idx": 55, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37a96cc7-7ec8-4cf5-915f-c53fd1715562": {"__data__": {"id_": "37a96cc7-7ec8-4cf5-915f-c53fd1715562", "embedding": null, "metadata": {"window": "5Includes $55.0 million of expense relating to Swiss tax reform and $20.4 million of discrete tax benefits primarily attributable to\nthe income tax deductions resulting from the permanent shutdown of the PharMEDium business in the six months ended\nMarch 31, 2021.  Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting\nfrom the permanent shutdown of the PharMEDium business in the six months ended March 31, 2020.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \n Expense \u00a0Net Loss \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\nGAAP \u00a0$1,533,381 \u00a0\u00a0$909,034 \u00a0\u00a0$624,347 \u00a0\u00a0$566,511 \u00a0\u00a0$132,506 \u00a0\u00a0$1,262 \u00a0\u00a0$435,267 \u00a0\u00a0$2.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(20,918 )\u00a0\u2014 \u00a0\u00a0(20,918 )\u00a0(20,918 )\u00a0(4,957 )\u00a0\u2014 \u00a0\u00a0(15,961 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(24,973 )\u00a024,973 \u00a0\u00a024,973 \u00a0\u00a03,302 \u00a0\u00a0(437 )\u00a021,234 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(78,156 )\u00a078,156 \u00a0\u00a078,156 \u00a0\u00a018,494 \u00a0\u00a0\u2014 \u00a0\u00a059,662 \u00a0\u00a00.29 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a021,368 \u00a0\u00a0(2,701 )\u00a0\u2014 \u00a0\u00a024,069 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP \u00a0$1,512,463 \u00a0\u00a0$805,905 \u00a0\u00a0$706,558 \u00a0\u00a0$670,090 \u00a0\u00a0$146,644 \u00a0\u00a0$825 \u00a0\u00a0$524,271 \u00a0\u00a0$2.53 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a06.7 % \u00a08.1 % \u00a05.2 % \u00a05.0 % \u00a06.9 % \u00a0\u00a0 \u00a05.4 % \u00a05.4 %\n\u00a0\n10", "original_text": "5Includes $55.0 million of expense relating to Swiss tax reform and $20.4 million of discrete tax benefits primarily attributable to\nthe income tax deductions resulting from the permanent shutdown of the PharMEDium business in the six months ended\nMarch 31, 2021. ", "page_label": "10", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bf856a2-789c-4c58-a81d-a38694217eaf", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac5e365d27f1a98d763e0a12ca86375a660fa212d3182bc024cd88f14a0630ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4562fdba-7491-46b3-9eea-c9406f1da834", "node_type": "1", "metadata": {"window": "3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $56.9 million of litigation and opioid-related costs related to legal fees in connection\nwith opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.\n\u00a0\u00a0\n 4Includes a $7.3 million loss on the currency remeasurement of the deferred tax assets relating to Swiss tax reform in the six\nmonths ended March 31, 2021.\n\u00a0\u00a0\n 9", "original_text": "9", "page_label": "9", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "735d7ca60060d7eba44ee0877505c903d0873e9ca8269797cf53cdf505219d99", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8140a0a4-e7e2-4ac6-89c0-7b6dbfdad12c", "node_type": "1", "metadata": {"window": "5Includes $55.0 million of expense relating to Swiss tax reform and $20.4 million of discrete tax benefits primarily attributable to\nthe income tax deductions resulting from the permanent shutdown of the PharMEDium business in the six months ended\nMarch 31, 2021.  Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting\nfrom the permanent shutdown of the PharMEDium business in the six months ended March 31, 2020.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \n Expense \u00a0Net Loss \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\nGAAP \u00a0$1,533,381 \u00a0\u00a0$909,034 \u00a0\u00a0$624,347 \u00a0\u00a0$566,511 \u00a0\u00a0$132,506 \u00a0\u00a0$1,262 \u00a0\u00a0$435,267 \u00a0\u00a0$2.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(20,918 )\u00a0\u2014 \u00a0\u00a0(20,918 )\u00a0(20,918 )\u00a0(4,957 )\u00a0\u2014 \u00a0\u00a0(15,961 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(24,973 )\u00a024,973 \u00a0\u00a024,973 \u00a0\u00a03,302 \u00a0\u00a0(437 )\u00a021,234 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(78,156 )\u00a078,156 \u00a0\u00a078,156 \u00a0\u00a018,494 \u00a0\u00a0\u2014 \u00a0\u00a059,662 \u00a0\u00a00.29 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a021,368 \u00a0\u00a0(2,701 )\u00a0\u2014 \u00a0\u00a024,069 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP \u00a0$1,512,463 \u00a0\u00a0$805,905 \u00a0\u00a0$706,558 \u00a0\u00a0$670,090 \u00a0\u00a0$146,644 \u00a0\u00a0$825 \u00a0\u00a0$524,271 \u00a0\u00a0$2.53 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a06.7 % \u00a08.1 % \u00a05.2 % \u00a05.0 % \u00a06.9 % \u00a0\u00a0 \u00a05.4 % \u00a05.4 %\n\u00a0\n10", "original_text": "Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting\nfrom the permanent shutdown of the PharMEDium business in the six months ended March 31, 2020.\n"}, "hash": "0499e4fbf9a79c45c852b56630fe6ec3bdd8f30755f3ddcc7f6fb779313548f0", "class_name": "RelatedNodeInfo"}}, "text": "5Includes $55.0 million of expense relating to Swiss tax reform and $20.4 million of discrete tax benefits primarily attributable to\nthe income tax deductions resulting from the permanent shutdown of the PharMEDium business in the six months ended\nMarch 31, 2021. ", "start_char_idx": 0, "end_char_idx": 264, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8140a0a4-e7e2-4ac6-89c0-7b6dbfdad12c": {"__data__": {"id_": "8140a0a4-e7e2-4ac6-89c0-7b6dbfdad12c", "embedding": null, "metadata": {"window": "5Includes $55.0 million of expense relating to Swiss tax reform and $20.4 million of discrete tax benefits primarily attributable to\nthe income tax deductions resulting from the permanent shutdown of the PharMEDium business in the six months ended\nMarch 31, 2021.  Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting\nfrom the permanent shutdown of the PharMEDium business in the six months ended March 31, 2020.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \n Expense \u00a0Net Loss \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\nGAAP \u00a0$1,533,381 \u00a0\u00a0$909,034 \u00a0\u00a0$624,347 \u00a0\u00a0$566,511 \u00a0\u00a0$132,506 \u00a0\u00a0$1,262 \u00a0\u00a0$435,267 \u00a0\u00a0$2.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(20,918 )\u00a0\u2014 \u00a0\u00a0(20,918 )\u00a0(20,918 )\u00a0(4,957 )\u00a0\u2014 \u00a0\u00a0(15,961 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(24,973 )\u00a024,973 \u00a0\u00a024,973 \u00a0\u00a03,302 \u00a0\u00a0(437 )\u00a021,234 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(78,156 )\u00a078,156 \u00a0\u00a078,156 \u00a0\u00a018,494 \u00a0\u00a0\u2014 \u00a0\u00a059,662 \u00a0\u00a00.29 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a021,368 \u00a0\u00a0(2,701 )\u00a0\u2014 \u00a0\u00a024,069 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP \u00a0$1,512,463 \u00a0\u00a0$805,905 \u00a0\u00a0$706,558 \u00a0\u00a0$670,090 \u00a0\u00a0$146,644 \u00a0\u00a0$825 \u00a0\u00a0$524,271 \u00a0\u00a0$2.53 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a06.7 % \u00a08.1 % \u00a05.2 % \u00a05.0 % \u00a06.9 % \u00a0\u00a0 \u00a05.4 % \u00a05.4 %\n\u00a0\n10", "original_text": "Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting\nfrom the permanent shutdown of the PharMEDium business in the six months ended March 31, 2020.\n", "page_label": "10", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bf856a2-789c-4c58-a81d-a38694217eaf", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac5e365d27f1a98d763e0a12ca86375a660fa212d3182bc024cd88f14a0630ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37a96cc7-7ec8-4cf5-915f-c53fd1715562", "node_type": "1", "metadata": {"window": "5Includes $55.0 million of expense relating to Swiss tax reform and $20.4 million of discrete tax benefits primarily attributable to\nthe income tax deductions resulting from the permanent shutdown of the PharMEDium business in the six months ended\nMarch 31, 2021.  Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting\nfrom the permanent shutdown of the PharMEDium business in the six months ended March 31, 2020.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \n Expense \u00a0Net Loss \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\nGAAP \u00a0$1,533,381 \u00a0\u00a0$909,034 \u00a0\u00a0$624,347 \u00a0\u00a0$566,511 \u00a0\u00a0$132,506 \u00a0\u00a0$1,262 \u00a0\u00a0$435,267 \u00a0\u00a0$2.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(20,918 )\u00a0\u2014 \u00a0\u00a0(20,918 )\u00a0(20,918 )\u00a0(4,957 )\u00a0\u2014 \u00a0\u00a0(15,961 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(24,973 )\u00a024,973 \u00a0\u00a024,973 \u00a0\u00a03,302 \u00a0\u00a0(437 )\u00a021,234 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(78,156 )\u00a078,156 \u00a0\u00a078,156 \u00a0\u00a018,494 \u00a0\u00a0\u2014 \u00a0\u00a059,662 \u00a0\u00a00.29 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a021,368 \u00a0\u00a0(2,701 )\u00a0\u2014 \u00a0\u00a024,069 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP \u00a0$1,512,463 \u00a0\u00a0$805,905 \u00a0\u00a0$706,558 \u00a0\u00a0$670,090 \u00a0\u00a0$146,644 \u00a0\u00a0$825 \u00a0\u00a0$524,271 \u00a0\u00a0$2.53 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a06.7 % \u00a08.1 % \u00a05.2 % \u00a05.0 % \u00a06.9 % \u00a0\u00a0 \u00a05.4 % \u00a05.4 %\n\u00a0\n10", "original_text": "5Includes $55.0 million of expense relating to Swiss tax reform and $20.4 million of discrete tax benefits primarily attributable to\nthe income tax deductions resulting from the permanent shutdown of the PharMEDium business in the six months ended\nMarch 31, 2021. ", "page_label": "10", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b3bc6edeb68ea213a9a62ee0494d7356ca554d3729b6d2a9929185ff6a131878", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58a74d7e-e2f9-4163-b449-ed8ad9d055b0", "node_type": "1", "metadata": {"window": "5Includes $55.0 million of expense relating to Swiss tax reform and $20.4 million of discrete tax benefits primarily attributable to\nthe income tax deductions resulting from the permanent shutdown of the PharMEDium business in the six months ended\nMarch 31, 2021.  Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting\nfrom the permanent shutdown of the PharMEDium business in the six months ended March 31, 2020.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \n Expense \u00a0Net Loss \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\nGAAP \u00a0$1,533,381 \u00a0\u00a0$909,034 \u00a0\u00a0$624,347 \u00a0\u00a0$566,511 \u00a0\u00a0$132,506 \u00a0\u00a0$1,262 \u00a0\u00a0$435,267 \u00a0\u00a0$2.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(20,918 )\u00a0\u2014 \u00a0\u00a0(20,918 )\u00a0(20,918 )\u00a0(4,957 )\u00a0\u2014 \u00a0\u00a0(15,961 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(24,973 )\u00a024,973 \u00a0\u00a024,973 \u00a0\u00a03,302 \u00a0\u00a0(437 )\u00a021,234 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(78,156 )\u00a078,156 \u00a0\u00a078,156 \u00a0\u00a018,494 \u00a0\u00a0\u2014 \u00a0\u00a059,662 \u00a0\u00a00.29 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a021,368 \u00a0\u00a0(2,701 )\u00a0\u2014 \u00a0\u00a024,069 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP \u00a0$1,512,463 \u00a0\u00a0$805,905 \u00a0\u00a0$706,558 \u00a0\u00a0$670,090 \u00a0\u00a0$146,644 \u00a0\u00a0$825 \u00a0\u00a0$524,271 \u00a0\u00a0$2.53 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a06.7 % \u00a08.1 % \u00a05.2 % \u00a05.0 % \u00a06.9 % \u00a0\u00a0 \u00a05.4 % \u00a05.4 %\n\u00a0\n10", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \n Expense \u00a0Net Loss \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\nGAAP \u00a0$1,533,381 \u00a0\u00a0$909,034 \u00a0\u00a0$624,347 \u00a0\u00a0$566,511 \u00a0\u00a0$132,506 \u00a0\u00a0$1,262 \u00a0\u00a0$435,267 \u00a0\u00a0$2.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(20,918 )\u00a0\u2014 \u00a0\u00a0(20,918 )\u00a0(20,918 )\u00a0(4,957 )\u00a0\u2014 \u00a0\u00a0(15,961 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(24,973 )\u00a024,973 \u00a0\u00a024,973 \u00a0\u00a03,302 \u00a0\u00a0(437 )\u00a021,234 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(78,156 )\u00a078,156 \u00a0\u00a078,156 \u00a0\u00a018,494 \u00a0\u00a0\u2014 \u00a0\u00a059,662 \u00a0\u00a00.29 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a021,368 \u00a0\u00a0(2,701 )\u00a0\u2014 \u00a0\u00a024,069 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP \u00a0$1,512,463 \u00a0\u00a0$805,905 \u00a0\u00a0$706,558 \u00a0\u00a0$670,090 \u00a0\u00a0$146,644 \u00a0\u00a0$825 \u00a0\u00a0$524,271 \u00a0\u00a0$2.53 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP\n% change\nvs. "}, "hash": "07320a7253a3ebe5fd1b19f69985c573957f04a33daec892dd822599e1142b6b", "class_name": "RelatedNodeInfo"}}, "text": "Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting\nfrom the permanent shutdown of the PharMEDium business in the six months ended March 31, 2020.\n", "start_char_idx": 264, "end_char_idx": 470, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58a74d7e-e2f9-4163-b449-ed8ad9d055b0": {"__data__": {"id_": "58a74d7e-e2f9-4163-b449-ed8ad9d055b0", "embedding": null, "metadata": {"window": "5Includes $55.0 million of expense relating to Swiss tax reform and $20.4 million of discrete tax benefits primarily attributable to\nthe income tax deductions resulting from the permanent shutdown of the PharMEDium business in the six months ended\nMarch 31, 2021.  Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting\nfrom the permanent shutdown of the PharMEDium business in the six months ended March 31, 2020.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \n Expense \u00a0Net Loss \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\nGAAP \u00a0$1,533,381 \u00a0\u00a0$909,034 \u00a0\u00a0$624,347 \u00a0\u00a0$566,511 \u00a0\u00a0$132,506 \u00a0\u00a0$1,262 \u00a0\u00a0$435,267 \u00a0\u00a0$2.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(20,918 )\u00a0\u2014 \u00a0\u00a0(20,918 )\u00a0(20,918 )\u00a0(4,957 )\u00a0\u2014 \u00a0\u00a0(15,961 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(24,973 )\u00a024,973 \u00a0\u00a024,973 \u00a0\u00a03,302 \u00a0\u00a0(437 )\u00a021,234 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(78,156 )\u00a078,156 \u00a0\u00a078,156 \u00a0\u00a018,494 \u00a0\u00a0\u2014 \u00a0\u00a059,662 \u00a0\u00a00.29 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a021,368 \u00a0\u00a0(2,701 )\u00a0\u2014 \u00a0\u00a024,069 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP \u00a0$1,512,463 \u00a0\u00a0$805,905 \u00a0\u00a0$706,558 \u00a0\u00a0$670,090 \u00a0\u00a0$146,644 \u00a0\u00a0$825 \u00a0\u00a0$524,271 \u00a0\u00a0$2.53 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a06.7 % \u00a08.1 % \u00a05.2 % \u00a05.0 % \u00a06.9 % \u00a0\u00a0 \u00a05.4 % \u00a05.4 %\n\u00a0\n10", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \n Expense \u00a0Net Loss \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\nGAAP \u00a0$1,533,381 \u00a0\u00a0$909,034 \u00a0\u00a0$624,347 \u00a0\u00a0$566,511 \u00a0\u00a0$132,506 \u00a0\u00a0$1,262 \u00a0\u00a0$435,267 \u00a0\u00a0$2.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(20,918 )\u00a0\u2014 \u00a0\u00a0(20,918 )\u00a0(20,918 )\u00a0(4,957 )\u00a0\u2014 \u00a0\u00a0(15,961 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(24,973 )\u00a024,973 \u00a0\u00a024,973 \u00a0\u00a03,302 \u00a0\u00a0(437 )\u00a021,234 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(78,156 )\u00a078,156 \u00a0\u00a078,156 \u00a0\u00a018,494 \u00a0\u00a0\u2014 \u00a0\u00a059,662 \u00a0\u00a00.29 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a021,368 \u00a0\u00a0(2,701 )\u00a0\u2014 \u00a0\u00a024,069 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP \u00a0$1,512,463 \u00a0\u00a0$805,905 \u00a0\u00a0$706,558 \u00a0\u00a0$670,090 \u00a0\u00a0$146,644 \u00a0\u00a0$825 \u00a0\u00a0$524,271 \u00a0\u00a0$2.53 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP\n% change\nvs. ", "page_label": "10", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bf856a2-789c-4c58-a81d-a38694217eaf", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac5e365d27f1a98d763e0a12ca86375a660fa212d3182bc024cd88f14a0630ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8140a0a4-e7e2-4ac6-89c0-7b6dbfdad12c", "node_type": "1", "metadata": {"window": "5Includes $55.0 million of expense relating to Swiss tax reform and $20.4 million of discrete tax benefits primarily attributable to\nthe income tax deductions resulting from the permanent shutdown of the PharMEDium business in the six months ended\nMarch 31, 2021.  Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting\nfrom the permanent shutdown of the PharMEDium business in the six months ended March 31, 2020.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \n Expense \u00a0Net Loss \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\nGAAP \u00a0$1,533,381 \u00a0\u00a0$909,034 \u00a0\u00a0$624,347 \u00a0\u00a0$566,511 \u00a0\u00a0$132,506 \u00a0\u00a0$1,262 \u00a0\u00a0$435,267 \u00a0\u00a0$2.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(20,918 )\u00a0\u2014 \u00a0\u00a0(20,918 )\u00a0(20,918 )\u00a0(4,957 )\u00a0\u2014 \u00a0\u00a0(15,961 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(24,973 )\u00a024,973 \u00a0\u00a024,973 \u00a0\u00a03,302 \u00a0\u00a0(437 )\u00a021,234 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(78,156 )\u00a078,156 \u00a0\u00a078,156 \u00a0\u00a018,494 \u00a0\u00a0\u2014 \u00a0\u00a059,662 \u00a0\u00a00.29 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a021,368 \u00a0\u00a0(2,701 )\u00a0\u2014 \u00a0\u00a024,069 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP \u00a0$1,512,463 \u00a0\u00a0$805,905 \u00a0\u00a0$706,558 \u00a0\u00a0$670,090 \u00a0\u00a0$146,644 \u00a0\u00a0$825 \u00a0\u00a0$524,271 \u00a0\u00a0$2.53 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a06.7 % \u00a08.1 % \u00a05.2 % \u00a05.0 % \u00a06.9 % \u00a0\u00a0 \u00a05.4 % \u00a05.4 %\n\u00a0\n10", "original_text": "Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting\nfrom the permanent shutdown of the PharMEDium business in the six months ended March 31, 2020.\n", "page_label": "10", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4626c75a5686b9897259195fbef8e247f78b92f9ab67ce841c3bb194e57d3e52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f236e15-b1e9-40d0-898f-ba7771bb2f46", "node_type": "1", "metadata": {"window": "5Includes $55.0 million of expense relating to Swiss tax reform and $20.4 million of discrete tax benefits primarily attributable to\nthe income tax deductions resulting from the permanent shutdown of the PharMEDium business in the six months ended\nMarch 31, 2021.  Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting\nfrom the permanent shutdown of the PharMEDium business in the six months ended March 31, 2020.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \n Expense \u00a0Net Loss \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\nGAAP \u00a0$1,533,381 \u00a0\u00a0$909,034 \u00a0\u00a0$624,347 \u00a0\u00a0$566,511 \u00a0\u00a0$132,506 \u00a0\u00a0$1,262 \u00a0\u00a0$435,267 \u00a0\u00a0$2.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(20,918 )\u00a0\u2014 \u00a0\u00a0(20,918 )\u00a0(20,918 )\u00a0(4,957 )\u00a0\u2014 \u00a0\u00a0(15,961 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(24,973 )\u00a024,973 \u00a0\u00a024,973 \u00a0\u00a03,302 \u00a0\u00a0(437 )\u00a021,234 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(78,156 )\u00a078,156 \u00a0\u00a078,156 \u00a0\u00a018,494 \u00a0\u00a0\u2014 \u00a0\u00a059,662 \u00a0\u00a00.29 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a021,368 \u00a0\u00a0(2,701 )\u00a0\u2014 \u00a0\u00a024,069 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP \u00a0$1,512,463 \u00a0\u00a0$805,905 \u00a0\u00a0$706,558 \u00a0\u00a0$670,090 \u00a0\u00a0$146,644 \u00a0\u00a0$825 \u00a0\u00a0$524,271 \u00a0\u00a0$2.53 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a06.7 % \u00a08.1 % \u00a05.2 % \u00a05.0 % \u00a06.9 % \u00a0\u00a0 \u00a05.4 % \u00a05.4 %\n\u00a0\n10", "original_text": "prior\nyear \u00a06.7 % \u00a08.1 % \u00a05.2 % \u00a05.0 % \u00a06.9 % \u00a0\u00a0 \u00a05.4 % \u00a05.4 %\n\u00a0\n10"}, "hash": "46bb592f79f0d3732567504df7bb96969593f165031bca4ab6358aecfccf0444", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \n Expense \u00a0Net Loss \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\nGAAP \u00a0$1,533,381 \u00a0\u00a0$909,034 \u00a0\u00a0$624,347 \u00a0\u00a0$566,511 \u00a0\u00a0$132,506 \u00a0\u00a0$1,262 \u00a0\u00a0$435,267 \u00a0\u00a0$2.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(20,918 )\u00a0\u2014 \u00a0\u00a0(20,918 )\u00a0(20,918 )\u00a0(4,957 )\u00a0\u2014 \u00a0\u00a0(15,961 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(24,973 )\u00a024,973 \u00a0\u00a024,973 \u00a0\u00a03,302 \u00a0\u00a0(437 )\u00a021,234 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(78,156 )\u00a078,156 \u00a0\u00a078,156 \u00a0\u00a018,494 \u00a0\u00a0\u2014 \u00a0\u00a059,662 \u00a0\u00a00.29 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a021,368 \u00a0\u00a0(2,701 )\u00a0\u2014 \u00a0\u00a024,069 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP \u00a0$1,512,463 \u00a0\u00a0$805,905 \u00a0\u00a0$706,558 \u00a0\u00a0$670,090 \u00a0\u00a0$146,644 \u00a0\u00a0$825 \u00a0\u00a0$524,271 \u00a0\u00a0$2.53 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP\n% change\nvs. ", "start_char_idx": 470, "end_char_idx": 1600, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f236e15-b1e9-40d0-898f-ba7771bb2f46": {"__data__": {"id_": "5f236e15-b1e9-40d0-898f-ba7771bb2f46", "embedding": null, "metadata": {"window": "5Includes $55.0 million of expense relating to Swiss tax reform and $20.4 million of discrete tax benefits primarily attributable to\nthe income tax deductions resulting from the permanent shutdown of the PharMEDium business in the six months ended\nMarch 31, 2021.  Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting\nfrom the permanent shutdown of the PharMEDium business in the six months ended March 31, 2020.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \n Expense \u00a0Net Loss \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\nGAAP \u00a0$1,533,381 \u00a0\u00a0$909,034 \u00a0\u00a0$624,347 \u00a0\u00a0$566,511 \u00a0\u00a0$132,506 \u00a0\u00a0$1,262 \u00a0\u00a0$435,267 \u00a0\u00a0$2.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(20,918 )\u00a0\u2014 \u00a0\u00a0(20,918 )\u00a0(20,918 )\u00a0(4,957 )\u00a0\u2014 \u00a0\u00a0(15,961 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(24,973 )\u00a024,973 \u00a0\u00a024,973 \u00a0\u00a03,302 \u00a0\u00a0(437 )\u00a021,234 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(78,156 )\u00a078,156 \u00a0\u00a078,156 \u00a0\u00a018,494 \u00a0\u00a0\u2014 \u00a0\u00a059,662 \u00a0\u00a00.29 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a021,368 \u00a0\u00a0(2,701 )\u00a0\u2014 \u00a0\u00a024,069 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP \u00a0$1,512,463 \u00a0\u00a0$805,905 \u00a0\u00a0$706,558 \u00a0\u00a0$670,090 \u00a0\u00a0$146,644 \u00a0\u00a0$825 \u00a0\u00a0$524,271 \u00a0\u00a0$2.53 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a06.7 % \u00a08.1 % \u00a05.2 % \u00a05.0 % \u00a06.9 % \u00a0\u00a0 \u00a05.4 % \u00a05.4 %\n\u00a0\n10", "original_text": "prior\nyear \u00a06.7 % \u00a08.1 % \u00a05.2 % \u00a05.0 % \u00a06.9 % \u00a0\u00a0 \u00a05.4 % \u00a05.4 %\n\u00a0\n10", "page_label": "10", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4bf856a2-789c-4c58-a81d-a38694217eaf", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac5e365d27f1a98d763e0a12ca86375a660fa212d3182bc024cd88f14a0630ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58a74d7e-e2f9-4163-b449-ed8ad9d055b0", "node_type": "1", "metadata": {"window": "5Includes $55.0 million of expense relating to Swiss tax reform and $20.4 million of discrete tax benefits primarily attributable to\nthe income tax deductions resulting from the permanent shutdown of the PharMEDium business in the six months ended\nMarch 31, 2021.  Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting\nfrom the permanent shutdown of the PharMEDium business in the six months ended March 31, 2020.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \n Expense \u00a0Net Loss \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\nGAAP \u00a0$1,533,381 \u00a0\u00a0$909,034 \u00a0\u00a0$624,347 \u00a0\u00a0$566,511 \u00a0\u00a0$132,506 \u00a0\u00a0$1,262 \u00a0\u00a0$435,267 \u00a0\u00a0$2.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(20,918 )\u00a0\u2014 \u00a0\u00a0(20,918 )\u00a0(20,918 )\u00a0(4,957 )\u00a0\u2014 \u00a0\u00a0(15,961 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(24,973 )\u00a024,973 \u00a0\u00a024,973 \u00a0\u00a03,302 \u00a0\u00a0(437 )\u00a021,234 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(78,156 )\u00a078,156 \u00a0\u00a078,156 \u00a0\u00a018,494 \u00a0\u00a0\u2014 \u00a0\u00a059,662 \u00a0\u00a00.29 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a021,368 \u00a0\u00a0(2,701 )\u00a0\u2014 \u00a0\u00a024,069 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP \u00a0$1,512,463 \u00a0\u00a0$805,905 \u00a0\u00a0$706,558 \u00a0\u00a0$670,090 \u00a0\u00a0$146,644 \u00a0\u00a0$825 \u00a0\u00a0$524,271 \u00a0\u00a0$2.53 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a06.7 % \u00a08.1 % \u00a05.2 % \u00a05.0 % \u00a06.9 % \u00a0\u00a0 \u00a05.4 % \u00a05.4 %\n\u00a0\n10", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \n Expense \u00a0Net Loss \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\nGAAP \u00a0$1,533,381 \u00a0\u00a0$909,034 \u00a0\u00a0$624,347 \u00a0\u00a0$566,511 \u00a0\u00a0$132,506 \u00a0\u00a0$1,262 \u00a0\u00a0$435,267 \u00a0\u00a0$2.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(20,918 )\u00a0\u2014 \u00a0\u00a0(20,918 )\u00a0(20,918 )\u00a0(4,957 )\u00a0\u2014 \u00a0\u00a0(15,961 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(24,973 )\u00a024,973 \u00a0\u00a024,973 \u00a0\u00a03,302 \u00a0\u00a0(437 )\u00a021,234 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(78,156 )\u00a078,156 \u00a0\u00a078,156 \u00a0\u00a018,494 \u00a0\u00a0\u2014 \u00a0\u00a059,662 \u00a0\u00a00.29 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a021,368 \u00a0\u00a0(2,701 )\u00a0\u2014 \u00a0\u00a024,069 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP \u00a0$1,512,463 \u00a0\u00a0$805,905 \u00a0\u00a0$706,558 \u00a0\u00a0$670,090 \u00a0\u00a0$146,644 \u00a0\u00a0$825 \u00a0\u00a0$524,271 \u00a0\u00a0$2.53 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP\n% change\nvs. ", "page_label": "10", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aec04949130d3b50fc86c9ff7a47dd2a7b2744e4474d4df810c10b74727e55e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b00246e5-d528-4d48-8d57-8bafb84d9034", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.12%\u00a03.08 %\nOperating expenses \u00a01.85%\u00a01.64 %\nOperating income \u00a01.27%\u00a01.44 %\n________________________________________\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n 2Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2020\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\nGAAP \u00a0$1,388,107 \u00a0\u00a0$1,078,592 \u00a0\u00a0$309,515 \u00a0\u00a0$276,203 \u00a0\u00a0$(694,908 )\u00a0$(10,834 )\u00a0$960,277 \u00a0\u00a0$4.64 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(54 )\u00a0\u2014 \u00a0\u00a0(54 )\u00a0(54 )\u00a0(111 )\u00a0\u2014 \u00a0\u00a057 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a023,853 \u00a0\u00a0\u2014 \u00a0\u00a023,853 \u00a0\u00a023,853 \u00a0\u00a05,972 \u00a0\u00a0\u2014 \u00a0\u00a017,881 \u00a0\u00a00.09 \u00a0\u00a0\n11", "original_text": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.12%\u00a03.08 %\nOperating expenses \u00a01.85%\u00a01.64 %\nOperating income \u00a01.27%\u00a01.44 %\n________________________________________\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n"}, "hash": "d1e798fd84554fd297ca168dbe35fe1a36a35d324491384a84815b8ffb4ca232", "class_name": "RelatedNodeInfo"}}, "text": "prior\nyear \u00a06.7 % \u00a08.1 % \u00a05.2 % \u00a05.0 % \u00a06.9 % \u00a0\u00a0 \u00a05.4 % \u00a05.4 %\n\u00a0\n10", "start_char_idx": 1600, "end_char_idx": 1667, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b00246e5-d528-4d48-8d57-8bafb84d9034": {"__data__": {"id_": "b00246e5-d528-4d48-8d57-8bafb84d9034", "embedding": null, "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.12%\u00a03.08 %\nOperating expenses \u00a01.85%\u00a01.64 %\nOperating income \u00a01.27%\u00a01.44 %\n________________________________________\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n 2Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2020\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\nGAAP \u00a0$1,388,107 \u00a0\u00a0$1,078,592 \u00a0\u00a0$309,515 \u00a0\u00a0$276,203 \u00a0\u00a0$(694,908 )\u00a0$(10,834 )\u00a0$960,277 \u00a0\u00a0$4.64 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(54 )\u00a0\u2014 \u00a0\u00a0(54 )\u00a0(54 )\u00a0(111 )\u00a0\u2014 \u00a0\u00a057 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a023,853 \u00a0\u00a0\u2014 \u00a0\u00a023,853 \u00a0\u00a023,853 \u00a0\u00a05,972 \u00a0\u00a0\u2014 \u00a0\u00a017,881 \u00a0\u00a00.09 \u00a0\u00a0\n11", "original_text": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.12%\u00a03.08 %\nOperating expenses \u00a01.85%\u00a01.64 %\nOperating income \u00a01.27%\u00a01.44 %\n________________________________________\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n", "page_label": "11", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7a40fb9d-1e17-4966-97ab-0e849d6490b7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "472096e2a0ce129f37074cc86c6bfb58309c91042ee6296cde3ef20e3821e7c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f236e15-b1e9-40d0-898f-ba7771bb2f46", "node_type": "1", "metadata": {"window": "5Includes $55.0 million of expense relating to Swiss tax reform and $20.4 million of discrete tax benefits primarily attributable to\nthe income tax deductions resulting from the permanent shutdown of the PharMEDium business in the six months ended\nMarch 31, 2021.  Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting\nfrom the permanent shutdown of the PharMEDium business in the six months ended March 31, 2020.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \n Expense \u00a0Net Loss \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\nGAAP \u00a0$1,533,381 \u00a0\u00a0$909,034 \u00a0\u00a0$624,347 \u00a0\u00a0$566,511 \u00a0\u00a0$132,506 \u00a0\u00a0$1,262 \u00a0\u00a0$435,267 \u00a0\u00a0$2.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(20,918 )\u00a0\u2014 \u00a0\u00a0(20,918 )\u00a0(20,918 )\u00a0(4,957 )\u00a0\u2014 \u00a0\u00a0(15,961 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(24,973 )\u00a024,973 \u00a0\u00a024,973 \u00a0\u00a03,302 \u00a0\u00a0(437 )\u00a021,234 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(78,156 )\u00a078,156 \u00a0\u00a078,156 \u00a0\u00a018,494 \u00a0\u00a0\u2014 \u00a0\u00a059,662 \u00a0\u00a00.29 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a021,368 \u00a0\u00a0(2,701 )\u00a0\u2014 \u00a0\u00a024,069 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP \u00a0$1,512,463 \u00a0\u00a0$805,905 \u00a0\u00a0$706,558 \u00a0\u00a0$670,090 \u00a0\u00a0$146,644 \u00a0\u00a0$825 \u00a0\u00a0$524,271 \u00a0\u00a0$2.53 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a06.7 % \u00a08.1 % \u00a05.2 % \u00a05.0 % \u00a06.9 % \u00a0\u00a0 \u00a05.4 % \u00a05.4 %\n\u00a0\n10", "original_text": "prior\nyear \u00a06.7 % \u00a08.1 % \u00a05.2 % \u00a05.0 % \u00a06.9 % \u00a0\u00a0 \u00a05.4 % \u00a05.4 %\n\u00a0\n10", "page_label": "10", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43d2b77ccf26b613caa78886f94173a338283e8984b87439177627bee1931637", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88de88cf-03d7-432e-89cb-22d6156e27bb", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.12%\u00a03.08 %\nOperating expenses \u00a01.85%\u00a01.64 %\nOperating income \u00a01.27%\u00a01.44 %\n________________________________________\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n 2Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2020\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\nGAAP \u00a0$1,388,107 \u00a0\u00a0$1,078,592 \u00a0\u00a0$309,515 \u00a0\u00a0$276,203 \u00a0\u00a0$(694,908 )\u00a0$(10,834 )\u00a0$960,277 \u00a0\u00a0$4.64 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(54 )\u00a0\u2014 \u00a0\u00a0(54 )\u00a0(54 )\u00a0(111 )\u00a0\u2014 \u00a0\u00a057 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a023,853 \u00a0\u00a0\u2014 \u00a0\u00a023,853 \u00a0\u00a023,853 \u00a0\u00a05,972 \u00a0\u00a0\u2014 \u00a0\u00a017,881 \u00a0\u00a00.09 \u00a0\u00a0\n11", "original_text": "2Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n\u00a0"}, "hash": "552a6bfaf1d80c914e2db7c7d3c255d617f9f18120e5b6083bc63af76fb19dbc", "class_name": "RelatedNodeInfo"}}, "text": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.12%\u00a03.08 %\nOperating expenses \u00a01.85%\u00a01.64 %\nOperating income \u00a01.27%\u00a01.44 %\n________________________________________\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n", "start_char_idx": 0, "end_char_idx": 473, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88de88cf-03d7-432e-89cb-22d6156e27bb": {"__data__": {"id_": "88de88cf-03d7-432e-89cb-22d6156e27bb", "embedding": null, "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.12%\u00a03.08 %\nOperating expenses \u00a01.85%\u00a01.64 %\nOperating income \u00a01.27%\u00a01.44 %\n________________________________________\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n 2Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2020\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\nGAAP \u00a0$1,388,107 \u00a0\u00a0$1,078,592 \u00a0\u00a0$309,515 \u00a0\u00a0$276,203 \u00a0\u00a0$(694,908 )\u00a0$(10,834 )\u00a0$960,277 \u00a0\u00a0$4.64 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(54 )\u00a0\u2014 \u00a0\u00a0(54 )\u00a0(54 )\u00a0(111 )\u00a0\u2014 \u00a0\u00a057 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a023,853 \u00a0\u00a0\u2014 \u00a0\u00a023,853 \u00a0\u00a023,853 \u00a0\u00a05,972 \u00a0\u00a0\u2014 \u00a0\u00a017,881 \u00a0\u00a00.09 \u00a0\u00a0\n11", "original_text": "2Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n\u00a0", "page_label": "11", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7a40fb9d-1e17-4966-97ab-0e849d6490b7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "472096e2a0ce129f37074cc86c6bfb58309c91042ee6296cde3ef20e3821e7c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b00246e5-d528-4d48-8d57-8bafb84d9034", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.12%\u00a03.08 %\nOperating expenses \u00a01.85%\u00a01.64 %\nOperating income \u00a01.27%\u00a01.44 %\n________________________________________\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n 2Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2020\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\nGAAP \u00a0$1,388,107 \u00a0\u00a0$1,078,592 \u00a0\u00a0$309,515 \u00a0\u00a0$276,203 \u00a0\u00a0$(694,908 )\u00a0$(10,834 )\u00a0$960,277 \u00a0\u00a0$4.64 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(54 )\u00a0\u2014 \u00a0\u00a0(54 )\u00a0(54 )\u00a0(111 )\u00a0\u2014 \u00a0\u00a057 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a023,853 \u00a0\u00a0\u2014 \u00a0\u00a023,853 \u00a0\u00a023,853 \u00a0\u00a05,972 \u00a0\u00a0\u2014 \u00a0\u00a017,881 \u00a0\u00a00.09 \u00a0\u00a0\n11", "original_text": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.12%\u00a03.08 %\nOperating expenses \u00a01.85%\u00a01.64 %\nOperating income \u00a01.27%\u00a01.44 %\n________________________________________\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n", "page_label": "11", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "abf0bcfe4640522e3a28ac2f60eaaba834172d1a5e566ebc04563e4e52db0007", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e42a7ea-fd6f-4b14-b5bb-40be9bdffb8a", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.12%\u00a03.08 %\nOperating expenses \u00a01.85%\u00a01.64 %\nOperating income \u00a01.27%\u00a01.44 %\n________________________________________\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n 2Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2020\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\nGAAP \u00a0$1,388,107 \u00a0\u00a0$1,078,592 \u00a0\u00a0$309,515 \u00a0\u00a0$276,203 \u00a0\u00a0$(694,908 )\u00a0$(10,834 )\u00a0$960,277 \u00a0\u00a0$4.64 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(54 )\u00a0\u2014 \u00a0\u00a0(54 )\u00a0(54 )\u00a0(111 )\u00a0\u2014 \u00a0\u00a057 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a023,853 \u00a0\u00a0\u2014 \u00a0\u00a023,853 \u00a0\u00a023,853 \u00a0\u00a05,972 \u00a0\u00a0\u2014 \u00a0\u00a017,881 \u00a0\u00a00.09 \u00a0\u00a0\n11", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "4065b0627a966a56d56f7d3463cbc318a38457ddc67eb092d837897e4ee6714b", "class_name": "RelatedNodeInfo"}}, "text": "2Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n\u00a0", "start_char_idx": 473, "end_char_idx": 651, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e42a7ea-fd6f-4b14-b5bb-40be9bdffb8a": {"__data__": {"id_": "7e42a7ea-fd6f-4b14-b5bb-40be9bdffb8a", "embedding": null, "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.12%\u00a03.08 %\nOperating expenses \u00a01.85%\u00a01.64 %\nOperating income \u00a01.27%\u00a01.44 %\n________________________________________\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n 2Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2020\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\nGAAP \u00a0$1,388,107 \u00a0\u00a0$1,078,592 \u00a0\u00a0$309,515 \u00a0\u00a0$276,203 \u00a0\u00a0$(694,908 )\u00a0$(10,834 )\u00a0$960,277 \u00a0\u00a0$4.64 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(54 )\u00a0\u2014 \u00a0\u00a0(54 )\u00a0(54 )\u00a0(111 )\u00a0\u2014 \u00a0\u00a057 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a023,853 \u00a0\u00a0\u2014 \u00a0\u00a023,853 \u00a0\u00a023,853 \u00a0\u00a05,972 \u00a0\u00a0\u2014 \u00a0\u00a017,881 \u00a0\u00a00.09 \u00a0\u00a0\n11", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "11", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7a40fb9d-1e17-4966-97ab-0e849d6490b7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "472096e2a0ce129f37074cc86c6bfb58309c91042ee6296cde3ef20e3821e7c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88de88cf-03d7-432e-89cb-22d6156e27bb", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.12%\u00a03.08 %\nOperating expenses \u00a01.85%\u00a01.64 %\nOperating income \u00a01.27%\u00a01.44 %\n________________________________________\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n 2Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2020\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\nGAAP \u00a0$1,388,107 \u00a0\u00a0$1,078,592 \u00a0\u00a0$309,515 \u00a0\u00a0$276,203 \u00a0\u00a0$(694,908 )\u00a0$(10,834 )\u00a0$960,277 \u00a0\u00a0$4.64 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(54 )\u00a0\u2014 \u00a0\u00a0(54 )\u00a0(54 )\u00a0(111 )\u00a0\u2014 \u00a0\u00a057 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a023,853 \u00a0\u00a0\u2014 \u00a0\u00a023,853 \u00a0\u00a023,853 \u00a0\u00a05,972 \u00a0\u00a0\u2014 \u00a0\u00a017,881 \u00a0\u00a00.09 \u00a0\u00a0\n11", "original_text": "2Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n\u00a0", "page_label": "11", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e8121f96a0c0c2a88470a17f1a7064d07184d04f36b1bcad3927f969d3573706", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "730fbaf2-1cfb-42c8-9d50-00e805e28f8b", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.12%\u00a03.08 %\nOperating expenses \u00a01.85%\u00a01.64 %\nOperating income \u00a01.27%\u00a01.44 %\n________________________________________\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n 2Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2020\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\nGAAP \u00a0$1,388,107 \u00a0\u00a0$1,078,592 \u00a0\u00a0$309,515 \u00a0\u00a0$276,203 \u00a0\u00a0$(694,908 )\u00a0$(10,834 )\u00a0$960,277 \u00a0\u00a0$4.64 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(54 )\u00a0\u2014 \u00a0\u00a0(54 )\u00a0(54 )\u00a0(111 )\u00a0\u2014 \u00a0\u00a057 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a023,853 \u00a0\u00a0\u2014 \u00a0\u00a023,853 \u00a0\u00a023,853 \u00a0\u00a05,972 \u00a0\u00a0\u2014 \u00a0\u00a017,881 \u00a0\u00a00.09 \u00a0\u00a0\n11", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2020\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\nGAAP \u00a0$1,388,107 \u00a0\u00a0$1,078,592 \u00a0\u00a0$309,515 \u00a0\u00a0$276,203 \u00a0\u00a0$(694,908 )\u00a0$(10,834 )\u00a0$960,277 \u00a0\u00a0$4.64 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(54 )\u00a0\u2014 \u00a0\u00a0(54 )\u00a0(54 )\u00a0(111 )\u00a0\u2014 \u00a0\u00a057 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a023,853 \u00a0\u00a0\u2014 \u00a0\u00a023,853 \u00a0\u00a023,853 \u00a0\u00a05,972 \u00a0\u00a0\u2014 \u00a0\u00a017,881 \u00a0\u00a00.09 \u00a0\u00a0\n11"}, "hash": "42895e1048ea0e7351dd6f496550342749fd6580e49eb2e72d4cc2f13c986a0e", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 651, "end_char_idx": 828, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "730fbaf2-1cfb-42c8-9d50-00e805e28f8b": {"__data__": {"id_": "730fbaf2-1cfb-42c8-9d50-00e805e28f8b", "embedding": null, "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.12%\u00a03.08 %\nOperating expenses \u00a01.85%\u00a01.64 %\nOperating income \u00a01.27%\u00a01.44 %\n________________________________________\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n 2Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2020\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\nGAAP \u00a0$1,388,107 \u00a0\u00a0$1,078,592 \u00a0\u00a0$309,515 \u00a0\u00a0$276,203 \u00a0\u00a0$(694,908 )\u00a0$(10,834 )\u00a0$960,277 \u00a0\u00a0$4.64 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(54 )\u00a0\u2014 \u00a0\u00a0(54 )\u00a0(54 )\u00a0(111 )\u00a0\u2014 \u00a0\u00a057 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a023,853 \u00a0\u00a0\u2014 \u00a0\u00a023,853 \u00a0\u00a023,853 \u00a0\u00a05,972 \u00a0\u00a0\u2014 \u00a0\u00a017,881 \u00a0\u00a00.09 \u00a0\u00a0\n11", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2020\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\nGAAP \u00a0$1,388,107 \u00a0\u00a0$1,078,592 \u00a0\u00a0$309,515 \u00a0\u00a0$276,203 \u00a0\u00a0$(694,908 )\u00a0$(10,834 )\u00a0$960,277 \u00a0\u00a0$4.64 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(54 )\u00a0\u2014 \u00a0\u00a0(54 )\u00a0(54 )\u00a0(111 )\u00a0\u2014 \u00a0\u00a057 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a023,853 \u00a0\u00a0\u2014 \u00a0\u00a023,853 \u00a0\u00a023,853 \u00a0\u00a05,972 \u00a0\u00a0\u2014 \u00a0\u00a017,881 \u00a0\u00a00.09 \u00a0\u00a0\n11", "page_label": "11", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7a40fb9d-1e17-4966-97ab-0e849d6490b7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "472096e2a0ce129f37074cc86c6bfb58309c91042ee6296cde3ef20e3821e7c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e42a7ea-fd6f-4b14-b5bb-40be9bdffb8a", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.12%\u00a03.08 %\nOperating expenses \u00a01.85%\u00a01.64 %\nOperating income \u00a01.27%\u00a01.44 %\n________________________________________\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n 2Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2020\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\nGAAP \u00a0$1,388,107 \u00a0\u00a0$1,078,592 \u00a0\u00a0$309,515 \u00a0\u00a0$276,203 \u00a0\u00a0$(694,908 )\u00a0$(10,834 )\u00a0$960,277 \u00a0\u00a0$4.64 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(54 )\u00a0\u2014 \u00a0\u00a0(54 )\u00a0(54 )\u00a0(111 )\u00a0\u2014 \u00a0\u00a057 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a023,853 \u00a0\u00a0\u2014 \u00a0\u00a023,853 \u00a0\u00a023,853 \u00a0\u00a05,972 \u00a0\u00a0\u2014 \u00a0\u00a017,881 \u00a0\u00a00.09 \u00a0\u00a0\n11", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "11", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d281abd9335079ffeaec54253494c4cbab8ee3724b5fe16db474b1f0236700dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a9fcca9-b46d-495b-b3ea-7c0ddf337f58", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a04,989 \u00a0\u00a0(27,481 )\u00a032,470 \u00a0\u00a032,470 \u00a0\u00a08,107 \u00a0\u00a0 \u2014 \u00a0\u00a024,363 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(26,670 )\u00a026,670 \u00a0\u00a026,670 \u00a0\u00a06,894 \u00a0\u00a0(435 )\u00a019,341 \u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(67,732 )\u00a067,732 \u00a0\u00a067,732 \u00a0\u00a016,978 \u00a0\u00a0\u2014 \u00a0\u00a050,754 \u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(223,652 )\u00a0223,652 \u00a0\u00a0223,652 \u00a0\u00a056,156 \u00a0\u00a0\u2014 \u00a0\u00a0167,496 \u00a0\u00a00.81 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,965 )\u00a07,511 \u00a0\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0741,015 \u00a0\u00a0\u2014 \u00a0\u00a0(741,015 )\u00a0(3.58 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP $1,416,895 \u00a0\u00a0$745,210 \u00a0\u00a0$671,685 \u00a0$638,373 \u00a0$137,138 \u00a0$(3,758 )\u00a0$497,477 \u00a0$2.40 2\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.93% \u00a02.99%\nOperating expenses \u00a02.27% \u00a01.57%\nOperating income \u00a00.65% \u00a01.42%\n________________________________________\n12", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a04,989 \u00a0\u00a0(27,481 )\u00a032,470 \u00a0\u00a032,470 \u00a0\u00a08,107 \u00a0\u00a0 \u2014 \u00a0\u00a024,363 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(26,670 )\u00a026,670 \u00a0\u00a026,670 \u00a0\u00a06,894 \u00a0\u00a0(435 )\u00a019,341 \u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(67,732 )\u00a067,732 \u00a0\u00a067,732 \u00a0\u00a016,978 \u00a0\u00a0\u2014 \u00a0\u00a050,754 \u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(223,652 )\u00a0223,652 \u00a0\u00a0223,652 \u00a0\u00a056,156 \u00a0\u00a0\u2014 \u00a0\u00a0167,496 \u00a0\u00a00.81 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,965 )\u00a07,511 \u00a0\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0741,015 \u00a0\u00a0\u2014 \u00a0\u00a0(741,015 )\u00a0(3.58 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP $1,416,895 \u00a0\u00a0$745,210 \u00a0\u00a0$671,685 \u00a0$638,373 \u00a0$137,138 \u00a0$(3,758 )\u00a0$497,477 \u00a0$2.40 2\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.93% \u00a02.99%\nOperating expenses \u00a02.27% \u00a01.57%\nOperating income \u00a00.65% \u00a01.42%\n________________________________________\n12"}, "hash": "d13355d84536a4154f8894404ee1f193e40e3f0c96fa88f075d0ece683f4fd63", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2020\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\nGAAP \u00a0$1,388,107 \u00a0\u00a0$1,078,592 \u00a0\u00a0$309,515 \u00a0\u00a0$276,203 \u00a0\u00a0$(694,908 )\u00a0$(10,834 )\u00a0$960,277 \u00a0\u00a0$4.64 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(54 )\u00a0\u2014 \u00a0\u00a0(54 )\u00a0(54 )\u00a0(111 )\u00a0\u2014 \u00a0\u00a057 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a023,853 \u00a0\u00a0\u2014 \u00a0\u00a023,853 \u00a0\u00a023,853 \u00a0\u00a05,972 \u00a0\u00a0\u2014 \u00a0\u00a017,881 \u00a0\u00a00.09 \u00a0\u00a0\n11", "start_char_idx": 828, "end_char_idx": 1552, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a9fcca9-b46d-495b-b3ea-7c0ddf337f58": {"__data__": {"id_": "9a9fcca9-b46d-495b-b3ea-7c0ddf337f58", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a04,989 \u00a0\u00a0(27,481 )\u00a032,470 \u00a0\u00a032,470 \u00a0\u00a08,107 \u00a0\u00a0 \u2014 \u00a0\u00a024,363 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(26,670 )\u00a026,670 \u00a0\u00a026,670 \u00a0\u00a06,894 \u00a0\u00a0(435 )\u00a019,341 \u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(67,732 )\u00a067,732 \u00a0\u00a067,732 \u00a0\u00a016,978 \u00a0\u00a0\u2014 \u00a0\u00a050,754 \u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(223,652 )\u00a0223,652 \u00a0\u00a0223,652 \u00a0\u00a056,156 \u00a0\u00a0\u2014 \u00a0\u00a0167,496 \u00a0\u00a00.81 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,965 )\u00a07,511 \u00a0\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0741,015 \u00a0\u00a0\u2014 \u00a0\u00a0(741,015 )\u00a0(3.58 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP $1,416,895 \u00a0\u00a0$745,210 \u00a0\u00a0$671,685 \u00a0$638,373 \u00a0$137,138 \u00a0$(3,758 )\u00a0$497,477 \u00a0$2.40 2\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.93% \u00a02.99%\nOperating expenses \u00a02.27% \u00a01.57%\nOperating income \u00a00.65% \u00a01.42%\n________________________________________\n12", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a04,989 \u00a0\u00a0(27,481 )\u00a032,470 \u00a0\u00a032,470 \u00a0\u00a08,107 \u00a0\u00a0 \u2014 \u00a0\u00a024,363 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(26,670 )\u00a026,670 \u00a0\u00a026,670 \u00a0\u00a06,894 \u00a0\u00a0(435 )\u00a019,341 \u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(67,732 )\u00a067,732 \u00a0\u00a067,732 \u00a0\u00a016,978 \u00a0\u00a0\u2014 \u00a0\u00a050,754 \u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(223,652 )\u00a0223,652 \u00a0\u00a0223,652 \u00a0\u00a056,156 \u00a0\u00a0\u2014 \u00a0\u00a0167,496 \u00a0\u00a00.81 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,965 )\u00a07,511 \u00a0\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0741,015 \u00a0\u00a0\u2014 \u00a0\u00a0(741,015 )\u00a0(3.58 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP $1,416,895 \u00a0\u00a0$745,210 \u00a0\u00a0$671,685 \u00a0$638,373 \u00a0$137,138 \u00a0$(3,758 )\u00a0$497,477 \u00a0$2.40 2\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.93% \u00a02.99%\nOperating expenses \u00a02.27% \u00a01.57%\nOperating income \u00a00.65% \u00a01.42%\n________________________________________\n12", "page_label": "12", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "374cea2e-e325-44de-b70c-29ba8342bbbd", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db4bd9e11aefad40f6ad7f3aa8619ba648e6a20880f39bc11498de0e7845e145", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "730fbaf2-1cfb-42c8-9d50-00e805e28f8b", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.12%\u00a03.08 %\nOperating expenses \u00a01.85%\u00a01.64 %\nOperating income \u00a01.27%\u00a01.44 %\n________________________________________\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n 2Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2020\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\nGAAP \u00a0$1,388,107 \u00a0\u00a0$1,078,592 \u00a0\u00a0$309,515 \u00a0\u00a0$276,203 \u00a0\u00a0$(694,908 )\u00a0$(10,834 )\u00a0$960,277 \u00a0\u00a0$4.64 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(54 )\u00a0\u2014 \u00a0\u00a0(54 )\u00a0(54 )\u00a0(111 )\u00a0\u2014 \u00a0\u00a057 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a023,853 \u00a0\u00a0\u2014 \u00a0\u00a023,853 \u00a0\u00a023,853 \u00a0\u00a05,972 \u00a0\u00a0\u2014 \u00a0\u00a017,881 \u00a0\u00a00.09 \u00a0\u00a0\n11", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2020\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\nGAAP \u00a0$1,388,107 \u00a0\u00a0$1,078,592 \u00a0\u00a0$309,515 \u00a0\u00a0$276,203 \u00a0\u00a0$(694,908 )\u00a0$(10,834 )\u00a0$960,277 \u00a0\u00a0$4.64 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(54 )\u00a0\u2014 \u00a0\u00a0(54 )\u00a0(54 )\u00a0(111 )\u00a0\u2014 \u00a0\u00a057 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a023,853 \u00a0\u00a0\u2014 \u00a0\u00a023,853 \u00a0\u00a023,853 \u00a0\u00a05,972 \u00a0\u00a0\u2014 \u00a0\u00a017,881 \u00a0\u00a00.09 \u00a0\u00a0\n11", "page_label": "11", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a266dd29229f8008e9fbe12cd45ea9f054718aab8d7c248dd9f7b3a283ae3434", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "566dca63-f2db-41de-9386-d643b712ef84", "node_type": "1", "metadata": {"window": "1Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$2,985,611 \u00a0\u00a0$1,814,036 \u00a0\u00a0$1,171,575 \u00a0\u00a0$1,094,393 \u00a0\u00a0$281,681 \u00a0\u00a0$(2,600 )\u00a0$810,112 \u00a0\u00a0$3.91\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(46,645 )\u00a0\u2014 \u00a0\u00a0(46,645 )\u00a0(46,645 )\u00a0(9,933 )\u00a0\u2014 \u00a0\u00a0(36,712 )\u00a0(0.18 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(50,007 )\u00a050,007 \u00a0\u00a050,007 \u00a0\u00a07,398 \u00a0\u00a0(874 )\u00a041,735 \u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(148,537 )\u00a0148,537 \u00a0\u00a0148,537 \u00a0\u00a030,468 \u00a0\u00a0\u2014 \u00a0\u00a0118,069 \u00a0\u00a00.57 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a07,329 \u00a0\u00a0(55,019 )\u00a0\u2014 \u00a0\u00a062,348 \u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "1Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n"}, "hash": "b6dea666dd2d88e3e89fb99a2226d72e856525f20a8d1b57a47b3154e1209644", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a04,989 \u00a0\u00a0(27,481 )\u00a032,470 \u00a0\u00a032,470 \u00a0\u00a08,107 \u00a0\u00a0 \u2014 \u00a0\u00a024,363 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(26,670 )\u00a026,670 \u00a0\u00a026,670 \u00a0\u00a06,894 \u00a0\u00a0(435 )\u00a019,341 \u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(67,732 )\u00a067,732 \u00a0\u00a067,732 \u00a0\u00a016,978 \u00a0\u00a0\u2014 \u00a0\u00a050,754 \u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(223,652 )\u00a0223,652 \u00a0\u00a0223,652 \u00a0\u00a056,156 \u00a0\u00a0\u2014 \u00a0\u00a0167,496 \u00a0\u00a00.81 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,965 )\u00a07,511 \u00a0\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0741,015 \u00a0\u00a0\u2014 \u00a0\u00a0(741,015 )\u00a0(3.58 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP $1,416,895 \u00a0\u00a0$745,210 \u00a0\u00a0$671,685 \u00a0$638,373 \u00a0$137,138 \u00a0$(3,758 )\u00a0$497,477 \u00a0$2.40 2\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.93% \u00a02.99%\nOperating expenses \u00a02.27% \u00a01.57%\nOperating income \u00a00.65% \u00a01.42%\n________________________________________\n12", "start_char_idx": 0, "end_char_idx": 1078, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "566dca63-f2db-41de-9386-d643b712ef84": {"__data__": {"id_": "566dca63-f2db-41de-9386-d643b712ef84", "embedding": null, "metadata": {"window": "1Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$2,985,611 \u00a0\u00a0$1,814,036 \u00a0\u00a0$1,171,575 \u00a0\u00a0$1,094,393 \u00a0\u00a0$281,681 \u00a0\u00a0$(2,600 )\u00a0$810,112 \u00a0\u00a0$3.91\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(46,645 )\u00a0\u2014 \u00a0\u00a0(46,645 )\u00a0(46,645 )\u00a0(9,933 )\u00a0\u2014 \u00a0\u00a0(36,712 )\u00a0(0.18 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(50,007 )\u00a050,007 \u00a0\u00a050,007 \u00a0\u00a07,398 \u00a0\u00a0(874 )\u00a041,735 \u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(148,537 )\u00a0148,537 \u00a0\u00a0148,537 \u00a0\u00a030,468 \u00a0\u00a0\u2014 \u00a0\u00a0118,069 \u00a0\u00a00.57 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a07,329 \u00a0\u00a0(55,019 )\u00a0\u2014 \u00a0\u00a062,348 \u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "1Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n", "page_label": "13", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0780b706-b2b7-40bc-8000-fe99c141007f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1dba369584cd3ca09bed556ad122e72aeb7361bde46350554387dde808ee492e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a9fcca9-b46d-495b-b3ea-7c0ddf337f58", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a04,989 \u00a0\u00a0(27,481 )\u00a032,470 \u00a0\u00a032,470 \u00a0\u00a08,107 \u00a0\u00a0 \u2014 \u00a0\u00a024,363 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(26,670 )\u00a026,670 \u00a0\u00a026,670 \u00a0\u00a06,894 \u00a0\u00a0(435 )\u00a019,341 \u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(67,732 )\u00a067,732 \u00a0\u00a067,732 \u00a0\u00a016,978 \u00a0\u00a0\u2014 \u00a0\u00a050,754 \u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(223,652 )\u00a0223,652 \u00a0\u00a0223,652 \u00a0\u00a056,156 \u00a0\u00a0\u2014 \u00a0\u00a0167,496 \u00a0\u00a00.81 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,965 )\u00a07,511 \u00a0\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0741,015 \u00a0\u00a0\u2014 \u00a0\u00a0(741,015 )\u00a0(3.58 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP $1,416,895 \u00a0\u00a0$745,210 \u00a0\u00a0$671,685 \u00a0$638,373 \u00a0$137,138 \u00a0$(3,758 )\u00a0$497,477 \u00a0$2.40 2\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.93% \u00a02.99%\nOperating expenses \u00a02.27% \u00a01.57%\nOperating income \u00a00.65% \u00a01.42%\n________________________________________\n12", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a04,989 \u00a0\u00a0(27,481 )\u00a032,470 \u00a0\u00a032,470 \u00a0\u00a08,107 \u00a0\u00a0 \u2014 \u00a0\u00a024,363 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(26,670 )\u00a026,670 \u00a0\u00a026,670 \u00a0\u00a06,894 \u00a0\u00a0(435 )\u00a019,341 \u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(67,732 )\u00a067,732 \u00a0\u00a067,732 \u00a0\u00a016,978 \u00a0\u00a0\u2014 \u00a0\u00a050,754 \u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(223,652 )\u00a0223,652 \u00a0\u00a0223,652 \u00a0\u00a056,156 \u00a0\u00a0\u2014 \u00a0\u00a0167,496 \u00a0\u00a00.81 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,965 )\u00a07,511 \u00a0\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0741,015 \u00a0\u00a0\u2014 \u00a0\u00a0(741,015 )\u00a0(3.58 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP $1,416,895 \u00a0\u00a0$745,210 \u00a0\u00a0$671,685 \u00a0$638,373 \u00a0$137,138 \u00a0$(3,758 )\u00a0$497,477 \u00a0$2.40 2\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.93% \u00a02.99%\nOperating expenses \u00a02.27% \u00a01.57%\nOperating income \u00a00.65% \u00a01.42%\n________________________________________\n12", "page_label": "12", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "993d1377ce32cf8a52039b8914497a4b721a42a0306c86b395fd78c3f88fb711", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c82542d0-53cf-4c99-8def-9a9bedf721fd", "node_type": "1", "metadata": {"window": "1Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$2,985,611 \u00a0\u00a0$1,814,036 \u00a0\u00a0$1,171,575 \u00a0\u00a0$1,094,393 \u00a0\u00a0$281,681 \u00a0\u00a0$(2,600 )\u00a0$810,112 \u00a0\u00a0$3.91\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(46,645 )\u00a0\u2014 \u00a0\u00a0(46,645 )\u00a0(46,645 )\u00a0(9,933 )\u00a0\u2014 \u00a0\u00a0(36,712 )\u00a0(0.18 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(50,007 )\u00a050,007 \u00a0\u00a050,007 \u00a0\u00a07,398 \u00a0\u00a0(874 )\u00a041,735 \u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(148,537 )\u00a0148,537 \u00a0\u00a0148,537 \u00a0\u00a030,468 \u00a0\u00a0\u2014 \u00a0\u00a0118,069 \u00a0\u00a00.57 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a07,329 \u00a0\u00a0(55,019 )\u00a0\u2014 \u00a0\u00a062,348 \u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0"}, "hash": "45bc60a769517c1b9db7679f9854201b84508bee000dc3d19021bc6482954d44", "class_name": "RelatedNodeInfo"}}, "text": "1Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n", "start_char_idx": 0, "end_char_idx": 155, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c82542d0-53cf-4c99-8def-9a9bedf721fd": {"__data__": {"id_": "c82542d0-53cf-4c99-8def-9a9bedf721fd", "embedding": null, "metadata": {"window": "1Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$2,985,611 \u00a0\u00a0$1,814,036 \u00a0\u00a0$1,171,575 \u00a0\u00a0$1,094,393 \u00a0\u00a0$281,681 \u00a0\u00a0$(2,600 )\u00a0$810,112 \u00a0\u00a0$3.91\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(46,645 )\u00a0\u2014 \u00a0\u00a0(46,645 )\u00a0(46,645 )\u00a0(9,933 )\u00a0\u2014 \u00a0\u00a0(36,712 )\u00a0(0.18 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(50,007 )\u00a050,007 \u00a0\u00a050,007 \u00a0\u00a07,398 \u00a0\u00a0(874 )\u00a041,735 \u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(148,537 )\u00a0148,537 \u00a0\u00a0148,537 \u00a0\u00a030,468 \u00a0\u00a0\u2014 \u00a0\u00a0118,069 \u00a0\u00a00.57 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a07,329 \u00a0\u00a0(55,019 )\u00a0\u2014 \u00a0\u00a062,348 \u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0", "page_label": "13", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0780b706-b2b7-40bc-8000-fe99c141007f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1dba369584cd3ca09bed556ad122e72aeb7361bde46350554387dde808ee492e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "566dca63-f2db-41de-9386-d643b712ef84", "node_type": "1", "metadata": {"window": "1Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$2,985,611 \u00a0\u00a0$1,814,036 \u00a0\u00a0$1,171,575 \u00a0\u00a0$1,094,393 \u00a0\u00a0$281,681 \u00a0\u00a0$(2,600 )\u00a0$810,112 \u00a0\u00a0$3.91\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(46,645 )\u00a0\u2014 \u00a0\u00a0(46,645 )\u00a0(46,645 )\u00a0(9,933 )\u00a0\u2014 \u00a0\u00a0(36,712 )\u00a0(0.18 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(50,007 )\u00a050,007 \u00a0\u00a050,007 \u00a0\u00a07,398 \u00a0\u00a0(874 )\u00a041,735 \u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(148,537 )\u00a0148,537 \u00a0\u00a0148,537 \u00a0\u00a030,468 \u00a0\u00a0\u2014 \u00a0\u00a0118,069 \u00a0\u00a00.57 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a07,329 \u00a0\u00a0(55,019 )\u00a0\u2014 \u00a0\u00a062,348 \u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "1Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n", "page_label": "13", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c97632967809088cee299fd39aa4d2e40192545e889170dfab6fa37214151e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f668ad9-0f06-48d1-a08b-e5365fecf0de", "node_type": "1", "metadata": {"window": "1Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$2,985,611 \u00a0\u00a0$1,814,036 \u00a0\u00a0$1,171,575 \u00a0\u00a0$1,094,393 \u00a0\u00a0$281,681 \u00a0\u00a0$(2,600 )\u00a0$810,112 \u00a0\u00a0$3.91\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(46,645 )\u00a0\u2014 \u00a0\u00a0(46,645 )\u00a0(46,645 )\u00a0(9,933 )\u00a0\u2014 \u00a0\u00a0(36,712 )\u00a0(0.18 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(50,007 )\u00a050,007 \u00a0\u00a050,007 \u00a0\u00a07,398 \u00a0\u00a0(874 )\u00a041,735 \u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(148,537 )\u00a0148,537 \u00a0\u00a0148,537 \u00a0\u00a030,468 \u00a0\u00a0\u2014 \u00a0\u00a0118,069 \u00a0\u00a00.57 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a07,329 \u00a0\u00a0(55,019 )\u00a0\u2014 \u00a0\u00a062,348 \u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "e0e493a8501ff5d9441d6484fb2f9d312eb26ea89ce616850065466a54f4a70e", "class_name": "RelatedNodeInfo"}}, "text": "2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0", "start_char_idx": 155, "end_char_idx": 228, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f668ad9-0f06-48d1-a08b-e5365fecf0de": {"__data__": {"id_": "1f668ad9-0f06-48d1-a08b-e5365fecf0de", "embedding": null, "metadata": {"window": "1Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$2,985,611 \u00a0\u00a0$1,814,036 \u00a0\u00a0$1,171,575 \u00a0\u00a0$1,094,393 \u00a0\u00a0$281,681 \u00a0\u00a0$(2,600 )\u00a0$810,112 \u00a0\u00a0$3.91\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(46,645 )\u00a0\u2014 \u00a0\u00a0(46,645 )\u00a0(46,645 )\u00a0(9,933 )\u00a0\u2014 \u00a0\u00a0(36,712 )\u00a0(0.18 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(50,007 )\u00a050,007 \u00a0\u00a050,007 \u00a0\u00a07,398 \u00a0\u00a0(874 )\u00a041,735 \u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(148,537 )\u00a0148,537 \u00a0\u00a0148,537 \u00a0\u00a030,468 \u00a0\u00a0\u2014 \u00a0\u00a0118,069 \u00a0\u00a00.57 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a07,329 \u00a0\u00a0(55,019 )\u00a0\u2014 \u00a0\u00a062,348 \u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "13", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0780b706-b2b7-40bc-8000-fe99c141007f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1dba369584cd3ca09bed556ad122e72aeb7361bde46350554387dde808ee492e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c82542d0-53cf-4c99-8def-9a9bedf721fd", "node_type": "1", "metadata": {"window": "1Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$2,985,611 \u00a0\u00a0$1,814,036 \u00a0\u00a0$1,171,575 \u00a0\u00a0$1,094,393 \u00a0\u00a0$281,681 \u00a0\u00a0$(2,600 )\u00a0$810,112 \u00a0\u00a0$3.91\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(46,645 )\u00a0\u2014 \u00a0\u00a0(46,645 )\u00a0(46,645 )\u00a0(9,933 )\u00a0\u2014 \u00a0\u00a0(36,712 )\u00a0(0.18 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(50,007 )\u00a050,007 \u00a0\u00a050,007 \u00a0\u00a07,398 \u00a0\u00a0(874 )\u00a041,735 \u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(148,537 )\u00a0148,537 \u00a0\u00a0148,537 \u00a0\u00a030,468 \u00a0\u00a0\u2014 \u00a0\u00a0118,069 \u00a0\u00a00.57 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a07,329 \u00a0\u00a0(55,019 )\u00a0\u2014 \u00a0\u00a062,348 \u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0", "page_label": "13", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6cfe231a7d3586da58e94cb18f69e5c0e56074a258e2cb028895c10922c3b78c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d459bb75-635a-466f-9a90-b3b7af307314", "node_type": "1", "metadata": {"window": "1Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$2,985,611 \u00a0\u00a0$1,814,036 \u00a0\u00a0$1,171,575 \u00a0\u00a0$1,094,393 \u00a0\u00a0$281,681 \u00a0\u00a0$(2,600 )\u00a0$810,112 \u00a0\u00a0$3.91\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(46,645 )\u00a0\u2014 \u00a0\u00a0(46,645 )\u00a0(46,645 )\u00a0(9,933 )\u00a0\u2014 \u00a0\u00a0(36,712 )\u00a0(0.18 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(50,007 )\u00a050,007 \u00a0\u00a050,007 \u00a0\u00a07,398 \u00a0\u00a0(874 )\u00a041,735 \u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(148,537 )\u00a0148,537 \u00a0\u00a0148,537 \u00a0\u00a030,468 \u00a0\u00a0\u2014 \u00a0\u00a0118,069 \u00a0\u00a00.57 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a07,329 \u00a0\u00a0(55,019 )\u00a0\u2014 \u00a0\u00a062,348 \u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$2,985,611 \u00a0\u00a0$1,814,036 \u00a0\u00a0$1,171,575 \u00a0\u00a0$1,094,393 \u00a0\u00a0$281,681 \u00a0\u00a0$(2,600 )\u00a0$810,112 \u00a0\u00a0$3.91\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(46,645 )\u00a0\u2014 \u00a0\u00a0(46,645 )\u00a0(46,645 )\u00a0(9,933 )\u00a0\u2014 \u00a0\u00a0(36,712 )\u00a0(0.18 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(50,007 )\u00a050,007 \u00a0\u00a050,007 \u00a0\u00a07,398 \u00a0\u00a0(874 )\u00a041,735 \u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(148,537 )\u00a0148,537 \u00a0\u00a0148,537 \u00a0\u00a030,468 \u00a0\u00a0\u2014 \u00a0\u00a0118,069 \u00a0\u00a00.57 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a07,329 \u00a0\u00a0(55,019 )\u00a0\u2014 \u00a0\u00a062,348 \u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13"}, "hash": "652f3d7e82e58e0610d81a24e7ef4cddd8ac0a230c22e68c24de6fb179c01391", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 228, "end_char_idx": 405, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d459bb75-635a-466f-9a90-b3b7af307314": {"__data__": {"id_": "d459bb75-635a-466f-9a90-b3b7af307314", "embedding": null, "metadata": {"window": "1Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$2,985,611 \u00a0\u00a0$1,814,036 \u00a0\u00a0$1,171,575 \u00a0\u00a0$1,094,393 \u00a0\u00a0$281,681 \u00a0\u00a0$(2,600 )\u00a0$810,112 \u00a0\u00a0$3.91\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(46,645 )\u00a0\u2014 \u00a0\u00a0(46,645 )\u00a0(46,645 )\u00a0(9,933 )\u00a0\u2014 \u00a0\u00a0(36,712 )\u00a0(0.18 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(50,007 )\u00a050,007 \u00a0\u00a050,007 \u00a0\u00a07,398 \u00a0\u00a0(874 )\u00a041,735 \u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(148,537 )\u00a0148,537 \u00a0\u00a0148,537 \u00a0\u00a030,468 \u00a0\u00a0\u2014 \u00a0\u00a0118,069 \u00a0\u00a00.57 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a07,329 \u00a0\u00a0(55,019 )\u00a0\u2014 \u00a0\u00a062,348 \u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$2,985,611 \u00a0\u00a0$1,814,036 \u00a0\u00a0$1,171,575 \u00a0\u00a0$1,094,393 \u00a0\u00a0$281,681 \u00a0\u00a0$(2,600 )\u00a0$810,112 \u00a0\u00a0$3.91\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(46,645 )\u00a0\u2014 \u00a0\u00a0(46,645 )\u00a0(46,645 )\u00a0(9,933 )\u00a0\u2014 \u00a0\u00a0(36,712 )\u00a0(0.18 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(50,007 )\u00a050,007 \u00a0\u00a050,007 \u00a0\u00a07,398 \u00a0\u00a0(874 )\u00a041,735 \u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(148,537 )\u00a0148,537 \u00a0\u00a0148,537 \u00a0\u00a030,468 \u00a0\u00a0\u2014 \u00a0\u00a0118,069 \u00a0\u00a00.57 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a07,329 \u00a0\u00a0(55,019 )\u00a0\u2014 \u00a0\u00a062,348 \u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "page_label": "13", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0780b706-b2b7-40bc-8000-fe99c141007f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1dba369584cd3ca09bed556ad122e72aeb7361bde46350554387dde808ee492e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f668ad9-0f06-48d1-a08b-e5365fecf0de", "node_type": "1", "metadata": {"window": "1Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$2,985,611 \u00a0\u00a0$1,814,036 \u00a0\u00a0$1,171,575 \u00a0\u00a0$1,094,393 \u00a0\u00a0$281,681 \u00a0\u00a0$(2,600 )\u00a0$810,112 \u00a0\u00a0$3.91\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(46,645 )\u00a0\u2014 \u00a0\u00a0(46,645 )\u00a0(46,645 )\u00a0(9,933 )\u00a0\u2014 \u00a0\u00a0(36,712 )\u00a0(0.18 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(50,007 )\u00a050,007 \u00a0\u00a050,007 \u00a0\u00a07,398 \u00a0\u00a0(874 )\u00a041,735 \u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(148,537 )\u00a0148,537 \u00a0\u00a0148,537 \u00a0\u00a030,468 \u00a0\u00a0\u2014 \u00a0\u00a0118,069 \u00a0\u00a00.57 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a07,329 \u00a0\u00a0(55,019 )\u00a0\u2014 \u00a0\u00a062,348 \u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "13", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ba9b5d7a00240b992122125a5d0e6038fba134c2cbd73658414e566bf7841532", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95cd578f-bcc4-489e-9499-12d235fc7ff6", "node_type": "1", "metadata": {"window": "Adjusted\nNon-GAAP \u00a0$2,938,966 \u00a0\u00a0$1,615,492 \u00a0\u00a0$1,323,474 \u00a0\u00a0$1,253,621 \u00a0\u00a0$275,020 \u00a0\u00a0$(3,474 )\u00a0$975,127 \u00a0\u00a0$4.714\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a010.5 % \u00a08.2 % \u00a013.4 % \u00a014.0 % \u00a017.5 % \u00a0\u00a0 \u00a013.0 % \u00a013.2 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n\u00a0\u00a0\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n 2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 3Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n", "original_text": "Adjusted\nNon-GAAP \u00a0$2,938,966 \u00a0\u00a0$1,615,492 \u00a0\u00a0$1,323,474 \u00a0\u00a0$1,253,621 \u00a0\u00a0$275,020 \u00a0\u00a0$(3,474 )\u00a0$975,127 \u00a0\u00a0$4.714\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs. "}, "hash": "a2e11c81aebea7ca57caea40d2461d8a4f9da68802938ec2dd6702c03861ece4", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$2,985,611 \u00a0\u00a0$1,814,036 \u00a0\u00a0$1,171,575 \u00a0\u00a0$1,094,393 \u00a0\u00a0$281,681 \u00a0\u00a0$(2,600 )\u00a0$810,112 \u00a0\u00a0$3.91\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(46,645 )\u00a0\u2014 \u00a0\u00a0(46,645 )\u00a0(46,645 )\u00a0(9,933 )\u00a0\u2014 \u00a0\u00a0(36,712 )\u00a0(0.18 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(50,007 )\u00a050,007 \u00a0\u00a050,007 \u00a0\u00a07,398 \u00a0\u00a0(874 )\u00a041,735 \u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(148,537 )\u00a0148,537 \u00a0\u00a0148,537 \u00a0\u00a030,468 \u00a0\u00a0\u2014 \u00a0\u00a0118,069 \u00a0\u00a00.57 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a07,329 \u00a0\u00a0(55,019 )\u00a0\u2014 \u00a0\u00a062,348 \u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "start_char_idx": 405, "end_char_idx": 1500, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95cd578f-bcc4-489e-9499-12d235fc7ff6": {"__data__": {"id_": "95cd578f-bcc4-489e-9499-12d235fc7ff6", "embedding": null, "metadata": {"window": "Adjusted\nNon-GAAP \u00a0$2,938,966 \u00a0\u00a0$1,615,492 \u00a0\u00a0$1,323,474 \u00a0\u00a0$1,253,621 \u00a0\u00a0$275,020 \u00a0\u00a0$(3,474 )\u00a0$975,127 \u00a0\u00a0$4.714\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a010.5 % \u00a08.2 % \u00a013.4 % \u00a014.0 % \u00a017.5 % \u00a0\u00a0 \u00a013.0 % \u00a013.2 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n\u00a0\u00a0\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n 2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 3Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n", "original_text": "Adjusted\nNon-GAAP \u00a0$2,938,966 \u00a0\u00a0$1,615,492 \u00a0\u00a0$1,323,474 \u00a0\u00a0$1,253,621 \u00a0\u00a0$275,020 \u00a0\u00a0$(3,474 )\u00a0$975,127 \u00a0\u00a0$4.714\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs. ", "page_label": "14", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7864a61f-7fc9-4b9b-bbff-7e463982f88a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "61e291b2a948f7154cfdfa2755cc4ad6ef9f12dd5d178be28e85f8cd819f32f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d459bb75-635a-466f-9a90-b3b7af307314", "node_type": "1", "metadata": {"window": "1Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$2,985,611 \u00a0\u00a0$1,814,036 \u00a0\u00a0$1,171,575 \u00a0\u00a0$1,094,393 \u00a0\u00a0$281,681 \u00a0\u00a0$(2,600 )\u00a0$810,112 \u00a0\u00a0$3.91\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(46,645 )\u00a0\u2014 \u00a0\u00a0(46,645 )\u00a0(46,645 )\u00a0(9,933 )\u00a0\u2014 \u00a0\u00a0(36,712 )\u00a0(0.18 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(50,007 )\u00a050,007 \u00a0\u00a050,007 \u00a0\u00a07,398 \u00a0\u00a0(874 )\u00a041,735 \u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(148,537 )\u00a0148,537 \u00a0\u00a0148,537 \u00a0\u00a030,468 \u00a0\u00a0\u2014 \u00a0\u00a0118,069 \u00a0\u00a00.57 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a07,329 \u00a0\u00a0(55,019 )\u00a0\u2014 \u00a0\u00a062,348 \u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$2,985,611 \u00a0\u00a0$1,814,036 \u00a0\u00a0$1,171,575 \u00a0\u00a0$1,094,393 \u00a0\u00a0$281,681 \u00a0\u00a0$(2,600 )\u00a0$810,112 \u00a0\u00a0$3.91\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(46,645 )\u00a0\u2014 \u00a0\u00a0(46,645 )\u00a0(46,645 )\u00a0(9,933 )\u00a0\u2014 \u00a0\u00a0(36,712 )\u00a0(0.18 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(50,007 )\u00a050,007 \u00a0\u00a050,007 \u00a0\u00a07,398 \u00a0\u00a0(874 )\u00a041,735 \u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(148,537 )\u00a0148,537 \u00a0\u00a0148,537 \u00a0\u00a030,468 \u00a0\u00a0\u2014 \u00a0\u00a0118,069 \u00a0\u00a00.57 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a07,329 \u00a0\u00a0(55,019 )\u00a0\u2014 \u00a0\u00a062,348 \u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "page_label": "13", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "66f657a436b15e7e928a81ce661b4243b8d806ca8960f11a90289eb77507d372", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e570085-3e40-4e1a-bc92-0dd4de9636aa", "node_type": "1", "metadata": {"window": "Adjusted\nNon-GAAP \u00a0$2,938,966 \u00a0\u00a0$1,615,492 \u00a0\u00a0$1,323,474 \u00a0\u00a0$1,253,621 \u00a0\u00a0$275,020 \u00a0\u00a0$(3,474 )\u00a0$975,127 \u00a0\u00a0$4.714\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a010.5 % \u00a08.2 % \u00a013.4 % \u00a014.0 % \u00a017.5 % \u00a0\u00a0 \u00a013.0 % \u00a013.2 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n\u00a0\u00a0\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n 2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 3Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n 4The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0", "original_text": "prior\nyear \u00a010.5 % \u00a08.2 % \u00a013.4 % \u00a014.0 % \u00a017.5 % \u00a0\u00a0 \u00a013.0 % \u00a013.2 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n\u00a0\u00a0\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n"}, "hash": "af415cc70475a531bee4c7ab758a9695313b4ac65e76a267d1f758842520ea85", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted\nNon-GAAP \u00a0$2,938,966 \u00a0\u00a0$1,615,492 \u00a0\u00a0$1,323,474 \u00a0\u00a0$1,253,621 \u00a0\u00a0$275,020 \u00a0\u00a0$(3,474 )\u00a0$975,127 \u00a0\u00a0$4.714\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs. ", "start_char_idx": 0, "end_char_idx": 169, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e570085-3e40-4e1a-bc92-0dd4de9636aa": {"__data__": {"id_": "3e570085-3e40-4e1a-bc92-0dd4de9636aa", "embedding": null, "metadata": {"window": "Adjusted\nNon-GAAP \u00a0$2,938,966 \u00a0\u00a0$1,615,492 \u00a0\u00a0$1,323,474 \u00a0\u00a0$1,253,621 \u00a0\u00a0$275,020 \u00a0\u00a0$(3,474 )\u00a0$975,127 \u00a0\u00a0$4.714\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a010.5 % \u00a08.2 % \u00a013.4 % \u00a014.0 % \u00a017.5 % \u00a0\u00a0 \u00a013.0 % \u00a013.2 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n\u00a0\u00a0\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n 2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 3Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n 4The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0", "original_text": "prior\nyear \u00a010.5 % \u00a08.2 % \u00a013.4 % \u00a014.0 % \u00a017.5 % \u00a0\u00a0 \u00a013.0 % \u00a013.2 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n\u00a0\u00a0\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n", "page_label": "14", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7864a61f-7fc9-4b9b-bbff-7e463982f88a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "61e291b2a948f7154cfdfa2755cc4ad6ef9f12dd5d178be28e85f8cd819f32f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95cd578f-bcc4-489e-9499-12d235fc7ff6", "node_type": "1", "metadata": {"window": "Adjusted\nNon-GAAP \u00a0$2,938,966 \u00a0\u00a0$1,615,492 \u00a0\u00a0$1,323,474 \u00a0\u00a0$1,253,621 \u00a0\u00a0$275,020 \u00a0\u00a0$(3,474 )\u00a0$975,127 \u00a0\u00a0$4.714\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a010.5 % \u00a08.2 % \u00a013.4 % \u00a014.0 % \u00a017.5 % \u00a0\u00a0 \u00a013.0 % \u00a013.2 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n\u00a0\u00a0\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n 2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 3Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n", "original_text": "Adjusted\nNon-GAAP \u00a0$2,938,966 \u00a0\u00a0$1,615,492 \u00a0\u00a0$1,323,474 \u00a0\u00a0$1,253,621 \u00a0\u00a0$275,020 \u00a0\u00a0$(3,474 )\u00a0$975,127 \u00a0\u00a0$4.714\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs. ", "page_label": "14", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fc5a3c8bd32c6718264cbf4a5880ad2a0965e377abef070837311543c70a8621", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0764c2e3-ba47-4654-b916-0ea3404d318f", "node_type": "1", "metadata": {"window": "Adjusted\nNon-GAAP \u00a0$2,938,966 \u00a0\u00a0$1,615,492 \u00a0\u00a0$1,323,474 \u00a0\u00a0$1,253,621 \u00a0\u00a0$275,020 \u00a0\u00a0$(3,474 )\u00a0$975,127 \u00a0\u00a0$4.714\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a010.5 % \u00a08.2 % \u00a013.4 % \u00a014.0 % \u00a017.5 % \u00a0\u00a0 \u00a013.0 % \u00a013.2 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n\u00a0\u00a0\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n 2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 3Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n 4The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n"}, "hash": "d1ebf037212ae77b95f9644decd24e80bcb3c6e7a6c78c8519ff8d4402546e42", "class_name": "RelatedNodeInfo"}}, "text": "prior\nyear \u00a010.5 % \u00a08.2 % \u00a013.4 % \u00a014.0 % \u00a017.5 % \u00a0\u00a0 \u00a013.0 % \u00a013.2 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n\u00a0\u00a0\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n", "start_char_idx": 169, "end_char_idx": 717, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0764c2e3-ba47-4654-b916-0ea3404d318f": {"__data__": {"id_": "0764c2e3-ba47-4654-b916-0ea3404d318f", "embedding": null, "metadata": {"window": "Adjusted\nNon-GAAP \u00a0$2,938,966 \u00a0\u00a0$1,615,492 \u00a0\u00a0$1,323,474 \u00a0\u00a0$1,253,621 \u00a0\u00a0$275,020 \u00a0\u00a0$(3,474 )\u00a0$975,127 \u00a0\u00a0$4.714\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a010.5 % \u00a08.2 % \u00a013.4 % \u00a014.0 % \u00a017.5 % \u00a0\u00a0 \u00a013.0 % \u00a013.2 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n\u00a0\u00a0\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n 2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 3Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n 4The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n", "page_label": "14", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7864a61f-7fc9-4b9b-bbff-7e463982f88a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "61e291b2a948f7154cfdfa2755cc4ad6ef9f12dd5d178be28e85f8cd819f32f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e570085-3e40-4e1a-bc92-0dd4de9636aa", "node_type": "1", "metadata": {"window": "Adjusted\nNon-GAAP \u00a0$2,938,966 \u00a0\u00a0$1,615,492 \u00a0\u00a0$1,323,474 \u00a0\u00a0$1,253,621 \u00a0\u00a0$275,020 \u00a0\u00a0$(3,474 )\u00a0$975,127 \u00a0\u00a0$4.714\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a010.5 % \u00a08.2 % \u00a013.4 % \u00a014.0 % \u00a017.5 % \u00a0\u00a0 \u00a013.0 % \u00a013.2 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n\u00a0\u00a0\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n 2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 3Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n 4The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0", "original_text": "prior\nyear \u00a010.5 % \u00a08.2 % \u00a013.4 % \u00a014.0 % \u00a017.5 % \u00a0\u00a0 \u00a013.0 % \u00a013.2 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n\u00a0\u00a0\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n", "page_label": "14", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "48425dbcf8f869402621163722295f168ab297d2126e70d3f6aaacea67b84154", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "605f0256-b86c-46e1-9934-4598088ffefc", "node_type": "1", "metadata": {"window": "Adjusted\nNon-GAAP \u00a0$2,938,966 \u00a0\u00a0$1,615,492 \u00a0\u00a0$1,323,474 \u00a0\u00a0$1,253,621 \u00a0\u00a0$275,020 \u00a0\u00a0$(3,474 )\u00a0$975,127 \u00a0\u00a0$4.714\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a010.5 % \u00a08.2 % \u00a013.4 % \u00a014.0 % \u00a017.5 % \u00a0\u00a0 \u00a013.0 % \u00a013.2 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n\u00a0\u00a0\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n 2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 3Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n 4The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n14", "original_text": "3Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n"}, "hash": "f5dfd5f9046b48a2e5e9f4605d6af7c137c7879b25e300d32b18f629c1d95ee1", "class_name": "RelatedNodeInfo"}}, "text": "2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n", "start_char_idx": 717, "end_char_idx": 872, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "605f0256-b86c-46e1-9934-4598088ffefc": {"__data__": {"id_": "605f0256-b86c-46e1-9934-4598088ffefc", "embedding": null, "metadata": {"window": "Adjusted\nNon-GAAP \u00a0$2,938,966 \u00a0\u00a0$1,615,492 \u00a0\u00a0$1,323,474 \u00a0\u00a0$1,253,621 \u00a0\u00a0$275,020 \u00a0\u00a0$(3,474 )\u00a0$975,127 \u00a0\u00a0$4.714\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a010.5 % \u00a08.2 % \u00a013.4 % \u00a014.0 % \u00a017.5 % \u00a0\u00a0 \u00a013.0 % \u00a013.2 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n\u00a0\u00a0\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n 2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 3Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n 4The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n14", "original_text": "3Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n", "page_label": "14", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7864a61f-7fc9-4b9b-bbff-7e463982f88a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "61e291b2a948f7154cfdfa2755cc4ad6ef9f12dd5d178be28e85f8cd819f32f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0764c2e3-ba47-4654-b916-0ea3404d318f", "node_type": "1", "metadata": {"window": "Adjusted\nNon-GAAP \u00a0$2,938,966 \u00a0\u00a0$1,615,492 \u00a0\u00a0$1,323,474 \u00a0\u00a0$1,253,621 \u00a0\u00a0$275,020 \u00a0\u00a0$(3,474 )\u00a0$975,127 \u00a0\u00a0$4.714\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a010.5 % \u00a08.2 % \u00a013.4 % \u00a014.0 % \u00a017.5 % \u00a0\u00a0 \u00a013.0 % \u00a013.2 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n\u00a0\u00a0\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n 2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 3Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n 4The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n", "page_label": "14", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "36bebc7d94d42b9396fcd53e134966a78d41190209fce59882c8bc015d97e734", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8aa05b61-df02-4069-8e23-042ac2fdf635", "node_type": "1", "metadata": {"window": "prior\nyear \u00a010.5 % \u00a08.2 % \u00a013.4 % \u00a014.0 % \u00a017.5 % \u00a0\u00a0 \u00a013.0 % \u00a013.2 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n\u00a0\u00a0\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n 2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 3Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n 4The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n14", "original_text": "4The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0"}, "hash": "ebb93d6e4ea425d3b763a18a8aabcaf9c0b388004fb4615a6aaa6a2e97759fdc", "class_name": "RelatedNodeInfo"}}, "text": "3Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n", "start_char_idx": 872, "end_char_idx": 1049, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8aa05b61-df02-4069-8e23-042ac2fdf635": {"__data__": {"id_": "8aa05b61-df02-4069-8e23-042ac2fdf635", "embedding": null, "metadata": {"window": "prior\nyear \u00a010.5 % \u00a08.2 % \u00a013.4 % \u00a014.0 % \u00a017.5 % \u00a0\u00a0 \u00a013.0 % \u00a013.2 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n\u00a0\u00a0\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n 2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 3Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n 4The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n14", "original_text": "4The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0", "page_label": "14", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7864a61f-7fc9-4b9b-bbff-7e463982f88a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "61e291b2a948f7154cfdfa2755cc4ad6ef9f12dd5d178be28e85f8cd819f32f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "605f0256-b86c-46e1-9934-4598088ffefc", "node_type": "1", "metadata": {"window": "Adjusted\nNon-GAAP \u00a0$2,938,966 \u00a0\u00a0$1,615,492 \u00a0\u00a0$1,323,474 \u00a0\u00a0$1,253,621 \u00a0\u00a0$275,020 \u00a0\u00a0$(3,474 )\u00a0$975,127 \u00a0\u00a0$4.714\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a010.5 % \u00a08.2 % \u00a013.4 % \u00a014.0 % \u00a017.5 % \u00a0\u00a0 \u00a013.0 % \u00a013.2 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n\u00a0\u00a0\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n 2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 3Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n 4The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n14", "original_text": "3Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n", "page_label": "14", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "901a791c8f35d763082c1d8011a91af7a4b911a8d8fb248ee5dd52153880e822", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf539da6-804d-46ee-a572-b561ab369e2d", "node_type": "1", "metadata": {"window": "2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 3Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n 4The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n14", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "b6ed25a86e302caf02c3d5e83527155c34a0fceff5f680c543223a6d620e401d", "class_name": "RelatedNodeInfo"}}, "text": "4The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0", "start_char_idx": 1049, "end_char_idx": 1122, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf539da6-804d-46ee-a572-b561ab369e2d": {"__data__": {"id_": "bf539da6-804d-46ee-a572-b561ab369e2d", "embedding": null, "metadata": {"window": "2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 3Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n 4The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n14", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "14", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7864a61f-7fc9-4b9b-bbff-7e463982f88a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "61e291b2a948f7154cfdfa2755cc4ad6ef9f12dd5d178be28e85f8cd819f32f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8aa05b61-df02-4069-8e23-042ac2fdf635", "node_type": "1", "metadata": {"window": "prior\nyear \u00a010.5 % \u00a08.2 % \u00a013.4 % \u00a014.0 % \u00a017.5 % \u00a0\u00a0 \u00a013.0 % \u00a013.2 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n\u00a0\u00a0\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n 2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 3Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n 4The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n14", "original_text": "4The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0", "page_label": "14", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ae2ae0950ca86d4075ddf06b0106d1034dd021dd8a9c05f32c259dd38a2743f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21a1c872-df2f-40d4-86cf-a2d485dfe92a", "node_type": "1", "metadata": {"window": "3Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n 4The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n14", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n14"}, "hash": "629971de2fe5245858f2a114e890ec91f5446b08cb4f32eba889f0ff963c3a45", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 1122, "end_char_idx": 1299, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21a1c872-df2f-40d4-86cf-a2d485dfe92a": {"__data__": {"id_": "21a1c872-df2f-40d4-86cf-a2d485dfe92a", "embedding": null, "metadata": {"window": "3Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n 4The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n14", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n14", "page_label": "14", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7864a61f-7fc9-4b9b-bbff-7e463982f88a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "61e291b2a948f7154cfdfa2755cc4ad6ef9f12dd5d178be28e85f8cd819f32f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf539da6-804d-46ee-a572-b561ab369e2d", "node_type": "1", "metadata": {"window": "2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 3Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n 4The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n14", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "14", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ad940839a33e39403e771fd7db4b76292631a137e9471272baecec33637d3b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc72b2a3-e214-48c7-b44d-d78ec53b0d14", "node_type": "1", "metadata": {"window": "(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2020\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed Earnings \n Per Shar e\nGAAP \u00a0$2,619,321 \u00a0\u00a0\u00a0$2,046,369 \u00a0\u00a0\u00a0$572,952 \u00a0\u00a0\u00a0$505,791 \u00a0\u00a0$(651,888 )\u00a0$(9,762 )\u00a0$1,147,917 \u00a0\u00a0$ 5.54 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,546 )\u00a0\u2014 \u00a0\u00a0\u00a0(8,546 )\u00a0\u00a0(8,546 )\u00a0(2,085 )\u00a0\u2014 \u00a0\u00a0(6,461 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a037,134 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a037,134 \u00a0\u00a0\u00a037,134 \u00a0\u00a09,059 \u00a0\u00a0\u2014 \u00a0\u00a028,075 \u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,124 \u00a0\u00a0\u00a0(36,511 )\u00a0\u00a048,635 \u00a0\u00a0\u00a048,635 \u00a0\u00a011,864 \u00a0\u00a0\u2014 \u00a0\u00a036,771 \u00a0\u00a00.18 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0\u00a0(60,236 )\u00a0\u00a060,236 \u00a0\u00a0\u00a060,236 \u00a0\u00a014,695 \u00a0\u00a0(871 )\u00a044,670 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0\u00a0(107,041 )\u00a0\u00a0107,041 \u00a0\u00a0\u00a0107,041 \u00a0\u00a026,114 \u00a0\u00a0\u2014 \u00a0\u00a080,927 \u00a0\u00a00.39 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u00a0(361,652 )\u00a0\u00a0361,652 \u00a0\u00a0\u00a0361,652 \u00a0\u00a088,227 \u00a0\u00a0\u2014 \u00a0\u00a0273,425 \u00a0\u00a01.32 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u00a012,153 \u00a0\u00a0\u00a0(12,153 )\u00a0\u00a0(12,153 )\u00a0(2,965 )\u00a07,511 \u00a0\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0741,015 \u00a0\u00a0\u2014 \u00a0\u00a0(741,015 )\u00a0(3.57 )\u00a0\n15", "original_text": "(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2020\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed Earnings \n Per Shar e\nGAAP \u00a0$2,619,321 \u00a0\u00a0\u00a0$2,046,369 \u00a0\u00a0\u00a0$572,952 \u00a0\u00a0\u00a0$505,791 \u00a0\u00a0$(651,888 )\u00a0$(9,762 )\u00a0$1,147,917 \u00a0\u00a0$ 5.54 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,546 )\u00a0\u2014 \u00a0\u00a0\u00a0(8,546 )\u00a0\u00a0(8,546 )\u00a0(2,085 )\u00a0\u2014 \u00a0\u00a0(6,461 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a037,134 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a037,134 \u00a0\u00a0\u00a037,134 \u00a0\u00a09,059 \u00a0\u00a0\u2014 \u00a0\u00a028,075 \u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,124 \u00a0\u00a0\u00a0(36,511 )\u00a0\u00a048,635 \u00a0\u00a0\u00a048,635 \u00a0\u00a011,864 \u00a0\u00a0\u2014 \u00a0\u00a036,771 \u00a0\u00a00.18 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0\u00a0(60,236 )\u00a0\u00a060,236 \u00a0\u00a0\u00a060,236 \u00a0\u00a014,695 \u00a0\u00a0(871 )\u00a044,670 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0\u00a0(107,041 )\u00a0\u00a0107,041 \u00a0\u00a0\u00a0107,041 \u00a0\u00a026,114 \u00a0\u00a0\u2014 \u00a0\u00a080,927 \u00a0\u00a00.39 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u00a0(361,652 )\u00a0\u00a0361,652 \u00a0\u00a0\u00a0361,652 \u00a0\u00a088,227 \u00a0\u00a0\u2014 \u00a0\u00a0273,425 \u00a0\u00a01.32 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u00a012,153 \u00a0\u00a0\u00a0(12,153 )\u00a0\u00a0(12,153 )\u00a0(2,965 )\u00a07,511 \u00a0\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0741,015 \u00a0\u00a0\u2014 \u00a0\u00a0(741,015 )\u00a0(3.57 )\u00a0\n15"}, "hash": "694d8f13537998884c72e781589ba6f0beedce2687b795b1a61645558db45273", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n14", "start_char_idx": 1299, "end_char_idx": 1364, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc72b2a3-e214-48c7-b44d-d78ec53b0d14": {"__data__": {"id_": "dc72b2a3-e214-48c7-b44d-d78ec53b0d14", "embedding": null, "metadata": {"window": "(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2020\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed Earnings \n Per Shar e\nGAAP \u00a0$2,619,321 \u00a0\u00a0\u00a0$2,046,369 \u00a0\u00a0\u00a0$572,952 \u00a0\u00a0\u00a0$505,791 \u00a0\u00a0$(651,888 )\u00a0$(9,762 )\u00a0$1,147,917 \u00a0\u00a0$ 5.54 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,546 )\u00a0\u2014 \u00a0\u00a0\u00a0(8,546 )\u00a0\u00a0(8,546 )\u00a0(2,085 )\u00a0\u2014 \u00a0\u00a0(6,461 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a037,134 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a037,134 \u00a0\u00a0\u00a037,134 \u00a0\u00a09,059 \u00a0\u00a0\u2014 \u00a0\u00a028,075 \u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,124 \u00a0\u00a0\u00a0(36,511 )\u00a0\u00a048,635 \u00a0\u00a0\u00a048,635 \u00a0\u00a011,864 \u00a0\u00a0\u2014 \u00a0\u00a036,771 \u00a0\u00a00.18 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0\u00a0(60,236 )\u00a0\u00a060,236 \u00a0\u00a0\u00a060,236 \u00a0\u00a014,695 \u00a0\u00a0(871 )\u00a044,670 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0\u00a0(107,041 )\u00a0\u00a0107,041 \u00a0\u00a0\u00a0107,041 \u00a0\u00a026,114 \u00a0\u00a0\u2014 \u00a0\u00a080,927 \u00a0\u00a00.39 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u00a0(361,652 )\u00a0\u00a0361,652 \u00a0\u00a0\u00a0361,652 \u00a0\u00a088,227 \u00a0\u00a0\u2014 \u00a0\u00a0273,425 \u00a0\u00a01.32 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u00a012,153 \u00a0\u00a0\u00a0(12,153 )\u00a0\u00a0(12,153 )\u00a0(2,965 )\u00a07,511 \u00a0\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0741,015 \u00a0\u00a0\u2014 \u00a0\u00a0(741,015 )\u00a0(3.57 )\u00a0\n15", "original_text": "(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2020\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed Earnings \n Per Shar e\nGAAP \u00a0$2,619,321 \u00a0\u00a0\u00a0$2,046,369 \u00a0\u00a0\u00a0$572,952 \u00a0\u00a0\u00a0$505,791 \u00a0\u00a0$(651,888 )\u00a0$(9,762 )\u00a0$1,147,917 \u00a0\u00a0$ 5.54 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,546 )\u00a0\u2014 \u00a0\u00a0\u00a0(8,546 )\u00a0\u00a0(8,546 )\u00a0(2,085 )\u00a0\u2014 \u00a0\u00a0(6,461 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a037,134 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a037,134 \u00a0\u00a0\u00a037,134 \u00a0\u00a09,059 \u00a0\u00a0\u2014 \u00a0\u00a028,075 \u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,124 \u00a0\u00a0\u00a0(36,511 )\u00a0\u00a048,635 \u00a0\u00a0\u00a048,635 \u00a0\u00a011,864 \u00a0\u00a0\u2014 \u00a0\u00a036,771 \u00a0\u00a00.18 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0\u00a0(60,236 )\u00a0\u00a060,236 \u00a0\u00a0\u00a060,236 \u00a0\u00a014,695 \u00a0\u00a0(871 )\u00a044,670 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0\u00a0(107,041 )\u00a0\u00a0107,041 \u00a0\u00a0\u00a0107,041 \u00a0\u00a026,114 \u00a0\u00a0\u2014 \u00a0\u00a080,927 \u00a0\u00a00.39 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u00a0(361,652 )\u00a0\u00a0361,652 \u00a0\u00a0\u00a0361,652 \u00a0\u00a088,227 \u00a0\u00a0\u2014 \u00a0\u00a0273,425 \u00a0\u00a01.32 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u00a012,153 \u00a0\u00a0\u00a0(12,153 )\u00a0\u00a0(12,153 )\u00a0(2,965 )\u00a07,511 \u00a0\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0741,015 \u00a0\u00a0\u2014 \u00a0\u00a0(741,015 )\u00a0(3.57 )\u00a0\n15", "page_label": "15", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "11e6f6d8-10f0-42f8-874f-446d356ceb59", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f0a8e9287357d0db353434644f965c6e84f911412c37aa27aaa41fce23071ef4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21a1c872-df2f-40d4-86cf-a2d485dfe92a", "node_type": "1", "metadata": {"window": "3Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n 4The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n14", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n14", "page_label": "14", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d93fab1883d4f028d57a41ddf56f6eafe8d44fb8e023102ece3984d702e4d671", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03ff985c-03fa-418e-906d-be2ed3f769c2", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,660,033 \u00a0\u00a0\u00a0$1,493,082 \u00a0\u00a0\u00a0$1,166,951 \u00a0\u00a0\u00a0$1,099,790 \u00a0\u00a0$234,036 \u00a0\u00a0$(3,122 )\u00a0$862,632 \u00a0\u00a0$ 4.16 2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a02021 \u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$47,101,331 \u00a0\u00a0\u00a0$45,562,670 \u00a0\u00a03.4 %\nOther \u00a02,092,772 \u00a0\u00a0\u00a01,876,593 \u00a0\u00a011.5 %\nIntersegment eliminations \u00a0(39,932 )\u00a0\u00a0\u00a0(21,624 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$49,154,171 \u00a0\u00a0\u00a0$47,417,639 \u00a0\u00a03.7 %\n16", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,660,033 \u00a0\u00a0\u00a0$1,493,082 \u00a0\u00a0\u00a0$1,166,951 \u00a0\u00a0\u00a0$1,099,790 \u00a0\u00a0$234,036 \u00a0\u00a0$(3,122 )\u00a0$862,632 \u00a0\u00a0$ 4.16 2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n"}, "hash": "e0ee82a924b04ccaf6a90203a2e421232c57482ad304f579585026772c63bae2", "class_name": "RelatedNodeInfo"}}, "text": "(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2020\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed Earnings \n Per Shar e\nGAAP \u00a0$2,619,321 \u00a0\u00a0\u00a0$2,046,369 \u00a0\u00a0\u00a0$572,952 \u00a0\u00a0\u00a0$505,791 \u00a0\u00a0$(651,888 )\u00a0$(9,762 )\u00a0$1,147,917 \u00a0\u00a0$ 5.54 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,546 )\u00a0\u2014 \u00a0\u00a0\u00a0(8,546 )\u00a0\u00a0(8,546 )\u00a0(2,085 )\u00a0\u2014 \u00a0\u00a0(6,461 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a037,134 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a037,134 \u00a0\u00a0\u00a037,134 \u00a0\u00a09,059 \u00a0\u00a0\u2014 \u00a0\u00a028,075 \u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,124 \u00a0\u00a0\u00a0(36,511 )\u00a0\u00a048,635 \u00a0\u00a0\u00a048,635 \u00a0\u00a011,864 \u00a0\u00a0\u2014 \u00a0\u00a036,771 \u00a0\u00a00.18 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0\u00a0(60,236 )\u00a0\u00a060,236 \u00a0\u00a0\u00a060,236 \u00a0\u00a014,695 \u00a0\u00a0(871 )\u00a044,670 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0\u00a0(107,041 )\u00a0\u00a0107,041 \u00a0\u00a0\u00a0107,041 \u00a0\u00a026,114 \u00a0\u00a0\u2014 \u00a0\u00a080,927 \u00a0\u00a00.39 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u00a0(361,652 )\u00a0\u00a0361,652 \u00a0\u00a0\u00a0361,652 \u00a0\u00a088,227 \u00a0\u00a0\u2014 \u00a0\u00a0273,425 \u00a0\u00a01.32 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u00a012,153 \u00a0\u00a0\u00a0(12,153 )\u00a0\u00a0(12,153 )\u00a0(2,965 )\u00a07,511 \u00a0\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0741,015 \u00a0\u00a0\u2014 \u00a0\u00a0(741,015 )\u00a0(3.57 )\u00a0\n15", "start_char_idx": 0, "end_char_idx": 1488, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03ff985c-03fa-418e-906d-be2ed3f769c2": {"__data__": {"id_": "03ff985c-03fa-418e-906d-be2ed3f769c2", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,660,033 \u00a0\u00a0\u00a0$1,493,082 \u00a0\u00a0\u00a0$1,166,951 \u00a0\u00a0\u00a0$1,099,790 \u00a0\u00a0$234,036 \u00a0\u00a0$(3,122 )\u00a0$862,632 \u00a0\u00a0$ 4.16 2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a02021 \u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$47,101,331 \u00a0\u00a0\u00a0$45,562,670 \u00a0\u00a03.4 %\nOther \u00a02,092,772 \u00a0\u00a0\u00a01,876,593 \u00a0\u00a011.5 %\nIntersegment eliminations \u00a0(39,932 )\u00a0\u00a0\u00a0(21,624 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$49,154,171 \u00a0\u00a0\u00a0$47,417,639 \u00a0\u00a03.7 %\n16", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,660,033 \u00a0\u00a0\u00a0$1,493,082 \u00a0\u00a0\u00a0$1,166,951 \u00a0\u00a0\u00a0$1,099,790 \u00a0\u00a0$234,036 \u00a0\u00a0$(3,122 )\u00a0$862,632 \u00a0\u00a0$ 4.16 2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n", "page_label": "16", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c25fe30-2e61-4f35-9843-0d422ef324be", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7517472cea68954061d0cbef2462878077b46e043d3ee4de1c99a571585e947c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc72b2a3-e214-48c7-b44d-d78ec53b0d14", "node_type": "1", "metadata": {"window": "(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2020\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed Earnings \n Per Shar e\nGAAP \u00a0$2,619,321 \u00a0\u00a0\u00a0$2,046,369 \u00a0\u00a0\u00a0$572,952 \u00a0\u00a0\u00a0$505,791 \u00a0\u00a0$(651,888 )\u00a0$(9,762 )\u00a0$1,147,917 \u00a0\u00a0$ 5.54 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,546 )\u00a0\u2014 \u00a0\u00a0\u00a0(8,546 )\u00a0\u00a0(8,546 )\u00a0(2,085 )\u00a0\u2014 \u00a0\u00a0(6,461 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a037,134 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a037,134 \u00a0\u00a0\u00a037,134 \u00a0\u00a09,059 \u00a0\u00a0\u2014 \u00a0\u00a028,075 \u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,124 \u00a0\u00a0\u00a0(36,511 )\u00a0\u00a048,635 \u00a0\u00a0\u00a048,635 \u00a0\u00a011,864 \u00a0\u00a0\u2014 \u00a0\u00a036,771 \u00a0\u00a00.18 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0\u00a0(60,236 )\u00a0\u00a060,236 \u00a0\u00a0\u00a060,236 \u00a0\u00a014,695 \u00a0\u00a0(871 )\u00a044,670 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0\u00a0(107,041 )\u00a0\u00a0107,041 \u00a0\u00a0\u00a0107,041 \u00a0\u00a026,114 \u00a0\u00a0\u2014 \u00a0\u00a080,927 \u00a0\u00a00.39 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u00a0(361,652 )\u00a0\u00a0361,652 \u00a0\u00a0\u00a0361,652 \u00a0\u00a088,227 \u00a0\u00a0\u2014 \u00a0\u00a0273,425 \u00a0\u00a01.32 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u00a012,153 \u00a0\u00a0\u00a0(12,153 )\u00a0\u00a0(12,153 )\u00a0(2,965 )\u00a07,511 \u00a0\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0741,015 \u00a0\u00a0\u2014 \u00a0\u00a0(741,015 )\u00a0(3.57 )\u00a0\n15", "original_text": "(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2020\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed Earnings \n Per Shar e\nGAAP \u00a0$2,619,321 \u00a0\u00a0\u00a0$2,046,369 \u00a0\u00a0\u00a0$572,952 \u00a0\u00a0\u00a0$505,791 \u00a0\u00a0$(651,888 )\u00a0$(9,762 )\u00a0$1,147,917 \u00a0\u00a0$ 5.54 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,546 )\u00a0\u2014 \u00a0\u00a0\u00a0(8,546 )\u00a0\u00a0(8,546 )\u00a0(2,085 )\u00a0\u2014 \u00a0\u00a0(6,461 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a037,134 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a037,134 \u00a0\u00a0\u00a037,134 \u00a0\u00a09,059 \u00a0\u00a0\u2014 \u00a0\u00a028,075 \u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,124 \u00a0\u00a0\u00a0(36,511 )\u00a0\u00a048,635 \u00a0\u00a0\u00a048,635 \u00a0\u00a011,864 \u00a0\u00a0\u2014 \u00a0\u00a036,771 \u00a0\u00a00.18 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0\u00a0(60,236 )\u00a0\u00a060,236 \u00a0\u00a0\u00a060,236 \u00a0\u00a014,695 \u00a0\u00a0(871 )\u00a044,670 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0\u00a0(107,041 )\u00a0\u00a0107,041 \u00a0\u00a0\u00a0107,041 \u00a0\u00a026,114 \u00a0\u00a0\u2014 \u00a0\u00a080,927 \u00a0\u00a00.39 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u00a0(361,652 )\u00a0\u00a0361,652 \u00a0\u00a0\u00a0361,652 \u00a0\u00a088,227 \u00a0\u00a0\u2014 \u00a0\u00a0273,425 \u00a0\u00a01.32 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u00a012,153 \u00a0\u00a0\u00a0(12,153 )\u00a0\u00a0(12,153 )\u00a0(2,965 )\u00a07,511 \u00a0\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0741,015 \u00a0\u00a0\u2014 \u00a0\u00a0(741,015 )\u00a0(3.57 )\u00a0\n15", "page_label": "15", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d60d266f17c41a11e01a1b98b7488c38b7bab6a9c29a270845248c5353e60e82", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36551470-2787-4664-bb36-e1ee344acd28", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,660,033 \u00a0\u00a0\u00a0$1,493,082 \u00a0\u00a0\u00a0$1,166,951 \u00a0\u00a0\u00a0$1,099,790 \u00a0\u00a0$234,036 \u00a0\u00a0$(3,122 )\u00a0$862,632 \u00a0\u00a0$ 4.16 2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a02021 \u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$47,101,331 \u00a0\u00a0\u00a0$45,562,670 \u00a0\u00a03.4 %\nOther \u00a02,092,772 \u00a0\u00a0\u00a01,876,593 \u00a0\u00a011.5 %\nIntersegment eliminations \u00a0(39,932 )\u00a0\u00a0\u00a0(21,624 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$49,154,171 \u00a0\u00a0\u00a0$47,417,639 \u00a0\u00a03.7 %\n16", "original_text": "2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0"}, "hash": "db85a8bae76e98004e6bd9283f0771a556de35a6ecd71533d4c18965dc1a59f7", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,660,033 \u00a0\u00a0\u00a0$1,493,082 \u00a0\u00a0\u00a0$1,166,951 \u00a0\u00a0\u00a0$1,099,790 \u00a0\u00a0$234,036 \u00a0\u00a0$(3,122 )\u00a0$862,632 \u00a0\u00a0$ 4.16 2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n", "start_char_idx": 0, "end_char_idx": 483, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36551470-2787-4664-bb36-e1ee344acd28": {"__data__": {"id_": "36551470-2787-4664-bb36-e1ee344acd28", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,660,033 \u00a0\u00a0\u00a0$1,493,082 \u00a0\u00a0\u00a0$1,166,951 \u00a0\u00a0\u00a0$1,099,790 \u00a0\u00a0$234,036 \u00a0\u00a0$(3,122 )\u00a0$862,632 \u00a0\u00a0$ 4.16 2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a02021 \u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$47,101,331 \u00a0\u00a0\u00a0$45,562,670 \u00a0\u00a03.4 %\nOther \u00a02,092,772 \u00a0\u00a0\u00a01,876,593 \u00a0\u00a011.5 %\nIntersegment eliminations \u00a0(39,932 )\u00a0\u00a0\u00a0(21,624 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$49,154,171 \u00a0\u00a0\u00a0$47,417,639 \u00a0\u00a03.7 %\n16", "original_text": "2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0", "page_label": "16", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c25fe30-2e61-4f35-9843-0d422ef324be", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7517472cea68954061d0cbef2462878077b46e043d3ee4de1c99a571585e947c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03ff985c-03fa-418e-906d-be2ed3f769c2", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,660,033 \u00a0\u00a0\u00a0$1,493,082 \u00a0\u00a0\u00a0$1,166,951 \u00a0\u00a0\u00a0$1,099,790 \u00a0\u00a0$234,036 \u00a0\u00a0$(3,122 )\u00a0$862,632 \u00a0\u00a0$ 4.16 2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a02021 \u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$47,101,331 \u00a0\u00a0\u00a0$45,562,670 \u00a0\u00a03.4 %\nOther \u00a02,092,772 \u00a0\u00a0\u00a01,876,593 \u00a0\u00a011.5 %\nIntersegment eliminations \u00a0(39,932 )\u00a0\u00a0\u00a0(21,624 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$49,154,171 \u00a0\u00a0\u00a0$47,417,639 \u00a0\u00a03.7 %\n16", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,660,033 \u00a0\u00a0\u00a0$1,493,082 \u00a0\u00a0\u00a0$1,166,951 \u00a0\u00a0\u00a0$1,099,790 \u00a0\u00a0$234,036 \u00a0\u00a0$(3,122 )\u00a0$862,632 \u00a0\u00a0$ 4.16 2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n", "page_label": "16", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "47c067ba4c671f23488cfb9efbc97bc4cf02394df7ff53cb9019e83bf773ab0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "486bedbc-de31-4d74-8a55-76f13bc30518", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,660,033 \u00a0\u00a0\u00a0$1,493,082 \u00a0\u00a0\u00a0$1,166,951 \u00a0\u00a0\u00a0$1,099,790 \u00a0\u00a0$234,036 \u00a0\u00a0$(3,122 )\u00a0$862,632 \u00a0\u00a0$ 4.16 2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a02021 \u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$47,101,331 \u00a0\u00a0\u00a0$45,562,670 \u00a0\u00a03.4 %\nOther \u00a02,092,772 \u00a0\u00a0\u00a01,876,593 \u00a0\u00a011.5 %\nIntersegment eliminations \u00a0(39,932 )\u00a0\u00a0\u00a0(21,624 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$49,154,171 \u00a0\u00a0\u00a0$47,417,639 \u00a0\u00a03.7 %\n16", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "c6fd8f3e718a38c65e86c5064e42db713e6df88062add7e816cc58c0ce9dc60f", "class_name": "RelatedNodeInfo"}}, "text": "2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0", "start_char_idx": 483, "end_char_idx": 556, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "486bedbc-de31-4d74-8a55-76f13bc30518": {"__data__": {"id_": "486bedbc-de31-4d74-8a55-76f13bc30518", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,660,033 \u00a0\u00a0\u00a0$1,493,082 \u00a0\u00a0\u00a0$1,166,951 \u00a0\u00a0\u00a0$1,099,790 \u00a0\u00a0$234,036 \u00a0\u00a0$(3,122 )\u00a0$862,632 \u00a0\u00a0$ 4.16 2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a02021 \u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$47,101,331 \u00a0\u00a0\u00a0$45,562,670 \u00a0\u00a03.4 %\nOther \u00a02,092,772 \u00a0\u00a0\u00a01,876,593 \u00a0\u00a011.5 %\nIntersegment eliminations \u00a0(39,932 )\u00a0\u00a0\u00a0(21,624 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$49,154,171 \u00a0\u00a0\u00a0$47,417,639 \u00a0\u00a03.7 %\n16", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "16", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c25fe30-2e61-4f35-9843-0d422ef324be", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7517472cea68954061d0cbef2462878077b46e043d3ee4de1c99a571585e947c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36551470-2787-4664-bb36-e1ee344acd28", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,660,033 \u00a0\u00a0\u00a0$1,493,082 \u00a0\u00a0\u00a0$1,166,951 \u00a0\u00a0\u00a0$1,099,790 \u00a0\u00a0$234,036 \u00a0\u00a0$(3,122 )\u00a0$862,632 \u00a0\u00a0$ 4.16 2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a02021 \u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$47,101,331 \u00a0\u00a0\u00a0$45,562,670 \u00a0\u00a03.4 %\nOther \u00a02,092,772 \u00a0\u00a0\u00a01,876,593 \u00a0\u00a011.5 %\nIntersegment eliminations \u00a0(39,932 )\u00a0\u00a0\u00a0(21,624 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$49,154,171 \u00a0\u00a0\u00a0$47,417,639 \u00a0\u00a03.7 %\n16", "original_text": "2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0", "page_label": "16", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5697633690a36b5dc9e6a7c4f43009d19b3f4771819ab2e58fe636b8e94ff23", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "235025b7-e802-4183-8a69-a112946adf01", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,660,033 \u00a0\u00a0\u00a0$1,493,082 \u00a0\u00a0\u00a0$1,166,951 \u00a0\u00a0\u00a0$1,099,790 \u00a0\u00a0$234,036 \u00a0\u00a0$(3,122 )\u00a0$862,632 \u00a0\u00a0$ 4.16 2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a02021 \u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$47,101,331 \u00a0\u00a0\u00a0$45,562,670 \u00a0\u00a03.4 %\nOther \u00a02,092,772 \u00a0\u00a0\u00a01,876,593 \u00a0\u00a011.5 %\nIntersegment eliminations \u00a0(39,932 )\u00a0\u00a0\u00a0(21,624 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$49,154,171 \u00a0\u00a0\u00a0$47,417,639 \u00a0\u00a03.7 %\n16", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a02021 \u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$47,101,331 \u00a0\u00a0\u00a0$45,562,670 \u00a0\u00a03.4 %\nOther \u00a02,092,772 \u00a0\u00a0\u00a01,876,593 \u00a0\u00a011.5 %\nIntersegment eliminations \u00a0(39,932 )\u00a0\u00a0\u00a0(21,624 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$49,154,171 \u00a0\u00a0\u00a0$47,417,639 \u00a0\u00a03.7 %\n16"}, "hash": "f09599a3cee5ef757990677c6389e40c4aa7ce68be496d42493f9884c71b7972", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 556, "end_char_idx": 733, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "235025b7-e802-4183-8a69-a112946adf01": {"__data__": {"id_": "235025b7-e802-4183-8a69-a112946adf01", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,660,033 \u00a0\u00a0\u00a0$1,493,082 \u00a0\u00a0\u00a0$1,166,951 \u00a0\u00a0\u00a0$1,099,790 \u00a0\u00a0$234,036 \u00a0\u00a0$(3,122 )\u00a0$862,632 \u00a0\u00a0$ 4.16 2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a02021 \u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$47,101,331 \u00a0\u00a0\u00a0$45,562,670 \u00a0\u00a03.4 %\nOther \u00a02,092,772 \u00a0\u00a0\u00a01,876,593 \u00a0\u00a011.5 %\nIntersegment eliminations \u00a0(39,932 )\u00a0\u00a0\u00a0(21,624 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$49,154,171 \u00a0\u00a0\u00a0$47,417,639 \u00a0\u00a03.7 %\n16", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a02021 \u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$47,101,331 \u00a0\u00a0\u00a0$45,562,670 \u00a0\u00a03.4 %\nOther \u00a02,092,772 \u00a0\u00a0\u00a01,876,593 \u00a0\u00a011.5 %\nIntersegment eliminations \u00a0(39,932 )\u00a0\u00a0\u00a0(21,624 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$49,154,171 \u00a0\u00a0\u00a0$47,417,639 \u00a0\u00a03.7 %\n16", "page_label": "16", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c25fe30-2e61-4f35-9843-0d422ef324be", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7517472cea68954061d0cbef2462878077b46e043d3ee4de1c99a571585e947c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "486bedbc-de31-4d74-8a55-76f13bc30518", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,660,033 \u00a0\u00a0\u00a0$1,493,082 \u00a0\u00a0\u00a0$1,166,951 \u00a0\u00a0\u00a0$1,099,790 \u00a0\u00a0$234,036 \u00a0\u00a0$(3,122 )\u00a0$862,632 \u00a0\u00a0$ 4.16 2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a02021 \u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$47,101,331 \u00a0\u00a0\u00a0$45,562,670 \u00a0\u00a03.4 %\nOther \u00a02,092,772 \u00a0\u00a0\u00a01,876,593 \u00a0\u00a011.5 %\nIntersegment eliminations \u00a0(39,932 )\u00a0\u00a0\u00a0(21,624 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$49,154,171 \u00a0\u00a0\u00a0$47,417,639 \u00a0\u00a03.7 %\n16", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "16", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5cc76ad2b2b7855d4fe8fe578d7c98fb583ff5be4902e96e1a853b1be7b4c8e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b81bcff-eb29-4d01-80cd-daaf8bd46e9c", "node_type": "1", "metadata": {"window": "\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a02021 \u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$589,033 \u00a0\u00a0\u00a0$563,097 \u00a0\u00a04.6 %\nOther \u00a0123,180 \u00a0\u00a0\u00a0108,260 \u00a0\u00a013.8 %\nIntersegment eliminations \u00a0(5,655 )\u00a0\u00a0328 \u00a0\u00a0\u00a0\nTotal segment operating income \u00a0706,558 \u00a0\u00a0\u00a0671,685 \u00a0\u00a05.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a0\u00a054 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a020,918 \u00a0\u00a0\u00a0(23,853 )\u00a0\u00a0\nPharMEDium shutdown costs \u00a0\u2014 \u00a0\u00a0\u00a0(32,470 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(24,973 )\u00a0\u00a0(26,670 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(78,156 )\u00a0\u00a0(67,732 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0(223,652 )\u00a0\u00a0\nContingent consideration adjustment \u00a0\u2014 \u00a0\u00a0\u00a012,153 \u00a0\u00a0\u00a0\nOperating income \u00a0$624,347 \u00a0\u00a0\u00a0$309,515 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.39 \u00a0%\u00a02.32 %\u00a0\u00a0\nOperating expenses \u00a01.14 \u00a0%\u00a01.08 %\u00a0\u00a0\nOperating income \u00a01.25 \u00a0%\u00a01.24 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.81 \u00a0%\u00a019.15 %\u00a0\u00a0\nOperating expenses \u00a012.92 \u00a0%\u00a013.38 %\u00a0\u00a0\nOperating income \u00a05.89 \u00a0%\u00a05.77 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n17", "original_text": "\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a02021 \u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$589,033 \u00a0\u00a0\u00a0$563,097 \u00a0\u00a04.6 %\nOther \u00a0123,180 \u00a0\u00a0\u00a0108,260 \u00a0\u00a013.8 %\nIntersegment eliminations \u00a0(5,655 )\u00a0\u00a0328 \u00a0\u00a0\u00a0\nTotal segment operating income \u00a0706,558 \u00a0\u00a0\u00a0671,685 \u00a0\u00a05.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a0\u00a054 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a020,918 \u00a0\u00a0\u00a0(23,853 )\u00a0\u00a0\nPharMEDium shutdown costs \u00a0\u2014 \u00a0\u00a0\u00a0(32,470 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(24,973 )\u00a0\u00a0(26,670 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(78,156 )\u00a0\u00a0(67,732 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0(223,652 )\u00a0\u00a0\nContingent consideration adjustment \u00a0\u2014 \u00a0\u00a0\u00a012,153 \u00a0\u00a0\u00a0\nOperating income \u00a0$624,347 \u00a0\u00a0\u00a0$309,515 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.39 \u00a0%\u00a02.32 %\u00a0\u00a0\nOperating expenses \u00a01.14 \u00a0%\u00a01.08 %\u00a0\u00a0\nOperating income \u00a01.25 \u00a0%\u00a01.24 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.81 \u00a0%\u00a019.15 %\u00a0\u00a0\nOperating expenses \u00a012.92 \u00a0%\u00a013.38 %\u00a0\u00a0\nOperating income \u00a05.89 \u00a0%\u00a05.77 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n17"}, "hash": "f54ce66d720d3e81b700f492530528b76af1efcf6533e8fe4b72448d5eb533ae", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a02021 \u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$47,101,331 \u00a0\u00a0\u00a0$45,562,670 \u00a0\u00a03.4 %\nOther \u00a02,092,772 \u00a0\u00a0\u00a01,876,593 \u00a0\u00a011.5 %\nIntersegment eliminations \u00a0(39,932 )\u00a0\u00a0\u00a0(21,624 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$49,154,171 \u00a0\u00a0\u00a0$47,417,639 \u00a0\u00a03.7 %\n16", "start_char_idx": 733, "end_char_idx": 1109, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b81bcff-eb29-4d01-80cd-daaf8bd46e9c": {"__data__": {"id_": "5b81bcff-eb29-4d01-80cd-daaf8bd46e9c", "embedding": null, "metadata": {"window": "\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a02021 \u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$589,033 \u00a0\u00a0\u00a0$563,097 \u00a0\u00a04.6 %\nOther \u00a0123,180 \u00a0\u00a0\u00a0108,260 \u00a0\u00a013.8 %\nIntersegment eliminations \u00a0(5,655 )\u00a0\u00a0328 \u00a0\u00a0\u00a0\nTotal segment operating income \u00a0706,558 \u00a0\u00a0\u00a0671,685 \u00a0\u00a05.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a0\u00a054 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a020,918 \u00a0\u00a0\u00a0(23,853 )\u00a0\u00a0\nPharMEDium shutdown costs \u00a0\u2014 \u00a0\u00a0\u00a0(32,470 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(24,973 )\u00a0\u00a0(26,670 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(78,156 )\u00a0\u00a0(67,732 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0(223,652 )\u00a0\u00a0\nContingent consideration adjustment \u00a0\u2014 \u00a0\u00a0\u00a012,153 \u00a0\u00a0\u00a0\nOperating income \u00a0$624,347 \u00a0\u00a0\u00a0$309,515 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.39 \u00a0%\u00a02.32 %\u00a0\u00a0\nOperating expenses \u00a01.14 \u00a0%\u00a01.08 %\u00a0\u00a0\nOperating income \u00a01.25 \u00a0%\u00a01.24 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.81 \u00a0%\u00a019.15 %\u00a0\u00a0\nOperating expenses \u00a012.92 \u00a0%\u00a013.38 %\u00a0\u00a0\nOperating income \u00a05.89 \u00a0%\u00a05.77 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n17", "original_text": "\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a02021 \u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$589,033 \u00a0\u00a0\u00a0$563,097 \u00a0\u00a04.6 %\nOther \u00a0123,180 \u00a0\u00a0\u00a0108,260 \u00a0\u00a013.8 %\nIntersegment eliminations \u00a0(5,655 )\u00a0\u00a0328 \u00a0\u00a0\u00a0\nTotal segment operating income \u00a0706,558 \u00a0\u00a0\u00a0671,685 \u00a0\u00a05.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a0\u00a054 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a020,918 \u00a0\u00a0\u00a0(23,853 )\u00a0\u00a0\nPharMEDium shutdown costs \u00a0\u2014 \u00a0\u00a0\u00a0(32,470 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(24,973 )\u00a0\u00a0(26,670 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(78,156 )\u00a0\u00a0(67,732 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0(223,652 )\u00a0\u00a0\nContingent consideration adjustment \u00a0\u2014 \u00a0\u00a0\u00a012,153 \u00a0\u00a0\u00a0\nOperating income \u00a0$624,347 \u00a0\u00a0\u00a0$309,515 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.39 \u00a0%\u00a02.32 %\u00a0\u00a0\nOperating expenses \u00a01.14 \u00a0%\u00a01.08 %\u00a0\u00a0\nOperating income \u00a01.25 \u00a0%\u00a01.24 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.81 \u00a0%\u00a019.15 %\u00a0\u00a0\nOperating expenses \u00a012.92 \u00a0%\u00a013.38 %\u00a0\u00a0\nOperating income \u00a05.89 \u00a0%\u00a05.77 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n17", "page_label": "17", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "885760b4-c525-41c4-a6df-5e5e52416695", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a94e4344e3386bfc9b803f74b218e578a6fd87d0882d371c6c48975c7955a622", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "235025b7-e802-4183-8a69-a112946adf01", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,660,033 \u00a0\u00a0\u00a0$1,493,082 \u00a0\u00a0\u00a0$1,166,951 \u00a0\u00a0\u00a0$1,099,790 \u00a0\u00a0$234,036 \u00a0\u00a0$(3,122 )\u00a0$862,632 \u00a0\u00a0$ 4.16 2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a02021 \u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$47,101,331 \u00a0\u00a0\u00a0$45,562,670 \u00a0\u00a03.4 %\nOther \u00a02,092,772 \u00a0\u00a0\u00a01,876,593 \u00a0\u00a011.5 %\nIntersegment eliminations \u00a0(39,932 )\u00a0\u00a0\u00a0(21,624 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$49,154,171 \u00a0\u00a0\u00a0$47,417,639 \u00a0\u00a03.7 %\n16", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a02021 \u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$47,101,331 \u00a0\u00a0\u00a0$45,562,670 \u00a0\u00a03.4 %\nOther \u00a02,092,772 \u00a0\u00a0\u00a01,876,593 \u00a0\u00a011.5 %\nIntersegment eliminations \u00a0(39,932 )\u00a0\u00a0\u00a0(21,624 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$49,154,171 \u00a0\u00a0\u00a0$47,417,639 \u00a0\u00a03.7 %\n16", "page_label": "16", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6184b3293b8e5d5a5de760290b6e8c4e7cc1991e67043efff3f71c6946196ec0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d49302b0-99a8-4234-b8ea-b5053cc69c0a", "node_type": "1", "metadata": {"window": "AmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.12 \u00a0%\u00a02.93 %\u00a0\u00a0\nOperating expenses \u00a01.85 \u00a0%\u00a02.27 %\u00a0\u00a0\nOperating income \u00a01.27 \u00a0%\u00a00.65 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.08 \u00a0%\u00a02.99 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.64 \u00a0%\u00a01.57 %\u00a0\u00a0\nAdjusted operating income \u00a01.44 \u00a0%\u00a01.42 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a02021 \u00a0\u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$97,593,841 \u00a0\u00a0$91,599,498 \u00a0\u00a06.5 %\nOther \u00a04,145,046 \u00a0\u00a03,723,577 \u00a0\u00a011.3 %\nIntersegment eliminations \u00a0(68,160 )(40,694 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nRevenue \u00a0$101,670,727 \u00a0\u00a0$95,282,381 \u00a0\u00a06.7 %\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, \u00a0\nOperating income \u00a02021 \u00a0\u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$1,085,100 \u00a0\u00a0$954,791 \u00a0\u00a013.6 %\nOther \u00a0244,827 \u00a0\u00a0212,739 \u00a0\u00a015.1 %\n18", "original_text": "AmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.12 \u00a0%\u00a02.93 %\u00a0\u00a0\nOperating expenses \u00a01.85 \u00a0%\u00a02.27 %\u00a0\u00a0\nOperating income \u00a01.27 \u00a0%\u00a00.65 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.08 \u00a0%\u00a02.99 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.64 \u00a0%\u00a01.57 %\u00a0\u00a0\nAdjusted operating income \u00a01.44 \u00a0%\u00a01.42 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "b31f388693fda6fffea1e5d09fe5b919bde1d26a55a11ae9261dfceb8b4f2a9d", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a02021 \u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$589,033 \u00a0\u00a0\u00a0$563,097 \u00a0\u00a04.6 %\nOther \u00a0123,180 \u00a0\u00a0\u00a0108,260 \u00a0\u00a013.8 %\nIntersegment eliminations \u00a0(5,655 )\u00a0\u00a0328 \u00a0\u00a0\u00a0\nTotal segment operating income \u00a0706,558 \u00a0\u00a0\u00a0671,685 \u00a0\u00a05.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a0\u00a054 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a020,918 \u00a0\u00a0\u00a0(23,853 )\u00a0\u00a0\nPharMEDium shutdown costs \u00a0\u2014 \u00a0\u00a0\u00a0(32,470 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(24,973 )\u00a0\u00a0(26,670 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(78,156 )\u00a0\u00a0(67,732 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0(223,652 )\u00a0\u00a0\nContingent consideration adjustment \u00a0\u2014 \u00a0\u00a0\u00a012,153 \u00a0\u00a0\u00a0\nOperating income \u00a0$624,347 \u00a0\u00a0\u00a0$309,515 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.39 \u00a0%\u00a02.32 %\u00a0\u00a0\nOperating expenses \u00a01.14 \u00a0%\u00a01.08 %\u00a0\u00a0\nOperating income \u00a01.25 \u00a0%\u00a01.24 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.81 \u00a0%\u00a019.15 %\u00a0\u00a0\nOperating expenses \u00a012.92 \u00a0%\u00a013.38 %\u00a0\u00a0\nOperating income \u00a05.89 \u00a0%\u00a05.77 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n17", "start_char_idx": 0, "end_char_idx": 1068, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d49302b0-99a8-4234-b8ea-b5053cc69c0a": {"__data__": {"id_": "d49302b0-99a8-4234-b8ea-b5053cc69c0a", "embedding": null, "metadata": {"window": "AmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.12 \u00a0%\u00a02.93 %\u00a0\u00a0\nOperating expenses \u00a01.85 \u00a0%\u00a02.27 %\u00a0\u00a0\nOperating income \u00a01.27 \u00a0%\u00a00.65 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.08 \u00a0%\u00a02.99 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.64 \u00a0%\u00a01.57 %\u00a0\u00a0\nAdjusted operating income \u00a01.44 \u00a0%\u00a01.42 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a02021 \u00a0\u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$97,593,841 \u00a0\u00a0$91,599,498 \u00a0\u00a06.5 %\nOther \u00a04,145,046 \u00a0\u00a03,723,577 \u00a0\u00a011.3 %\nIntersegment eliminations \u00a0(68,160 )(40,694 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nRevenue \u00a0$101,670,727 \u00a0\u00a0$95,282,381 \u00a0\u00a06.7 %\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, \u00a0\nOperating income \u00a02021 \u00a0\u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$1,085,100 \u00a0\u00a0$954,791 \u00a0\u00a013.6 %\nOther \u00a0244,827 \u00a0\u00a0212,739 \u00a0\u00a015.1 %\n18", "original_text": "AmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.12 \u00a0%\u00a02.93 %\u00a0\u00a0\nOperating expenses \u00a01.85 \u00a0%\u00a02.27 %\u00a0\u00a0\nOperating income \u00a01.27 \u00a0%\u00a00.65 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.08 \u00a0%\u00a02.99 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.64 \u00a0%\u00a01.57 %\u00a0\u00a0\nAdjusted operating income \u00a01.44 \u00a0%\u00a01.42 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "18", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1207c990-1544-45c3-9819-27f84ccfa8bb", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "708271304008f525e58cd334b88cee03f944c34bacdac04560f4ca6dde54c5ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b81bcff-eb29-4d01-80cd-daaf8bd46e9c", "node_type": "1", "metadata": {"window": "\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a02021 \u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$589,033 \u00a0\u00a0\u00a0$563,097 \u00a0\u00a04.6 %\nOther \u00a0123,180 \u00a0\u00a0\u00a0108,260 \u00a0\u00a013.8 %\nIntersegment eliminations \u00a0(5,655 )\u00a0\u00a0328 \u00a0\u00a0\u00a0\nTotal segment operating income \u00a0706,558 \u00a0\u00a0\u00a0671,685 \u00a0\u00a05.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a0\u00a054 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a020,918 \u00a0\u00a0\u00a0(23,853 )\u00a0\u00a0\nPharMEDium shutdown costs \u00a0\u2014 \u00a0\u00a0\u00a0(32,470 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(24,973 )\u00a0\u00a0(26,670 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(78,156 )\u00a0\u00a0(67,732 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0(223,652 )\u00a0\u00a0\nContingent consideration adjustment \u00a0\u2014 \u00a0\u00a0\u00a012,153 \u00a0\u00a0\u00a0\nOperating income \u00a0$624,347 \u00a0\u00a0\u00a0$309,515 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.39 \u00a0%\u00a02.32 %\u00a0\u00a0\nOperating expenses \u00a01.14 \u00a0%\u00a01.08 %\u00a0\u00a0\nOperating income \u00a01.25 \u00a0%\u00a01.24 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.81 \u00a0%\u00a019.15 %\u00a0\u00a0\nOperating expenses \u00a012.92 \u00a0%\u00a013.38 %\u00a0\u00a0\nOperating income \u00a05.89 \u00a0%\u00a05.77 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n17", "original_text": "\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a02021 \u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$589,033 \u00a0\u00a0\u00a0$563,097 \u00a0\u00a04.6 %\nOther \u00a0123,180 \u00a0\u00a0\u00a0108,260 \u00a0\u00a013.8 %\nIntersegment eliminations \u00a0(5,655 )\u00a0\u00a0328 \u00a0\u00a0\u00a0\nTotal segment operating income \u00a0706,558 \u00a0\u00a0\u00a0671,685 \u00a0\u00a05.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a0\u00a054 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a020,918 \u00a0\u00a0\u00a0(23,853 )\u00a0\u00a0\nPharMEDium shutdown costs \u00a0\u2014 \u00a0\u00a0\u00a0(32,470 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(24,973 )\u00a0\u00a0(26,670 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(78,156 )\u00a0\u00a0(67,732 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0(223,652 )\u00a0\u00a0\nContingent consideration adjustment \u00a0\u2014 \u00a0\u00a0\u00a012,153 \u00a0\u00a0\u00a0\nOperating income \u00a0$624,347 \u00a0\u00a0\u00a0$309,515 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.39 \u00a0%\u00a02.32 %\u00a0\u00a0\nOperating expenses \u00a01.14 \u00a0%\u00a01.08 %\u00a0\u00a0\nOperating income \u00a01.25 \u00a0%\u00a01.24 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.81 \u00a0%\u00a019.15 %\u00a0\u00a0\nOperating expenses \u00a012.92 \u00a0%\u00a013.38 %\u00a0\u00a0\nOperating income \u00a05.89 \u00a0%\u00a05.77 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n17", "page_label": "17", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01f469990b7cb89966376bc3e45912bb7a0fffe37d9bed0dcffa713736763209", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "443be014-a4cc-4f28-9ec9-149d45c36d9f", "node_type": "1", "metadata": {"window": "AmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.12 \u00a0%\u00a02.93 %\u00a0\u00a0\nOperating expenses \u00a01.85 \u00a0%\u00a02.27 %\u00a0\u00a0\nOperating income \u00a01.27 \u00a0%\u00a00.65 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.08 \u00a0%\u00a02.99 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.64 \u00a0%\u00a01.57 %\u00a0\u00a0\nAdjusted operating income \u00a01.44 \u00a0%\u00a01.42 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a02021 \u00a0\u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$97,593,841 \u00a0\u00a0$91,599,498 \u00a0\u00a06.5 %\nOther \u00a04,145,046 \u00a0\u00a03,723,577 \u00a0\u00a011.3 %\nIntersegment eliminations \u00a0(68,160 )(40,694 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nRevenue \u00a0$101,670,727 \u00a0\u00a0$95,282,381 \u00a0\u00a06.7 %\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, \u00a0\nOperating income \u00a02021 \u00a0\u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$1,085,100 \u00a0\u00a0$954,791 \u00a0\u00a013.6 %\nOther \u00a0244,827 \u00a0\u00a0212,739 \u00a0\u00a015.1 %\n18", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a02021 \u00a0\u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$97,593,841 \u00a0\u00a0$91,599,498 \u00a0\u00a06.5 %\nOther \u00a04,145,046 \u00a0\u00a03,723,577 \u00a0\u00a011.3 %\nIntersegment eliminations \u00a0(68,160 )(40,694 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nRevenue \u00a0$101,670,727 \u00a0\u00a0$95,282,381 \u00a0\u00a06.7 %\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, \u00a0\nOperating income \u00a02021 \u00a0\u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$1,085,100 \u00a0\u00a0$954,791 \u00a0\u00a013.6 %\nOther \u00a0244,827 \u00a0\u00a0212,739 \u00a0\u00a015.1 %\n18"}, "hash": "f2958d3695bda2eb353436a27b52baa1bd1c5494626af5be8cb9f4fa6d515dd9", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.12 \u00a0%\u00a02.93 %\u00a0\u00a0\nOperating expenses \u00a01.85 \u00a0%\u00a02.27 %\u00a0\u00a0\nOperating income \u00a01.27 \u00a0%\u00a00.65 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.08 \u00a0%\u00a02.99 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.64 \u00a0%\u00a01.57 %\u00a0\u00a0\nAdjusted operating income \u00a01.44 \u00a0%\u00a01.42 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 0, "end_char_idx": 517, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "443be014-a4cc-4f28-9ec9-149d45c36d9f": {"__data__": {"id_": "443be014-a4cc-4f28-9ec9-149d45c36d9f", "embedding": null, "metadata": {"window": "AmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.12 \u00a0%\u00a02.93 %\u00a0\u00a0\nOperating expenses \u00a01.85 \u00a0%\u00a02.27 %\u00a0\u00a0\nOperating income \u00a01.27 \u00a0%\u00a00.65 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.08 \u00a0%\u00a02.99 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.64 \u00a0%\u00a01.57 %\u00a0\u00a0\nAdjusted operating income \u00a01.44 \u00a0%\u00a01.42 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a02021 \u00a0\u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$97,593,841 \u00a0\u00a0$91,599,498 \u00a0\u00a06.5 %\nOther \u00a04,145,046 \u00a0\u00a03,723,577 \u00a0\u00a011.3 %\nIntersegment eliminations \u00a0(68,160 )(40,694 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nRevenue \u00a0$101,670,727 \u00a0\u00a0$95,282,381 \u00a0\u00a06.7 %\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, \u00a0\nOperating income \u00a02021 \u00a0\u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$1,085,100 \u00a0\u00a0$954,791 \u00a0\u00a013.6 %\nOther \u00a0244,827 \u00a0\u00a0212,739 \u00a0\u00a015.1 %\n18", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a02021 \u00a0\u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$97,593,841 \u00a0\u00a0$91,599,498 \u00a0\u00a06.5 %\nOther \u00a04,145,046 \u00a0\u00a03,723,577 \u00a0\u00a011.3 %\nIntersegment eliminations \u00a0(68,160 )(40,694 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nRevenue \u00a0$101,670,727 \u00a0\u00a0$95,282,381 \u00a0\u00a06.7 %\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, \u00a0\nOperating income \u00a02021 \u00a0\u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$1,085,100 \u00a0\u00a0$954,791 \u00a0\u00a013.6 %\nOther \u00a0244,827 \u00a0\u00a0212,739 \u00a0\u00a015.1 %\n18", "page_label": "18", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1207c990-1544-45c3-9819-27f84ccfa8bb", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "708271304008f525e58cd334b88cee03f944c34bacdac04560f4ca6dde54c5ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d49302b0-99a8-4234-b8ea-b5053cc69c0a", "node_type": "1", "metadata": {"window": "AmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.12 \u00a0%\u00a02.93 %\u00a0\u00a0\nOperating expenses \u00a01.85 \u00a0%\u00a02.27 %\u00a0\u00a0\nOperating income \u00a01.27 \u00a0%\u00a00.65 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.08 \u00a0%\u00a02.99 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.64 \u00a0%\u00a01.57 %\u00a0\u00a0\nAdjusted operating income \u00a01.44 \u00a0%\u00a01.42 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a02021 \u00a0\u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$97,593,841 \u00a0\u00a0$91,599,498 \u00a0\u00a06.5 %\nOther \u00a04,145,046 \u00a0\u00a03,723,577 \u00a0\u00a011.3 %\nIntersegment eliminations \u00a0(68,160 )(40,694 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nRevenue \u00a0$101,670,727 \u00a0\u00a0$95,282,381 \u00a0\u00a06.7 %\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, \u00a0\nOperating income \u00a02021 \u00a0\u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$1,085,100 \u00a0\u00a0$954,791 \u00a0\u00a013.6 %\nOther \u00a0244,827 \u00a0\u00a0212,739 \u00a0\u00a015.1 %\n18", "original_text": "AmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.12 \u00a0%\u00a02.93 %\u00a0\u00a0\nOperating expenses \u00a01.85 \u00a0%\u00a02.27 %\u00a0\u00a0\nOperating income \u00a01.27 \u00a0%\u00a00.65 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.08 \u00a0%\u00a02.99 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.64 \u00a0%\u00a01.57 %\u00a0\u00a0\nAdjusted operating income \u00a01.44 \u00a0%\u00a01.42 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "18", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c92db371d60302e9d098f284858595598f79ea4a629303b372be33bdf5c1a96", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce13a88f-f62a-401e-8bd4-0bec83c7a2be", "node_type": "1", "metadata": {"window": "Intersegment eliminations \u00a0(6,453 )\u00a0(579 )\u00a0\u00a0\nTotal segment operating income \u00a01,323,474 \u00a0\u00a01,166,951 \u00a0\u00a013.4 %\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a08,546 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a046,645 \u00a0\u00a0(37,134 )\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0\u2014 \u00a0\u00a0(48,635 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(50,007 )\u00a0(60,236 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(148,537 )\u00a0(107,041 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0(361,652 )\u00a0\u00a0\nContingent consideration adjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,171,575 \u00a0\u00a0$572,952 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0 \u00a0\u00a0\nGross profit \u00a02.22 \u00a0%2.13 %\u00a0\u00a0\nOperating expenses \u00a01.11 \u00a0%1.09 %\u00a0\u00a0\nOperating income \u00a01.11 \u00a0%1.04 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0 \u00a0\u00a0\nGross profit \u00a018.84 \u00a0%19.08 %\u00a0\u00a0\nOperating expenses \u00a012.94 \u00a0%13.37 %\u00a0\u00a0\nOperating income \u00a05.91 \u00a0%5.71 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0 \u00a0\u00a0\nGross profit \u00a02.94 \u00a0%2.75 %\u00a0\u00a0\nOperating expenses \u00a01.78 \u00a0%2.15 %\u00a0\u00a0\nOperating income \u00a01.15 \u00a0%0.60 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\n19", "original_text": "Intersegment eliminations \u00a0(6,453 )\u00a0(579 )\u00a0\u00a0\nTotal segment operating income \u00a01,323,474 \u00a0\u00a01,166,951 \u00a0\u00a013.4 %\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a08,546 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a046,645 \u00a0\u00a0(37,134 )\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0\u2014 \u00a0\u00a0(48,635 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(50,007 )\u00a0(60,236 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(148,537 )\u00a0(107,041 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0(361,652 )\u00a0\u00a0\nContingent consideration adjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,171,575 \u00a0\u00a0$572,952 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0 \u00a0\u00a0\nGross profit \u00a02.22 \u00a0%2.13 %\u00a0\u00a0\nOperating expenses \u00a01.11 \u00a0%1.09 %\u00a0\u00a0\nOperating income \u00a01.11 \u00a0%1.04 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0 \u00a0\u00a0\nGross profit \u00a018.84 \u00a0%19.08 %\u00a0\u00a0\nOperating expenses \u00a012.94 \u00a0%13.37 %\u00a0\u00a0\nOperating income \u00a05.91 \u00a0%5.71 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0 \u00a0\u00a0\nGross profit \u00a02.94 \u00a0%2.75 %\u00a0\u00a0\nOperating expenses \u00a01.78 \u00a0%2.15 %\u00a0\u00a0\nOperating income \u00a01.15 \u00a0%0.60 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\n19"}, "hash": "a25de3dc3f05deb60d1407266b057c0c643e3b0c0cfb31c445319e639c17ad5e", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a02021 \u00a0\u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$97,593,841 \u00a0\u00a0$91,599,498 \u00a0\u00a06.5 %\nOther \u00a04,145,046 \u00a0\u00a03,723,577 \u00a0\u00a011.3 %\nIntersegment eliminations \u00a0(68,160 )(40,694 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nRevenue \u00a0$101,670,727 \u00a0\u00a0$95,282,381 \u00a0\u00a06.7 %\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, \u00a0\nOperating income \u00a02021 \u00a0\u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$1,085,100 \u00a0\u00a0$954,791 \u00a0\u00a013.6 %\nOther \u00a0244,827 \u00a0\u00a0212,739 \u00a0\u00a015.1 %\n18", "start_char_idx": 517, "end_char_idx": 1064, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce13a88f-f62a-401e-8bd4-0bec83c7a2be": {"__data__": {"id_": "ce13a88f-f62a-401e-8bd4-0bec83c7a2be", "embedding": null, "metadata": {"window": "Intersegment eliminations \u00a0(6,453 )\u00a0(579 )\u00a0\u00a0\nTotal segment operating income \u00a01,323,474 \u00a0\u00a01,166,951 \u00a0\u00a013.4 %\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a08,546 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a046,645 \u00a0\u00a0(37,134 )\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0\u2014 \u00a0\u00a0(48,635 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(50,007 )\u00a0(60,236 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(148,537 )\u00a0(107,041 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0(361,652 )\u00a0\u00a0\nContingent consideration adjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,171,575 \u00a0\u00a0$572,952 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0 \u00a0\u00a0\nGross profit \u00a02.22 \u00a0%2.13 %\u00a0\u00a0\nOperating expenses \u00a01.11 \u00a0%1.09 %\u00a0\u00a0\nOperating income \u00a01.11 \u00a0%1.04 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0 \u00a0\u00a0\nGross profit \u00a018.84 \u00a0%19.08 %\u00a0\u00a0\nOperating expenses \u00a012.94 \u00a0%13.37 %\u00a0\u00a0\nOperating income \u00a05.91 \u00a0%5.71 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0 \u00a0\u00a0\nGross profit \u00a02.94 \u00a0%2.75 %\u00a0\u00a0\nOperating expenses \u00a01.78 \u00a0%2.15 %\u00a0\u00a0\nOperating income \u00a01.15 \u00a0%0.60 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\n19", "original_text": "Intersegment eliminations \u00a0(6,453 )\u00a0(579 )\u00a0\u00a0\nTotal segment operating income \u00a01,323,474 \u00a0\u00a01,166,951 \u00a0\u00a013.4 %\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a08,546 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a046,645 \u00a0\u00a0(37,134 )\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0\u2014 \u00a0\u00a0(48,635 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(50,007 )\u00a0(60,236 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(148,537 )\u00a0(107,041 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0(361,652 )\u00a0\u00a0\nContingent consideration adjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,171,575 \u00a0\u00a0$572,952 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0 \u00a0\u00a0\nGross profit \u00a02.22 \u00a0%2.13 %\u00a0\u00a0\nOperating expenses \u00a01.11 \u00a0%1.09 %\u00a0\u00a0\nOperating income \u00a01.11 \u00a0%1.04 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0 \u00a0\u00a0\nGross profit \u00a018.84 \u00a0%19.08 %\u00a0\u00a0\nOperating expenses \u00a012.94 \u00a0%13.37 %\u00a0\u00a0\nOperating income \u00a05.91 \u00a0%5.71 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0 \u00a0\u00a0\nGross profit \u00a02.94 \u00a0%2.75 %\u00a0\u00a0\nOperating expenses \u00a01.78 \u00a0%2.15 %\u00a0\u00a0\nOperating income \u00a01.15 \u00a0%0.60 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\n19", "page_label": "19", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cee84c53-8da1-4b2a-9ff8-0c1fec5d5f8d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dcb7ffeced4e585c54c5160ae96fd9b03e3192d2f6dd5215f7f4644e16d47f41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "443be014-a4cc-4f28-9ec9-149d45c36d9f", "node_type": "1", "metadata": {"window": "AmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.12 \u00a0%\u00a02.93 %\u00a0\u00a0\nOperating expenses \u00a01.85 \u00a0%\u00a02.27 %\u00a0\u00a0\nOperating income \u00a01.27 \u00a0%\u00a00.65 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.08 \u00a0%\u00a02.99 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.64 \u00a0%\u00a01.57 %\u00a0\u00a0\nAdjusted operating income \u00a01.44 \u00a0%\u00a01.42 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a02021 \u00a0\u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$97,593,841 \u00a0\u00a0$91,599,498 \u00a0\u00a06.5 %\nOther \u00a04,145,046 \u00a0\u00a03,723,577 \u00a0\u00a011.3 %\nIntersegment eliminations \u00a0(68,160 )(40,694 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nRevenue \u00a0$101,670,727 \u00a0\u00a0$95,282,381 \u00a0\u00a06.7 %\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, \u00a0\nOperating income \u00a02021 \u00a0\u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$1,085,100 \u00a0\u00a0$954,791 \u00a0\u00a013.6 %\nOther \u00a0244,827 \u00a0\u00a0212,739 \u00a0\u00a015.1 %\n18", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a02021 \u00a0\u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$97,593,841 \u00a0\u00a0$91,599,498 \u00a0\u00a06.5 %\nOther \u00a04,145,046 \u00a0\u00a03,723,577 \u00a0\u00a011.3 %\nIntersegment eliminations \u00a0(68,160 )(40,694 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nRevenue \u00a0$101,670,727 \u00a0\u00a0$95,282,381 \u00a0\u00a06.7 %\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, \u00a0\nOperating income \u00a02021 \u00a0\u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$1,085,100 \u00a0\u00a0$954,791 \u00a0\u00a013.6 %\nOther \u00a0244,827 \u00a0\u00a0212,739 \u00a0\u00a015.1 %\n18", "page_label": "18", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f5a5d2c640bdb2fdace5cb37f93d16aaf3ea407d02f6dec3278fcf965be7891f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01ab6bc0-2ae3-4f5c-b3ee-7917fdf752e0", "node_type": "1", "metadata": {"window": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.89 \u00a0%2.79 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.59 \u00a0%1.57 %\u00a0\u00a0\nAdjusted operating income \u00a01.30 \u00a0%1.22 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0 March 31, \u00a0September 30,\n\u00a0 2021 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $6,641,180 \u00a0\u00a0\u00a0$4,597,746 \u00a0\u00a0\nAccounts receivable, net 14,134,326 \u00a0\u00a0\u00a013,846,301 \u00a0\u00a0\nInventories 12,954,676 \u00a0\u00a0\u00a012,589,278 \u00a0\u00a0\nRight to recover assets 1,217,032 \u00a0\u00a0\u00a01,344,649 \u00a0\u00a0\nIncome tax receivable 331,291 \u00a0\u00a0\u00a0488,428 \u00a0\u00a0\nPrepaid expenses and other 190,644 \u00a0\u00a0\u00a0189,300 \u00a0\u00a0\nTotal current assets 35,469,149 \u00a0\u00a0\u00a033,055,702 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,482,753 \u00a0\u00a0\u00a01,484,808 \u00a0\u00a0\nGoodwill and other intangible assets 8,548,906 \u00a0\u00a0\u00a08,592,826 \u00a0\u00a0\nDeferred income taxes 302,554 \u00a0\u00a0\u00a0361,640 \u00a0\u00a0\nOther long-term assets 1,199,888 \u00a0\u00a0\u00a0779,854 \u00a0\u00a0\n20", "original_text": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.89 \u00a0%2.79 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.59 \u00a0%1.57 %\u00a0\u00a0\nAdjusted operating income \u00a01.30 \u00a0%1.22 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "6068c1466869764a09086938e6b296afd8ddb646181fd1d481a34abefeaccf58", "class_name": "RelatedNodeInfo"}}, "text": "Intersegment eliminations \u00a0(6,453 )\u00a0(579 )\u00a0\u00a0\nTotal segment operating income \u00a01,323,474 \u00a0\u00a01,166,951 \u00a0\u00a013.4 %\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a08,546 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a046,645 \u00a0\u00a0(37,134 )\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0\u2014 \u00a0\u00a0(48,635 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(50,007 )\u00a0(60,236 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(148,537 )\u00a0(107,041 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0(361,652 )\u00a0\u00a0\nContingent consideration adjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,171,575 \u00a0\u00a0$572,952 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0 \u00a0\u00a0\nGross profit \u00a02.22 \u00a0%2.13 %\u00a0\u00a0\nOperating expenses \u00a01.11 \u00a0%1.09 %\u00a0\u00a0\nOperating income \u00a01.11 \u00a0%1.04 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0 \u00a0\u00a0\nGross profit \u00a018.84 \u00a0%19.08 %\u00a0\u00a0\nOperating expenses \u00a012.94 \u00a0%13.37 %\u00a0\u00a0\nOperating income \u00a05.91 \u00a0%5.71 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0 \u00a0\u00a0\nGross profit \u00a02.94 \u00a0%2.75 %\u00a0\u00a0\nOperating expenses \u00a01.78 \u00a0%2.15 %\u00a0\u00a0\nOperating income \u00a01.15 \u00a0%0.60 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\n19", "start_char_idx": 0, "end_char_idx": 1052, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01ab6bc0-2ae3-4f5c-b3ee-7917fdf752e0": {"__data__": {"id_": "01ab6bc0-2ae3-4f5c-b3ee-7917fdf752e0", "embedding": null, "metadata": {"window": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.89 \u00a0%2.79 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.59 \u00a0%1.57 %\u00a0\u00a0\nAdjusted operating income \u00a01.30 \u00a0%1.22 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0 March 31, \u00a0September 30,\n\u00a0 2021 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $6,641,180 \u00a0\u00a0\u00a0$4,597,746 \u00a0\u00a0\nAccounts receivable, net 14,134,326 \u00a0\u00a0\u00a013,846,301 \u00a0\u00a0\nInventories 12,954,676 \u00a0\u00a0\u00a012,589,278 \u00a0\u00a0\nRight to recover assets 1,217,032 \u00a0\u00a0\u00a01,344,649 \u00a0\u00a0\nIncome tax receivable 331,291 \u00a0\u00a0\u00a0488,428 \u00a0\u00a0\nPrepaid expenses and other 190,644 \u00a0\u00a0\u00a0189,300 \u00a0\u00a0\nTotal current assets 35,469,149 \u00a0\u00a0\u00a033,055,702 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,482,753 \u00a0\u00a0\u00a01,484,808 \u00a0\u00a0\nGoodwill and other intangible assets 8,548,906 \u00a0\u00a0\u00a08,592,826 \u00a0\u00a0\nDeferred income taxes 302,554 \u00a0\u00a0\u00a0361,640 \u00a0\u00a0\nOther long-term assets 1,199,888 \u00a0\u00a0\u00a0779,854 \u00a0\u00a0\n20", "original_text": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.89 \u00a0%2.79 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.59 \u00a0%1.57 %\u00a0\u00a0\nAdjusted operating income \u00a01.30 \u00a0%1.22 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "20", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1822fead-8efa-432d-bc81-0cf5b64dd207", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "447f6a07213a7bafe7a92220d1cfacbeff628d2acf2fd4b568de80daa7c2d40a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce13a88f-f62a-401e-8bd4-0bec83c7a2be", "node_type": "1", "metadata": {"window": "Intersegment eliminations \u00a0(6,453 )\u00a0(579 )\u00a0\u00a0\nTotal segment operating income \u00a01,323,474 \u00a0\u00a01,166,951 \u00a0\u00a013.4 %\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a08,546 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a046,645 \u00a0\u00a0(37,134 )\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0\u2014 \u00a0\u00a0(48,635 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(50,007 )\u00a0(60,236 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(148,537 )\u00a0(107,041 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0(361,652 )\u00a0\u00a0\nContingent consideration adjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,171,575 \u00a0\u00a0$572,952 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0 \u00a0\u00a0\nGross profit \u00a02.22 \u00a0%2.13 %\u00a0\u00a0\nOperating expenses \u00a01.11 \u00a0%1.09 %\u00a0\u00a0\nOperating income \u00a01.11 \u00a0%1.04 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0 \u00a0\u00a0\nGross profit \u00a018.84 \u00a0%19.08 %\u00a0\u00a0\nOperating expenses \u00a012.94 \u00a0%13.37 %\u00a0\u00a0\nOperating income \u00a05.91 \u00a0%5.71 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0 \u00a0\u00a0\nGross profit \u00a02.94 \u00a0%2.75 %\u00a0\u00a0\nOperating expenses \u00a01.78 \u00a0%2.15 %\u00a0\u00a0\nOperating income \u00a01.15 \u00a0%0.60 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\n19", "original_text": "Intersegment eliminations \u00a0(6,453 )\u00a0(579 )\u00a0\u00a0\nTotal segment operating income \u00a01,323,474 \u00a0\u00a01,166,951 \u00a0\u00a013.4 %\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a08,546 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a046,645 \u00a0\u00a0(37,134 )\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0\u2014 \u00a0\u00a0(48,635 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(50,007 )\u00a0(60,236 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(148,537 )\u00a0(107,041 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0(361,652 )\u00a0\u00a0\nContingent consideration adjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,171,575 \u00a0\u00a0$572,952 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0 \u00a0\u00a0\nGross profit \u00a02.22 \u00a0%2.13 %\u00a0\u00a0\nOperating expenses \u00a01.11 \u00a0%1.09 %\u00a0\u00a0\nOperating income \u00a01.11 \u00a0%1.04 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0 \u00a0\u00a0\nGross profit \u00a018.84 \u00a0%19.08 %\u00a0\u00a0\nOperating expenses \u00a012.94 \u00a0%13.37 %\u00a0\u00a0\nOperating income \u00a05.91 \u00a0%5.71 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0 \u00a0\u00a0\nGross profit \u00a02.94 \u00a0%2.75 %\u00a0\u00a0\nOperating expenses \u00a01.78 \u00a0%2.15 %\u00a0\u00a0\nOperating income \u00a01.15 \u00a0%0.60 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\n19", "page_label": "19", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "399c3066d260d12c4f5ccfacdf5b85a69b3be1851f7d58a75c36432386ef0a6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c96a8c8-d247-437a-935a-ba93dcd0f342", "node_type": "1", "metadata": {"window": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.89 \u00a0%2.79 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.59 \u00a0%1.57 %\u00a0\u00a0\nAdjusted operating income \u00a01.30 \u00a0%1.22 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0 March 31, \u00a0September 30,\n\u00a0 2021 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $6,641,180 \u00a0\u00a0\u00a0$4,597,746 \u00a0\u00a0\nAccounts receivable, net 14,134,326 \u00a0\u00a0\u00a013,846,301 \u00a0\u00a0\nInventories 12,954,676 \u00a0\u00a0\u00a012,589,278 \u00a0\u00a0\nRight to recover assets 1,217,032 \u00a0\u00a0\u00a01,344,649 \u00a0\u00a0\nIncome tax receivable 331,291 \u00a0\u00a0\u00a0488,428 \u00a0\u00a0\nPrepaid expenses and other 190,644 \u00a0\u00a0\u00a0189,300 \u00a0\u00a0\nTotal current assets 35,469,149 \u00a0\u00a0\u00a033,055,702 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,482,753 \u00a0\u00a0\u00a01,484,808 \u00a0\u00a0\nGoodwill and other intangible assets 8,548,906 \u00a0\u00a0\u00a08,592,826 \u00a0\u00a0\nDeferred income taxes 302,554 \u00a0\u00a0\u00a0361,640 \u00a0\u00a0\nOther long-term assets 1,199,888 \u00a0\u00a0\u00a0779,854 \u00a0\u00a0\n20", "original_text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0 March 31, \u00a0September 30,\n\u00a0 2021 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $6,641,180 \u00a0\u00a0\u00a0$4,597,746 \u00a0\u00a0\nAccounts receivable, net 14,134,326 \u00a0\u00a0\u00a013,846,301 \u00a0\u00a0\nInventories 12,954,676 \u00a0\u00a0\u00a012,589,278 \u00a0\u00a0\nRight to recover assets 1,217,032 \u00a0\u00a0\u00a01,344,649 \u00a0\u00a0\nIncome tax receivable 331,291 \u00a0\u00a0\u00a0488,428 \u00a0\u00a0\nPrepaid expenses and other 190,644 \u00a0\u00a0\u00a0189,300 \u00a0\u00a0\nTotal current assets 35,469,149 \u00a0\u00a0\u00a033,055,702 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,482,753 \u00a0\u00a0\u00a01,484,808 \u00a0\u00a0\nGoodwill and other intangible assets 8,548,906 \u00a0\u00a0\u00a08,592,826 \u00a0\u00a0\nDeferred income taxes 302,554 \u00a0\u00a0\u00a0361,640 \u00a0\u00a0\nOther long-term assets 1,199,888 \u00a0\u00a0\u00a0779,854 \u00a0\u00a0\n20"}, "hash": "981ed9e9f2f51ee00011b4baa68bdada59bbf3e0e0c5e9136e67ce8b3072aada", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.89 \u00a0%2.79 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.59 \u00a0%1.57 %\u00a0\u00a0\nAdjusted operating income \u00a01.30 \u00a0%1.22 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 0, "end_char_idx": 353, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c96a8c8-d247-437a-935a-ba93dcd0f342": {"__data__": {"id_": "6c96a8c8-d247-437a-935a-ba93dcd0f342", "embedding": null, "metadata": {"window": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.89 \u00a0%2.79 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.59 \u00a0%1.57 %\u00a0\u00a0\nAdjusted operating income \u00a01.30 \u00a0%1.22 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0 March 31, \u00a0September 30,\n\u00a0 2021 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $6,641,180 \u00a0\u00a0\u00a0$4,597,746 \u00a0\u00a0\nAccounts receivable, net 14,134,326 \u00a0\u00a0\u00a013,846,301 \u00a0\u00a0\nInventories 12,954,676 \u00a0\u00a0\u00a012,589,278 \u00a0\u00a0\nRight to recover assets 1,217,032 \u00a0\u00a0\u00a01,344,649 \u00a0\u00a0\nIncome tax receivable 331,291 \u00a0\u00a0\u00a0488,428 \u00a0\u00a0\nPrepaid expenses and other 190,644 \u00a0\u00a0\u00a0189,300 \u00a0\u00a0\nTotal current assets 35,469,149 \u00a0\u00a0\u00a033,055,702 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,482,753 \u00a0\u00a0\u00a01,484,808 \u00a0\u00a0\nGoodwill and other intangible assets 8,548,906 \u00a0\u00a0\u00a08,592,826 \u00a0\u00a0\nDeferred income taxes 302,554 \u00a0\u00a0\u00a0361,640 \u00a0\u00a0\nOther long-term assets 1,199,888 \u00a0\u00a0\u00a0779,854 \u00a0\u00a0\n20", "original_text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0 March 31, \u00a0September 30,\n\u00a0 2021 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $6,641,180 \u00a0\u00a0\u00a0$4,597,746 \u00a0\u00a0\nAccounts receivable, net 14,134,326 \u00a0\u00a0\u00a013,846,301 \u00a0\u00a0\nInventories 12,954,676 \u00a0\u00a0\u00a012,589,278 \u00a0\u00a0\nRight to recover assets 1,217,032 \u00a0\u00a0\u00a01,344,649 \u00a0\u00a0\nIncome tax receivable 331,291 \u00a0\u00a0\u00a0488,428 \u00a0\u00a0\nPrepaid expenses and other 190,644 \u00a0\u00a0\u00a0189,300 \u00a0\u00a0\nTotal current assets 35,469,149 \u00a0\u00a0\u00a033,055,702 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,482,753 \u00a0\u00a0\u00a01,484,808 \u00a0\u00a0\nGoodwill and other intangible assets 8,548,906 \u00a0\u00a0\u00a08,592,826 \u00a0\u00a0\nDeferred income taxes 302,554 \u00a0\u00a0\u00a0361,640 \u00a0\u00a0\nOther long-term assets 1,199,888 \u00a0\u00a0\u00a0779,854 \u00a0\u00a0\n20", "page_label": "20", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1822fead-8efa-432d-bc81-0cf5b64dd207", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "447f6a07213a7bafe7a92220d1cfacbeff628d2acf2fd4b568de80daa7c2d40a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01ab6bc0-2ae3-4f5c-b3ee-7917fdf752e0", "node_type": "1", "metadata": {"window": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.89 \u00a0%2.79 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.59 \u00a0%1.57 %\u00a0\u00a0\nAdjusted operating income \u00a01.30 \u00a0%1.22 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0 March 31, \u00a0September 30,\n\u00a0 2021 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $6,641,180 \u00a0\u00a0\u00a0$4,597,746 \u00a0\u00a0\nAccounts receivable, net 14,134,326 \u00a0\u00a0\u00a013,846,301 \u00a0\u00a0\nInventories 12,954,676 \u00a0\u00a0\u00a012,589,278 \u00a0\u00a0\nRight to recover assets 1,217,032 \u00a0\u00a0\u00a01,344,649 \u00a0\u00a0\nIncome tax receivable 331,291 \u00a0\u00a0\u00a0488,428 \u00a0\u00a0\nPrepaid expenses and other 190,644 \u00a0\u00a0\u00a0189,300 \u00a0\u00a0\nTotal current assets 35,469,149 \u00a0\u00a0\u00a033,055,702 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,482,753 \u00a0\u00a0\u00a01,484,808 \u00a0\u00a0\nGoodwill and other intangible assets 8,548,906 \u00a0\u00a0\u00a08,592,826 \u00a0\u00a0\nDeferred income taxes 302,554 \u00a0\u00a0\u00a0361,640 \u00a0\u00a0\nOther long-term assets 1,199,888 \u00a0\u00a0\u00a0779,854 \u00a0\u00a0\n20", "original_text": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.89 \u00a0%2.79 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.59 \u00a0%1.57 %\u00a0\u00a0\nAdjusted operating income \u00a01.30 \u00a0%1.22 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "20", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a39c0414a77486ab923ee5e94d0529261f33ca28a8426136e6822fd9a6863f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f481639f-3a55-43c3-bb42-8e0c591e47c2", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $47,003,250 \u00a0\u00a0\u00a0$44,274,830 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 DEFICIT \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $31,420,390 \u00a0\u00a0\u00a0$31,705,055 \u00a0\u00a0\nOther current liabilities 1,532,171 \u00a0\u00a0\u00a01,646,763 \u00a0\u00a0\nShort-term debt 43,885 \u00a0\u00a0\u00a0501,259 \u00a0\u00a0\nTotal current liabilities 32,996,446 \u00a0\u00a0\u00a033,853,077 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 6,147,112 \u00a0\u00a0\u00a03,618,261 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 273,031 \u00a0\u00a0\u00a0284,845 \u00a0\u00a0\nDeferred income taxes 768,551 \u00a0\u00a0\u00a0686,485 \u00a0\u00a0\nOther long-term liabilities 708,174 \u00a0\u00a0\u00a0472,855 \u00a0\u00a0\nAccrued litigation liability 6,212,718 \u00a0\u00a0\u00a06,198,943 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal deficit (102,782 )\u00a0\u00a0(839,636 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' deficit $47,003,250 \u00a0\u00a0\u00a0$44,274,830 \u00a0\u00a0\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0 Six Months Ended Mar ch 31,\n\u00a0 2021 \u00a02020\nOperating Activities: \u00a0 \u00a0\u00a0\n21", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $47,003,250 \u00a0\u00a0\u00a0$44,274,830 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 DEFICIT \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $31,420,390 \u00a0\u00a0\u00a0$31,705,055 \u00a0\u00a0\nOther current liabilities 1,532,171 \u00a0\u00a0\u00a01,646,763 \u00a0\u00a0\nShort-term debt 43,885 \u00a0\u00a0\u00a0501,259 \u00a0\u00a0\nTotal current liabilities 32,996,446 \u00a0\u00a0\u00a033,853,077 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 6,147,112 \u00a0\u00a0\u00a03,618,261 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 273,031 \u00a0\u00a0\u00a0284,845 \u00a0\u00a0\nDeferred income taxes 768,551 \u00a0\u00a0\u00a0686,485 \u00a0\u00a0\nOther long-term liabilities 708,174 \u00a0\u00a0\u00a0472,855 \u00a0\u00a0\nAccrued litigation liability 6,212,718 \u00a0\u00a0\u00a06,198,943 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal deficit (102,782 )\u00a0\u00a0(839,636 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' deficit $47,003,250 \u00a0\u00a0\u00a0$44,274,830 \u00a0\u00a0\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0 Six Months Ended Mar ch 31,\n\u00a0 2021 \u00a02020\nOperating Activities: \u00a0 \u00a0\u00a0\n21"}, "hash": "35c3199b729fad3002e35ce0863563ee53a980dcc0cafc2043bead9b655ddd87", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0 March 31, \u00a0September 30,\n\u00a0 2021 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $6,641,180 \u00a0\u00a0\u00a0$4,597,746 \u00a0\u00a0\nAccounts receivable, net 14,134,326 \u00a0\u00a0\u00a013,846,301 \u00a0\u00a0\nInventories 12,954,676 \u00a0\u00a0\u00a012,589,278 \u00a0\u00a0\nRight to recover assets 1,217,032 \u00a0\u00a0\u00a01,344,649 \u00a0\u00a0\nIncome tax receivable 331,291 \u00a0\u00a0\u00a0488,428 \u00a0\u00a0\nPrepaid expenses and other 190,644 \u00a0\u00a0\u00a0189,300 \u00a0\u00a0\nTotal current assets 35,469,149 \u00a0\u00a0\u00a033,055,702 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,482,753 \u00a0\u00a0\u00a01,484,808 \u00a0\u00a0\nGoodwill and other intangible assets 8,548,906 \u00a0\u00a0\u00a08,592,826 \u00a0\u00a0\nDeferred income taxes 302,554 \u00a0\u00a0\u00a0361,640 \u00a0\u00a0\nOther long-term assets 1,199,888 \u00a0\u00a0\u00a0779,854 \u00a0\u00a0\n20", "start_char_idx": 353, "end_char_idx": 1084, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f481639f-3a55-43c3-bb42-8e0c591e47c2": {"__data__": {"id_": "f481639f-3a55-43c3-bb42-8e0c591e47c2", "embedding": null, "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $47,003,250 \u00a0\u00a0\u00a0$44,274,830 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 DEFICIT \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $31,420,390 \u00a0\u00a0\u00a0$31,705,055 \u00a0\u00a0\nOther current liabilities 1,532,171 \u00a0\u00a0\u00a01,646,763 \u00a0\u00a0\nShort-term debt 43,885 \u00a0\u00a0\u00a0501,259 \u00a0\u00a0\nTotal current liabilities 32,996,446 \u00a0\u00a0\u00a033,853,077 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 6,147,112 \u00a0\u00a0\u00a03,618,261 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 273,031 \u00a0\u00a0\u00a0284,845 \u00a0\u00a0\nDeferred income taxes 768,551 \u00a0\u00a0\u00a0686,485 \u00a0\u00a0\nOther long-term liabilities 708,174 \u00a0\u00a0\u00a0472,855 \u00a0\u00a0\nAccrued litigation liability 6,212,718 \u00a0\u00a0\u00a06,198,943 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal deficit (102,782 )\u00a0\u00a0(839,636 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' deficit $47,003,250 \u00a0\u00a0\u00a0$44,274,830 \u00a0\u00a0\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0 Six Months Ended Mar ch 31,\n\u00a0 2021 \u00a02020\nOperating Activities: \u00a0 \u00a0\u00a0\n21", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $47,003,250 \u00a0\u00a0\u00a0$44,274,830 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 DEFICIT \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $31,420,390 \u00a0\u00a0\u00a0$31,705,055 \u00a0\u00a0\nOther current liabilities 1,532,171 \u00a0\u00a0\u00a01,646,763 \u00a0\u00a0\nShort-term debt 43,885 \u00a0\u00a0\u00a0501,259 \u00a0\u00a0\nTotal current liabilities 32,996,446 \u00a0\u00a0\u00a033,853,077 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 6,147,112 \u00a0\u00a0\u00a03,618,261 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 273,031 \u00a0\u00a0\u00a0284,845 \u00a0\u00a0\nDeferred income taxes 768,551 \u00a0\u00a0\u00a0686,485 \u00a0\u00a0\nOther long-term liabilities 708,174 \u00a0\u00a0\u00a0472,855 \u00a0\u00a0\nAccrued litigation liability 6,212,718 \u00a0\u00a0\u00a06,198,943 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal deficit (102,782 )\u00a0\u00a0(839,636 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' deficit $47,003,250 \u00a0\u00a0\u00a0$44,274,830 \u00a0\u00a0\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0 Six Months Ended Mar ch 31,\n\u00a0 2021 \u00a02020\nOperating Activities: \u00a0 \u00a0\u00a0\n21", "page_label": "21", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ee094e4-d0dc-4ce6-8296-c8877a54f241", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eedddb641203ddb0584e9ae8fa114e6775a34ed91ed6188419da2a0279b6de4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c96a8c8-d247-437a-935a-ba93dcd0f342", "node_type": "1", "metadata": {"window": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.89 \u00a0%2.79 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.59 \u00a0%1.57 %\u00a0\u00a0\nAdjusted operating income \u00a01.30 \u00a0%1.22 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0 March 31, \u00a0September 30,\n\u00a0 2021 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $6,641,180 \u00a0\u00a0\u00a0$4,597,746 \u00a0\u00a0\nAccounts receivable, net 14,134,326 \u00a0\u00a0\u00a013,846,301 \u00a0\u00a0\nInventories 12,954,676 \u00a0\u00a0\u00a012,589,278 \u00a0\u00a0\nRight to recover assets 1,217,032 \u00a0\u00a0\u00a01,344,649 \u00a0\u00a0\nIncome tax receivable 331,291 \u00a0\u00a0\u00a0488,428 \u00a0\u00a0\nPrepaid expenses and other 190,644 \u00a0\u00a0\u00a0189,300 \u00a0\u00a0\nTotal current assets 35,469,149 \u00a0\u00a0\u00a033,055,702 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,482,753 \u00a0\u00a0\u00a01,484,808 \u00a0\u00a0\nGoodwill and other intangible assets 8,548,906 \u00a0\u00a0\u00a08,592,826 \u00a0\u00a0\nDeferred income taxes 302,554 \u00a0\u00a0\u00a0361,640 \u00a0\u00a0\nOther long-term assets 1,199,888 \u00a0\u00a0\u00a0779,854 \u00a0\u00a0\n20", "original_text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0 March 31, \u00a0September 30,\n\u00a0 2021 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $6,641,180 \u00a0\u00a0\u00a0$4,597,746 \u00a0\u00a0\nAccounts receivable, net 14,134,326 \u00a0\u00a0\u00a013,846,301 \u00a0\u00a0\nInventories 12,954,676 \u00a0\u00a0\u00a012,589,278 \u00a0\u00a0\nRight to recover assets 1,217,032 \u00a0\u00a0\u00a01,344,649 \u00a0\u00a0\nIncome tax receivable 331,291 \u00a0\u00a0\u00a0488,428 \u00a0\u00a0\nPrepaid expenses and other 190,644 \u00a0\u00a0\u00a0189,300 \u00a0\u00a0\nTotal current assets 35,469,149 \u00a0\u00a0\u00a033,055,702 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,482,753 \u00a0\u00a0\u00a01,484,808 \u00a0\u00a0\nGoodwill and other intangible assets 8,548,906 \u00a0\u00a0\u00a08,592,826 \u00a0\u00a0\nDeferred income taxes 302,554 \u00a0\u00a0\u00a0361,640 \u00a0\u00a0\nOther long-term assets 1,199,888 \u00a0\u00a0\u00a0779,854 \u00a0\u00a0\n20", "page_label": "20", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "642af4f2e73fc3413b5799ce819d777520af8235890238893f70d8fa3c8356a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2aa8372b-993b-4947-afee-19c7fa4e5600", "node_type": "1", "metadata": {"window": "Net income $812,712 \u00a0\u00a0\u00a0$1,157,679 \u00a0\u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1415,159 \u00a0\u00a0\u00a0643,981 \u00a0\u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (193,770 )\u00a0\u00a0(2,052,216 )\u00a0\nInventories (314,294 )\u00a0\u00a0(152,359 )\u00a0\nAccounts payable (292,555 )\u00a0\u00a02,395,847 \u00a0\u00a0\nOther, net 2 21,898 \u00a0\u00a0\u00a0(997,225 )\u00a0\nNet cash provided by operating activities 449,150 \u00a0\u00a0\u00a0995,707 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (151,612 )\u00a0\u00a0(144,382 )\u00a0\nCost of equity investments (162,620 )\u00a0\u00a0(30,580 )\u00a0\nOther, net \u2014 \u00a0\u00a0\u00a07,162 \u00a0\u00a0\nNet cash used in investing activities (314,232 )\u00a0\u00a0(167,800 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings 3 2,069,645 \u00a0\u00a0\u00a0947 \u00a0\u00a0\nPurchases of common stock 4 (82,150 )\u00a0\u00a0(407,152 )\u00a0\nExercises of stock options 130,326 \u00a0\u00a0\u00a076,757 \u00a0\u00a0\nCash dividends on common stock (182,365 )\u00a0\u00a0(170,541 )\u00a0\nOther (26,940 )\u00a0\u00a0(10,174 )\u00a0\nNet cash provided by (used in) financing activities 1,908,516 \u00a0\u00a0\u00a0(510,163 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash and cash equivalents 2,043,434 \u00a0\u00a0\u00a0317,744 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $6,641,180 \u00a0\u00a0\u00a0$3,691,938 \u00a0\u00a0\n________________________________________\n22", "original_text": "Net income $812,712 \u00a0\u00a0\u00a0$1,157,679 \u00a0\u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1415,159 \u00a0\u00a0\u00a0643,981 \u00a0\u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (193,770 )\u00a0\u00a0(2,052,216 )\u00a0\nInventories (314,294 )\u00a0\u00a0(152,359 )\u00a0\nAccounts payable (292,555 )\u00a0\u00a02,395,847 \u00a0\u00a0\nOther, net 2 21,898 \u00a0\u00a0\u00a0(997,225 )\u00a0\nNet cash provided by operating activities 449,150 \u00a0\u00a0\u00a0995,707 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (151,612 )\u00a0\u00a0(144,382 )\u00a0\nCost of equity investments (162,620 )\u00a0\u00a0(30,580 )\u00a0\nOther, net \u2014 \u00a0\u00a0\u00a07,162 \u00a0\u00a0\nNet cash used in investing activities (314,232 )\u00a0\u00a0(167,800 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings 3 2,069,645 \u00a0\u00a0\u00a0947 \u00a0\u00a0\nPurchases of common stock 4 (82,150 )\u00a0\u00a0(407,152 )\u00a0\nExercises of stock options 130,326 \u00a0\u00a0\u00a076,757 \u00a0\u00a0\nCash dividends on common stock (182,365 )\u00a0\u00a0(170,541 )\u00a0\nOther (26,940 )\u00a0\u00a0(10,174 )\u00a0\nNet cash provided by (used in) financing activities 1,908,516 \u00a0\u00a0\u00a0(510,163 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash and cash equivalents 2,043,434 \u00a0\u00a0\u00a0317,744 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $6,641,180 \u00a0\u00a0\u00a0$3,691,938 \u00a0\u00a0\n________________________________________\n22"}, "hash": "4236dee6ebf564035c7ae5afc99011fc1ec6d5cc0ecc990786df8aaf58e4c56e", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $47,003,250 \u00a0\u00a0\u00a0$44,274,830 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 DEFICIT \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $31,420,390 \u00a0\u00a0\u00a0$31,705,055 \u00a0\u00a0\nOther current liabilities 1,532,171 \u00a0\u00a0\u00a01,646,763 \u00a0\u00a0\nShort-term debt 43,885 \u00a0\u00a0\u00a0501,259 \u00a0\u00a0\nTotal current liabilities 32,996,446 \u00a0\u00a0\u00a033,853,077 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 6,147,112 \u00a0\u00a0\u00a03,618,261 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 273,031 \u00a0\u00a0\u00a0284,845 \u00a0\u00a0\nDeferred income taxes 768,551 \u00a0\u00a0\u00a0686,485 \u00a0\u00a0\nOther long-term liabilities 708,174 \u00a0\u00a0\u00a0472,855 \u00a0\u00a0\nAccrued litigation liability 6,212,718 \u00a0\u00a0\u00a06,198,943 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal deficit (102,782 )\u00a0\u00a0(839,636 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' deficit $47,003,250 \u00a0\u00a0\u00a0$44,274,830 \u00a0\u00a0\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0 Six Months Ended Mar ch 31,\n\u00a0 2021 \u00a02020\nOperating Activities: \u00a0 \u00a0\u00a0\n21", "start_char_idx": 0, "end_char_idx": 873, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2aa8372b-993b-4947-afee-19c7fa4e5600": {"__data__": {"id_": "2aa8372b-993b-4947-afee-19c7fa4e5600", "embedding": null, "metadata": {"window": "Net income $812,712 \u00a0\u00a0\u00a0$1,157,679 \u00a0\u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1415,159 \u00a0\u00a0\u00a0643,981 \u00a0\u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (193,770 )\u00a0\u00a0(2,052,216 )\u00a0\nInventories (314,294 )\u00a0\u00a0(152,359 )\u00a0\nAccounts payable (292,555 )\u00a0\u00a02,395,847 \u00a0\u00a0\nOther, net 2 21,898 \u00a0\u00a0\u00a0(997,225 )\u00a0\nNet cash provided by operating activities 449,150 \u00a0\u00a0\u00a0995,707 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (151,612 )\u00a0\u00a0(144,382 )\u00a0\nCost of equity investments (162,620 )\u00a0\u00a0(30,580 )\u00a0\nOther, net \u2014 \u00a0\u00a0\u00a07,162 \u00a0\u00a0\nNet cash used in investing activities (314,232 )\u00a0\u00a0(167,800 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings 3 2,069,645 \u00a0\u00a0\u00a0947 \u00a0\u00a0\nPurchases of common stock 4 (82,150 )\u00a0\u00a0(407,152 )\u00a0\nExercises of stock options 130,326 \u00a0\u00a0\u00a076,757 \u00a0\u00a0\nCash dividends on common stock (182,365 )\u00a0\u00a0(170,541 )\u00a0\nOther (26,940 )\u00a0\u00a0(10,174 )\u00a0\nNet cash provided by (used in) financing activities 1,908,516 \u00a0\u00a0\u00a0(510,163 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash and cash equivalents 2,043,434 \u00a0\u00a0\u00a0317,744 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $6,641,180 \u00a0\u00a0\u00a0$3,691,938 \u00a0\u00a0\n________________________________________\n22", "original_text": "Net income $812,712 \u00a0\u00a0\u00a0$1,157,679 \u00a0\u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1415,159 \u00a0\u00a0\u00a0643,981 \u00a0\u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (193,770 )\u00a0\u00a0(2,052,216 )\u00a0\nInventories (314,294 )\u00a0\u00a0(152,359 )\u00a0\nAccounts payable (292,555 )\u00a0\u00a02,395,847 \u00a0\u00a0\nOther, net 2 21,898 \u00a0\u00a0\u00a0(997,225 )\u00a0\nNet cash provided by operating activities 449,150 \u00a0\u00a0\u00a0995,707 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (151,612 )\u00a0\u00a0(144,382 )\u00a0\nCost of equity investments (162,620 )\u00a0\u00a0(30,580 )\u00a0\nOther, net \u2014 \u00a0\u00a0\u00a07,162 \u00a0\u00a0\nNet cash used in investing activities (314,232 )\u00a0\u00a0(167,800 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings 3 2,069,645 \u00a0\u00a0\u00a0947 \u00a0\u00a0\nPurchases of common stock 4 (82,150 )\u00a0\u00a0(407,152 )\u00a0\nExercises of stock options 130,326 \u00a0\u00a0\u00a076,757 \u00a0\u00a0\nCash dividends on common stock (182,365 )\u00a0\u00a0(170,541 )\u00a0\nOther (26,940 )\u00a0\u00a0(10,174 )\u00a0\nNet cash provided by (used in) financing activities 1,908,516 \u00a0\u00a0\u00a0(510,163 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash and cash equivalents 2,043,434 \u00a0\u00a0\u00a0317,744 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $6,641,180 \u00a0\u00a0\u00a0$3,691,938 \u00a0\u00a0\n________________________________________\n22", "page_label": "22", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d56b4157-8ffb-43b5-8e6b-707f8b385440", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63c14e41d424d0837736c76d4bbb76069e098a6cc4d1b01bde9f5546817f9598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f481639f-3a55-43c3-bb42-8e0c591e47c2", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $47,003,250 \u00a0\u00a0\u00a0$44,274,830 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 DEFICIT \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $31,420,390 \u00a0\u00a0\u00a0$31,705,055 \u00a0\u00a0\nOther current liabilities 1,532,171 \u00a0\u00a0\u00a01,646,763 \u00a0\u00a0\nShort-term debt 43,885 \u00a0\u00a0\u00a0501,259 \u00a0\u00a0\nTotal current liabilities 32,996,446 \u00a0\u00a0\u00a033,853,077 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 6,147,112 \u00a0\u00a0\u00a03,618,261 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 273,031 \u00a0\u00a0\u00a0284,845 \u00a0\u00a0\nDeferred income taxes 768,551 \u00a0\u00a0\u00a0686,485 \u00a0\u00a0\nOther long-term liabilities 708,174 \u00a0\u00a0\u00a0472,855 \u00a0\u00a0\nAccrued litigation liability 6,212,718 \u00a0\u00a0\u00a06,198,943 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal deficit (102,782 )\u00a0\u00a0(839,636 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' deficit $47,003,250 \u00a0\u00a0\u00a0$44,274,830 \u00a0\u00a0\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0 Six Months Ended Mar ch 31,\n\u00a0 2021 \u00a02020\nOperating Activities: \u00a0 \u00a0\u00a0\n21", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $47,003,250 \u00a0\u00a0\u00a0$44,274,830 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 DEFICIT \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $31,420,390 \u00a0\u00a0\u00a0$31,705,055 \u00a0\u00a0\nOther current liabilities 1,532,171 \u00a0\u00a0\u00a01,646,763 \u00a0\u00a0\nShort-term debt 43,885 \u00a0\u00a0\u00a0501,259 \u00a0\u00a0\nTotal current liabilities 32,996,446 \u00a0\u00a0\u00a033,853,077 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 6,147,112 \u00a0\u00a0\u00a03,618,261 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 273,031 \u00a0\u00a0\u00a0284,845 \u00a0\u00a0\nDeferred income taxes 768,551 \u00a0\u00a0\u00a0686,485 \u00a0\u00a0\nOther long-term liabilities 708,174 \u00a0\u00a0\u00a0472,855 \u00a0\u00a0\nAccrued litigation liability 6,212,718 \u00a0\u00a0\u00a06,198,943 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal deficit (102,782 )\u00a0\u00a0(839,636 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' deficit $47,003,250 \u00a0\u00a0\u00a0$44,274,830 \u00a0\u00a0\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0 Six Months Ended Mar ch 31,\n\u00a0 2021 \u00a02020\nOperating Activities: \u00a0 \u00a0\u00a0\n21", "page_label": "21", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1660ed3124b7df7959df4b9190a7de32cc4c6861010c92a776297d149c6e16cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd33ba48-77ff-4319-b9b8-632613bdd9c3", "node_type": "1", "metadata": {"window": "1Includes a $361.7 million impairment of PharMEDium assets in the six months ended March 31, 2020.\n\u00a0\u00a0\n 2Includes a $693.6 million increase in income tax receivable for the six months ended March 31, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\u00a0\n 3Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes and $1,000 million of 2.700%\nsenior notes that will be used to finance a portion of the acquisition of a majority of WBA's Alliance Healthcare businesses.\n\u00a0\u00a0\n 4Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.\n", "original_text": "1Includes a $361.7 million impairment of PharMEDium assets in the six months ended March 31, 2020.\n\u00a0\u00a0\n"}, "hash": "ace1084aad94dee3882ac552d5b3c13699a5120ecd09243c00253dd7c4ba5d22", "class_name": "RelatedNodeInfo"}}, "text": "Net income $812,712 \u00a0\u00a0\u00a0$1,157,679 \u00a0\u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1415,159 \u00a0\u00a0\u00a0643,981 \u00a0\u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (193,770 )\u00a0\u00a0(2,052,216 )\u00a0\nInventories (314,294 )\u00a0\u00a0(152,359 )\u00a0\nAccounts payable (292,555 )\u00a0\u00a02,395,847 \u00a0\u00a0\nOther, net 2 21,898 \u00a0\u00a0\u00a0(997,225 )\u00a0\nNet cash provided by operating activities 449,150 \u00a0\u00a0\u00a0995,707 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (151,612 )\u00a0\u00a0(144,382 )\u00a0\nCost of equity investments (162,620 )\u00a0\u00a0(30,580 )\u00a0\nOther, net \u2014 \u00a0\u00a0\u00a07,162 \u00a0\u00a0\nNet cash used in investing activities (314,232 )\u00a0\u00a0(167,800 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings 3 2,069,645 \u00a0\u00a0\u00a0947 \u00a0\u00a0\nPurchases of common stock 4 (82,150 )\u00a0\u00a0(407,152 )\u00a0\nExercises of stock options 130,326 \u00a0\u00a0\u00a076,757 \u00a0\u00a0\nCash dividends on common stock (182,365 )\u00a0\u00a0(170,541 )\u00a0\nOther (26,940 )\u00a0\u00a0(10,174 )\u00a0\nNet cash provided by (used in) financing activities 1,908,516 \u00a0\u00a0\u00a0(510,163 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash and cash equivalents 2,043,434 \u00a0\u00a0\u00a0317,744 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $6,641,180 \u00a0\u00a0\u00a0$3,691,938 \u00a0\u00a0\n________________________________________\n22", "start_char_idx": 0, "end_char_idx": 1271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd33ba48-77ff-4319-b9b8-632613bdd9c3": {"__data__": {"id_": "fd33ba48-77ff-4319-b9b8-632613bdd9c3", "embedding": null, "metadata": {"window": "1Includes a $361.7 million impairment of PharMEDium assets in the six months ended March 31, 2020.\n\u00a0\u00a0\n 2Includes a $693.6 million increase in income tax receivable for the six months ended March 31, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\u00a0\n 3Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes and $1,000 million of 2.700%\nsenior notes that will be used to finance a portion of the acquisition of a majority of WBA's Alliance Healthcare businesses.\n\u00a0\u00a0\n 4Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.\n", "original_text": "1Includes a $361.7 million impairment of PharMEDium assets in the six months ended March 31, 2020.\n\u00a0\u00a0\n", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0d5cbb9245d9a80de70d279cf5de5ce9efe5ab02abbd2990b4454bc42d05c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2aa8372b-993b-4947-afee-19c7fa4e5600", "node_type": "1", "metadata": {"window": "Net income $812,712 \u00a0\u00a0\u00a0$1,157,679 \u00a0\u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1415,159 \u00a0\u00a0\u00a0643,981 \u00a0\u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (193,770 )\u00a0\u00a0(2,052,216 )\u00a0\nInventories (314,294 )\u00a0\u00a0(152,359 )\u00a0\nAccounts payable (292,555 )\u00a0\u00a02,395,847 \u00a0\u00a0\nOther, net 2 21,898 \u00a0\u00a0\u00a0(997,225 )\u00a0\nNet cash provided by operating activities 449,150 \u00a0\u00a0\u00a0995,707 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (151,612 )\u00a0\u00a0(144,382 )\u00a0\nCost of equity investments (162,620 )\u00a0\u00a0(30,580 )\u00a0\nOther, net \u2014 \u00a0\u00a0\u00a07,162 \u00a0\u00a0\nNet cash used in investing activities (314,232 )\u00a0\u00a0(167,800 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings 3 2,069,645 \u00a0\u00a0\u00a0947 \u00a0\u00a0\nPurchases of common stock 4 (82,150 )\u00a0\u00a0(407,152 )\u00a0\nExercises of stock options 130,326 \u00a0\u00a0\u00a076,757 \u00a0\u00a0\nCash dividends on common stock (182,365 )\u00a0\u00a0(170,541 )\u00a0\nOther (26,940 )\u00a0\u00a0(10,174 )\u00a0\nNet cash provided by (used in) financing activities 1,908,516 \u00a0\u00a0\u00a0(510,163 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash and cash equivalents 2,043,434 \u00a0\u00a0\u00a0317,744 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $6,641,180 \u00a0\u00a0\u00a0$3,691,938 \u00a0\u00a0\n________________________________________\n22", "original_text": "Net income $812,712 \u00a0\u00a0\u00a0$1,157,679 \u00a0\u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1415,159 \u00a0\u00a0\u00a0643,981 \u00a0\u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (193,770 )\u00a0\u00a0(2,052,216 )\u00a0\nInventories (314,294 )\u00a0\u00a0(152,359 )\u00a0\nAccounts payable (292,555 )\u00a0\u00a02,395,847 \u00a0\u00a0\nOther, net 2 21,898 \u00a0\u00a0\u00a0(997,225 )\u00a0\nNet cash provided by operating activities 449,150 \u00a0\u00a0\u00a0995,707 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (151,612 )\u00a0\u00a0(144,382 )\u00a0\nCost of equity investments (162,620 )\u00a0\u00a0(30,580 )\u00a0\nOther, net \u2014 \u00a0\u00a0\u00a07,162 \u00a0\u00a0\nNet cash used in investing activities (314,232 )\u00a0\u00a0(167,800 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings 3 2,069,645 \u00a0\u00a0\u00a0947 \u00a0\u00a0\nPurchases of common stock 4 (82,150 )\u00a0\u00a0(407,152 )\u00a0\nExercises of stock options 130,326 \u00a0\u00a0\u00a076,757 \u00a0\u00a0\nCash dividends on common stock (182,365 )\u00a0\u00a0(170,541 )\u00a0\nOther (26,940 )\u00a0\u00a0(10,174 )\u00a0\nNet cash provided by (used in) financing activities 1,908,516 \u00a0\u00a0\u00a0(510,163 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash and cash equivalents 2,043,434 \u00a0\u00a0\u00a0317,744 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $6,641,180 \u00a0\u00a0\u00a0$3,691,938 \u00a0\u00a0\n________________________________________\n22", "page_label": "22", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d56c6ff8fcde850e261a210032cc959f36f66c39b766de7701eaa80b13300e2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "702e8d60-1094-49b0-b060-55fd1db4b493", "node_type": "1", "metadata": {"window": "1Includes a $361.7 million impairment of PharMEDium assets in the six months ended March 31, 2020.\n\u00a0\u00a0\n 2Includes a $693.6 million increase in income tax receivable for the six months ended March 31, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\u00a0\n 3Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes and $1,000 million of 2.700%\nsenior notes that will be used to finance a portion of the acquisition of a majority of WBA's Alliance Healthcare businesses.\n\u00a0\u00a0\n 4Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.\n SUPPLEMENT AL INFORMA TION REGARDING NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "original_text": "2Includes a $693.6 million increase in income tax receivable for the six months ended March 31, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\u00a0\n"}, "hash": "ca9d47cdf81ac9c503a155d204548a73995eadeaa507aeb70a75638be83a4a33", "class_name": "RelatedNodeInfo"}}, "text": "1Includes a $361.7 million impairment of PharMEDium assets in the six months ended March 31, 2020.\n\u00a0\u00a0\n", "start_char_idx": 0, "end_char_idx": 102, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "702e8d60-1094-49b0-b060-55fd1db4b493": {"__data__": {"id_": "702e8d60-1094-49b0-b060-55fd1db4b493", "embedding": null, "metadata": {"window": "1Includes a $361.7 million impairment of PharMEDium assets in the six months ended March 31, 2020.\n\u00a0\u00a0\n 2Includes a $693.6 million increase in income tax receivable for the six months ended March 31, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\u00a0\n 3Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes and $1,000 million of 2.700%\nsenior notes that will be used to finance a portion of the acquisition of a majority of WBA's Alliance Healthcare businesses.\n\u00a0\u00a0\n 4Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.\n SUPPLEMENT AL INFORMA TION REGARDING NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "original_text": "2Includes a $693.6 million increase in income tax receivable for the six months ended March 31, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\u00a0\n", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0d5cbb9245d9a80de70d279cf5de5ce9efe5ab02abbd2990b4454bc42d05c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd33ba48-77ff-4319-b9b8-632613bdd9c3", "node_type": "1", "metadata": {"window": "1Includes a $361.7 million impairment of PharMEDium assets in the six months ended March 31, 2020.\n\u00a0\u00a0\n 2Includes a $693.6 million increase in income tax receivable for the six months ended March 31, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\u00a0\n 3Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes and $1,000 million of 2.700%\nsenior notes that will be used to finance a portion of the acquisition of a majority of WBA's Alliance Healthcare businesses.\n\u00a0\u00a0\n 4Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.\n", "original_text": "1Includes a $361.7 million impairment of PharMEDium assets in the six months ended March 31, 2020.\n\u00a0\u00a0\n", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1001e7f81f28a26e5e4dabe802a2b27a4c0c13a6425c0e637cd414415479a66c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f85a9c9c-b7bc-44e0-a87c-d019e33800f5", "node_type": "1", "metadata": {"window": "1Includes a $361.7 million impairment of PharMEDium assets in the six months ended March 31, 2020.\n\u00a0\u00a0\n 2Includes a $693.6 million increase in income tax receivable for the six months ended March 31, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\u00a0\n 3Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes and $1,000 million of 2.700%\nsenior notes that will be used to finance a portion of the acquisition of a majority of WBA's Alliance Healthcare businesses.\n\u00a0\u00a0\n 4Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.\n SUPPLEMENT AL INFORMA TION REGARDING NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "original_text": "3Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes and $1,000 million of 2.700%\nsenior notes that will be used to finance a portion of the acquisition of a majority of WBA's Alliance Healthcare businesses.\n\u00a0\u00a0\n"}, "hash": "b909e4c6bcc0772a1035d4e88eb2808c24207eb66b647398a187358618cdb78d", "class_name": "RelatedNodeInfo"}}, "text": "2Includes a $693.6 million increase in income tax receivable for the six months ended March 31, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\u00a0\n", "start_char_idx": 102, "end_char_idx": 274, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f85a9c9c-b7bc-44e0-a87c-d019e33800f5": {"__data__": {"id_": "f85a9c9c-b7bc-44e0-a87c-d019e33800f5", "embedding": null, "metadata": {"window": "1Includes a $361.7 million impairment of PharMEDium assets in the six months ended March 31, 2020.\n\u00a0\u00a0\n 2Includes a $693.6 million increase in income tax receivable for the six months ended March 31, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\u00a0\n 3Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes and $1,000 million of 2.700%\nsenior notes that will be used to finance a portion of the acquisition of a majority of WBA's Alliance Healthcare businesses.\n\u00a0\u00a0\n 4Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.\n SUPPLEMENT AL INFORMA TION REGARDING NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "original_text": "3Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes and $1,000 million of 2.700%\nsenior notes that will be used to finance a portion of the acquisition of a majority of WBA's Alliance Healthcare businesses.\n\u00a0\u00a0\n", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0d5cbb9245d9a80de70d279cf5de5ce9efe5ab02abbd2990b4454bc42d05c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "702e8d60-1094-49b0-b060-55fd1db4b493", "node_type": "1", "metadata": {"window": "1Includes a $361.7 million impairment of PharMEDium assets in the six months ended March 31, 2020.\n\u00a0\u00a0\n 2Includes a $693.6 million increase in income tax receivable for the six months ended March 31, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\u00a0\n 3Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes and $1,000 million of 2.700%\nsenior notes that will be used to finance a portion of the acquisition of a majority of WBA's Alliance Healthcare businesses.\n\u00a0\u00a0\n 4Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.\n SUPPLEMENT AL INFORMA TION REGARDING NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "original_text": "2Includes a $693.6 million increase in income tax receivable for the six months ended March 31, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\u00a0\n", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5284bd600626b39c0efa3f84ee629876d1b7d0faa5336452ecc5d392f07f6661", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7df945f-6340-43c3-8292-6656a8d4099d", "node_type": "1", "metadata": {"window": "1Includes a $361.7 million impairment of PharMEDium assets in the six months ended March 31, 2020.\n\u00a0\u00a0\n 2Includes a $693.6 million increase in income tax receivable for the six months ended March 31, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\u00a0\n 3Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes and $1,000 million of 2.700%\nsenior notes that will be used to finance a portion of the acquisition of a majority of WBA's Alliance Healthcare businesses.\n\u00a0\u00a0\n 4Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.\n SUPPLEMENT AL INFORMA TION REGARDING NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "4Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.\n"}, "hash": "5ad78148ce0b870cd13257112a6f77d9b96cbccb1978a4848b8e3eeadafab7d2", "class_name": "RelatedNodeInfo"}}, "text": "3Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes and $1,000 million of 2.700%\nsenior notes that will be used to finance a portion of the acquisition of a majority of WBA's Alliance Healthcare businesses.\n\u00a0\u00a0\n", "start_char_idx": 274, "end_char_idx": 524, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7df945f-6340-43c3-8292-6656a8d4099d": {"__data__": {"id_": "b7df945f-6340-43c3-8292-6656a8d4099d", "embedding": null, "metadata": {"window": "1Includes a $361.7 million impairment of PharMEDium assets in the six months ended March 31, 2020.\n\u00a0\u00a0\n 2Includes a $693.6 million increase in income tax receivable for the six months ended March 31, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\u00a0\n 3Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes and $1,000 million of 2.700%\nsenior notes that will be used to finance a portion of the acquisition of a majority of WBA's Alliance Healthcare businesses.\n\u00a0\u00a0\n 4Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.\n SUPPLEMENT AL INFORMA TION REGARDING NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "4Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.\n", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0d5cbb9245d9a80de70d279cf5de5ce9efe5ab02abbd2990b4454bc42d05c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f85a9c9c-b7bc-44e0-a87c-d019e33800f5", "node_type": "1", "metadata": {"window": "1Includes a $361.7 million impairment of PharMEDium assets in the six months ended March 31, 2020.\n\u00a0\u00a0\n 2Includes a $693.6 million increase in income tax receivable for the six months ended March 31, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\u00a0\n 3Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes and $1,000 million of 2.700%\nsenior notes that will be used to finance a portion of the acquisition of a majority of WBA's Alliance Healthcare businesses.\n\u00a0\u00a0\n 4Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.\n SUPPLEMENT AL INFORMA TION REGARDING NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "original_text": "3Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes and $1,000 million of 2.700%\nsenior notes that will be used to finance a portion of the acquisition of a majority of WBA's Alliance Healthcare businesses.\n\u00a0\u00a0\n", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "761daf9f1ac24bc028c57ae22c03c927056b35ba49682ed00ef0bdba3e012821", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f958a16-e853-43bc-bc81-e20110072bb3", "node_type": "1", "metadata": {"window": "2Includes a $693.6 million increase in income tax receivable for the six months ended March 31, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\u00a0\n 3Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes and $1,000 million of 2.700%\nsenior notes that will be used to finance a portion of the acquisition of a majority of WBA's Alliance Healthcare businesses.\n\u00a0\u00a0\n 4Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.\n SUPPLEMENT AL INFORMA TION REGARDING NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "SUPPLEMENT AL INFORMA TION REGARDING NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. "}, "hash": "97af3594ad1740452d4e0defc0ffc107be5eed9e82392f395192965a5b6dbbf9", "class_name": "RelatedNodeInfo"}}, "text": "4Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.\n", "start_char_idx": 524, "end_char_idx": 676, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f958a16-e853-43bc-bc81-e20110072bb3": {"__data__": {"id_": "6f958a16-e853-43bc-bc81-e20110072bb3", "embedding": null, "metadata": {"window": "2Includes a $693.6 million increase in income tax receivable for the six months ended March 31, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\u00a0\n 3Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes and $1,000 million of 2.700%\nsenior notes that will be used to finance a portion of the acquisition of a majority of WBA's Alliance Healthcare businesses.\n\u00a0\u00a0\n 4Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.\n SUPPLEMENT AL INFORMA TION REGARDING NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "SUPPLEMENT AL INFORMA TION REGARDING NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0d5cbb9245d9a80de70d279cf5de5ce9efe5ab02abbd2990b4454bc42d05c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7df945f-6340-43c3-8292-6656a8d4099d", "node_type": "1", "metadata": {"window": "1Includes a $361.7 million impairment of PharMEDium assets in the six months ended March 31, 2020.\n\u00a0\u00a0\n 2Includes a $693.6 million increase in income tax receivable for the six months ended March 31, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\u00a0\n 3Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes and $1,000 million of 2.700%\nsenior notes that will be used to finance a portion of the acquisition of a majority of WBA's Alliance Healthcare businesses.\n\u00a0\u00a0\n 4Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.\n SUPPLEMENT AL INFORMA TION REGARDING NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "4Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.\n", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a13952c67b3518c8b9c7f0ec2996ec17351227e1d97433cd404f1c2c7f6dab6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ad730c6-6d58-40a2-a815-1d6618c4bc05", "node_type": "1", "metadata": {"window": "3Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes and $1,000 million of 2.700%\nsenior notes that will be used to finance a portion of the acquisition of a majority of WBA's Alliance Healthcare businesses.\n\u00a0\u00a0\n 4Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.\n SUPPLEMENT AL INFORMA TION REGARDING NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. "}, "hash": "cf344d1f5d100016d21e098bab1744252113b5256aee32e58dada50199834f9f", "class_name": "RelatedNodeInfo"}}, "text": "SUPPLEMENT AL INFORMA TION REGARDING NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "start_char_idx": 676, "end_char_idx": 812, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ad730c6-6d58-40a2-a815-1d6618c4bc05": {"__data__": {"id_": "5ad730c6-6d58-40a2-a815-1d6618c4bc05", "embedding": null, "metadata": {"window": "3Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes and $1,000 million of 2.700%\nsenior notes that will be used to finance a portion of the acquisition of a majority of WBA's Alliance Healthcare businesses.\n\u00a0\u00a0\n 4Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.\n SUPPLEMENT AL INFORMA TION REGARDING NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0d5cbb9245d9a80de70d279cf5de5ce9efe5ab02abbd2990b4454bc42d05c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f958a16-e853-43bc-bc81-e20110072bb3", "node_type": "1", "metadata": {"window": "2Includes a $693.6 million increase in income tax receivable for the six months ended March 31, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\u00a0\n 3Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes and $1,000 million of 2.700%\nsenior notes that will be used to finance a portion of the acquisition of a majority of WBA's Alliance Healthcare businesses.\n\u00a0\u00a0\n 4Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.\n SUPPLEMENT AL INFORMA TION REGARDING NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "SUPPLEMENT AL INFORMA TION REGARDING NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4f2bde21880a5f7937dd81da390eb9d63d3bff0a2354ba13a23f7b7f59bfc52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35f0ff08-6e17-4b08-bc85-293731668c1d", "node_type": "1", "metadata": {"window": "4Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.\n SUPPLEMENT AL INFORMA TION REGARDING NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. "}, "hash": "40a2233382b342bb18e9dde34ab2c8bd7dba2eee360153df50f3d1acb54f2da6", "class_name": "RelatedNodeInfo"}}, "text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "start_char_idx": 812, "end_char_idx": 927, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35f0ff08-6e17-4b08-bc85-293731668c1d": {"__data__": {"id_": "35f0ff08-6e17-4b08-bc85-293731668c1d", "embedding": null, "metadata": {"window": "4Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.\n SUPPLEMENT AL INFORMA TION REGARDING NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0d5cbb9245d9a80de70d279cf5de5ce9efe5ab02abbd2990b4454bc42d05c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ad730c6-6d58-40a2-a815-1d6618c4bc05", "node_type": "1", "metadata": {"window": "3Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes and $1,000 million of 2.700%\nsenior notes that will be used to finance a portion of the acquisition of a majority of WBA's Alliance Healthcare businesses.\n\u00a0\u00a0\n 4Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.\n SUPPLEMENT AL INFORMA TION REGARDING NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28b080c0b063ddb201adcaadb182fb28621198671aa6f91fc178536c6ab94ff7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9652ee9-d68e-4c50-9406-2dd906b3ecf4", "node_type": "1", "metadata": {"window": "SUPPLEMENT AL INFORMA TION REGARDING NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n"}, "hash": "588af761c137ed853e9e072f362b566b72f8b13334a53dfa9d5d12a00ef0990d", "class_name": "RelatedNodeInfo"}}, "text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "start_char_idx": 927, "end_char_idx": 1067, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9652ee9-d68e-4c50-9406-2dd906b3ecf4": {"__data__": {"id_": "c9652ee9-d68e-4c50-9406-2dd906b3ecf4", "embedding": null, "metadata": {"window": "SUPPLEMENT AL INFORMA TION REGARDING NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0d5cbb9245d9a80de70d279cf5de5ce9efe5ab02abbd2990b4454bc42d05c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35f0ff08-6e17-4b08-bc85-293731668c1d", "node_type": "1", "metadata": {"window": "4Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.\n SUPPLEMENT AL INFORMA TION REGARDING NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1955542a4f4a68a4e959d0a3abf66a64d05a17b3e66d1db31a7f1cb2d33d1671", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "433d9204-fd11-4f66-b0d5-bbd2dc5fc967", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. "}, "hash": "0d0949bd76d3b52e97f462dbf1b1c66a893fc6603db85b711f860511cd406375", "class_name": "RelatedNodeInfo"}}, "text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "start_char_idx": 1067, "end_char_idx": 1186, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "433d9204-fd11-4f66-b0d5-bbd2dc5fc967": {"__data__": {"id_": "433d9204-fd11-4f66-b0d5-bbd2dc5fc967", "embedding": null, "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0d5cbb9245d9a80de70d279cf5de5ce9efe5ab02abbd2990b4454bc42d05c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9652ee9-d68e-4c50-9406-2dd906b3ecf4", "node_type": "1", "metadata": {"window": "SUPPLEMENT AL INFORMA TION REGARDING NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ab98e8018189ca60fd79d31d82214fd838556d9dc028340574485cda48282ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8bc5cf17-41ac-4799-be07-25d26a60f480", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n Gain from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. "}, "hash": "cda20169ade4a20dac18879c933c171b43388c7dd9c1780ab92ab0e00d0eb8c9", "class_name": "RelatedNodeInfo"}}, "text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "start_char_idx": 1186, "end_char_idx": 1405, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8bc5cf17-41ac-4799-be07-25d26a60f480": {"__data__": {"id_": "8bc5cf17-41ac-4799-be07-25d26a60f480", "embedding": null, "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n Gain from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0d5cbb9245d9a80de70d279cf5de5ce9efe5ab02abbd2990b4454bc42d05c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "433d9204-fd11-4f66-b0d5-bbd2dc5fc967", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb1f4f230a534e5671418d382a35968a8d79973818c0ffc3d2f315835d90c97e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a2b7b64-dc1e-4a70-b638-ed5bbe4eeeba", "node_type": "1", "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n Gain from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\nexpenses. ", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. "}, "hash": "964a0c9298b6d155a2107b59992f161e839707d603e4e940d1189ea9643a4a10", "class_name": "RelatedNodeInfo"}}, "text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "start_char_idx": 1405, "end_char_idx": 1587, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a2b7b64-dc1e-4a70-b638-ed5bbe4eeeba": {"__data__": {"id_": "1a2b7b64-dc1e-4a70-b638-ed5bbe4eeeba", "embedding": null, "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n Gain from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\nexpenses. ", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0d5cbb9245d9a80de70d279cf5de5ce9efe5ab02abbd2990b4454bc42d05c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8bc5cf17-41ac-4799-be07-25d26a60f480", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n Gain from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aedf0c42f918799a11df7d5d16c6dc0424a566a36e974f5638fe81e23b049deb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6cdaa795-769d-4690-9235-4fa354351837", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n Gain from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\nexpenses.  PharMEDium shutdown costs are excluded because they were unusual and non-recurring. ", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n"}, "hash": "4d4de3a012ca7237facfdb2e1072e4bfd45a40af76e4e37b5f74f099f805eb80", "class_name": "RelatedNodeInfo"}}, "text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "start_char_idx": 1587, "end_char_idx": 1868, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6cdaa795-769d-4690-9235-4fa354351837": {"__data__": {"id_": "6cdaa795-769d-4690-9235-4fa354351837", "embedding": null, "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n Gain from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\nexpenses.  PharMEDium shutdown costs are excluded because they were unusual and non-recurring. ", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0d5cbb9245d9a80de70d279cf5de5ce9efe5ab02abbd2990b4454bc42d05c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a2b7b64-dc1e-4a70-b638-ed5bbe4eeeba", "node_type": "1", "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n Gain from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\nexpenses. ", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0692478d556f174672a046606a4be6a939081f9c1178a74a506499313036bfb9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f88b23a0-1ea8-427f-b146-6d351fb0fb8c", "node_type": "1", "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n Gain from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\nexpenses.  PharMEDium shutdown costs are excluded because they were unusual and non-recurring.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "original_text": "Gain from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items. "}, "hash": "433494f566a73303763d7c0414c818e194431de20af475801f3865851d4ade23", "class_name": "RelatedNodeInfo"}}, "text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n", "start_char_idx": 1868, "end_char_idx": 2212, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f88b23a0-1ea8-427f-b146-6d351fb0fb8c": {"__data__": {"id_": "f88b23a0-1ea8-427f-b146-6d351fb0fb8c", "embedding": null, "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n Gain from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\nexpenses.  PharMEDium shutdown costs are excluded because they were unusual and non-recurring.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "original_text": "Gain from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0d5cbb9245d9a80de70d279cf5de5ce9efe5ab02abbd2990b4454bc42d05c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6cdaa795-769d-4690-9235-4fa354351837", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n Gain from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\nexpenses.  PharMEDium shutdown costs are excluded because they were unusual and non-recurring. ", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c692f7fe9e68f74ea3d5ad3cd655ae8dad4e4a87b5899311c1b6f06831eaff5e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c74e45df-42e4-4f3d-93b0-de59bf5a8de9", "node_type": "1", "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n Gain from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\nexpenses.  PharMEDium shutdown costs are excluded because they were unusual and non-recurring.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "original_text": "PharMEDium remediation costs are excluded because they were unpredictable\nexpenses. "}, "hash": "50e39e59272e4fd187da6ace617fb0e4ec3dd9370c345f3e2ae37751be57fcbc", "class_name": "RelatedNodeInfo"}}, "text": "Gain from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items. ", "start_char_idx": 2212, "end_char_idx": 2378, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c74e45df-42e4-4f3d-93b0-de59bf5a8de9": {"__data__": {"id_": "c74e45df-42e4-4f3d-93b0-de59bf5a8de9", "embedding": null, "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n Gain from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\nexpenses.  PharMEDium shutdown costs are excluded because they were unusual and non-recurring.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "original_text": "PharMEDium remediation costs are excluded because they were unpredictable\nexpenses. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0d5cbb9245d9a80de70d279cf5de5ce9efe5ab02abbd2990b4454bc42d05c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f88b23a0-1ea8-427f-b146-6d351fb0fb8c", "node_type": "1", "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n Gain from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\nexpenses.  PharMEDium shutdown costs are excluded because they were unusual and non-recurring.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "original_text": "Gain from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b00dedabb2e76564f3904b02c71e91f67d8453f9a69fbd867e3b067af3d1cab7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3cdece7e-3876-4512-a0f2-78f328907f4a", "node_type": "1", "metadata": {"window": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n Gain from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\nexpenses.  PharMEDium shutdown costs are excluded because they were unusual and non-recurring.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust\nlitigation settlements relates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market. ", "original_text": "PharMEDium shutdown costs are excluded because they were unusual and non-recurring. "}, "hash": "bb1b06952bd5a07f6e3f56b775dab8026026af6165ef0ec1bf2d7453e4a4214a", "class_name": "RelatedNodeInfo"}}, "text": "PharMEDium remediation costs are excluded because they were unpredictable\nexpenses. ", "start_char_idx": 2378, "end_char_idx": 2462, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3cdece7e-3876-4512-a0f2-78f328907f4a": {"__data__": {"id_": "3cdece7e-3876-4512-a0f2-78f328907f4a", "embedding": null, "metadata": {"window": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n Gain from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\nexpenses.  PharMEDium shutdown costs are excluded because they were unusual and non-recurring.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust\nlitigation settlements relates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market. ", "original_text": "PharMEDium shutdown costs are excluded because they were unusual and non-recurring. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0d5cbb9245d9a80de70d279cf5de5ce9efe5ab02abbd2990b4454bc42d05c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c74e45df-42e4-4f3d-93b0-de59bf5a8de9", "node_type": "1", "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n Gain from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\nexpenses.  PharMEDium shutdown costs are excluded because they were unusual and non-recurring.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "original_text": "PharMEDium remediation costs are excluded because they were unpredictable\nexpenses. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e622e951e4224fe469ed00565c6bb58ed035a0b2ec97fe430b01b208f9d177a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c4cdb70-1a31-4cd4-b465-cc56ab5aa03d", "node_type": "1", "metadata": {"window": "Gain from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\nexpenses.  PharMEDium shutdown costs are excluded because they were unusual and non-recurring.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust\nlitigation settlements relates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market.  The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S. ", "original_text": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. "}, "hash": "c0399e96974643652c884d6267078e81be128109a09e8ec109fba16403060106", "class_name": "RelatedNodeInfo"}}, "text": "PharMEDium shutdown costs are excluded because they were unusual and non-recurring. ", "start_char_idx": 2462, "end_char_idx": 2546, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c4cdb70-1a31-4cd4-b465-cc56ab5aa03d": {"__data__": {"id_": "6c4cdb70-1a31-4cd4-b465-cc56ab5aa03d", "embedding": null, "metadata": {"window": "Gain from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\nexpenses.  PharMEDium shutdown costs are excluded because they were unusual and non-recurring.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust\nlitigation settlements relates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market.  The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S. ", "original_text": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0d5cbb9245d9a80de70d279cf5de5ce9efe5ab02abbd2990b4454bc42d05c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3cdece7e-3876-4512-a0f2-78f328907f4a", "node_type": "1", "metadata": {"window": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n Gain from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\nexpenses.  PharMEDium shutdown costs are excluded because they were unusual and non-recurring.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust\nlitigation settlements relates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market. ", "original_text": "PharMEDium shutdown costs are excluded because they were unusual and non-recurring. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5121fd9cb15021a542a215ba9de6f18a52a524a17611b7c1d41a126fe6195b78", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2aee4e3a-f83d-486c-90af-9e825702a80b", "node_type": "1", "metadata": {"window": "PharMEDium remediation costs are excluded because they were unpredictable\nexpenses.  PharMEDium shutdown costs are excluded because they were unusual and non-recurring.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust\nlitigation settlements relates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market.  The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S.  Food and Drug Administration inspections. ", "original_text": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. "}, "hash": "321013807bf441d790bd149b00a58e15e26e86d61395ca205e9f1b0b7dd70c23", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "start_char_idx": 2546, "end_char_idx": 2631, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2aee4e3a-f83d-486c-90af-9e825702a80b": {"__data__": {"id_": "2aee4e3a-f83d-486c-90af-9e825702a80b", "embedding": null, "metadata": {"window": "PharMEDium remediation costs are excluded because they were unpredictable\nexpenses.  PharMEDium shutdown costs are excluded because they were unusual and non-recurring.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust\nlitigation settlements relates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market.  The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S.  Food and Drug Administration inspections. ", "original_text": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0d5cbb9245d9a80de70d279cf5de5ce9efe5ab02abbd2990b4454bc42d05c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c4cdb70-1a31-4cd4-b465-cc56ab5aa03d", "node_type": "1", "metadata": {"window": "Gain from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\nexpenses.  PharMEDium shutdown costs are excluded because they were unusual and non-recurring.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust\nlitigation settlements relates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market.  The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S. ", "original_text": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4136829b7b8a668a49192d1c31b31526012103c185e589d7280e471438a55b33", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a3088c9-089e-4387-ace4-2f1967e0dd6f", "node_type": "1", "metadata": {"window": "PharMEDium shutdown costs are excluded because they were unusual and non-recurring.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust\nlitigation settlements relates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market.  The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business. ", "original_text": "The gain from antitrust\nlitigation settlements relates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market. "}, "hash": "e4d5728be81f83665b3f9bdf40599953b840daba09f5e0ffd4a6cf2273fe1603", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "start_char_idx": 2631, "end_char_idx": 2788, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a3088c9-089e-4387-ace4-2f1967e0dd6f": {"__data__": {"id_": "8a3088c9-089e-4387-ace4-2f1967e0dd6f", "embedding": null, "metadata": {"window": "PharMEDium shutdown costs are excluded because they were unusual and non-recurring.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust\nlitigation settlements relates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market.  The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business. ", "original_text": "The gain from antitrust\nlitigation settlements relates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0d5cbb9245d9a80de70d279cf5de5ce9efe5ab02abbd2990b4454bc42d05c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2aee4e3a-f83d-486c-90af-9e825702a80b", "node_type": "1", "metadata": {"window": "PharMEDium remediation costs are excluded because they were unpredictable\nexpenses.  PharMEDium shutdown costs are excluded because they were unusual and non-recurring.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust\nlitigation settlements relates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market.  The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S.  Food and Drug Administration inspections. ", "original_text": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01ef7d704c5757869dd9259425c6538ef1081ee319dd285c787abe77c8b9be99", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4066649-479a-4441-9387-1b99e079abd5", "node_type": "1", "metadata": {"window": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust\nlitigation settlements relates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market.  The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n", "original_text": "The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S. "}, "hash": "c7ed338d2d0efd883e73754621d6190cb20c5050ca80af4e4136bd0211969e19", "class_name": "RelatedNodeInfo"}}, "text": "The gain from antitrust\nlitigation settlements relates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market. ", "start_char_idx": 2788, "end_char_idx": 3088, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4066649-479a-4441-9387-1b99e079abd5": {"__data__": {"id_": "a4066649-479a-4441-9387-1b99e079abd5", "embedding": null, "metadata": {"window": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust\nlitigation settlements relates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market.  The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n", "original_text": "The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0d5cbb9245d9a80de70d279cf5de5ce9efe5ab02abbd2990b4454bc42d05c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a3088c9-089e-4387-ace4-2f1967e0dd6f", "node_type": "1", "metadata": {"window": "PharMEDium shutdown costs are excluded because they were unusual and non-recurring.  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust\nlitigation settlements relates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market.  The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business. ", "original_text": "The gain from antitrust\nlitigation settlements relates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8da67640350554118bb1a5c90398fbf01bb2d0676509948b190a93e91e8425b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38e910dc-f2fe-4253-a975-9ac7a4498ba7", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust\nlitigation settlements relates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market.  The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment. ", "original_text": "Food and Drug Administration inspections. "}, "hash": "edbf246d4f5aeb8da592f30c7873f59ebba9f55fb95fe72f326d5b7b63d1e782", "class_name": "RelatedNodeInfo"}}, "text": "The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S. ", "start_char_idx": 3088, "end_char_idx": 3212, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38e910dc-f2fe-4253-a975-9ac7a4498ba7": {"__data__": {"id_": "38e910dc-f2fe-4253-a975-9ac7a4498ba7", "embedding": null, "metadata": {"window": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust\nlitigation settlements relates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market.  The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment. ", "original_text": "Food and Drug Administration inspections. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0d5cbb9245d9a80de70d279cf5de5ce9efe5ab02abbd2990b4454bc42d05c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4066649-479a-4441-9387-1b99e079abd5", "node_type": "1", "metadata": {"window": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust\nlitigation settlements relates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market.  The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n", "original_text": "The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8417cf4a891910b268385759ba8a40744862a1577cc027662b37c3bd9081f0b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57cf8892-f785-43df-a9ab-420c035bc6a8", "node_type": "1", "metadata": {"window": "The gain from antitrust\nlitigation settlements relates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market.  The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue. ", "original_text": "PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business. "}, "hash": "7027f1b1e64d9abd5237cfc3decb04569f08660c24a35ff8cc6ce767b716e204", "class_name": "RelatedNodeInfo"}}, "text": "Food and Drug Administration inspections. ", "start_char_idx": 3212, "end_char_idx": 3254, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57cf8892-f785-43df-a9ab-420c035bc6a8": {"__data__": {"id_": "57cf8892-f785-43df-a9ab-420c035bc6a8", "embedding": null, "metadata": {"window": "The gain from antitrust\nlitigation settlements relates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market.  The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue. ", "original_text": "PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0d5cbb9245d9a80de70d279cf5de5ce9efe5ab02abbd2990b4454bc42d05c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38e910dc-f2fe-4253-a975-9ac7a4498ba7", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust\nlitigation settlements relates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market.  The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment. ", "original_text": "Food and Drug Administration inspections. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7d3ff023c9c5ec432b947b1fd4c2f399a62c3abef4081744f3fba663fa359a1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0517d427-a449-41d1-ae28-1faae85f1ac7", "node_type": "1", "metadata": {"window": "The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies. ", "original_text": "LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n"}, "hash": "a3cdef101279a75d955d616a363c7c9ba7423228e9989ae25b98e493964eb8e0", "class_name": "RelatedNodeInfo"}}, "text": "PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business. ", "start_char_idx": 3254, "end_char_idx": 3370, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0517d427-a449-41d1-ae28-1faae85f1ac7": {"__data__": {"id_": "0517d427-a449-41d1-ae28-1faae85f1ac7", "embedding": null, "metadata": {"window": "The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies. ", "original_text": "LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0d5cbb9245d9a80de70d279cf5de5ce9efe5ab02abbd2990b4454bc42d05c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57cf8892-f785-43df-a9ab-420c035bc6a8", "node_type": "1", "metadata": {"window": "The gain from antitrust\nlitigation settlements relates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market.  The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue. ", "original_text": "PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2956191377b47eedd956a6ae862342162b686f98a610c41f4e8c24c0cf0a06d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "669cb27d-3ddd-4692-b57f-2072ab08ba8f", "node_type": "1", "metadata": {"window": "Food and Drug Administration inspections.  PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment. "}, "hash": "52882abbdb967e09440e0ad916455cd5a31025488d1379c95ef9c56265c29c3b", "class_name": "RelatedNodeInfo"}}, "text": "LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n", "start_char_idx": 3370, "end_char_idx": 3552, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "669cb27d-3ddd-4692-b57f-2072ab08ba8f": {"__data__": {"id_": "669cb27d-3ddd-4692-b57f-2072ab08ba8f", "embedding": null, "metadata": {"window": "Food and Drug Administration inspections.  PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0d5cbb9245d9a80de70d279cf5de5ce9efe5ab02abbd2990b4454bc42d05c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0517d427-a449-41d1-ae28-1faae85f1ac7", "node_type": "1", "metadata": {"window": "The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies. ", "original_text": "LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fd25c9f55d60d06651bab704a0339cc542df6e1a9cd2407859f92282c4666c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79fb7cb8-5279-46eb-88b1-7f3e3be069c4", "node_type": "1", "metadata": {"window": "PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\n23", "original_text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue. "}, "hash": "a8dc26d3aadc1e89a05e8852547fbc08fb29de0479c381582d0caea808bf2c88", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment. ", "start_char_idx": 3552, "end_char_idx": 3909, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79fb7cb8-5279-46eb-88b1-7f3e3be069c4": {"__data__": {"id_": "79fb7cb8-5279-46eb-88b1-7f3e3be069c4", "embedding": null, "metadata": {"window": "PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\n23", "original_text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0d5cbb9245d9a80de70d279cf5de5ce9efe5ab02abbd2990b4454bc42d05c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "669cb27d-3ddd-4692-b57f-2072ab08ba8f", "node_type": "1", "metadata": {"window": "Food and Drug Administration inspections.  PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f85f81441f33c20e6ca2db2a756714859d7c0b899dff96e10ea516352b2cd73d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40e1f09b-7f9e-4535-9a6e-eb0d047f7f5c", "node_type": "1", "metadata": {"window": "LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\n23", "original_text": "Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies. "}, "hash": "14f72413421185aa1311f2321c865cfcf5389eab7a0e5f2b917036c4a79b521a", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue. ", "start_char_idx": 3909, "end_char_idx": 4005, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40e1f09b-7f9e-4535-9a6e-eb0d047f7f5c": {"__data__": {"id_": "40e1f09b-7f9e-4535-9a6e-eb0d047f7f5c", "embedding": null, "metadata": {"window": "LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\n23", "original_text": "Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0d5cbb9245d9a80de70d279cf5de5ce9efe5ab02abbd2990b4454bc42d05c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79fb7cb8-5279-46eb-88b1-7f3e3be069c4", "node_type": "1", "metadata": {"window": "PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\n23", "original_text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "424ae156409c0b85e385c257742ff08135e5d22b08baaaad24625e085f57108d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8de97e96-03b9-4aa0-b0c0-1aafdf63c37f", "node_type": "1", "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\n23", "original_text": "We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring. "}, "hash": "18bc65fd643a31b925c2167857145ecca6f3f2c2ce9b16ab2665b28e9d0b26a5", "class_name": "RelatedNodeInfo"}}, "text": "Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies. ", "start_char_idx": 4005, "end_char_idx": 4167, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8de97e96-03b9-4aa0-b0c0-1aafdf63c37f": {"__data__": {"id_": "8de97e96-03b9-4aa0-b0c0-1aafdf63c37f", "embedding": null, "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\n23", "original_text": "We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0d5cbb9245d9a80de70d279cf5de5ce9efe5ab02abbd2990b4454bc42d05c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40e1f09b-7f9e-4535-9a6e-eb0d047f7f5c", "node_type": "1", "metadata": {"window": "LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\n23", "original_text": "Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eba8ee22bda3f394fb65576e433980b705816b9d9afa02c5b65d334c945daaf2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa58eb67-8727-48fe-8e59-2095a2fb2835", "node_type": "1", "metadata": {"window": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\n23", "original_text": "We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\n23"}, "hash": "230c2fbc53591d9eae7de219fe6d6e710f7d674ffc92258a22ce2c056bc8decb", "class_name": "RelatedNodeInfo"}}, "text": "We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring. ", "start_char_idx": 4167, "end_char_idx": 4279, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa58eb67-8727-48fe-8e59-2095a2fb2835": {"__data__": {"id_": "aa58eb67-8727-48fe-8e59-2095a2fb2835", "embedding": null, "metadata": {"window": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\n23", "original_text": "We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\n23", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0d5cbb9245d9a80de70d279cf5de5ce9efe5ab02abbd2990b4454bc42d05c29", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8de97e96-03b9-4aa0-b0c0-1aafdf63c37f", "node_type": "1", "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\n23", "original_text": "We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring. ", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1bdf3544518a396468ab1914b792c5560e478fcbc0daf7a0af23267e2b209ad7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "896ae604-b722-4e30-9809-1315986cb6a2", "node_type": "1", "metadata": {"window": "analysis of our ongoing operational performance.  The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "analysis of our ongoing operational performance. "}, "hash": "cd3d2ae0fa88f4f5b0a236316e89efc446a02f7ac0a0a8b55f250e5c018c39d4", "class_name": "RelatedNodeInfo"}}, "text": "We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\n23", "start_char_idx": 4279, "end_char_idx": 4617, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "896ae604-b722-4e30-9809-1315986cb6a2": {"__data__": {"id_": "896ae604-b722-4e30-9809-1315986cb6a2", "embedding": null, "metadata": {"window": "analysis of our ongoing operational performance.  The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "analysis of our ongoing operational performance. ", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fe04d1c-1513-4449-a463-b3501c9148e1", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "169cbb83ed74111ea3c1cffdd7e2018b8ab6943a90a5ded22469b7300a038655", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa58eb67-8727-48fe-8e59-2095a2fb2835", "node_type": "1", "metadata": {"window": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\n23", "original_text": "We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\n23", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29c2a4f7158bc0bc4b19c0e5fa981f3ecba5e5a77de215ee2c081f6831bcdd97", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69872798-c38b-429a-9fe5-259c1404fae0", "node_type": "1", "metadata": {"window": "analysis of our ongoing operational performance.  The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n"}, "hash": "9e0da300fb90b2dca17a5d15d899e7fa0cd97b517deb9c6f6afb28bf3a1a4bdf", "class_name": "RelatedNodeInfo"}}, "text": "analysis of our ongoing operational performance. ", "start_char_idx": 0, "end_char_idx": 49, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69872798-c38b-429a-9fe5-259c1404fae0": {"__data__": {"id_": "69872798-c38b-429a-9fe5-259c1404fae0", "embedding": null, "metadata": {"window": "analysis of our ongoing operational performance.  The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fe04d1c-1513-4449-a463-b3501c9148e1", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "169cbb83ed74111ea3c1cffdd7e2018b8ab6943a90a5ded22469b7300a038655", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "896ae604-b722-4e30-9809-1315986cb6a2", "node_type": "1", "metadata": {"window": "analysis of our ongoing operational performance.  The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "analysis of our ongoing operational performance. ", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "17c92e939d5297762e82b6fbae4ba4a3648e04972222031f091f54edc5fbd513", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e1846ed-725c-4982-a4e4-036b06e3370d", "node_type": "1", "metadata": {"window": "analysis of our ongoing operational performance.  The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. "}, "hash": "45f486d2398869b3edf48d5d9e901bbec6b95f132fb9e190f90759cfda3fb600", "class_name": "RelatedNodeInfo"}}, "text": "The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n", "start_char_idx": 49, "end_char_idx": 343, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e1846ed-725c-4982-a4e4-036b06e3370d": {"__data__": {"id_": "3e1846ed-725c-4982-a4e4-036b06e3370d", "embedding": null, "metadata": {"window": "analysis of our ongoing operational performance.  The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fe04d1c-1513-4449-a463-b3501c9148e1", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "169cbb83ed74111ea3c1cffdd7e2018b8ab6943a90a5ded22469b7300a038655", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69872798-c38b-429a-9fe5-259c1404fae0", "node_type": "1", "metadata": {"window": "analysis of our ongoing operational performance.  The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b26983e80ad295e41d3984f3a0e83e99aa1b2383833b19a3325d0798acb69ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9dd86cf3-99b9-492a-aaee-a7d12f7ced66", "node_type": "1", "metadata": {"window": "analysis of our ongoing operational performance.  The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and six months ended March 31, 2021 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n"}, "hash": "e978c8f6d12fca0c4ebf2aeb8488eeb867e7d04552c2bb3152487dd25fb8bd09", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "start_char_idx": 343, "end_char_idx": 592, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9dd86cf3-99b9-492a-aaee-a7d12f7ced66": {"__data__": {"id_": "9dd86cf3-99b9-492a-aaee-a7d12f7ced66", "embedding": null, "metadata": {"window": "analysis of our ongoing operational performance.  The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and six months ended March 31, 2021 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fe04d1c-1513-4449-a463-b3501c9148e1", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "169cbb83ed74111ea3c1cffdd7e2018b8ab6943a90a5ded22469b7300a038655", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e1846ed-725c-4982-a4e4-036b06e3370d", "node_type": "1", "metadata": {"window": "analysis of our ongoing operational performance.  The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db12d427db03ba6cec773ead5e4b88e6ec151b26ecfcf7428b0cd69dc01f7a6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca53759c-6de5-4885-9dee-cfce8df364c6", "node_type": "1", "metadata": {"window": "The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and six months ended March 31, 2021 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n"}, "hash": "216e80936803fb207c99631b216a19f1a5d5f6984774bcea10cd57c950ac612a", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "start_char_idx": 592, "end_char_idx": 685, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca53759c-6de5-4885-9dee-cfce8df364c6": {"__data__": {"id_": "ca53759c-6de5-4885-9dee-cfce8df364c6", "embedding": null, "metadata": {"window": "The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and six months ended March 31, 2021 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fe04d1c-1513-4449-a463-b3501c9148e1", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "169cbb83ed74111ea3c1cffdd7e2018b8ab6943a90a5ded22469b7300a038655", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9dd86cf3-99b9-492a-aaee-a7d12f7ced66", "node_type": "1", "metadata": {"window": "analysis of our ongoing operational performance.  The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and six months ended March 31, 2021 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c3350ba6a826d8716c344f18c6f79420662dcad38937e744dc12b2c09dbe643", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4cd5d840-7d27-4a46-a9d2-96aa20159ed3", "node_type": "1", "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and six months ended March 31, 2021 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. "}, "hash": "8aca1a096abc4c2367225054c36359c8a01d2ac34de0ad7be9029f351b59f626", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "start_char_idx": 685, "end_char_idx": 932, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4cd5d840-7d27-4a46-a9d2-96aa20159ed3": {"__data__": {"id_": "4cd5d840-7d27-4a46-a9d2-96aa20159ed3", "embedding": null, "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and six months ended March 31, 2021 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fe04d1c-1513-4449-a463-b3501c9148e1", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "169cbb83ed74111ea3c1cffdd7e2018b8ab6943a90a5ded22469b7300a038655", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca53759c-6de5-4885-9dee-cfce8df364c6", "node_type": "1", "metadata": {"window": "The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and six months ended March 31, 2021 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "598733ef27a5a29e5b251c3f3d45a8dc96f5836fadcd4388bafd54ea20e097bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8b001c0-d67b-4a52-a5e4-9e68ded9e93d", "node_type": "1", "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and six months ended March 31, 2021 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and six months ended March 31, 2021 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring. "}, "hash": "65413ddf3a0df6f1f3c1c37d5e521601c41042f5f3804e0dd788f9afe10b4b08", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "start_char_idx": 932, "end_char_idx": 1137, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8b001c0-d67b-4a52-a5e4-9e68ded9e93d": {"__data__": {"id_": "c8b001c0-d67b-4a52-a5e4-9e68ded9e93d", "embedding": null, "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and six months ended March 31, 2021 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and six months ended March 31, 2021 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring. ", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fe04d1c-1513-4449-a463-b3501c9148e1", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "169cbb83ed74111ea3c1cffdd7e2018b8ab6943a90a5ded22469b7300a038655", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4cd5d840-7d27-4a46-a9d2-96aa20159ed3", "node_type": "1", "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and six months ended March 31, 2021 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4491f8c10f8f4074298811796d0f6c41707804d2d6f60cb7bdad8ab1927616ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c60416ab-21c6-4647-8298-0827b8f0cdd1", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and six months ended March 31, 2021 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n"}, "hash": "8b995ffd4640982b16c4ddd0828a5e94b51774ef09a60552473c7686b972054e", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and six months ended March 31, 2021 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring. ", "start_char_idx": 1137, "end_char_idx": 1403, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c60416ab-21c6-4647-8298-0827b8f0cdd1": {"__data__": {"id_": "c60416ab-21c6-4647-8298-0827b8f0cdd1", "embedding": null, "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and six months ended March 31, 2021 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fe04d1c-1513-4449-a463-b3501c9148e1", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "169cbb83ed74111ea3c1cffdd7e2018b8ab6943a90a5ded22469b7300a038655", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8b001c0-d67b-4a52-a5e4-9e68ded9e93d", "node_type": "1", "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and six months ended March 31, 2021 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and six months ended March 31, 2021 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring. ", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "05634b243e2b8c606c20372cac48869e22bf46e2d1ab4b0d3ee3656e70ad47de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b77091d-22d6-43a3-9c71-c7cfe22b5167", "node_type": "1", "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and six months ended March 31, 2021 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020 and the six months ended\nMarch 31, 2021. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. "}, "hash": "c183bcc7ec0e8a3d6768785826e74ca3dc7f98c8ad69bc4503168e98c38953ea", "class_name": "RelatedNodeInfo"}}, "text": "Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n", "start_char_idx": 1403, "end_char_idx": 1568, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b77091d-22d6-43a3-9c71-c7cfe22b5167": {"__data__": {"id_": "7b77091d-22d6-43a3-9c71-c7cfe22b5167", "embedding": null, "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and six months ended March 31, 2021 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020 and the six months ended\nMarch 31, 2021. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fe04d1c-1513-4449-a463-b3501c9148e1", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "169cbb83ed74111ea3c1cffdd7e2018b8ab6943a90a5ded22469b7300a038655", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c60416ab-21c6-4647-8298-0827b8f0cdd1", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and six months ended March 31, 2021 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "919baaab96e7f99786a4704dfc4c42a33fbb10a6961ee48e0088675d69b6b442", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df7a2a6f-14e0-4869-b81d-c4c96b01e0f6", "node_type": "1", "metadata": {"window": "In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and six months ended March 31, 2021 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020 and the six months ended\nMarch 31, 2021.  Further, certain expenses relating to tax reform in Switzerland is excluded from adjusted income tax expense\nfor the three and six months ended March 31, 2021. ", "original_text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n"}, "hash": "f4c019bd7d5f00a2be1ae70071a61e4b3d827d1836b1532a94c73abf456f481a", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "start_char_idx": 1568, "end_char_idx": 1765, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df7a2a6f-14e0-4869-b81d-c4c96b01e0f6": {"__data__": {"id_": "df7a2a6f-14e0-4869-b81d-c4c96b01e0f6", "embedding": null, "metadata": {"window": "In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and six months ended March 31, 2021 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020 and the six months ended\nMarch 31, 2021.  Further, certain expenses relating to tax reform in Switzerland is excluded from adjusted income tax expense\nfor the three and six months ended March 31, 2021. ", "original_text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fe04d1c-1513-4449-a463-b3501c9148e1", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "169cbb83ed74111ea3c1cffdd7e2018b8ab6943a90a5ded22469b7300a038655", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b77091d-22d6-43a3-9c71-c7cfe22b5167", "node_type": "1", "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and six months ended March 31, 2021 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020 and the six months ended\nMarch 31, 2021. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "33ccfff64af0eff471474ad8748c2eb30cbf1833ceb590227911269f3b57e3e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "578314c2-7dac-4b8c-9a2a-d27c4b51c17d", "node_type": "1", "metadata": {"window": "Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020 and the six months ended\nMarch 31, 2021.  Further, certain expenses relating to tax reform in Switzerland is excluded from adjusted income tax expense\nfor the three and six months ended March 31, 2021.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n"}, "hash": "6952ce908ef7040c40b9b7e0f3c46e07f8b7d1fbed8daf555bd7e913109e61d2", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "start_char_idx": 1765, "end_char_idx": 2037, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "578314c2-7dac-4b8c-9a2a-d27c4b51c17d": {"__data__": {"id_": "578314c2-7dac-4b8c-9a2a-d27c4b51c17d", "embedding": null, "metadata": {"window": "Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020 and the six months ended\nMarch 31, 2021.  Further, certain expenses relating to tax reform in Switzerland is excluded from adjusted income tax expense\nfor the three and six months ended March 31, 2021.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fe04d1c-1513-4449-a463-b3501c9148e1", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "169cbb83ed74111ea3c1cffdd7e2018b8ab6943a90a5ded22469b7300a038655", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df7a2a6f-14e0-4869-b81d-c4c96b01e0f6", "node_type": "1", "metadata": {"window": "In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and six months ended March 31, 2021 is\nexcluded from adjusted income before income taxes because it is unusual, non-operating, and non-recurring.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020 and the six months ended\nMarch 31, 2021.  Further, certain expenses relating to tax reform in Switzerland is excluded from adjusted income tax expense\nfor the three and six months ended March 31, 2021. ", "original_text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "72ce2d6e0cd0d2d6c811d67e998cec6060f5e7b2a02b094684cb97154136d626", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb7f3eed-4951-4eed-8dbc-c5942329600d", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020 and the six months ended\nMarch 31, 2021.  Further, certain expenses relating to tax reform in Switzerland is excluded from adjusted income tax expense\nfor the three and six months ended March 31, 2021.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. ", "original_text": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020 and the six months ended\nMarch 31, 2021. "}, "hash": "9a9e539175c54dbeedff4d881feb7304ae89c9c2b4726011b4cb669b421271be", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "start_char_idx": 2037, "end_char_idx": 2275, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb7f3eed-4951-4eed-8dbc-c5942329600d": {"__data__": {"id_": "eb7f3eed-4951-4eed-8dbc-c5942329600d", "embedding": null, "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020 and the six months ended\nMarch 31, 2021.  Further, certain expenses relating to tax reform in Switzerland is excluded from adjusted income tax expense\nfor the three and six months ended March 31, 2021.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. ", "original_text": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020 and the six months ended\nMarch 31, 2021. ", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fe04d1c-1513-4449-a463-b3501c9148e1", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "169cbb83ed74111ea3c1cffdd7e2018b8ab6943a90a5ded22469b7300a038655", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "578314c2-7dac-4b8c-9a2a-d27c4b51c17d", "node_type": "1", "metadata": {"window": "Management\nbelieves that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s\nadjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020 and the six months ended\nMarch 31, 2021.  Further, certain expenses relating to tax reform in Switzerland is excluded from adjusted income tax expense\nfor the three and six months ended March 31, 2021.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bf3093f8663020a96623d37b750d5a922fa7c093704973b40e0914f08d66b4a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b110535c-4abe-41b6-a6f6-ea0bc8e33cba", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020 and the six months ended\nMarch 31, 2021.  Further, certain expenses relating to tax reform in Switzerland is excluded from adjusted income tax expense\nfor the three and six months ended March 31, 2021.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n", "original_text": "Further, certain expenses relating to tax reform in Switzerland is excluded from adjusted income tax expense\nfor the three and six months ended March 31, 2021. "}, "hash": "e094f227ccb7a43cf00b75e2825b4a38bd7a4275e1d10af5b4412883d726719a", "class_name": "RelatedNodeInfo"}}, "text": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020 and the six months ended\nMarch 31, 2021. ", "start_char_idx": 2275, "end_char_idx": 2648, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b110535c-4abe-41b6-a6f6-ea0bc8e33cba": {"__data__": {"id_": "b110535c-4abe-41b6-a6f6-ea0bc8e33cba", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020 and the six months ended\nMarch 31, 2021.  Further, certain expenses relating to tax reform in Switzerland is excluded from adjusted income tax expense\nfor the three and six months ended March 31, 2021.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n", "original_text": "Further, certain expenses relating to tax reform in Switzerland is excluded from adjusted income tax expense\nfor the three and six months ended March 31, 2021. ", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fe04d1c-1513-4449-a463-b3501c9148e1", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "169cbb83ed74111ea3c1cffdd7e2018b8ab6943a90a5ded22469b7300a038655", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb7f3eed-4951-4eed-8dbc-c5942329600d", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020 and the six months ended\nMarch 31, 2021.  Further, certain expenses relating to tax reform in Switzerland is excluded from adjusted income tax expense\nfor the three and six months ended March 31, 2021.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. ", "original_text": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020 and the six months ended\nMarch 31, 2021. ", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e0f20091eb3044e5486e505646db90addf01ae4ce1657dc8c16ce991b9d81ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb0d966c-5d29-40e5-8f39-b0e5e83f4d92", "node_type": "1", "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020 and the six months ended\nMarch 31, 2021.  Further, certain expenses relating to tax reform in Switzerland is excluded from adjusted income tax expense\nfor the three and six months ended March 31, 2021.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "original_text": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n"}, "hash": "d5c99e4237082fa79b6744c6e861776d18ccbadd2a778f98a8721a2bb8db3c50", "class_name": "RelatedNodeInfo"}}, "text": "Further, certain expenses relating to tax reform in Switzerland is excluded from adjusted income tax expense\nfor the three and six months ended March 31, 2021. ", "start_char_idx": 2648, "end_char_idx": 2808, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb0d966c-5d29-40e5-8f39-b0e5e83f4d92": {"__data__": {"id_": "cb0d966c-5d29-40e5-8f39-b0e5e83f4d92", "embedding": null, "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020 and the six months ended\nMarch 31, 2021.  Further, certain expenses relating to tax reform in Switzerland is excluded from adjusted income tax expense\nfor the three and six months ended March 31, 2021.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "original_text": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fe04d1c-1513-4449-a463-b3501c9148e1", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "169cbb83ed74111ea3c1cffdd7e2018b8ab6943a90a5ded22469b7300a038655", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b110535c-4abe-41b6-a6f6-ea0bc8e33cba", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020 and the six months ended\nMarch 31, 2021.  Further, certain expenses relating to tax reform in Switzerland is excluded from adjusted income tax expense\nfor the three and six months ended March 31, 2021.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n", "original_text": "Further, certain expenses relating to tax reform in Switzerland is excluded from adjusted income tax expense\nfor the three and six months ended March 31, 2021. ", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d89c47b3c84da6c818ec4533604505db4e3723b99fbbe541f5b4e1c419ac2bab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5fc4dafe-c4a8-40e7-9927-bc78f3bfb5ed", "node_type": "1", "metadata": {"window": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020 and the six months ended\nMarch 31, 2021.  Further, certain expenses relating to tax reform in Switzerland is excluded from adjusted income tax expense\nfor the three and six months ended March 31, 2021.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. "}, "hash": "67301d125effae913760c2b417ff0e9a436015d00b1dcd3fb7b2e505e9906673", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "start_char_idx": 2808, "end_char_idx": 3053, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5fc4dafe-c4a8-40e7-9927-bc78f3bfb5ed": {"__data__": {"id_": "5fc4dafe-c4a8-40e7-9927-bc78f3bfb5ed", "embedding": null, "metadata": {"window": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020 and the six months ended\nMarch 31, 2021.  Further, certain expenses relating to tax reform in Switzerland is excluded from adjusted income tax expense\nfor the three and six months ended March 31, 2021.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. ", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fe04d1c-1513-4449-a463-b3501c9148e1", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "169cbb83ed74111ea3c1cffdd7e2018b8ab6943a90a5ded22469b7300a038655", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb0d966c-5d29-40e5-8f39-b0e5e83f4d92", "node_type": "1", "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020 and the six months ended\nMarch 31, 2021.  Further, certain expenses relating to tax reform in Switzerland is excluded from adjusted income tax expense\nfor the three and six months ended March 31, 2021.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "original_text": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "247622b259ebe7bc44e8c32182b507670c4fc0a543a4fd6014d6925a5ce65cec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7304958d-7def-4ba2-9cf3-e298eaffcf5f", "node_type": "1", "metadata": {"window": "Further, certain expenses relating to tax reform in Switzerland is excluded from adjusted income tax expense\nfor the three and six months ended March 31, 2021.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nand a contingent consideration adjustment, in each case net of the tax effect calculated using the applicable effective tax rate\nfor those items. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n"}, "hash": "9239e0fdee831c14f35455ec987c680f52e86036c41f389f9ffdae6306221879", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. ", "start_char_idx": 3053, "end_char_idx": 3323, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7304958d-7def-4ba2-9cf3-e298eaffcf5f": {"__data__": {"id_": "7304958d-7def-4ba2-9cf3-e298eaffcf5f", "embedding": null, "metadata": {"window": "Further, certain expenses relating to tax reform in Switzerland is excluded from adjusted income tax expense\nfor the three and six months ended March 31, 2021.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nand a contingent consideration adjustment, in each case net of the tax effect calculated using the applicable effective tax rate\nfor those items. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fe04d1c-1513-4449-a463-b3501c9148e1", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "169cbb83ed74111ea3c1cffdd7e2018b8ab6943a90a5ded22469b7300a038655", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5fc4dafe-c4a8-40e7-9927-bc78f3bfb5ed", "node_type": "1", "metadata": {"window": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020 and the six months ended\nMarch 31, 2021.  Further, certain expenses relating to tax reform in Switzerland is excluded from adjusted income tax expense\nfor the three and six months ended March 31, 2021.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. ", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "561b5824e0eb79ff89d8a3f4f80970de9b0fe9a1b3bad8cdaf1e68d46342612c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c8ab8e2-049e-49fd-93c6-31df417baff4", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nand a contingent consideration adjustment, in each case net of the tax effect calculated using the applicable effective tax rate\nfor those items.  In addition, the per share impact of certain discrete tax benefits primarily attributable to the income tax\ndeduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act for the three and\nsix months ended March 31, 2020 and the six months ended March 31, 2021, and the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and six months\nended March 31, 2021. ", "original_text": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. "}, "hash": "b2ece0ada06be4267d8e6d4024a3b1d3e5143f6fa38f94a095c3733434b66595", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n", "start_char_idx": 3323, "end_char_idx": 3486, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c8ab8e2-049e-49fd-93c6-31df417baff4": {"__data__": {"id_": "3c8ab8e2-049e-49fd-93c6-31df417baff4", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nand a contingent consideration adjustment, in each case net of the tax effect calculated using the applicable effective tax rate\nfor those items.  In addition, the per share impact of certain discrete tax benefits primarily attributable to the income tax\ndeduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act for the three and\nsix months ended March 31, 2020 and the six months ended March 31, 2021, and the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and six months\nended March 31, 2021. ", "original_text": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fe04d1c-1513-4449-a463-b3501c9148e1", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "169cbb83ed74111ea3c1cffdd7e2018b8ab6943a90a5ded22469b7300a038655", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7304958d-7def-4ba2-9cf3-e298eaffcf5f", "node_type": "1", "metadata": {"window": "Further, certain expenses relating to tax reform in Switzerland is excluded from adjusted income tax expense\nfor the three and six months ended March 31, 2021.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nand a contingent consideration adjustment, in each case net of the tax effect calculated using the applicable effective tax rate\nfor those items. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "086758f63ba129327956a3424af514a5ec4c3f4e4e50ef9175c8f5356d43cb0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76029f32-88f5-4b60-95dd-e2feb2c1f687", "node_type": "1", "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nand a contingent consideration adjustment, in each case net of the tax effect calculated using the applicable effective tax rate\nfor those items.  In addition, the per share impact of certain discrete tax benefits primarily attributable to the income tax\ndeduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act for the three and\nsix months ended March 31, 2020 and the six months ended March 31, 2021, and the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and six months\nended March 31, 2021.  Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n"}, "hash": "337189ed4b682bf3c799c83a0eb60fc0088c28b0f7571ed6a4b0b31cc560f021", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "start_char_idx": 3486, "end_char_idx": 3655, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76029f32-88f5-4b60-95dd-e2feb2c1f687": {"__data__": {"id_": "76029f32-88f5-4b60-95dd-e2feb2c1f687", "embedding": null, "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nand a contingent consideration adjustment, in each case net of the tax effect calculated using the applicable effective tax rate\nfor those items.  In addition, the per share impact of certain discrete tax benefits primarily attributable to the income tax\ndeduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act for the three and\nsix months ended March 31, 2020 and the six months ended March 31, 2021, and the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and six months\nended March 31, 2021.  Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fe04d1c-1513-4449-a463-b3501c9148e1", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "169cbb83ed74111ea3c1cffdd7e2018b8ab6943a90a5ded22469b7300a038655", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c8ab8e2-049e-49fd-93c6-31df417baff4", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nand a contingent consideration adjustment, in each case net of the tax effect calculated using the applicable effective tax rate\nfor those items.  In addition, the per share impact of certain discrete tax benefits primarily attributable to the income tax\ndeduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act for the three and\nsix months ended March 31, 2020 and the six months ended March 31, 2021, and the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and six months\nended March 31, 2021. ", "original_text": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "245677ba4af50813dc32286047843612b8f6b457c87f452848146a255c547aef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fdb325b9-23cd-46f9-8b83-b6d8ecd11a8b", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nand a contingent consideration adjustment, in each case net of the tax effect calculated using the applicable effective tax rate\nfor those items.  In addition, the per share impact of certain discrete tax benefits primarily attributable to the income tax\ndeduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act for the three and\nsix months ended March 31, 2020 and the six months ended March 31, 2021, and the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and six months\nended March 31, 2021.  Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense and\noperating income and has previously provided non-GAAP fiscal year 2021 guidance for effective income tax rate. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nand a contingent consideration adjustment, in each case net of the tax effect calculated using the applicable effective tax rate\nfor those items. "}, "hash": "3d670869e06c05979b282d4fc43a9ef341a218ac6002fc030740931dd565e6d9", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "start_char_idx": 3655, "end_char_idx": 3900, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fdb325b9-23cd-46f9-8b83-b6d8ecd11a8b": {"__data__": {"id_": "fdb325b9-23cd-46f9-8b83-b6d8ecd11a8b", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nand a contingent consideration adjustment, in each case net of the tax effect calculated using the applicable effective tax rate\nfor those items.  In addition, the per share impact of certain discrete tax benefits primarily attributable to the income tax\ndeduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act for the three and\nsix months ended March 31, 2020 and the six months ended March 31, 2021, and the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and six months\nended March 31, 2021.  Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense and\noperating income and has previously provided non-GAAP fiscal year 2021 guidance for effective income tax rate. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nand a contingent consideration adjustment, in each case net of the tax effect calculated using the applicable effective tax rate\nfor those items. ", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fe04d1c-1513-4449-a463-b3501c9148e1", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "169cbb83ed74111ea3c1cffdd7e2018b8ab6943a90a5ded22469b7300a038655", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76029f32-88f5-4b60-95dd-e2feb2c1f687", "node_type": "1", "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nand a contingent consideration adjustment, in each case net of the tax effect calculated using the applicable effective tax rate\nfor those items.  In addition, the per share impact of certain discrete tax benefits primarily attributable to the income tax\ndeduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act for the three and\nsix months ended March 31, 2020 and the six months ended March 31, 2021, and the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and six months\nended March 31, 2021.  Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74613dd4adcdabdd456899cf7da56b425e3308a8bcc13569fedf3ee67efa154b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3ec5e0a-f817-4144-ab80-b4ef2257c053", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nand a contingent consideration adjustment, in each case net of the tax effect calculated using the applicable effective tax rate\nfor those items.  In addition, the per share impact of certain discrete tax benefits primarily attributable to the income tax\ndeduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act for the three and\nsix months ended March 31, 2020 and the six months ended March 31, 2021, and the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and six months\nended March 31, 2021.  Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense and\noperating income and has previously provided non-GAAP fiscal year 2021 guidance for effective income tax rate.  The guidance for\neach metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as well\nas significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-recurring\nor non-cash in nature. ", "original_text": "In addition, the per share impact of certain discrete tax benefits primarily attributable to the income tax\ndeduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act for the three and\nsix months ended March 31, 2020 and the six months ended March 31, 2021, and the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and six months\nended March 31, 2021. "}, "hash": "1e570063fc1e9226e9b3c0e91c66f51b835b13055a2563c8b2b897a3622569ee", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nand a contingent consideration adjustment, in each case net of the tax effect calculated using the applicable effective tax rate\nfor those items. ", "start_char_idx": 3900, "end_char_idx": 4406, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3ec5e0a-f817-4144-ab80-b4ef2257c053": {"__data__": {"id_": "d3ec5e0a-f817-4144-ab80-b4ef2257c053", "embedding": null, "metadata": {"window": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nand a contingent consideration adjustment, in each case net of the tax effect calculated using the applicable effective tax rate\nfor those items.  In addition, the per share impact of certain discrete tax benefits primarily attributable to the income tax\ndeduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act for the three and\nsix months ended March 31, 2020 and the six months ended March 31, 2021, and the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and six months\nended March 31, 2021.  Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense and\noperating income and has previously provided non-GAAP fiscal year 2021 guidance for effective income tax rate.  The guidance for\neach metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as well\nas significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-recurring\nor non-cash in nature. ", "original_text": "In addition, the per share impact of certain discrete tax benefits primarily attributable to the income tax\ndeduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act for the three and\nsix months ended March 31, 2020 and the six months ended March 31, 2021, and the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and six months\nended March 31, 2021. ", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fe04d1c-1513-4449-a463-b3501c9148e1", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "169cbb83ed74111ea3c1cffdd7e2018b8ab6943a90a5ded22469b7300a038655", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fdb325b9-23cd-46f9-8b83-b6d8ecd11a8b", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nand a contingent consideration adjustment, in each case net of the tax effect calculated using the applicable effective tax rate\nfor those items.  In addition, the per share impact of certain discrete tax benefits primarily attributable to the income tax\ndeduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act for the three and\nsix months ended March 31, 2020 and the six months ended March 31, 2021, and the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and six months\nended March 31, 2021.  Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense and\noperating income and has previously provided non-GAAP fiscal year 2021 guidance for effective income tax rate. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nand a contingent consideration adjustment, in each case net of the tax effect calculated using the applicable effective tax rate\nfor those items. ", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "062aefd4f413d67b98bf12bd870ee226b369ec884618f98bacee1e5375d832e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b84b4bcd-878f-495b-b364-3caf7b128544", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nand a contingent consideration adjustment, in each case net of the tax effect calculated using the applicable effective tax rate\nfor those items.  In addition, the per share impact of certain discrete tax benefits primarily attributable to the income tax\ndeduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act for the three and\nsix months ended March 31, 2020 and the six months ended March 31, 2021, and the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and six months\nended March 31, 2021.  Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense and\noperating income and has previously provided non-GAAP fiscal year 2021 guidance for effective income tax rate.  The guidance for\neach metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as well\nas significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-recurring\nor non-cash in nature.  In addition, it has previously provided fiscal year 2021 adjusted free cash flow guidance. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n"}, "hash": "b415e3159c8c87601086ba149e0e3a0438e941c1948b00dba8f19f01d1693c8c", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the per share impact of certain discrete tax benefits primarily attributable to the income tax\ndeduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act for the three and\nsix months ended March 31, 2020 and the six months ended March 31, 2021, and the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and six months\nended March 31, 2021. ", "start_char_idx": 4406, "end_char_idx": 4900, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b84b4bcd-878f-495b-b364-3caf7b128544": {"__data__": {"id_": "b84b4bcd-878f-495b-b364-3caf7b128544", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nand a contingent consideration adjustment, in each case net of the tax effect calculated using the applicable effective tax rate\nfor those items.  In addition, the per share impact of certain discrete tax benefits primarily attributable to the income tax\ndeduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act for the three and\nsix months ended March 31, 2020 and the six months ended March 31, 2021, and the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and six months\nended March 31, 2021.  Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense and\noperating income and has previously provided non-GAAP fiscal year 2021 guidance for effective income tax rate.  The guidance for\neach metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as well\nas significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-recurring\nor non-cash in nature.  In addition, it has previously provided fiscal year 2021 adjusted free cash flow guidance. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fe04d1c-1513-4449-a463-b3501c9148e1", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "169cbb83ed74111ea3c1cffdd7e2018b8ab6943a90a5ded22469b7300a038655", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3ec5e0a-f817-4144-ab80-b4ef2257c053", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nand a contingent consideration adjustment, in each case net of the tax effect calculated using the applicable effective tax rate\nfor those items.  In addition, the per share impact of certain discrete tax benefits primarily attributable to the income tax\ndeduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act for the three and\nsix months ended March 31, 2020 and the six months ended March 31, 2021, and the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and six months\nended March 31, 2021.  Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense and\noperating income and has previously provided non-GAAP fiscal year 2021 guidance for effective income tax rate.  The guidance for\neach metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as well\nas significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-recurring\nor non-cash in nature. ", "original_text": "In addition, the per share impact of certain discrete tax benefits primarily attributable to the income tax\ndeduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act for the three and\nsix months ended March 31, 2020 and the six months ended March 31, 2021, and the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and six months\nended March 31, 2021. ", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ef270a93b17b347a47bd9259efb04f444669e62aab6e27d1b9cfb9b009e5709", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e84c4117-2e98-4e4a-8182-47defdff8502", "node_type": "1", "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nand a contingent consideration adjustment, in each case net of the tax effect calculated using the applicable effective tax rate\nfor those items.  In addition, the per share impact of certain discrete tax benefits primarily attributable to the income tax\ndeduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act for the three and\nsix months ended March 31, 2020 and the six months ended March 31, 2021, and the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and six months\nended March 31, 2021.  Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense and\noperating income and has previously provided non-GAAP fiscal year 2021 guidance for effective income tax rate.  The guidance for\neach metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as well\nas significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-recurring\nor non-cash in nature.  In addition, it has previously provided fiscal year 2021 adjusted free cash flow guidance.  For fiscal year 2021,\n24", "original_text": "In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense and\noperating income and has previously provided non-GAAP fiscal year 2021 guidance for effective income tax rate. "}, "hash": "d3c8248e315d6dab05473c6f6d1d1e2bae32ec35710a5cc49f0fe41118593673", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n", "start_char_idx": 4900, "end_char_idx": 5254, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e84c4117-2e98-4e4a-8182-47defdff8502": {"__data__": {"id_": "e84c4117-2e98-4e4a-8182-47defdff8502", "embedding": null, "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nand a contingent consideration adjustment, in each case net of the tax effect calculated using the applicable effective tax rate\nfor those items.  In addition, the per share impact of certain discrete tax benefits primarily attributable to the income tax\ndeduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act for the three and\nsix months ended March 31, 2020 and the six months ended March 31, 2021, and the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and six months\nended March 31, 2021.  Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense and\noperating income and has previously provided non-GAAP fiscal year 2021 guidance for effective income tax rate.  The guidance for\neach metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as well\nas significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-recurring\nor non-cash in nature.  In addition, it has previously provided fiscal year 2021 adjusted free cash flow guidance.  For fiscal year 2021,\n24", "original_text": "In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense and\noperating income and has previously provided non-GAAP fiscal year 2021 guidance for effective income tax rate. ", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fe04d1c-1513-4449-a463-b3501c9148e1", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "169cbb83ed74111ea3c1cffdd7e2018b8ab6943a90a5ded22469b7300a038655", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b84b4bcd-878f-495b-b364-3caf7b128544", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nand a contingent consideration adjustment, in each case net of the tax effect calculated using the applicable effective tax rate\nfor those items.  In addition, the per share impact of certain discrete tax benefits primarily attributable to the income tax\ndeduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act for the three and\nsix months ended March 31, 2020 and the six months ended March 31, 2021, and the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and six months\nended March 31, 2021.  Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense and\noperating income and has previously provided non-GAAP fiscal year 2021 guidance for effective income tax rate.  The guidance for\neach metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as well\nas significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-recurring\nor non-cash in nature.  In addition, it has previously provided fiscal year 2021 adjusted free cash flow guidance. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2a2e55cfa5be41c64d91fb48f1347ac5aef4392b54a34b2436d7c6ee07699b94", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a102aadc-c173-4eb0-ae8e-3406a012b9ef", "node_type": "1", "metadata": {"window": "In addition, the per share impact of certain discrete tax benefits primarily attributable to the income tax\ndeduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act for the three and\nsix months ended March 31, 2020 and the six months ended March 31, 2021, and the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and six months\nended March 31, 2021.  Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense and\noperating income and has previously provided non-GAAP fiscal year 2021 guidance for effective income tax rate.  The guidance for\neach metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as well\nas significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-recurring\nor non-cash in nature.  In addition, it has previously provided fiscal year 2021 adjusted free cash flow guidance.  For fiscal year 2021,\n24", "original_text": "The guidance for\neach metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as well\nas significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-recurring\nor non-cash in nature. "}, "hash": "dc438ad5dd6bf68243ebe66ce8ed291b206eb5b250bcc127677e0dda7b34ef78", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense and\noperating income and has previously provided non-GAAP fiscal year 2021 guidance for effective income tax rate. ", "start_char_idx": 5254, "end_char_idx": 5491, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a102aadc-c173-4eb0-ae8e-3406a012b9ef": {"__data__": {"id_": "a102aadc-c173-4eb0-ae8e-3406a012b9ef", "embedding": null, "metadata": {"window": "In addition, the per share impact of certain discrete tax benefits primarily attributable to the income tax\ndeduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act for the three and\nsix months ended March 31, 2020 and the six months ended March 31, 2021, and the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and six months\nended March 31, 2021.  Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense and\noperating income and has previously provided non-GAAP fiscal year 2021 guidance for effective income tax rate.  The guidance for\neach metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as well\nas significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-recurring\nor non-cash in nature.  In addition, it has previously provided fiscal year 2021 adjusted free cash flow guidance.  For fiscal year 2021,\n24", "original_text": "The guidance for\neach metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as well\nas significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-recurring\nor non-cash in nature. ", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fe04d1c-1513-4449-a463-b3501c9148e1", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "169cbb83ed74111ea3c1cffdd7e2018b8ab6943a90a5ded22469b7300a038655", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e84c4117-2e98-4e4a-8182-47defdff8502", "node_type": "1", "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nand a contingent consideration adjustment, in each case net of the tax effect calculated using the applicable effective tax rate\nfor those items.  In addition, the per share impact of certain discrete tax benefits primarily attributable to the income tax\ndeduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act for the three and\nsix months ended March 31, 2020 and the six months ended March 31, 2021, and the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and six months\nended March 31, 2021.  Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense and\noperating income and has previously provided non-GAAP fiscal year 2021 guidance for effective income tax rate.  The guidance for\neach metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as well\nas significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-recurring\nor non-cash in nature.  In addition, it has previously provided fiscal year 2021 adjusted free cash flow guidance.  For fiscal year 2021,\n24", "original_text": "In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense and\noperating income and has previously provided non-GAAP fiscal year 2021 guidance for effective income tax rate. ", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9155a2368d8e618ee1b0306c9d183c4b99ade17109430449a009acc533a6eaf2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e96638c-178f-486c-a836-85990b3b8dfa", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense and\noperating income and has previously provided non-GAAP fiscal year 2021 guidance for effective income tax rate.  The guidance for\neach metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as well\nas significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-recurring\nor non-cash in nature.  In addition, it has previously provided fiscal year 2021 adjusted free cash flow guidance.  For fiscal year 2021,\n24", "original_text": "In addition, it has previously provided fiscal year 2021 adjusted free cash flow guidance. "}, "hash": "e2ce309c0668509c72b59067028e0304446365c1a82041d9a25f67a04f984be1", "class_name": "RelatedNodeInfo"}}, "text": "The guidance for\neach metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as well\nas significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-recurring\nor non-cash in nature. ", "start_char_idx": 5491, "end_char_idx": 5794, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e96638c-178f-486c-a836-85990b3b8dfa": {"__data__": {"id_": "5e96638c-178f-486c-a836-85990b3b8dfa", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense and\noperating income and has previously provided non-GAAP fiscal year 2021 guidance for effective income tax rate.  The guidance for\neach metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as well\nas significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-recurring\nor non-cash in nature.  In addition, it has previously provided fiscal year 2021 adjusted free cash flow guidance.  For fiscal year 2021,\n24", "original_text": "In addition, it has previously provided fiscal year 2021 adjusted free cash flow guidance. ", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fe04d1c-1513-4449-a463-b3501c9148e1", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "169cbb83ed74111ea3c1cffdd7e2018b8ab6943a90a5ded22469b7300a038655", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a102aadc-c173-4eb0-ae8e-3406a012b9ef", "node_type": "1", "metadata": {"window": "In addition, the per share impact of certain discrete tax benefits primarily attributable to the income tax\ndeduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act for the three and\nsix months ended March 31, 2020 and the six months ended March 31, 2021, and the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and six months\nended March 31, 2021.  Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense and\noperating income and has previously provided non-GAAP fiscal year 2021 guidance for effective income tax rate.  The guidance for\neach metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as well\nas significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-recurring\nor non-cash in nature.  In addition, it has previously provided fiscal year 2021 adjusted free cash flow guidance.  For fiscal year 2021,\n24", "original_text": "The guidance for\neach metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as well\nas significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-recurring\nor non-cash in nature. ", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "742c0d2f8dfb7ee7c87ac619768159de23282338478abba6b4b4606dd39cdc1d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "369eb69f-0486-4722-b985-a0eba6e588ce", "node_type": "1", "metadata": {"window": "In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense and\noperating income and has previously provided non-GAAP fiscal year 2021 guidance for effective income tax rate.  The guidance for\neach metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as well\nas significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-recurring\nor non-cash in nature.  In addition, it has previously provided fiscal year 2021 adjusted free cash flow guidance.  For fiscal year 2021,\n24", "original_text": "For fiscal year 2021,\n24"}, "hash": "5416ebf279fb770de695b9eb88bb8ff28db437db646832ec8660adb27ea3422f", "class_name": "RelatedNodeInfo"}}, "text": "In addition, it has previously provided fiscal year 2021 adjusted free cash flow guidance. ", "start_char_idx": 5794, "end_char_idx": 5885, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "369eb69f-0486-4722-b985-a0eba6e588ce": {"__data__": {"id_": "369eb69f-0486-4722-b985-a0eba6e588ce", "embedding": null, "metadata": {"window": "In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense and\noperating income and has previously provided non-GAAP fiscal year 2021 guidance for effective income tax rate.  The guidance for\neach metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as well\nas significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-recurring\nor non-cash in nature.  In addition, it has previously provided fiscal year 2021 adjusted free cash flow guidance.  For fiscal year 2021,\n24", "original_text": "For fiscal year 2021,\n24", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fe04d1c-1513-4449-a463-b3501c9148e1", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "169cbb83ed74111ea3c1cffdd7e2018b8ab6943a90a5ded22469b7300a038655", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e96638c-178f-486c-a836-85990b3b8dfa", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense and\noperating income and has previously provided non-GAAP fiscal year 2021 guidance for effective income tax rate.  The guidance for\neach metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as well\nas significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-recurring\nor non-cash in nature.  In addition, it has previously provided fiscal year 2021 adjusted free cash flow guidance.  For fiscal year 2021,\n24", "original_text": "In addition, it has previously provided fiscal year 2021 adjusted free cash flow guidance. ", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d25dcacef81d7316aed8048baeaa21b629c2f5f6608d0db36550c99eb9e86e56", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9526277c-8e13-493b-a028-5bd0888eabaf", "node_type": "1", "metadata": {"window": "we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating activities, excluding\nother significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus capital expenditures.\n For the six months ended March 31, 2021 adjusted free cash flow of $297.5 million consisted of net cash provided by operating\nactivities of $449.2 million minus capital expenditures of $151.6 million.  The Company does not provide forward looking guidance\non a GAAP basis for such metrics because certain financial information, the probable significance of which cannot be determined, is\nnot available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation\nor deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "original_text": "we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating activities, excluding\nother significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus capital expenditures.\n"}, "hash": "12d44b07228e63d30770b9b7d6d638e848f307986d281a77519658dab7a69c68", "class_name": "RelatedNodeInfo"}}, "text": "For fiscal year 2021,\n24", "start_char_idx": 5885, "end_char_idx": 5909, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9526277c-8e13-493b-a028-5bd0888eabaf": {"__data__": {"id_": "9526277c-8e13-493b-a028-5bd0888eabaf", "embedding": null, "metadata": {"window": "we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating activities, excluding\nother significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus capital expenditures.\n For the six months ended March 31, 2021 adjusted free cash flow of $297.5 million consisted of net cash provided by operating\nactivities of $449.2 million minus capital expenditures of $151.6 million.  The Company does not provide forward looking guidance\non a GAAP basis for such metrics because certain financial information, the probable significance of which cannot be determined, is\nnot available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation\nor deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "original_text": "we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating activities, excluding\nother significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus capital expenditures.\n", "page_label": "25", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e7e90b2-727a-4238-a631-ce3709745632", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b09f50f17763c943088351873b77e9899dd401f18a19c5823db0aa99511ae71f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "369eb69f-0486-4722-b985-a0eba6e588ce", "node_type": "1", "metadata": {"window": "In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense and\noperating income and has previously provided non-GAAP fiscal year 2021 guidance for effective income tax rate.  The guidance for\neach metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as well\nas significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-recurring\nor non-cash in nature.  In addition, it has previously provided fiscal year 2021 adjusted free cash flow guidance.  For fiscal year 2021,\n24", "original_text": "For fiscal year 2021,\n24", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c51b9bdf20fbf0ca29c4910fd793b871f1cabc0479a229b10a6f0547a681b36c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6fe1665a-2130-4d5a-b40c-adef252231fe", "node_type": "1", "metadata": {"window": "we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating activities, excluding\nother significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus capital expenditures.\n For the six months ended March 31, 2021 adjusted free cash flow of $297.5 million consisted of net cash provided by operating\nactivities of $449.2 million minus capital expenditures of $151.6 million.  The Company does not provide forward looking guidance\non a GAAP basis for such metrics because certain financial information, the probable significance of which cannot be determined, is\nnot available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation\nor deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of litigation settlements is unpredictable and non-recurring.\n", "original_text": "For the six months ended March 31, 2021 adjusted free cash flow of $297.5 million consisted of net cash provided by operating\nactivities of $449.2 million minus capital expenditures of $151.6 million. "}, "hash": "a5b9511b52c469a2714df8657d8c05577fe11c62dd2adfe1d206c320faca8efe", "class_name": "RelatedNodeInfo"}}, "text": "we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating activities, excluding\nother significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus capital expenditures.\n", "start_char_idx": 0, "end_char_idx": 264, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6fe1665a-2130-4d5a-b40c-adef252231fe": {"__data__": {"id_": "6fe1665a-2130-4d5a-b40c-adef252231fe", "embedding": null, "metadata": {"window": "we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating activities, excluding\nother significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus capital expenditures.\n For the six months ended March 31, 2021 adjusted free cash flow of $297.5 million consisted of net cash provided by operating\nactivities of $449.2 million minus capital expenditures of $151.6 million.  The Company does not provide forward looking guidance\non a GAAP basis for such metrics because certain financial information, the probable significance of which cannot be determined, is\nnot available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation\nor deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of litigation settlements is unpredictable and non-recurring.\n", "original_text": "For the six months ended March 31, 2021 adjusted free cash flow of $297.5 million consisted of net cash provided by operating\nactivities of $449.2 million minus capital expenditures of $151.6 million. ", "page_label": "25", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e7e90b2-727a-4238-a631-ce3709745632", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b09f50f17763c943088351873b77e9899dd401f18a19c5823db0aa99511ae71f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9526277c-8e13-493b-a028-5bd0888eabaf", "node_type": "1", "metadata": {"window": "we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating activities, excluding\nother significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus capital expenditures.\n For the six months ended March 31, 2021 adjusted free cash flow of $297.5 million consisted of net cash provided by operating\nactivities of $449.2 million minus capital expenditures of $151.6 million.  The Company does not provide forward looking guidance\non a GAAP basis for such metrics because certain financial information, the probable significance of which cannot be determined, is\nnot available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation\nor deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "original_text": "we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating activities, excluding\nother significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus capital expenditures.\n", "page_label": "25", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b87df352c34617c1cb3208e912d0db3b81a2900ca26643063e68b77720937064", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4b3c67e-2ed2-4186-9292-764d64f89415", "node_type": "1", "metadata": {"window": "we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating activities, excluding\nother significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus capital expenditures.\n For the six months ended March 31, 2021 adjusted free cash flow of $297.5 million consisted of net cash provided by operating\nactivities of $449.2 million minus capital expenditures of $151.6 million.  The Company does not provide forward looking guidance\non a GAAP basis for such metrics because certain financial information, the probable significance of which cannot be determined, is\nnot available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation\nor deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20210505005225/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n25", "original_text": "The Company does not provide forward looking guidance\non a GAAP basis for such metrics because certain financial information, the probable significance of which cannot be determined, is\nnot available and cannot be reasonably estimated. "}, "hash": "e46bcc4710f40adeed7c34aaf46d5fe2bdb87e520776b159478eb1ee3bc35797", "class_name": "RelatedNodeInfo"}}, "text": "For the six months ended March 31, 2021 adjusted free cash flow of $297.5 million consisted of net cash provided by operating\nactivities of $449.2 million minus capital expenditures of $151.6 million. ", "start_char_idx": 264, "end_char_idx": 465, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4b3c67e-2ed2-4186-9292-764d64f89415": {"__data__": {"id_": "f4b3c67e-2ed2-4186-9292-764d64f89415", "embedding": null, "metadata": {"window": "we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating activities, excluding\nother significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus capital expenditures.\n For the six months ended March 31, 2021 adjusted free cash flow of $297.5 million consisted of net cash provided by operating\nactivities of $449.2 million minus capital expenditures of $151.6 million.  The Company does not provide forward looking guidance\non a GAAP basis for such metrics because certain financial information, the probable significance of which cannot be determined, is\nnot available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation\nor deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20210505005225/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n25", "original_text": "The Company does not provide forward looking guidance\non a GAAP basis for such metrics because certain financial information, the probable significance of which cannot be determined, is\nnot available and cannot be reasonably estimated. ", "page_label": "25", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e7e90b2-727a-4238-a631-ce3709745632", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b09f50f17763c943088351873b77e9899dd401f18a19c5823db0aa99511ae71f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6fe1665a-2130-4d5a-b40c-adef252231fe", "node_type": "1", "metadata": {"window": "we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating activities, excluding\nother significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus capital expenditures.\n For the six months ended March 31, 2021 adjusted free cash flow of $297.5 million consisted of net cash provided by operating\nactivities of $449.2 million minus capital expenditures of $151.6 million.  The Company does not provide forward looking guidance\non a GAAP basis for such metrics because certain financial information, the probable significance of which cannot be determined, is\nnot available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation\nor deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of litigation settlements is unpredictable and non-recurring.\n", "original_text": "For the six months ended March 31, 2021 adjusted free cash flow of $297.5 million consisted of net cash provided by operating\nactivities of $449.2 million minus capital expenditures of $151.6 million. ", "page_label": "25", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23432f2744f036a9d72d3591207257101ccfaaccaa038dc02c838df00bf3d1d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f39df59-a5e5-4431-b004-a2d4aa25ebbc", "node_type": "1", "metadata": {"window": "we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating activities, excluding\nother significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus capital expenditures.\n For the six months ended March 31, 2021 adjusted free cash flow of $297.5 million consisted of net cash provided by operating\nactivities of $449.2 million minus capital expenditures of $151.6 million.  The Company does not provide forward looking guidance\non a GAAP basis for such metrics because certain financial information, the probable significance of which cannot be determined, is\nnot available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation\nor deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20210505005225/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n25", "original_text": "For example, LIFO expense (credit) is largely dependent upon the future inflation\nor deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. "}, "hash": "0d976174f380c468716e8087ca34fcb106b26306e19de014a07b2c2de6ece277", "class_name": "RelatedNodeInfo"}}, "text": "The Company does not provide forward looking guidance\non a GAAP basis for such metrics because certain financial information, the probable significance of which cannot be determined, is\nnot available and cannot be reasonably estimated. ", "start_char_idx": 465, "end_char_idx": 701, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f39df59-a5e5-4431-b004-a2d4aa25ebbc": {"__data__": {"id_": "0f39df59-a5e5-4431-b004-a2d4aa25ebbc", "embedding": null, "metadata": {"window": "we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating activities, excluding\nother significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus capital expenditures.\n For the six months ended March 31, 2021 adjusted free cash flow of $297.5 million consisted of net cash provided by operating\nactivities of $449.2 million minus capital expenditures of $151.6 million.  The Company does not provide forward looking guidance\non a GAAP basis for such metrics because certain financial information, the probable significance of which cannot be determined, is\nnot available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation\nor deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20210505005225/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n25", "original_text": "For example, LIFO expense (credit) is largely dependent upon the future inflation\nor deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "page_label": "25", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e7e90b2-727a-4238-a631-ce3709745632", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b09f50f17763c943088351873b77e9899dd401f18a19c5823db0aa99511ae71f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4b3c67e-2ed2-4186-9292-764d64f89415", "node_type": "1", "metadata": {"window": "we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating activities, excluding\nother significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus capital expenditures.\n For the six months ended March 31, 2021 adjusted free cash flow of $297.5 million consisted of net cash provided by operating\nactivities of $449.2 million minus capital expenditures of $151.6 million.  The Company does not provide forward looking guidance\non a GAAP basis for such metrics because certain financial information, the probable significance of which cannot be determined, is\nnot available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation\nor deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20210505005225/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n25", "original_text": "The Company does not provide forward looking guidance\non a GAAP basis for such metrics because certain financial information, the probable significance of which cannot be determined, is\nnot available and cannot be reasonably estimated. ", "page_label": "25", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1fbfedcdd9735d1e940de3ff5aff457a06d5b06494c04319c29ce38fb1f9bca2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85696409-ea3c-4021-b312-c960dc60a1f7", "node_type": "1", "metadata": {"window": "For the six months ended March 31, 2021 adjusted free cash flow of $297.5 million consisted of net cash provided by operating\nactivities of $449.2 million minus capital expenditures of $151.6 million.  The Company does not provide forward looking guidance\non a GAAP basis for such metrics because certain financial information, the probable significance of which cannot be determined, is\nnot available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation\nor deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20210505005225/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n25", "original_text": "Similarly, the timing\nand amount of litigation settlements is unpredictable and non-recurring.\n"}, "hash": "341142f271f6a88ab82415ae5d1955b850cdbf45bdcd34d70e43ffbd90725280", "class_name": "RelatedNodeInfo"}}, "text": "For example, LIFO expense (credit) is largely dependent upon the future inflation\nor deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "start_char_idx": 701, "end_char_idx": 1017, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85696409-ea3c-4021-b312-c960dc60a1f7": {"__data__": {"id_": "85696409-ea3c-4021-b312-c960dc60a1f7", "embedding": null, "metadata": {"window": "For the six months ended March 31, 2021 adjusted free cash flow of $297.5 million consisted of net cash provided by operating\nactivities of $449.2 million minus capital expenditures of $151.6 million.  The Company does not provide forward looking guidance\non a GAAP basis for such metrics because certain financial information, the probable significance of which cannot be determined, is\nnot available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation\nor deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20210505005225/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n25", "original_text": "Similarly, the timing\nand amount of litigation settlements is unpredictable and non-recurring.\n", "page_label": "25", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e7e90b2-727a-4238-a631-ce3709745632", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b09f50f17763c943088351873b77e9899dd401f18a19c5823db0aa99511ae71f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f39df59-a5e5-4431-b004-a2d4aa25ebbc", "node_type": "1", "metadata": {"window": "we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating activities, excluding\nother significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus capital expenditures.\n For the six months ended March 31, 2021 adjusted free cash flow of $297.5 million consisted of net cash provided by operating\nactivities of $449.2 million minus capital expenditures of $151.6 million.  The Company does not provide forward looking guidance\non a GAAP basis for such metrics because certain financial information, the probable significance of which cannot be determined, is\nnot available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation\nor deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20210505005225/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n25", "original_text": "For example, LIFO expense (credit) is largely dependent upon the future inflation\nor deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "page_label": "25", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f7d8f17c9d7729e5d269bf75d02175a2a599d25a40152c4330354b4fa2a2a64", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78ee81ec-0d3d-4c38-ba0b-4a723b378767", "node_type": "1", "metadata": {"window": "The Company does not provide forward looking guidance\non a GAAP basis for such metrics because certain financial information, the probable significance of which cannot be determined, is\nnot available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation\nor deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20210505005225/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n25", "original_text": "View source version on businesswire.com : https://www.businesswire.com/news/home/20210505005225/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n25"}, "hash": "f2a4799a3f3f49d3ccd6b59cd0d721c9f9f604a461aff442ef0ef04d1b7796be", "class_name": "RelatedNodeInfo"}}, "text": "Similarly, the timing\nand amount of litigation settlements is unpredictable and non-recurring.\n", "start_char_idx": 1017, "end_char_idx": 1112, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78ee81ec-0d3d-4c38-ba0b-4a723b378767": {"__data__": {"id_": "78ee81ec-0d3d-4c38-ba0b-4a723b378767", "embedding": null, "metadata": {"window": "The Company does not provide forward looking guidance\non a GAAP basis for such metrics because certain financial information, the probable significance of which cannot be determined, is\nnot available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation\nor deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20210505005225/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n25", "original_text": "View source version on businesswire.com : https://www.businesswire.com/news/home/20210505005225/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n25", "page_label": "25", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e7e90b2-727a-4238-a631-ce3709745632", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b09f50f17763c943088351873b77e9899dd401f18a19c5823db0aa99511ae71f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85696409-ea3c-4021-b312-c960dc60a1f7", "node_type": "1", "metadata": {"window": "For the six months ended March 31, 2021 adjusted free cash flow of $297.5 million consisted of net cash provided by operating\nactivities of $449.2 million minus capital expenditures of $151.6 million.  The Company does not provide forward looking guidance\non a GAAP basis for such metrics because certain financial information, the probable significance of which cannot be determined, is\nnot available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation\nor deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20210505005225/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n25", "original_text": "Similarly, the timing\nand amount of litigation settlements is unpredictable and non-recurring.\n", "page_label": "25", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13858741ab0a731618bc0ea50090c8c66d24ae7d26e0511ce9aa3e0199370a96", "class_name": "RelatedNodeInfo"}}, "text": "View source version on businesswire.com : https://www.businesswire.com/news/home/20210505005225/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n25", "start_char_idx": 1112, "end_char_idx": 1362, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"615e526e-4034-47f5-8b7d-b4be0cdf60c0": {"doc_hash": "ab6f887c41fe7bdad10008b392adfe724103dd8cf3ec7f74a03184ba24a11ae7", "ref_doc_id": "984951f4-9f9e-491e-8d76-75fdf91ef9cd"}, "8364cd3e-a06d-4c67-93ff-710ce5ae78c7": {"doc_hash": "95e80bf00c3a60070f300374bbd0c1590b4c8c2780035b4137191b2006b89b53", "ref_doc_id": "984951f4-9f9e-491e-8d76-75fdf91ef9cd"}, "d37bb5bc-1308-470d-af3c-49339acc6100": {"doc_hash": "d543b0a2d9c36aacf4296f92879c486f6668d36b2638d7c483e8ab13456597cb", "ref_doc_id": "984951f4-9f9e-491e-8d76-75fdf91ef9cd"}, "370ce6f7-51e2-40f7-bda1-7d9ddc508234": {"doc_hash": "ae5361bb038c80188189912923197ccd8df3a2e8200f0777c0ce689e6cdd64c7", "ref_doc_id": "984951f4-9f9e-491e-8d76-75fdf91ef9cd"}, "96ef3d31-b9ce-4f79-ac17-4ca145075c08": {"doc_hash": "3f5aee829320cc4f6d12b73fba53e4f481ae39103ebde70c10dbad0b4e3d7a0c", "ref_doc_id": "984951f4-9f9e-491e-8d76-75fdf91ef9cd"}, "860bc0da-9781-4300-b7b1-c67b263d008d": {"doc_hash": "493b823ca00aa9d28c1a0b83bad82009da27543e6ba43585abc6a67588582e12", "ref_doc_id": "984951f4-9f9e-491e-8d76-75fdf91ef9cd"}, "3e288a38-0c12-48d6-b94e-a1a8e1e5eb1d": {"doc_hash": "818e2afb6f6177bb8db980df79fc1f5cee5bac51fcdeae3cf2e9e4a0167172bf", "ref_doc_id": "984951f4-9f9e-491e-8d76-75fdf91ef9cd"}, "c3660089-e092-4b3c-96eb-2903f84f6a9c": {"doc_hash": "f3b553cdf866f72fe72f5912b49c7134c555bdaa1ca6637ae218b7c9c1880814", "ref_doc_id": "984951f4-9f9e-491e-8d76-75fdf91ef9cd"}, "ca9244d7-0d5d-48d1-bcdc-3d0ba5dfd45a": {"doc_hash": "749478d0969211176599167e0752f1499354687fb3578ef36260af16cd5a581a", "ref_doc_id": "984951f4-9f9e-491e-8d76-75fdf91ef9cd"}, "a6b5c116-b791-460e-b7ab-12e82a98bd60": {"doc_hash": "7d2fc32f0b3730fa498fc849de3e1349a7f61dcf62afdcc8cf8917ca96c892ab", "ref_doc_id": "984951f4-9f9e-491e-8d76-75fdf91ef9cd"}, "c29c869b-f26c-4f9b-91ba-5a037472b3ab": {"doc_hash": "48e75f7462a9aea63596224131ecf63b2addc35037e41e6d757db049a512903c", "ref_doc_id": "984951f4-9f9e-491e-8d76-75fdf91ef9cd"}, "7211ee8f-65db-4d37-b604-8157b3742dc1": {"doc_hash": "0ef4c50392ffe0fc0d140405217db2a9acc96a1cb3f390e78840fd261b1855f6", "ref_doc_id": "984951f4-9f9e-491e-8d76-75fdf91ef9cd"}, "d5b86314-4ab9-493c-9f03-ea0e60675613": {"doc_hash": "98040c9bf1ba66817c12eafbbeaacb393bd2a9ecd6d5ed667601e3631655700f", "ref_doc_id": "984951f4-9f9e-491e-8d76-75fdf91ef9cd"}, "42e0a856-75dd-4309-8bdf-95450ec9f0a9": {"doc_hash": "fd641dfad069af634c6934ad9e8012f9638254847bf6ce1b007c817a5f6a7726", "ref_doc_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b"}, "4d8f9bc6-7088-40bb-9652-f40c3e685004": {"doc_hash": "fb391d46ad9845f5718ad6d72753d6818cf92418c72c3d5fb3ec206b23b25e16", "ref_doc_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b"}, "20112f3f-d549-4c55-93c4-df05f65e2053": {"doc_hash": "778a1aca58e5a9e50273883deb08836b7cababb5df43d671d30dbdbbd65f2588", "ref_doc_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b"}, "f0e77ce5-0489-4d98-a8d7-99ad6a18011a": {"doc_hash": "3a5c122049927f1ec89434ba451aaaf351c04a8cb25f65b019c4cac4744b3aa1", "ref_doc_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b"}, "475059ba-f952-40dd-8a92-c4cd62ac7574": {"doc_hash": "74a02168302e5e57a4b79e032df75a0a7ebe4fb553d04e12d15fb56d440f2107", "ref_doc_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b"}, "d314b52d-6551-481b-9034-4ad423b79d7b": {"doc_hash": "2fb87f11b572639c6ebb0c2bbcaeb353d1e3167118486370883c6b997fb67655", "ref_doc_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b"}, "270d06d4-065d-40c9-b239-2a4a6549379f": {"doc_hash": "dc794833157b9b085d12138c91743ff2d2b8888f6fb6295fa169c996270e7de5", "ref_doc_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b"}, "bf6b3ca9-bafd-4f04-b8f9-38482cc4ae68": {"doc_hash": "439b0c33d463d6b7e33e9936d4cf2ade26bc46e7f1350ad37ef104f4b9003a8e", "ref_doc_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b"}, "a64fe025-50d6-44a8-afec-deb3500c3bcf": {"doc_hash": "e48e1e7e5cc8ae7509e2275175aa5de1515c1ccab71618bb69c37ad21f95919b", "ref_doc_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b"}, "c7f1cae9-4b4e-4837-92dd-c59437d173eb": {"doc_hash": "e0902fb9a37f0d84b789a24e7fa47b53dbd9fc7d49363747e591a90da1d99edb", "ref_doc_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b"}, "705543bb-e966-4ed4-96f1-d78b72720351": {"doc_hash": "e3408b3f05da3f08d4e2e092d10e78831ab49d9fe4858109c4e3398b29a5a1bf", "ref_doc_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b"}, "236f7dfd-aeb4-4828-aeb9-ed8a447fc688": {"doc_hash": "32f3a91cbb6d4fc8ad70ad5d4e470cbd9c0c263aedb76a2fa228745e2df60074", "ref_doc_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b"}, "2560f576-0c69-4ec5-9620-bbf5e392e5f8": {"doc_hash": "46ab8c764345a8a71ee7a0a3b7b2b1ec4e281855354cbbd8c6d7ade4ad3099e2", "ref_doc_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b"}, "3637fd8f-bab8-4b7f-87ce-1c278da938bf": {"doc_hash": "d1f257f7c70bbd49f9f51d1204dfcf3a7f01541f21804c535e54030573722d58", "ref_doc_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b"}, "abbb2155-1714-439e-9387-2802d9f30b96": {"doc_hash": "ff63aefa65bf641ab2d72f624e3e6ccca807f9d47d07d698067429169ed20666", "ref_doc_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b"}, "ddb9fc65-93d1-4efb-b0a3-0710fc0b59cc": {"doc_hash": "cd21f2ebb3d3df07efb632cf7b11d3deac24c615dbfd61c86a1a9f3958cf1119", "ref_doc_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b"}, "4554a903-2bdc-485b-bde0-b36489e8f032": {"doc_hash": "28767a61f605a972442c50a06a39f3f85a576181e2bfdf03dfee6f32cc038fd6", "ref_doc_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b"}, "f7f3e227-30f6-4d09-8469-4c97553e1c7a": {"doc_hash": "97ff1c494c66aa8c28f2bf5a69b0f838f8dfb6e52ba6f5ff4d5704d0720c39bb", "ref_doc_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b"}, "13086de3-a80b-4f83-bd0c-dd05b695d7ac": {"doc_hash": "3e4fb476f5af50e7154cdfdb1f8672814db4b4666c2436f8e1388ada4f481d0e", "ref_doc_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b"}, "33fb28e9-bca7-4ea2-bbca-25ca1dcd67f8": {"doc_hash": "036242570a7b864eaea32207e570b02baba5334670507dcf1193ac941bd1620e", "ref_doc_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b"}, "a943171c-022e-4a8c-8ef8-28339374733a": {"doc_hash": "9d848968d151095d4c9a661faf7c00f43df9fa16f5d5d30c600b0976769afdee", "ref_doc_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b"}, "6090f842-404c-4d00-ad65-243c60bfb10c": {"doc_hash": "10bb332c9415dc7c35652a1a453f32672b6bcbca97372b143f7fbdfd1192ea4e", "ref_doc_id": "ad3e50f8-92f3-423d-af82-d5876aef2f8b"}, "5df9172b-9ce6-4a36-9764-27e462fcf0a0": {"doc_hash": "5cc994e6ee6374c3d950065feaef0773e846afc87a70ad46b4c0874033a45b30", "ref_doc_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032"}, "7ce7bf8d-f0b3-4e79-8df5-c697cdad114b": {"doc_hash": "1b8a0eb44c93c6dc4d7fa7a6e9be7c2fadc43ca416c83af36d2dd3653a768098", "ref_doc_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032"}, "cb6ae3dd-7ffb-43a6-8a0a-9464303f0588": {"doc_hash": "97e2b0b05701eb448b400eb71adab0b2e8849f3c4270de3f048a83f049d15d0d", "ref_doc_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032"}, "77a6936f-715b-4932-87ad-e8713d0f5e96": {"doc_hash": "df080dc374939ab3daf0b188ad373f76d21b7dc6c1964fac05c2e02dc2317b4c", "ref_doc_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032"}, "2bc7e13c-c269-4f07-a99a-5e89a0cca435": {"doc_hash": "3eb5a96f5f48a998f039d567aa56c771d637e305c39e2635ebe50e8598804141", "ref_doc_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032"}, "9592d990-403c-4072-9a27-26144a56f307": {"doc_hash": "d05b23ca40191bf0ab012e8f7f43179fbb8e2de527b3f8c603dcaafaea94ccf5", "ref_doc_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032"}, "44015e49-9a4c-46bc-9342-55f80b54639f": {"doc_hash": "4b063d7c899b5e89c1b0d1e2c4e0b5bebf54c101abb790749a63ddaa1280b054", "ref_doc_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032"}, "9cee156b-4b92-4e30-85ff-8c356021b279": {"doc_hash": "28df473d0349b23e84891b8794773a18dd89a135fa7a8630fd7ae0a14cdac4e8", "ref_doc_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032"}, "a6f1373d-d38b-49e0-8bae-9d01da611d13": {"doc_hash": "4f5027f5a064c3495ffb8ec4ea84d60979ee71d3e0580a57f7db4673cb2f4fef", "ref_doc_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032"}, "c79e544a-1bb0-4a7a-9f46-cf0fec48bbe4": {"doc_hash": "b753125df10a3ba174685b79013b6bfa3f1d06623e4776a3e4ad7887a8020975", "ref_doc_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032"}, "8761f8c8-aec9-4d20-9a11-899d2e5ff9f8": {"doc_hash": "2f6bbb3b07aab3da53f5f893191fcea7ed37ca4ac6ba162d706d0a45af4cd756", "ref_doc_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032"}, "6e0bd691-4f91-49e8-a349-7b0407a9b431": {"doc_hash": "d470002384cd41d171271fe8d50aa53bf9761091ea0f7b1376ee1880c8fa0a63", "ref_doc_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032"}, "551f5751-93b3-49c2-91b6-f6129cff2c8b": {"doc_hash": "056176f84bf3343b59835d6b65c510ca4889070650337a22aa4ef953f1bc8b0c", "ref_doc_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032"}, "ee719b7d-7363-40bd-aeca-f21557ddd20b": {"doc_hash": "814a721ae9d2bc07bf723642899d52e33a14f0691e16578824a6fa35d09100aa", "ref_doc_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032"}, "bd2b827a-fe1c-48f3-9c63-7e72e99b98c3": {"doc_hash": "53337e7fe66391bdfb7157dc8d996fa0badf532e528427a6b19dcfdba87b6ecd", "ref_doc_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032"}, "bdbb774f-5f3e-4728-9113-8a10f821f033": {"doc_hash": "75d5f4c2ebd0e69225ddea5a867e34d8ce6ad971b6286b2e01834a31192d8054", "ref_doc_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032"}, "dee38d65-7a1f-4453-b70b-db66afa30ec8": {"doc_hash": "e473b0cc7ac8f347c857b9f24a3ec1535fb644d568a13d7baf6cd8502f6392db", "ref_doc_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032"}, "b6d6bc92-9a17-4ac0-9740-d60cf91490f9": {"doc_hash": "0e0f8e440a746849273a23defdd2ed63e81ba3e72421c623ab9bed3fc729170e", "ref_doc_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032"}, "a16c8ff3-1875-42e7-9817-e018833a4197": {"doc_hash": "2fb3f46df8aaa3a43af3c5905c517556a12fc99e994d9f8432814031570c17b6", "ref_doc_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032"}, "f421df79-0e2d-44c3-bcde-6e7cfa2b65e4": {"doc_hash": "88e913d519678be0438141423088b8c185366c1fe2867a7a32ae2f73132fe343", "ref_doc_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032"}, "38d6ec95-8885-4e56-856b-9214b8631697": {"doc_hash": "6cc0545b99a751b72733b19def5ea8d5c0c955035c48dc800c3baca02560d48a", "ref_doc_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032"}, "f217a0da-3c0e-4e2f-93a1-93b82c08361f": {"doc_hash": "03faef48333ae1ccb103fcac55af520705a27505ef750987ed3ee76cc65f7e65", "ref_doc_id": "5e7f174c-ef1f-4415-bfc3-56a6b1707032"}, "d2f55977-b190-4192-8c2a-295da12e7183": {"doc_hash": "05325de3066849e59015ec571f0903244fd4ff38646030b6e5b7ea126557a4c8", "ref_doc_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb"}, "73ff4732-5744-4d9e-a491-e68bc077ff09": {"doc_hash": "f291dcee9051e42eebc01c3b01d22fbb1164f4c3be0de7e90d53ee1045470768", "ref_doc_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb"}, "3aa54655-290d-46bd-ac5d-01e65e76dd8a": {"doc_hash": "3d1030d2dce9a23de710d6c25473dac3056f52304913cc1515182c5eddc1d415", "ref_doc_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb"}, "00fdab8c-f721-4967-a282-2f0cd0abe3e9": {"doc_hash": "a1c1317c8894d28cb823ccd46f94fce4a62c457dcb23946b3eab673355274a95", "ref_doc_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb"}, "413fa278-a10d-4015-9ecf-7d25b95dbc69": {"doc_hash": "844cc8aa6c1307e01ac24c27185fabf0ca1e5e7e4ab7c3e4c6874deba4a6198e", "ref_doc_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb"}, "12d23d64-13aa-42fa-a483-c7b32d4e1ddf": {"doc_hash": "558b64d71852049e177f72334a19de23a01209abb2a88611663d6d54f119282f", "ref_doc_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb"}, "8258d42c-1a2b-46be-abb7-1313c058ee08": {"doc_hash": "3b27471237870b45cf3ec8c2fae84ccec28f26c531304ab931c8aa54545d20ff", "ref_doc_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb"}, "da16ce54-eee0-4fa5-836d-a6169e3faf01": {"doc_hash": "0da2d9cff57b0114996320501aeef14ef6ed339c9ad4f7fbd159466547a3cfe5", "ref_doc_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb"}, "8ec6a258-c1d8-439a-9eb4-5567fb414a16": {"doc_hash": "c8b2558f938588541f21d7c1e71ebf9e0754f6431554728f4157ab5068ceec76", "ref_doc_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb"}, "26e4a0bb-0eb3-4c66-9233-819f1718915e": {"doc_hash": "3f18c695f520e122b02f3c7c2285c7b55aff4e5659bf6b2a52330c209ce64d2c", "ref_doc_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb"}, "d6114f95-2428-4716-af68-3dac6e1025e4": {"doc_hash": "f93f8f21f8b34cef822aa222052417dfa25138b00a56dc552d69531d44b875bc", "ref_doc_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb"}, "754f07a6-e2e8-4cd5-a6e1-2e610c7cf1ce": {"doc_hash": "d21289d873bb1e4d7a95c6098a5dd0c749494b46ce8227c7cfc453bbe21e1b77", "ref_doc_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb"}, "c2c527e5-6ac1-42e8-90d5-dae5db56a479": {"doc_hash": "3a704a797e4a7f2e422ebe0ed40dd3fbdce8a08cf78c980f22ec1867d66c7403", "ref_doc_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb"}, "0fc38fa0-6d4d-4b62-8647-133a4322a55a": {"doc_hash": "41a9dc43e73fd47d94006fdfbe960cf87b3a1b951fde8b5323fe7d7a5ec5c40d", "ref_doc_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb"}, "a7add16e-5246-4bdb-adae-372257c50e47": {"doc_hash": "b6fbabea6292d5440b1a7bdf08a07817d8b7fb789e42f95f81b607ca7db3d92f", "ref_doc_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb"}, "11a9555d-4b1b-44a7-bad0-82ce154449f0": {"doc_hash": "2f68d77eb226568a70c8f06b586ecdf0efeace738e42d019e0551eb78fcad76c", "ref_doc_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb"}, "6b05cf9c-3454-4a49-ae5c-94896e9eb185": {"doc_hash": "e909a484a45753680ce5edb2183dd6e5caaaede57ea05ff6459d3731407ff8f9", "ref_doc_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb"}, "7b9c733e-08e6-4c28-9fee-ea22f52a3352": {"doc_hash": "1753209da4c5812f759e6e711c8aea9e0ebc4d47dc49a315c3b3760fe91ed9b9", "ref_doc_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb"}, "9f3c75b5-41bf-4b55-a43d-2ea33f0da549": {"doc_hash": "647c31178cc784b05cbfeb5564476616f66efc6dab35f74593643147d82567c6", "ref_doc_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb"}, "612574e8-985f-4c76-91fc-2cd0bcfe1ffb": {"doc_hash": "6435737cb80270edbf05cf0d2759dadfa6d116e85027763c4c406ae1d0e5612e", "ref_doc_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb"}, "8f8eb318-f0ab-496b-8d43-2bbb3a3c5097": {"doc_hash": "c59c39247cf12bec9756b6ad0ff585972f811241f56cf8ca9e43260dd55b0ce0", "ref_doc_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb"}, "4266fc77-443c-4479-885e-87d47df5823e": {"doc_hash": "53e07eab273bfa491696b7aa9ea138c83800fd1ba031597e3aea47015a651649", "ref_doc_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb"}, "5d8fd312-1b67-4f22-93fc-57bfd3c263db": {"doc_hash": "4fa357a995541d50558405da8ee656f11b7dbeabeaa744f246a1c7c09bdc1ccc", "ref_doc_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb"}, "d576f0a6-c780-4e0e-97f1-1eba01ee8206": {"doc_hash": "4e0e39be8f109fda1fc23606bb78b49043386b9af9909f14a46cc27d03b8cb12", "ref_doc_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb"}, "bd08d2ef-2b11-47d1-86a3-414e093e93bc": {"doc_hash": "3d8f24cefe95e0f0e3a3744f8338d81aff7501f95a6cdd99696c6d8b5a98c5fa", "ref_doc_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb"}, "dbee68b9-1f5a-4c85-9db7-bb9f0ca9b9f2": {"doc_hash": "2a1ad16eaad1e5392de539192008131d7ebb166dcca90fc222ad8ec8401167f6", "ref_doc_id": "55632b38-3745-4ed5-a0a3-1b8a19f017cb"}, "a7d3c56b-d11b-4c72-b23f-45802d12c629": {"doc_hash": "56b1865a41a1dd772da459b1ee2546358c4c8cfaec633b9838236ac4e312c063", "ref_doc_id": "9c0bb4e5-b04e-460e-86a6-b70620fb2591"}, "a9e0f246-1c0c-46c2-8f0a-d88d5e0c6e3e": {"doc_hash": "151c7890e206a7f6cfa70c2acbf8a4481cf49fa91a3d9c76df5c1e7d5185c058", "ref_doc_id": "9c0bb4e5-b04e-460e-86a6-b70620fb2591"}, "b4e0d1b3-9c49-42ea-a0e4-36dd093b49be": {"doc_hash": "8d99666c3774da8e305496977af7bc8f662d38a3d44f3f090db413c0224f2f58", "ref_doc_id": "9c0bb4e5-b04e-460e-86a6-b70620fb2591"}, "bf70412e-87ff-4d4d-98b6-0cc2825be1cd": {"doc_hash": "ebb0fd7cd646cd2557781de7d6c15dfb262256b9724bce3a73e99c8acb2b6753", "ref_doc_id": "9c0bb4e5-b04e-460e-86a6-b70620fb2591"}, "67be2197-1743-4a59-86f1-343ae8e8ee22": {"doc_hash": "1c10de0e81b8b05e91baaa7c3d4a5ca72fa78368c430381d25583760a37b026c", "ref_doc_id": "9c0bb4e5-b04e-460e-86a6-b70620fb2591"}, "25413cb1-4f95-4ed4-8dbf-fca73b3203a8": {"doc_hash": "6c8d3a063293cf6225abb5922ee697c4927dfc67ba34ea3abf1d28cd773fb1da", "ref_doc_id": "9c0bb4e5-b04e-460e-86a6-b70620fb2591"}, "4560d255-65ba-4df9-9201-cebcf74cd8c6": {"doc_hash": "8a0161cfc76c0b58155795d3a2d4cecb1711a354c4ceb03f0fd9e799c3905539", "ref_doc_id": "9c0bb4e5-b04e-460e-86a6-b70620fb2591"}, "afa6e91b-b340-4bf0-9bf2-cebacb94ab08": {"doc_hash": "b1c6a044e9af9a105dee4c445f9711d693fb260366fafc9d23e05ce53f6582a5", "ref_doc_id": "9c0bb4e5-b04e-460e-86a6-b70620fb2591"}, "1a470d7c-e68d-4349-9afb-593c34d8aed1": {"doc_hash": "0deb3a8d3df943bf89c787a575ce336d4e9ca8b9ff1ff42b87a88847abaf4ed7", "ref_doc_id": "9c0bb4e5-b04e-460e-86a6-b70620fb2591"}, "afac8dce-f45f-4f63-bb9a-c10c006acaea": {"doc_hash": "80d55212443305c9f8ca82631a6e9608e23906a0fbabf85e0465e7dc0cf3b3d7", "ref_doc_id": "9c0bb4e5-b04e-460e-86a6-b70620fb2591"}, "c6d110ae-49c2-43a3-b35b-90f16a299b17": {"doc_hash": "291b9440831893941fad0f31695f35554e936520ce2b519bfc216e913072a136", "ref_doc_id": "9c0bb4e5-b04e-460e-86a6-b70620fb2591"}, "b21417bb-2de0-48e8-b01c-3b6c1b05cf73": {"doc_hash": "60319b0c8f4051864756563d1562289d41e107adf8b61614bb7858e1f1f11713", "ref_doc_id": "9c0bb4e5-b04e-460e-86a6-b70620fb2591"}, "bcd2b4ba-04cc-4ea8-8ce3-9558c0787be0": {"doc_hash": "a9c439e8117d8257653388d0c7e2235edeecc3a3ad844733fbfb533a5299758a", "ref_doc_id": "9c0bb4e5-b04e-460e-86a6-b70620fb2591"}, "50b95348-3bfc-4da7-85ff-d4760e6e95da": {"doc_hash": "4072223025e9229ad10269df2755a8e5fc792c38c671b89182cc9ee56f770e6c", "ref_doc_id": "0851a017-3b2c-4844-8e95-7505a16132d0"}, "807c2296-5361-4d23-89a2-353814dbdae1": {"doc_hash": "7bc05e48bde495ab605b2802a9d78c64b59eff9ae9591ab6ccfb9f020ec55357", "ref_doc_id": "0851a017-3b2c-4844-8e95-7505a16132d0"}, "7fd435b8-1dc8-4d0f-bb70-ef0daa8dbbcd": {"doc_hash": "e20fdc93dc7dbae18d3462264cc3f0ded77dbc58bd64de1d2a4a112d9ab9f337", "ref_doc_id": "ff0cb08d-f257-46de-95f4-d4816cbc4ebe"}, "f11e0955-2151-4de3-a7f0-ed4d8ebb4728": {"doc_hash": "cc2aa3a3098355a24fc8d1019b06f57f4c0bba503b2225d88b7bff544e3bc0cc", "ref_doc_id": "ff0cb08d-f257-46de-95f4-d4816cbc4ebe"}, "89938753-d4f9-4206-b8d9-8c49d34866f7": {"doc_hash": "59bcb80e6c9b59b914e5077e85f235130b346ed2429aefab69e025a1a6512d2e", "ref_doc_id": "ff0cb08d-f257-46de-95f4-d4816cbc4ebe"}, "36dad163-71d6-4b73-9f53-0ff96ed72467": {"doc_hash": "fcedb6af60b1dd054338cb8afe54ff8886cce39b583e04b756f11ecf9e3e2e89", "ref_doc_id": "ff0cb08d-f257-46de-95f4-d4816cbc4ebe"}, "ef33f21a-6112-47f9-8122-4addd28f2ab5": {"doc_hash": "a9a9d129ad155a958b2372d68b66b70458d8593d9a9c268912dd2eadf4862ba7", "ref_doc_id": "ff0cb08d-f257-46de-95f4-d4816cbc4ebe"}, "a31d8386-ada5-438e-8450-ee42c689a563": {"doc_hash": "6222ab9b7536f4be349af6ff9bc2dc64a2450c5322b16401c8b666f6b65d6164", "ref_doc_id": "ff0cb08d-f257-46de-95f4-d4816cbc4ebe"}, "5e504a89-1cd2-454e-b6dd-623439b5a225": {"doc_hash": "cb2e0ca46b5772d5f0bf13d0e1719cf1d0995ab1e466bf5ebadf3c659c31803e", "ref_doc_id": "ff0cb08d-f257-46de-95f4-d4816cbc4ebe"}, "a8be24d9-a0b5-4056-936e-e0081c0d2a16": {"doc_hash": "00600377d7a3ba2aea53f422c1d18b6fb90fda65e9030fe7036937abf150e5c9", "ref_doc_id": "ff0cb08d-f257-46de-95f4-d4816cbc4ebe"}, "a914bca4-67bb-4357-8214-9b425e7c007f": {"doc_hash": "0a94044bf89fee0ed7ec24a8a910214fb8b6eacb527616a04e83885f23a6c504", "ref_doc_id": "ca520586-707e-4b53-b512-5219e544df95"}, "579b8eda-750c-4518-8511-e361b9d03d1c": {"doc_hash": "86964fde195c5962c8fe4b09ca3d53177fbc920b7ba6525aa0de6caea9464132", "ref_doc_id": "ca520586-707e-4b53-b512-5219e544df95"}, "befcbe45-89fe-4367-ab89-0dc3fe8d3d46": {"doc_hash": "8420b0d51c1e5e1b719a786508fef1ccb6c4758b48734ca86064449b383425a6", "ref_doc_id": "f346ea14-bb69-427b-b23c-3ab5c70c3ac2"}, "3e2bef73-fa40-4241-a343-31b3b9d1d230": {"doc_hash": "62ed124fb94f09889efeefcd28f08495b8c3de3979e8e3f70367876415afc37a", "ref_doc_id": "f346ea14-bb69-427b-b23c-3ab5c70c3ac2"}, "2f37fec2-6431-47d8-87ad-2766dfd54fa3": {"doc_hash": "257fbd0254e5efaf94125464ab3d5339a452e05d58b14f4a0002f073acf1ba46", "ref_doc_id": "f346ea14-bb69-427b-b23c-3ab5c70c3ac2"}, "7cb20609-1051-4047-8921-e1866d571757": {"doc_hash": "9bc933c3e05b4427c47b5c0f71d2cb8123da4fa889c16451b93d981852aaaace", "ref_doc_id": "f346ea14-bb69-427b-b23c-3ab5c70c3ac2"}, "1b7e5cb5-c584-49ed-b103-5529eaf573d7": {"doc_hash": "00836e70e66220832cb39f9811a10d83348c49fdb706c07e8d8c3bd90cadc8da", "ref_doc_id": "f346ea14-bb69-427b-b23c-3ab5c70c3ac2"}, "21d2fc89-a1e3-4ad2-a78a-b6f3cc6ca2a5": {"doc_hash": "cf832af15d00acfefca26c45d98c2a033b3c3e4977ec6039245f8eb2785c1ea6", "ref_doc_id": "f346ea14-bb69-427b-b23c-3ab5c70c3ac2"}, "4562fdba-7491-46b3-9eea-c9406f1da834": {"doc_hash": "735d7ca60060d7eba44ee0877505c903d0873e9ca8269797cf53cdf505219d99", "ref_doc_id": "f346ea14-bb69-427b-b23c-3ab5c70c3ac2"}, "37a96cc7-7ec8-4cf5-915f-c53fd1715562": {"doc_hash": "b3bc6edeb68ea213a9a62ee0494d7356ca554d3729b6d2a9929185ff6a131878", "ref_doc_id": "4bf856a2-789c-4c58-a81d-a38694217eaf"}, "8140a0a4-e7e2-4ac6-89c0-7b6dbfdad12c": {"doc_hash": "4626c75a5686b9897259195fbef8e247f78b92f9ab67ce841c3bb194e57d3e52", "ref_doc_id": "4bf856a2-789c-4c58-a81d-a38694217eaf"}, "58a74d7e-e2f9-4163-b449-ed8ad9d055b0": {"doc_hash": "aec04949130d3b50fc86c9ff7a47dd2a7b2744e4474d4df810c10b74727e55e4", "ref_doc_id": "4bf856a2-789c-4c58-a81d-a38694217eaf"}, "5f236e15-b1e9-40d0-898f-ba7771bb2f46": {"doc_hash": "43d2b77ccf26b613caa78886f94173a338283e8984b87439177627bee1931637", "ref_doc_id": "4bf856a2-789c-4c58-a81d-a38694217eaf"}, "b00246e5-d528-4d48-8d57-8bafb84d9034": {"doc_hash": "abf0bcfe4640522e3a28ac2f60eaaba834172d1a5e566ebc04563e4e52db0007", "ref_doc_id": "7a40fb9d-1e17-4966-97ab-0e849d6490b7"}, "88de88cf-03d7-432e-89cb-22d6156e27bb": {"doc_hash": "e8121f96a0c0c2a88470a17f1a7064d07184d04f36b1bcad3927f969d3573706", "ref_doc_id": "7a40fb9d-1e17-4966-97ab-0e849d6490b7"}, "7e42a7ea-fd6f-4b14-b5bb-40be9bdffb8a": {"doc_hash": "d281abd9335079ffeaec54253494c4cbab8ee3724b5fe16db474b1f0236700dc", "ref_doc_id": "7a40fb9d-1e17-4966-97ab-0e849d6490b7"}, "730fbaf2-1cfb-42c8-9d50-00e805e28f8b": {"doc_hash": "a266dd29229f8008e9fbe12cd45ea9f054718aab8d7c248dd9f7b3a283ae3434", "ref_doc_id": "7a40fb9d-1e17-4966-97ab-0e849d6490b7"}, "9a9fcca9-b46d-495b-b3ea-7c0ddf337f58": {"doc_hash": "993d1377ce32cf8a52039b8914497a4b721a42a0306c86b395fd78c3f88fb711", "ref_doc_id": "374cea2e-e325-44de-b70c-29ba8342bbbd"}, "566dca63-f2db-41de-9386-d643b712ef84": {"doc_hash": "9c97632967809088cee299fd39aa4d2e40192545e889170dfab6fa37214151e3", "ref_doc_id": "0780b706-b2b7-40bc-8000-fe99c141007f"}, "c82542d0-53cf-4c99-8def-9a9bedf721fd": {"doc_hash": "6cfe231a7d3586da58e94cb18f69e5c0e56074a258e2cb028895c10922c3b78c", "ref_doc_id": "0780b706-b2b7-40bc-8000-fe99c141007f"}, "1f668ad9-0f06-48d1-a08b-e5365fecf0de": {"doc_hash": "ba9b5d7a00240b992122125a5d0e6038fba134c2cbd73658414e566bf7841532", "ref_doc_id": "0780b706-b2b7-40bc-8000-fe99c141007f"}, "d459bb75-635a-466f-9a90-b3b7af307314": {"doc_hash": "66f657a436b15e7e928a81ce661b4243b8d806ca8960f11a90289eb77507d372", "ref_doc_id": "0780b706-b2b7-40bc-8000-fe99c141007f"}, "95cd578f-bcc4-489e-9499-12d235fc7ff6": {"doc_hash": "fc5a3c8bd32c6718264cbf4a5880ad2a0965e377abef070837311543c70a8621", "ref_doc_id": "7864a61f-7fc9-4b9b-bbff-7e463982f88a"}, "3e570085-3e40-4e1a-bc92-0dd4de9636aa": {"doc_hash": "48425dbcf8f869402621163722295f168ab297d2126e70d3f6aaacea67b84154", "ref_doc_id": "7864a61f-7fc9-4b9b-bbff-7e463982f88a"}, "0764c2e3-ba47-4654-b916-0ea3404d318f": {"doc_hash": "36bebc7d94d42b9396fcd53e134966a78d41190209fce59882c8bc015d97e734", "ref_doc_id": "7864a61f-7fc9-4b9b-bbff-7e463982f88a"}, "605f0256-b86c-46e1-9934-4598088ffefc": {"doc_hash": "901a791c8f35d763082c1d8011a91af7a4b911a8d8fb248ee5dd52153880e822", "ref_doc_id": "7864a61f-7fc9-4b9b-bbff-7e463982f88a"}, "8aa05b61-df02-4069-8e23-042ac2fdf635": {"doc_hash": "4ae2ae0950ca86d4075ddf06b0106d1034dd021dd8a9c05f32c259dd38a2743f", "ref_doc_id": "7864a61f-7fc9-4b9b-bbff-7e463982f88a"}, "bf539da6-804d-46ee-a572-b561ab369e2d": {"doc_hash": "9ad940839a33e39403e771fd7db4b76292631a137e9471272baecec33637d3b9", "ref_doc_id": "7864a61f-7fc9-4b9b-bbff-7e463982f88a"}, "21a1c872-df2f-40d4-86cf-a2d485dfe92a": {"doc_hash": "d93fab1883d4f028d57a41ddf56f6eafe8d44fb8e023102ece3984d702e4d671", "ref_doc_id": "7864a61f-7fc9-4b9b-bbff-7e463982f88a"}, "dc72b2a3-e214-48c7-b44d-d78ec53b0d14": {"doc_hash": "d60d266f17c41a11e01a1b98b7488c38b7bab6a9c29a270845248c5353e60e82", "ref_doc_id": "11e6f6d8-10f0-42f8-874f-446d356ceb59"}, "03ff985c-03fa-418e-906d-be2ed3f769c2": {"doc_hash": "47c067ba4c671f23488cfb9efbc97bc4cf02394df7ff53cb9019e83bf773ab0f", "ref_doc_id": "9c25fe30-2e61-4f35-9843-0d422ef324be"}, "36551470-2787-4664-bb36-e1ee344acd28": {"doc_hash": "a5697633690a36b5dc9e6a7c4f43009d19b3f4771819ab2e58fe636b8e94ff23", "ref_doc_id": "9c25fe30-2e61-4f35-9843-0d422ef324be"}, "486bedbc-de31-4d74-8a55-76f13bc30518": {"doc_hash": "5cc76ad2b2b7855d4fe8fe578d7c98fb583ff5be4902e96e1a853b1be7b4c8e9", "ref_doc_id": "9c25fe30-2e61-4f35-9843-0d422ef324be"}, "235025b7-e802-4183-8a69-a112946adf01": {"doc_hash": "6184b3293b8e5d5a5de760290b6e8c4e7cc1991e67043efff3f71c6946196ec0", "ref_doc_id": "9c25fe30-2e61-4f35-9843-0d422ef324be"}, "5b81bcff-eb29-4d01-80cd-daaf8bd46e9c": {"doc_hash": "01f469990b7cb89966376bc3e45912bb7a0fffe37d9bed0dcffa713736763209", "ref_doc_id": "885760b4-c525-41c4-a6df-5e5e52416695"}, "d49302b0-99a8-4234-b8ea-b5053cc69c0a": {"doc_hash": "3c92db371d60302e9d098f284858595598f79ea4a629303b372be33bdf5c1a96", "ref_doc_id": "1207c990-1544-45c3-9819-27f84ccfa8bb"}, "443be014-a4cc-4f28-9ec9-149d45c36d9f": {"doc_hash": "f5a5d2c640bdb2fdace5cb37f93d16aaf3ea407d02f6dec3278fcf965be7891f", "ref_doc_id": "1207c990-1544-45c3-9819-27f84ccfa8bb"}, "ce13a88f-f62a-401e-8bd4-0bec83c7a2be": {"doc_hash": "399c3066d260d12c4f5ccfacdf5b85a69b3be1851f7d58a75c36432386ef0a6a", "ref_doc_id": "cee84c53-8da1-4b2a-9ff8-0c1fec5d5f8d"}, "01ab6bc0-2ae3-4f5c-b3ee-7917fdf752e0": {"doc_hash": "1a39c0414a77486ab923ee5e94d0529261f33ca28a8426136e6822fd9a6863f5", "ref_doc_id": "1822fead-8efa-432d-bc81-0cf5b64dd207"}, "6c96a8c8-d247-437a-935a-ba93dcd0f342": {"doc_hash": "642af4f2e73fc3413b5799ce819d777520af8235890238893f70d8fa3c8356a2", "ref_doc_id": "1822fead-8efa-432d-bc81-0cf5b64dd207"}, "f481639f-3a55-43c3-bb42-8e0c591e47c2": {"doc_hash": "1660ed3124b7df7959df4b9190a7de32cc4c6861010c92a776297d149c6e16cd", "ref_doc_id": "0ee094e4-d0dc-4ce6-8296-c8877a54f241"}, "2aa8372b-993b-4947-afee-19c7fa4e5600": {"doc_hash": "d56c6ff8fcde850e261a210032cc959f36f66c39b766de7701eaa80b13300e2b", "ref_doc_id": "d56b4157-8ffb-43b5-8e6b-707f8b385440"}, "fd33ba48-77ff-4319-b9b8-632613bdd9c3": {"doc_hash": "1001e7f81f28a26e5e4dabe802a2b27a4c0c13a6425c0e637cd414415479a66c", "ref_doc_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31"}, "702e8d60-1094-49b0-b060-55fd1db4b493": {"doc_hash": "5284bd600626b39c0efa3f84ee629876d1b7d0faa5336452ecc5d392f07f6661", "ref_doc_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31"}, "f85a9c9c-b7bc-44e0-a87c-d019e33800f5": {"doc_hash": "761daf9f1ac24bc028c57ae22c03c927056b35ba49682ed00ef0bdba3e012821", "ref_doc_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31"}, "b7df945f-6340-43c3-8292-6656a8d4099d": {"doc_hash": "6a13952c67b3518c8b9c7f0ec2996ec17351227e1d97433cd404f1c2c7f6dab6", "ref_doc_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31"}, "6f958a16-e853-43bc-bc81-e20110072bb3": {"doc_hash": "c4f2bde21880a5f7937dd81da390eb9d63d3bff0a2354ba13a23f7b7f59bfc52", "ref_doc_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31"}, "5ad730c6-6d58-40a2-a815-1d6618c4bc05": {"doc_hash": "28b080c0b063ddb201adcaadb182fb28621198671aa6f91fc178536c6ab94ff7", "ref_doc_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31"}, "35f0ff08-6e17-4b08-bc85-293731668c1d": {"doc_hash": "1955542a4f4a68a4e959d0a3abf66a64d05a17b3e66d1db31a7f1cb2d33d1671", "ref_doc_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31"}, "c9652ee9-d68e-4c50-9406-2dd906b3ecf4": {"doc_hash": "8ab98e8018189ca60fd79d31d82214fd838556d9dc028340574485cda48282ed", "ref_doc_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31"}, "433d9204-fd11-4f66-b0d5-bbd2dc5fc967": {"doc_hash": "bb1f4f230a534e5671418d382a35968a8d79973818c0ffc3d2f315835d90c97e", "ref_doc_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31"}, "8bc5cf17-41ac-4799-be07-25d26a60f480": {"doc_hash": "aedf0c42f918799a11df7d5d16c6dc0424a566a36e974f5638fe81e23b049deb", "ref_doc_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31"}, "1a2b7b64-dc1e-4a70-b638-ed5bbe4eeeba": {"doc_hash": "0692478d556f174672a046606a4be6a939081f9c1178a74a506499313036bfb9", "ref_doc_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31"}, "6cdaa795-769d-4690-9235-4fa354351837": {"doc_hash": "c692f7fe9e68f74ea3d5ad3cd655ae8dad4e4a87b5899311c1b6f06831eaff5e", "ref_doc_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31"}, "f88b23a0-1ea8-427f-b146-6d351fb0fb8c": {"doc_hash": "b00dedabb2e76564f3904b02c71e91f67d8453f9a69fbd867e3b067af3d1cab7", "ref_doc_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31"}, "c74e45df-42e4-4f3d-93b0-de59bf5a8de9": {"doc_hash": "e622e951e4224fe469ed00565c6bb58ed035a0b2ec97fe430b01b208f9d177a9", "ref_doc_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31"}, "3cdece7e-3876-4512-a0f2-78f328907f4a": {"doc_hash": "5121fd9cb15021a542a215ba9de6f18a52a524a17611b7c1d41a126fe6195b78", "ref_doc_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31"}, "6c4cdb70-1a31-4cd4-b465-cc56ab5aa03d": {"doc_hash": "4136829b7b8a668a49192d1c31b31526012103c185e589d7280e471438a55b33", "ref_doc_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31"}, "2aee4e3a-f83d-486c-90af-9e825702a80b": {"doc_hash": "01ef7d704c5757869dd9259425c6538ef1081ee319dd285c787abe77c8b9be99", "ref_doc_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31"}, "8a3088c9-089e-4387-ace4-2f1967e0dd6f": {"doc_hash": "8da67640350554118bb1a5c90398fbf01bb2d0676509948b190a93e91e8425b4", "ref_doc_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31"}, "a4066649-479a-4441-9387-1b99e079abd5": {"doc_hash": "8417cf4a891910b268385759ba8a40744862a1577cc027662b37c3bd9081f0b8", "ref_doc_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31"}, "38e910dc-f2fe-4253-a975-9ac7a4498ba7": {"doc_hash": "7d3ff023c9c5ec432b947b1fd4c2f399a62c3abef4081744f3fba663fa359a1f", "ref_doc_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31"}, "57cf8892-f785-43df-a9ab-420c035bc6a8": {"doc_hash": "2956191377b47eedd956a6ae862342162b686f98a610c41f4e8c24c0cf0a06d6", "ref_doc_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31"}, "0517d427-a449-41d1-ae28-1faae85f1ac7": {"doc_hash": "4fd25c9f55d60d06651bab704a0339cc542df6e1a9cd2407859f92282c4666c4", "ref_doc_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31"}, "669cb27d-3ddd-4692-b57f-2072ab08ba8f": {"doc_hash": "f85f81441f33c20e6ca2db2a756714859d7c0b899dff96e10ea516352b2cd73d", "ref_doc_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31"}, "79fb7cb8-5279-46eb-88b1-7f3e3be069c4": {"doc_hash": "424ae156409c0b85e385c257742ff08135e5d22b08baaaad24625e085f57108d", "ref_doc_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31"}, "40e1f09b-7f9e-4535-9a6e-eb0d047f7f5c": {"doc_hash": "eba8ee22bda3f394fb65576e433980b705816b9d9afa02c5b65d334c945daaf2", "ref_doc_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31"}, "8de97e96-03b9-4aa0-b0c0-1aafdf63c37f": {"doc_hash": "1bdf3544518a396468ab1914b792c5560e478fcbc0daf7a0af23267e2b209ad7", "ref_doc_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31"}, "aa58eb67-8727-48fe-8e59-2095a2fb2835": {"doc_hash": "29c2a4f7158bc0bc4b19c0e5fa981f3ecba5e5a77de215ee2c081f6831bcdd97", "ref_doc_id": "9ab178de-7e31-40c8-865d-dfbd67b65b31"}, "896ae604-b722-4e30-9809-1315986cb6a2": {"doc_hash": "17c92e939d5297762e82b6fbae4ba4a3648e04972222031f091f54edc5fbd513", "ref_doc_id": "4fe04d1c-1513-4449-a463-b3501c9148e1"}, "69872798-c38b-429a-9fe5-259c1404fae0": {"doc_hash": "6b26983e80ad295e41d3984f3a0e83e99aa1b2383833b19a3325d0798acb69ff", "ref_doc_id": "4fe04d1c-1513-4449-a463-b3501c9148e1"}, "3e1846ed-725c-4982-a4e4-036b06e3370d": {"doc_hash": "db12d427db03ba6cec773ead5e4b88e6ec151b26ecfcf7428b0cd69dc01f7a6b", "ref_doc_id": "4fe04d1c-1513-4449-a463-b3501c9148e1"}, "9dd86cf3-99b9-492a-aaee-a7d12f7ced66": {"doc_hash": "2c3350ba6a826d8716c344f18c6f79420662dcad38937e744dc12b2c09dbe643", "ref_doc_id": "4fe04d1c-1513-4449-a463-b3501c9148e1"}, "ca53759c-6de5-4885-9dee-cfce8df364c6": {"doc_hash": "598733ef27a5a29e5b251c3f3d45a8dc96f5836fadcd4388bafd54ea20e097bb", "ref_doc_id": "4fe04d1c-1513-4449-a463-b3501c9148e1"}, "4cd5d840-7d27-4a46-a9d2-96aa20159ed3": {"doc_hash": "4491f8c10f8f4074298811796d0f6c41707804d2d6f60cb7bdad8ab1927616ee", "ref_doc_id": "4fe04d1c-1513-4449-a463-b3501c9148e1"}, "c8b001c0-d67b-4a52-a5e4-9e68ded9e93d": {"doc_hash": "05634b243e2b8c606c20372cac48869e22bf46e2d1ab4b0d3ee3656e70ad47de", "ref_doc_id": "4fe04d1c-1513-4449-a463-b3501c9148e1"}, "c60416ab-21c6-4647-8298-0827b8f0cdd1": {"doc_hash": "919baaab96e7f99786a4704dfc4c42a33fbb10a6961ee48e0088675d69b6b442", "ref_doc_id": "4fe04d1c-1513-4449-a463-b3501c9148e1"}, "7b77091d-22d6-43a3-9c71-c7cfe22b5167": {"doc_hash": "33ccfff64af0eff471474ad8748c2eb30cbf1833ceb590227911269f3b57e3e0", "ref_doc_id": "4fe04d1c-1513-4449-a463-b3501c9148e1"}, "df7a2a6f-14e0-4869-b81d-c4c96b01e0f6": {"doc_hash": "72ce2d6e0cd0d2d6c811d67e998cec6060f5e7b2a02b094684cb97154136d626", "ref_doc_id": "4fe04d1c-1513-4449-a463-b3501c9148e1"}, "578314c2-7dac-4b8c-9a2a-d27c4b51c17d": {"doc_hash": "bf3093f8663020a96623d37b750d5a922fa7c093704973b40e0914f08d66b4a1", "ref_doc_id": "4fe04d1c-1513-4449-a463-b3501c9148e1"}, "eb7f3eed-4951-4eed-8dbc-c5942329600d": {"doc_hash": "1e0f20091eb3044e5486e505646db90addf01ae4ce1657dc8c16ce991b9d81ba", "ref_doc_id": "4fe04d1c-1513-4449-a463-b3501c9148e1"}, "b110535c-4abe-41b6-a6f6-ea0bc8e33cba": {"doc_hash": "d89c47b3c84da6c818ec4533604505db4e3723b99fbbe541f5b4e1c419ac2bab", "ref_doc_id": "4fe04d1c-1513-4449-a463-b3501c9148e1"}, "cb0d966c-5d29-40e5-8f39-b0e5e83f4d92": {"doc_hash": "247622b259ebe7bc44e8c32182b507670c4fc0a543a4fd6014d6925a5ce65cec", "ref_doc_id": "4fe04d1c-1513-4449-a463-b3501c9148e1"}, "5fc4dafe-c4a8-40e7-9927-bc78f3bfb5ed": {"doc_hash": "561b5824e0eb79ff89d8a3f4f80970de9b0fe9a1b3bad8cdaf1e68d46342612c", "ref_doc_id": "4fe04d1c-1513-4449-a463-b3501c9148e1"}, "7304958d-7def-4ba2-9cf3-e298eaffcf5f": {"doc_hash": "086758f63ba129327956a3424af514a5ec4c3f4e4e50ef9175c8f5356d43cb0f", "ref_doc_id": "4fe04d1c-1513-4449-a463-b3501c9148e1"}, "3c8ab8e2-049e-49fd-93c6-31df417baff4": {"doc_hash": "245677ba4af50813dc32286047843612b8f6b457c87f452848146a255c547aef", "ref_doc_id": "4fe04d1c-1513-4449-a463-b3501c9148e1"}, "76029f32-88f5-4b60-95dd-e2feb2c1f687": {"doc_hash": "74613dd4adcdabdd456899cf7da56b425e3308a8bcc13569fedf3ee67efa154b", "ref_doc_id": "4fe04d1c-1513-4449-a463-b3501c9148e1"}, "fdb325b9-23cd-46f9-8b83-b6d8ecd11a8b": {"doc_hash": "062aefd4f413d67b98bf12bd870ee226b369ec884618f98bacee1e5375d832e5", "ref_doc_id": "4fe04d1c-1513-4449-a463-b3501c9148e1"}, "d3ec5e0a-f817-4144-ab80-b4ef2257c053": {"doc_hash": "9ef270a93b17b347a47bd9259efb04f444669e62aab6e27d1b9cfb9b009e5709", "ref_doc_id": "4fe04d1c-1513-4449-a463-b3501c9148e1"}, "b84b4bcd-878f-495b-b364-3caf7b128544": {"doc_hash": "2a2e55cfa5be41c64d91fb48f1347ac5aef4392b54a34b2436d7c6ee07699b94", "ref_doc_id": "4fe04d1c-1513-4449-a463-b3501c9148e1"}, "e84c4117-2e98-4e4a-8182-47defdff8502": {"doc_hash": "9155a2368d8e618ee1b0306c9d183c4b99ade17109430449a009acc533a6eaf2", "ref_doc_id": "4fe04d1c-1513-4449-a463-b3501c9148e1"}, "a102aadc-c173-4eb0-ae8e-3406a012b9ef": {"doc_hash": "742c0d2f8dfb7ee7c87ac619768159de23282338478abba6b4b4606dd39cdc1d", "ref_doc_id": "4fe04d1c-1513-4449-a463-b3501c9148e1"}, "5e96638c-178f-486c-a836-85990b3b8dfa": {"doc_hash": "d25dcacef81d7316aed8048baeaa21b629c2f5f6608d0db36550c99eb9e86e56", "ref_doc_id": "4fe04d1c-1513-4449-a463-b3501c9148e1"}, "369eb69f-0486-4722-b985-a0eba6e588ce": {"doc_hash": "c51b9bdf20fbf0ca29c4910fd793b871f1cabc0479a229b10a6f0547a681b36c", "ref_doc_id": "4fe04d1c-1513-4449-a463-b3501c9148e1"}, "9526277c-8e13-493b-a028-5bd0888eabaf": {"doc_hash": "b87df352c34617c1cb3208e912d0db3b81a2900ca26643063e68b77720937064", "ref_doc_id": "8e7e90b2-727a-4238-a631-ce3709745632"}, "6fe1665a-2130-4d5a-b40c-adef252231fe": {"doc_hash": "23432f2744f036a9d72d3591207257101ccfaaccaa038dc02c838df00bf3d1d7", "ref_doc_id": "8e7e90b2-727a-4238-a631-ce3709745632"}, "f4b3c67e-2ed2-4186-9292-764d64f89415": {"doc_hash": "1fbfedcdd9735d1e940de3ff5aff457a06d5b06494c04319c29ce38fb1f9bca2", "ref_doc_id": "8e7e90b2-727a-4238-a631-ce3709745632"}, "0f39df59-a5e5-4431-b004-a2d4aa25ebbc": {"doc_hash": "8f7d8f17c9d7729e5d269bf75d02175a2a599d25a40152c4330354b4fa2a2a64", "ref_doc_id": "8e7e90b2-727a-4238-a631-ce3709745632"}, "85696409-ea3c-4021-b312-c960dc60a1f7": {"doc_hash": "13858741ab0a731618bc0ea50090c8c66d24ae7d26e0511ce9aa3e0199370a96", "ref_doc_id": "8e7e90b2-727a-4238-a631-ce3709745632"}, "78ee81ec-0d3d-4c38-ba0b-4a723b378767": {"doc_hash": "0586066728527780b2c3784720f45f78040ceb3a5a25d45b79bf643129ab00d7", "ref_doc_id": "8e7e90b2-727a-4238-a631-ce3709745632"}}, "docstore/ref_doc_info": {"984951f4-9f9e-491e-8d76-75fdf91ef9cd": {"node_ids": ["615e526e-4034-47f5-8b7d-b4be0cdf60c0", "8364cd3e-a06d-4c67-93ff-710ce5ae78c7", "d37bb5bc-1308-470d-af3c-49339acc6100", "370ce6f7-51e2-40f7-bda1-7d9ddc508234", "96ef3d31-b9ce-4f79-ac17-4ca145075c08", "860bc0da-9781-4300-b7b1-c67b263d008d", "3e288a38-0c12-48d6-b94e-a1a8e1e5eb1d", "c3660089-e092-4b3c-96eb-2903f84f6a9c", "ca9244d7-0d5d-48d1-bcdc-3d0ba5dfd45a", "a6b5c116-b791-460e-b7ab-12e82a98bd60", "c29c869b-f26c-4f9b-91ba-5a037472b3ab", "7211ee8f-65db-4d37-b604-8157b3742dc1", "d5b86314-4ab9-493c-9f03-ea0e60675613"], "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Second Quar ter Results\n5/5/2021\nRevenues of $49.2 billion for the Second Quarter, a 3.7 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.10 and Adjusted Diluted EPS of $2.53\nAdjusted Diluted EPS Guidance Range Raised to $8.45 to $8.60 for Fiscal 2021\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021\nsecond quarter ended March 31, 2021, revenue increased 3.7 percent year-over-year to $49.2 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.10 for the March quarter of fiscal 2021, compared to\n$4.64 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n5.4 percent to $2.53 in the fiscal second quarter.\n", "original_text": "Amerisour ceBer gen R epor ts Fiscal 2021 Second Quar ter Results\n5/5/2021\nRevenues of $49.2 billion for the Second Quarter, a 3.7 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.10 and Adjusted Diluted EPS of $2.53\nAdjusted Diluted EPS Guidance Range Raised to $8.45 to $8.60 for Fiscal 2021\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021\nsecond quarter ended March 31, 2021, revenue increased 3.7 percent year-over-year to $49.2 billion. ", "page_label": "1", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "ad3e50f8-92f3-423d-af82-d5876aef2f8b": {"node_ids": ["42e0a856-75dd-4309-8bdf-95450ec9f0a9", "4d8f9bc6-7088-40bb-9652-f40c3e685004", "20112f3f-d549-4c55-93c4-df05f65e2053", "f0e77ce5-0489-4d98-a8d7-99ad6a18011a", "475059ba-f952-40dd-8a92-c4cd62ac7574", "d314b52d-6551-481b-9034-4ad423b79d7b", "270d06d4-065d-40c9-b239-2a4a6549379f", "bf6b3ca9-bafd-4f04-b8f9-38482cc4ae68", "a64fe025-50d6-44a8-afec-deb3500c3bcf", "c7f1cae9-4b4e-4837-92dd-c59437d173eb", "705543bb-e966-4ed4-96f1-d78b72720351", "236f7dfd-aeb4-4828-aeb9-ed8a447fc688", "2560f576-0c69-4ec5-9620-bbf5e392e5f8", "3637fd8f-bab8-4b7f-87ce-1c278da938bf", "abbb2155-1714-439e-9387-2802d9f30b96", "ddb9fc65-93d1-4efb-b0a3-0710fc0b59cc", "4554a903-2bdc-485b-bde0-b36489e8f032", "f7f3e227-30f6-4d09-8469-4c97553e1c7a", "13086de3-a80b-4f83-bd0c-dd05b695d7ac", "33fb28e9-bca7-4ea2-bbca-25ca1dcd67f8", "a943171c-022e-4a8c-8ef8-28339374733a", "6090f842-404c-4d00-ad65-243c60bfb10c"], "metadata": {"window": "Dilut ed Shar es Outstanding 207M \u00a0207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2021, revenue was $49.2 billion, up 3.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 3.4 percent increase in Pharmaceutical Distribution Services revenue and an 11.5 percent\nincrease in revenue within Other.\n", "original_text": "Dilut ed Shar es Outstanding 207M \u00a0207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "page_label": "2", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "5e7f174c-ef1f-4415-bfc3-56a6b1707032": {"node_ids": ["5df9172b-9ce6-4a36-9764-27e462fcf0a0", "7ce7bf8d-f0b3-4e79-8df5-c697cdad114b", "cb6ae3dd-7ffb-43a6-8a0a-9464303f0588", "77a6936f-715b-4932-87ad-e8713d0f5e96", "2bc7e13c-c269-4f07-a99a-5e89a0cca435", "9592d990-403c-4072-9a27-26144a56f307", "44015e49-9a4c-46bc-9342-55f80b54639f", "9cee156b-4b92-4e30-85ff-8c356021b279", "a6f1373d-d38b-49e0-8bae-9d01da611d13", "c79e544a-1bb0-4a7a-9f46-cf0fec48bbe4", "8761f8c8-aec9-4d20-9a11-899d2e5ff9f8", "6e0bd691-4f91-49e8-a349-7b0407a9b431", "551f5751-93b3-49c2-91b6-f6129cff2c8b", "ee719b7d-7363-40bd-aeca-f21557ddd20b", "bd2b827a-fe1c-48f3-9c63-7e72e99b98c3", "bdbb774f-5f3e-4728-9113-8a10f821f033", "dee38d65-7a1f-4453-b70b-db66afa30ec8", "b6d6bc92-9a17-4ac0-9740-d60cf91490f9", "a16c8ff3-1875-42e7-9817-e018833a4197", "f421df79-0e2d-44c3-bcde-6e7cfa2b65e4", "38d6ec95-8885-4e56-856b-9214b8631697", "f217a0da-3c0e-4e2f-93a1-93b82c08361f"], "metadata": {"window": "future revenue growth.  Adjusted operating expenses as a percentage of revenue in the fiscal 2021 second quarter was 1.64\npercent, an increase of 7 basis points when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2021 second quarter, adjusted operating income of $706.6 million increased 5.2\npercent from the prior year period due to a 4.6 percent increase in Pharmaceutical Distribution Services' operating income\nand a 13.8 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.44 percent in the fiscal 2021 second quarter, an increase of 2 basis points when compared to the prior year quarter.\n", "original_text": "future revenue growth. ", "page_label": "3", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "55632b38-3745-4ed5-a0a3-1b8a19f017cb": {"node_ids": ["d2f55977-b190-4192-8c2a-295da12e7183", "73ff4732-5744-4d9e-a491-e68bc077ff09", "3aa54655-290d-46bd-ac5d-01e65e76dd8a", "00fdab8c-f721-4967-a282-2f0cd0abe3e9", "413fa278-a10d-4015-9ecf-7d25b95dbc69", "12d23d64-13aa-42fa-a483-c7b32d4e1ddf", "8258d42c-1a2b-46be-abb7-1313c058ee08", "da16ce54-eee0-4fa5-836d-a6169e3faf01", "8ec6a258-c1d8-439a-9eb4-5567fb414a16", "26e4a0bb-0eb3-4c66-9233-819f1718915e", "d6114f95-2428-4716-af68-3dac6e1025e4", "754f07a6-e2e8-4cd5-a6e1-2e610c7cf1ce", "c2c527e5-6ac1-42e8-90d5-dae5db56a479", "0fc38fa0-6d4d-4b62-8647-133a4322a55a", "a7add16e-5246-4bdb-adae-372257c50e47", "11a9555d-4b1b-44a7-bad0-82ce154449f0", "6b05cf9c-3454-4a49-ae5c-94896e9eb185", "7b9c733e-08e6-4c28-9fee-ea22f52a3352", "9f3c75b5-41bf-4b55-a43d-2ea33f0da549", "612574e8-985f-4c76-91fc-2cd0bcfe1ffb", "8f8eb318-f0ab-496b-8d43-2bbb3a3c5097", "4266fc77-443c-4479-885e-87d47df5823e", "5d8fd312-1b67-4f22-93fc-57bfd3c263db", "d576f0a6-c780-4e0e-97f1-1eba01ee8206", "bd08d2ef-2b11-47d1-86a3-414e093e93bc", "dbee68b9-1f5a-4c85-9db7-bb9f0ca9b9f2"], "metadata": {"window": "support COVID-19 vaccine education and awareness in an effort to remove barriers to vital healthcare access.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance,\nincluding better than expected performance in our Global Commercialization Services & Animal Health group, and an incrementally\nhigher expected share count for the year. ", "original_text": "support COVID-19 vaccine education and awareness in an effort to remove barriers to vital healthcare access.\n", "page_label": "4", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "9c0bb4e5-b04e-460e-86a6-b70620fb2591": {"node_ids": ["a7d3c56b-d11b-4c72-b23f-45802d12c629", "a9e0f246-1c0c-46c2-8f0a-d88d5e0c6e3e", "b4e0d1b3-9c49-42ea-a0e4-36dd093b49be", "bf70412e-87ff-4d4d-98b6-0cc2825be1cd", "67be2197-1743-4a59-86f1-343ae8e8ee22", "25413cb1-4f95-4ed4-8dbf-fca73b3203a8", "4560d255-65ba-4df9-9201-cebcf74cd8c6", "afa6e91b-b340-4bf0-9bf2-cebacb94ab08", "1a470d7c-e68d-4349-9afb-593c34d8aed1", "afac8dce-f45f-4f63-bb9a-c10c006acaea", "c6d110ae-49c2-43a3-b35b-90f16a299b17", "b21417bb-2de0-48e8-b01c-3b6c1b05cf73", "bcd2b4ba-04cc-4ea8-8ce3-9558c0787be0"], "metadata": {"window": "and reliability for human and animal health.  Our 22,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $185 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n", "original_text": "and reliability for human and animal health. ", "page_label": "5", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "0851a017-3b2c-4844-8e95-7505a16132d0": {"node_ids": ["50b95348-3bfc-4da7-85ff-d4760e6e95da", "807c2296-5361-4d23-89a2-353814dbdae1"], "metadata": {"window": "except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nMarch 31, 2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$49,154,171 \u00a0\u00a0\u00a0 \u00a0$47,417,639 \u00a0\u00a0\u00a0 \u00a03.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a047,620,790 \u00a0\u00a0\u00a0 \u00a046,029,532 \u00a0\u00a0\u00a0 \u00a03.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,533,381 \u00a0\u00a03.12 %\u00a01,388,107 \u00a0\u00a02.93 %\u00a010.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0730,081 \u00a0\u00a01.49 %\u00a0693,413 \u00a0\u00a01.46 %\u00a05.3 %\nDepreciation and amortization \u00a0100,797 \u00a0\u00a00.21 %\u00a093,795 \u00a0\u00a00.20 %\u00a07.5 %\nEmployee severance, litigation, and other 3 \u00a078,156 \u00a0\u00a0\u00a0 \u00a067,732 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0223,652 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0909,034 \u00a0\u00a01.85 %\u00a01,078,592 \u00a0\u00a02.27 %\u00a0(15.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0624,347 \u00a0\u00a01.27 %\u00a0309,515 \u00a0\u00a00.65 %\u00a0101.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 4 \u00a023,310 \u00a0\u00a0\u00a0 \u00a0(1,109 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a034,526 \u00a0\u00a0\u00a0 \u00a034,421 \u00a0\u00a0\u00a0 \u00a00.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0566,511 \u00a0\u00a01.15 %\u00a0276,203 \u00a0\u00a00.58 %\u00a0105.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0132,506 \u00a0\u00a0\u00a0 \u00a0(694,908 )\u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "except as required by the federal securities laws.\n", "page_label": "6", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "ff0cb08d-f257-46de-95f4-d4816cbc4ebe": {"node_ids": ["7fd435b8-1dc8-4d0f-bb70-ef0daa8dbbcd", "f11e0955-2151-4de3-a7f0-ed4d8ebb4728", "89938753-d4f9-4206-b8d9-8c49d34866f7", "36dad163-71d6-4b73-9f53-0ff96ed72467", "ef33f21a-6112-47f9-8122-4addd28f2ab5", "a31d8386-ada5-438e-8450-ee42c689a563", "5e504a89-1cd2-454e-b6dd-623439b5a225", "a8be24d9-a0b5-4056-936e-e0081c0d2a16"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0434,005 \u00a0\u00a00.88 %\u00a0971,111 \u00a0\u00a02.05 %\u00a0(55.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a01,262 \u00a0\u00a0\u00a0 \u00a0(10,834 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$435,267 \u00a0\u00a00.89 %\u00a0$960,277 \u00a0\u00a02.03 %\u00a0(54.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.12 \u00a0\u00a0\u00a0 \u00a0$4.68 \u00a0\u00a0\u00a0 \u00a0(54.7 )%\nDiluted \u00a0$2.10 \u00a0\u00a0\u00a0 \u00a0$4.64 \u00a0\u00a0\u00a0 \u00a0(54.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,916 \u00a0\u00a0\u00a0 \u00a0205,370 \u00a0\u00a0\u00a0 \u00a0(0.2 )%\nDiluted \u00a0207,315 \u00a0\u00a0\u00a0 \u00a0207,062 \u00a0\u00a0\u00a0 \u00a00.1 %\n________________________________________\n1Includes a $20.9 million LIFO credit in the three months ended March 31, 2021.  Includes a $23.9 million LIFO expense, a $0.1\nmillion gain from antitrust litigation settlements, and $5.0 million of PharMEDium shutdown costs in the three months ended\nMarch 31, 2020.\n\u00a0\u00a0\n 2Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $24.9 million of legal fees in connection with opioid lawsuits and investigations, and\n$36.2 million of other costs in connection with acquisition-related deal and integration costs, business transformation efforts,\nand other restructuring initiatives in the three months ended March 31, 2021. ", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0434,005 \u00a0\u00a00.88 %\u00a0971,111 \u00a0\u00a02.05 %\u00a0(55.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a01,262 \u00a0\u00a0\u00a0 \u00a0(10,834 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$435,267 \u00a0\u00a00.89 %\u00a0$960,277 \u00a0\u00a02.03 %\u00a0(54.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.12 \u00a0\u00a0\u00a0 \u00a0$4.68 \u00a0\u00a0\u00a0 \u00a0(54.7 )%\nDiluted \u00a0$2.10 \u00a0\u00a0\u00a0 \u00a0$4.64 \u00a0\u00a0\u00a0 \u00a0(54.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,916 \u00a0\u00a0\u00a0 \u00a0205,370 \u00a0\u00a0\u00a0 \u00a0(0.2 )%\nDiluted \u00a0207,315 \u00a0\u00a0\u00a0 \u00a0207,062 \u00a0\u00a0\u00a0 \u00a00.1 %\n________________________________________\n1Includes a $20.9 million LIFO credit in the three months ended March 31, 2021. ", "page_label": "7", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "ca520586-707e-4b53-b512-5219e544df95": {"node_ids": ["a914bca4-67bb-4357-8214-9b425e7c007f", "579b8eda-750c-4518-8511-e361b9d03d1c"], "metadata": {"window": "PharMEDium business in the three months ended March 31, 2020.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Six \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0Six \nMonths Ended \nMarch 31, 2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$101,670,727 \u00a0\u00a0\u00a0 \u00a0$95,282,381 \u00a0\u00a0\u00a0 \u00a06.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a098,685,116 \u00a0\u00a0\u00a0 \u00a092,663,060 \u00a0\u00a0\u00a0 \u00a06.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a02,985,611 \u00a0\u00a02.94 %\u00a02,619,321 \u00a0\u00a02.75 %\u00a014.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a01,465,149 \u00a0\u00a01.44 %\u00a01,379,366 \u00a0\u00a01.45 %\u00a06.2 %\nDepreciation and amortization \u00a0200,350 \u00a0\u00a00.20 %\u00a0198,310 \u00a0\u00a00.21 %\u00a01.0 %\nEmployee severance, litigation, and other 3 \u00a0148,537 \u00a0\u00a0\u00a0 \u00a0107,041 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,814,036 \u00a0\u00a01.78 %\u00a02,046,369 \u00a0\u00a02.15 %\u00a0(11.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a01,171,575 \u00a0\u00a01.15 %\u00a0572,952 \u00a0\u00a00.60 %\u00a0104.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss, net  4 \u00a09,042 \u00a0\u00a0\u00a0 \u00a01,733 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a068,140 \u00a0\u00a0\u00a0 \u00a065,428 \u00a0\u00a0\u00a0 \u00a04.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a01,094,393 \u00a0\u00a01.08 %\u00a0505,791 \u00a0\u00a00.53 %\u00a0116.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0281,681 \u00a0\u00a0\u00a0 \u00a0(651,888 )\u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "PharMEDium business in the three months ended March 31, 2020.\n", "page_label": "8", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "f346ea14-bb69-427b-b23c-3ab5c70c3ac2": {"node_ids": ["befcbe45-89fe-4367-ab89-0dc3fe8d3d46", "3e2bef73-fa40-4241-a343-31b3b9d1d230", "2f37fec2-6431-47d8-87ad-2766dfd54fa3", "7cb20609-1051-4047-8921-e1866d571757", "1b7e5cb5-c584-49ed-b103-5529eaf573d7", "21d2fc89-a1e3-4ad2-a78a-b6f3cc6ca2a5", "4562fdba-7491-46b3-9eea-c9406f1da834"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0812,712 \u00a0\u00a00.80 %\u00a01,157,679 \u00a0\u00a01.21 %\u00a0(29.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(2,600 )\u00a0\u00a0 \u00a0(9,762 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$810,112 \u00a0\u00a00.80 %\u00a0$1,147,917 \u00a0\u00a01.20 %\u00a0(29.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.96 \u00a0\u00a0\u00a0 \u00a0$5.58 \u00a0\u00a0\u00a0 \u00a0(29.0 )%\nDiluted \u00a0$3.91 \u00a0\u00a0\u00a0 \u00a0$5.54 \u00a0\u00a0\u00a0 \u00a0(29.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,804 \u00a0\u00a0\u00a0 \u00a0205,693 \u00a0\u00a0\u00a0 \u00a0(0.4 )%\nDiluted \u00a0207,063 \u00a0\u00a0\u00a0 \u00a0207,293 \u00a0\u00a0\u00a0 \u00a0(0.1 )%\n________________________________________\n\u00a0\u00a0\n1Includes a $46.6 million LIFO credit in the six months ended March 31, 2021.  Includes a $37.1 million LIFO expense, an $8.5\nmillion gain from antitrust litigation settlements, and $12.1 million of PharMEDium shutdown and remediation costs in the six\nmonths ended March 31, 2020.\n\u00a0\u00a0\n 2Includes $36.5 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended\nMarch 31, 2020.\n\u00a0\u00a0\n 3Includes a $17.1 million legal accrual for estimated costs related to injunctive relief terms associated with our Multidistrict\nLitigation opioid settlement discussions, $56.9 million of litigation and opioid-related costs related to legal fees in connection\nwith opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0812,712 \u00a0\u00a00.80 %\u00a01,157,679 \u00a0\u00a01.21 %\u00a0(29.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(2,600 )\u00a0\u00a0 \u00a0(9,762 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$810,112 \u00a0\u00a00.80 %\u00a0$1,147,917 \u00a0\u00a01.20 %\u00a0(29.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$3.96 \u00a0\u00a0\u00a0 \u00a0$5.58 \u00a0\u00a0\u00a0 \u00a0(29.0 )%\nDiluted \u00a0$3.91 \u00a0\u00a0\u00a0 \u00a0$5.54 \u00a0\u00a0\u00a0 \u00a0(29.4 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0204,804 \u00a0\u00a0\u00a0 \u00a0205,693 \u00a0\u00a0\u00a0 \u00a0(0.4 )%\nDiluted \u00a0207,063 \u00a0\u00a0\u00a0 \u00a0207,293 \u00a0\u00a0\u00a0 \u00a0(0.1 )%\n________________________________________\n\u00a0\u00a0\n1Includes a $46.6 million LIFO credit in the six months ended March 31, 2021. ", "page_label": "9", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "4bf856a2-789c-4c58-a81d-a38694217eaf": {"node_ids": ["37a96cc7-7ec8-4cf5-915f-c53fd1715562", "8140a0a4-e7e2-4ac6-89c0-7b6dbfdad12c", "58a74d7e-e2f9-4163-b449-ed8ad9d055b0", "5f236e15-b1e9-40d0-898f-ba7771bb2f46"], "metadata": {"window": "5Includes $55.0 million of expense relating to Swiss tax reform and $20.4 million of discrete tax benefits primarily attributable to\nthe income tax deductions resulting from the permanent shutdown of the PharMEDium business in the six months ended\nMarch 31, 2021.  Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting\nfrom the permanent shutdown of the PharMEDium business in the six months ended March 31, 2020.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \n Expense \u00a0Net Loss \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\nGAAP \u00a0$1,533,381 \u00a0\u00a0$909,034 \u00a0\u00a0$624,347 \u00a0\u00a0$566,511 \u00a0\u00a0$132,506 \u00a0\u00a0$1,262 \u00a0\u00a0$435,267 \u00a0\u00a0$2.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(20,918 )\u00a0\u2014 \u00a0\u00a0(20,918 )\u00a0(20,918 )\u00a0(4,957 )\u00a0\u2014 \u00a0\u00a0(15,961 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(24,973 )\u00a024,973 \u00a0\u00a024,973 \u00a0\u00a03,302 \u00a0\u00a0(437 )\u00a021,234 \u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(78,156 )\u00a078,156 \u00a0\u00a078,156 \u00a0\u00a018,494 \u00a0\u00a0\u2014 \u00a0\u00a059,662 \u00a0\u00a00.29 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a021,368 \u00a0\u00a0(2,701 )\u00a0\u2014 \u00a0\u00a024,069 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP \u00a0$1,512,463 \u00a0\u00a0$805,905 \u00a0\u00a0$706,558 \u00a0\u00a0$670,090 \u00a0\u00a0$146,644 \u00a0\u00a0$825 \u00a0\u00a0$524,271 \u00a0\u00a0$2.53 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a06.7 % \u00a08.1 % \u00a05.2 % \u00a05.0 % \u00a06.9 % \u00a0\u00a0 \u00a05.4 % \u00a05.4 %\n\u00a0\n10", "original_text": "5Includes $55.0 million of expense relating to Swiss tax reform and $20.4 million of discrete tax benefits primarily attributable to\nthe income tax deductions resulting from the permanent shutdown of the PharMEDium business in the six months ended\nMarch 31, 2021. ", "page_label": "10", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "7a40fb9d-1e17-4966-97ab-0e849d6490b7": {"node_ids": ["b00246e5-d528-4d48-8d57-8bafb84d9034", "88de88cf-03d7-432e-89cb-22d6156e27bb", "7e42a7ea-fd6f-4b14-b5bb-40be9bdffb8a", "730fbaf2-1cfb-42c8-9d50-00e805e28f8b"], "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.12%\u00a03.08 %\nOperating expenses \u00a01.85%\u00a01.64 %\nOperating income \u00a01.27%\u00a01.44 %\n________________________________________\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n 2Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2020\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\nGAAP \u00a0$1,388,107 \u00a0\u00a0$1,078,592 \u00a0\u00a0$309,515 \u00a0\u00a0$276,203 \u00a0\u00a0$(694,908 )\u00a0$(10,834 )\u00a0$960,277 \u00a0\u00a0$4.64 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(54 )\u00a0\u2014 \u00a0\u00a0(54 )\u00a0(54 )\u00a0(111 )\u00a0\u2014 \u00a0\u00a057 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a023,853 \u00a0\u00a0\u2014 \u00a0\u00a023,853 \u00a0\u00a023,853 \u00a0\u00a05,972 \u00a0\u00a0\u2014 \u00a0\u00a017,881 \u00a0\u00a00.09 \u00a0\u00a0\n11", "original_text": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.12%\u00a03.08 %\nOperating expenses \u00a01.85%\u00a01.64 %\nOperating income \u00a01.27%\u00a01.44 %\n________________________________________\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n", "page_label": "11", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "374cea2e-e325-44de-b70c-29ba8342bbbd": {"node_ids": ["9a9fcca9-b46d-495b-b3ea-7c0ddf337f58"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a04,989 \u00a0\u00a0(27,481 )\u00a032,470 \u00a0\u00a032,470 \u00a0\u00a08,107 \u00a0\u00a0 \u2014 \u00a0\u00a024,363 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(26,670 )\u00a026,670 \u00a0\u00a026,670 \u00a0\u00a06,894 \u00a0\u00a0(435 )\u00a019,341 \u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(67,732 )\u00a067,732 \u00a0\u00a067,732 \u00a0\u00a016,978 \u00a0\u00a0\u2014 \u00a0\u00a050,754 \u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(223,652 )\u00a0223,652 \u00a0\u00a0223,652 \u00a0\u00a056,156 \u00a0\u00a0\u2014 \u00a0\u00a0167,496 \u00a0\u00a00.81 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,965 )\u00a07,511 \u00a0\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0741,015 \u00a0\u00a0\u2014 \u00a0\u00a0(741,015 )\u00a0(3.58 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP $1,416,895 \u00a0\u00a0$745,210 \u00a0\u00a0$671,685 \u00a0$638,373 \u00a0$137,138 \u00a0$(3,758 )\u00a0$497,477 \u00a0$2.40 2\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.93% \u00a02.99%\nOperating expenses \u00a02.27% \u00a01.57%\nOperating income \u00a00.65% \u00a01.42%\n________________________________________\n12", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a04,989 \u00a0\u00a0(27,481 )\u00a032,470 \u00a0\u00a032,470 \u00a0\u00a08,107 \u00a0\u00a0 \u2014 \u00a0\u00a024,363 \u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(26,670 )\u00a026,670 \u00a0\u00a026,670 \u00a0\u00a06,894 \u00a0\u00a0(435 )\u00a019,341 \u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0(67,732 )\u00a067,732 \u00a0\u00a067,732 \u00a0\u00a016,978 \u00a0\u00a0\u2014 \u00a0\u00a050,754 \u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0(223,652 )\u00a0223,652 \u00a0\u00a0223,652 \u00a0\u00a056,156 \u00a0\u00a0\u2014 \u00a0\u00a0167,496 \u00a0\u00a00.81 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,965 )\u00a07,511 \u00a0\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0741,015 \u00a0\u00a0\u2014 \u00a0\u00a0(741,015 )\u00a0(3.58 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP $1,416,895 \u00a0\u00a0$745,210 \u00a0\u00a0$671,685 \u00a0$638,373 \u00a0$137,138 \u00a0$(3,758 )\u00a0$497,477 \u00a0$2.40 2\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.93% \u00a02.99%\nOperating expenses \u00a02.27% \u00a01.57%\nOperating income \u00a00.65% \u00a01.42%\n________________________________________\n12", "page_label": "12", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "0780b706-b2b7-40bc-8000-fe99c141007f": {"node_ids": ["566dca63-f2db-41de-9386-d643b712ef84", "c82542d0-53cf-4c99-8def-9a9bedf721fd", "1f668ad9-0f06-48d1-a08b-e5365fecf0de", "d459bb75-635a-466f-9a90-b3b7af307314"], "metadata": {"window": "1Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$2,985,611 \u00a0\u00a0$1,814,036 \u00a0\u00a0$1,171,575 \u00a0\u00a0$1,094,393 \u00a0\u00a0$281,681 \u00a0\u00a0$(2,600 )\u00a0$810,112 \u00a0\u00a0$3.91\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(46,645 )\u00a0\u2014 \u00a0\u00a0(46,645 )\u00a0(46,645 )\u00a0(9,933 )\u00a0\u2014 \u00a0\u00a0(36,712 )\u00a0(0.18 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(50,007 )\u00a050,007 \u00a0\u00a050,007 \u00a0\u00a07,398 \u00a0\u00a0(874 )\u00a041,735 \u00a0\u00a00.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(148,537 )\u00a0148,537 \u00a0\u00a0148,537 \u00a0\u00a030,468 \u00a0\u00a0\u2014 \u00a0\u00a0118,069 \u00a0\u00a00.57 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a07,329 \u00a0\u00a0(55,019 )\u00a0\u2014 \u00a0\u00a062,348 \u00a0\u00a00.30 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n13", "original_text": "1Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n", "page_label": "13", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "7864a61f-7fc9-4b9b-bbff-7e463982f88a": {"node_ids": ["95cd578f-bcc4-489e-9499-12d235fc7ff6", "3e570085-3e40-4e1a-bc92-0dd4de9636aa", "0764c2e3-ba47-4654-b916-0ea3404d318f", "605f0256-b86c-46e1-9934-4598088ffefc", "8aa05b61-df02-4069-8e23-042ac2fdf635", "bf539da6-804d-46ee-a572-b561ab369e2d", "21a1c872-df2f-40d4-86cf-a2d485dfe92a"], "metadata": {"window": "Adjusted\nNon-GAAP \u00a0$2,938,966 \u00a0\u00a0$1,615,492 \u00a0\u00a0$1,323,474 \u00a0\u00a0$1,253,621 \u00a0\u00a0$275,020 \u00a0\u00a0$(3,474 )\u00a0$975,127 \u00a0\u00a0$4.714\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a010.5 % \u00a08.2 % \u00a013.4 % \u00a014.0 % \u00a017.5 % \u00a0\u00a0 \u00a013.0 % \u00a013.2 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n\u00a0\u00a0\n1Includes a $17.1 million legal expense accrual for estimated costs associated with the injunctive relief terms of the potential\nframework that is part of the advanced discussions to reach a global settlement of the Multidistrict Litigation and related state-\ncourt opioid litigation.\n\u00a0\u00a0\n 2Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 3Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other Loss (Income).\n\u00a0\u00a0\n", "original_text": "Adjusted\nNon-GAAP \u00a0$2,938,966 \u00a0\u00a0$1,615,492 \u00a0\u00a0$1,323,474 \u00a0\u00a0$1,253,621 \u00a0\u00a0$275,020 \u00a0\u00a0$(3,474 )\u00a0$975,127 \u00a0\u00a0$4.714\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs. ", "page_label": "14", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "11e6f6d8-10f0-42f8-874f-446d356ceb59": {"node_ids": ["dc72b2a3-e214-48c7-b44d-d78ec53b0d14"], "metadata": {"window": "(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2020\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed Earnings \n Per Shar e\nGAAP \u00a0$2,619,321 \u00a0\u00a0\u00a0$2,046,369 \u00a0\u00a0\u00a0$572,952 \u00a0\u00a0\u00a0$505,791 \u00a0\u00a0$(651,888 )\u00a0$(9,762 )\u00a0$1,147,917 \u00a0\u00a0$ 5.54 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,546 )\u00a0\u2014 \u00a0\u00a0\u00a0(8,546 )\u00a0\u00a0(8,546 )\u00a0(2,085 )\u00a0\u2014 \u00a0\u00a0(6,461 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a037,134 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a037,134 \u00a0\u00a0\u00a037,134 \u00a0\u00a09,059 \u00a0\u00a0\u2014 \u00a0\u00a028,075 \u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,124 \u00a0\u00a0\u00a0(36,511 )\u00a0\u00a048,635 \u00a0\u00a0\u00a048,635 \u00a0\u00a011,864 \u00a0\u00a0\u2014 \u00a0\u00a036,771 \u00a0\u00a00.18 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0\u00a0(60,236 )\u00a0\u00a060,236 \u00a0\u00a0\u00a060,236 \u00a0\u00a014,695 \u00a0\u00a0(871 )\u00a044,670 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0\u00a0(107,041 )\u00a0\u00a0107,041 \u00a0\u00a0\u00a0107,041 \u00a0\u00a026,114 \u00a0\u00a0\u2014 \u00a0\u00a080,927 \u00a0\u00a00.39 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u00a0(361,652 )\u00a0\u00a0361,652 \u00a0\u00a0\u00a0361,652 \u00a0\u00a088,227 \u00a0\u00a0\u2014 \u00a0\u00a0273,425 \u00a0\u00a01.32 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u00a012,153 \u00a0\u00a0\u00a0(12,153 )\u00a0\u00a0(12,153 )\u00a0(2,965 )\u00a07,511 \u00a0\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0741,015 \u00a0\u00a0\u2014 \u00a0\u00a0(741,015 )\u00a0(3.57 )\u00a0\n15", "original_text": "(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2020\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed Earnings \n Per Shar e\nGAAP \u00a0$2,619,321 \u00a0\u00a0\u00a0$2,046,369 \u00a0\u00a0\u00a0$572,952 \u00a0\u00a0\u00a0$505,791 \u00a0\u00a0$(651,888 )\u00a0$(9,762 )\u00a0$1,147,917 \u00a0\u00a0$ 5.54 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,546 )\u00a0\u2014 \u00a0\u00a0\u00a0(8,546 )\u00a0\u00a0(8,546 )\u00a0(2,085 )\u00a0\u2014 \u00a0\u00a0(6,461 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a037,134 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a037,134 \u00a0\u00a0\u00a037,134 \u00a0\u00a09,059 \u00a0\u00a0\u2014 \u00a0\u00a028,075 \u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,124 \u00a0\u00a0\u00a0(36,511 )\u00a0\u00a048,635 \u00a0\u00a0\u00a048,635 \u00a0\u00a011,864 \u00a0\u00a0\u2014 \u00a0\u00a036,771 \u00a0\u00a00.18 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0\u00a0(60,236 )\u00a0\u00a060,236 \u00a0\u00a0\u00a060,236 \u00a0\u00a014,695 \u00a0\u00a0(871 )\u00a044,670 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0\u00a0(107,041 )\u00a0\u00a0107,041 \u00a0\u00a0\u00a0107,041 \u00a0\u00a026,114 \u00a0\u00a0\u2014 \u00a0\u00a080,927 \u00a0\u00a00.39 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u00a0(361,652 )\u00a0\u00a0361,652 \u00a0\u00a0\u00a0361,652 \u00a0\u00a088,227 \u00a0\u00a0\u2014 \u00a0\u00a0273,425 \u00a0\u00a01.32 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u00a012,153 \u00a0\u00a0\u00a0(12,153 )\u00a0\u00a0(12,153 )\u00a0(2,965 )\u00a07,511 \u00a0\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0741,015 \u00a0\u00a0\u2014 \u00a0\u00a0(741,015 )\u00a0(3.57 )\u00a0\n15", "page_label": "15", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "9c25fe30-2e61-4f35-9843-0d422ef324be": {"node_ids": ["03ff985c-03fa-418e-906d-be2ed3f769c2", "36551470-2787-4664-bb36-e1ee344acd28", "486bedbc-de31-4d74-8a55-76f13bc30518", "235025b7-e802-4183-8a69-a112946adf01"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,660,033 \u00a0\u00a0\u00a0$1,493,082 \u00a0\u00a0\u00a0$1,166,951 \u00a0\u00a0\u00a0$1,099,790 \u00a0\u00a0$234,036 \u00a0\u00a0$(3,122 )\u00a0$862,632 \u00a0\u00a0$ 4.16 2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\n\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a02021 \u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$47,101,331 \u00a0\u00a0\u00a0$45,562,670 \u00a0\u00a03.4 %\nOther \u00a02,092,772 \u00a0\u00a0\u00a01,876,593 \u00a0\u00a011.5 %\nIntersegment eliminations \u00a0(39,932 )\u00a0\u00a0\u00a0(21,624 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$49,154,171 \u00a0\u00a0\u00a0$47,417,639 \u00a0\u00a03.7 %\n16", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,660,033 \u00a0\u00a0\u00a0$1,493,082 \u00a0\u00a0\u00a0$1,166,951 \u00a0\u00a0\u00a0$1,099,790 \u00a0\u00a0$234,036 \u00a0\u00a0$(3,122 )\u00a0$862,632 \u00a0\u00a0$ 4.16 2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\u00a0\n", "page_label": "16", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "885760b4-c525-41c4-a6df-5e5e52416695": {"node_ids": ["5b81bcff-eb29-4d01-80cd-daaf8bd46e9c"], "metadata": {"window": "\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a02021 \u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$589,033 \u00a0\u00a0\u00a0$563,097 \u00a0\u00a04.6 %\nOther \u00a0123,180 \u00a0\u00a0\u00a0108,260 \u00a0\u00a013.8 %\nIntersegment eliminations \u00a0(5,655 )\u00a0\u00a0328 \u00a0\u00a0\u00a0\nTotal segment operating income \u00a0706,558 \u00a0\u00a0\u00a0671,685 \u00a0\u00a05.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a0\u00a054 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a020,918 \u00a0\u00a0\u00a0(23,853 )\u00a0\u00a0\nPharMEDium shutdown costs \u00a0\u2014 \u00a0\u00a0\u00a0(32,470 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(24,973 )\u00a0\u00a0(26,670 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(78,156 )\u00a0\u00a0(67,732 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0(223,652 )\u00a0\u00a0\nContingent consideration adjustment \u00a0\u2014 \u00a0\u00a0\u00a012,153 \u00a0\u00a0\u00a0\nOperating income \u00a0$624,347 \u00a0\u00a0\u00a0$309,515 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.39 \u00a0%\u00a02.32 %\u00a0\u00a0\nOperating expenses \u00a01.14 \u00a0%\u00a01.08 %\u00a0\u00a0\nOperating income \u00a01.25 \u00a0%\u00a01.24 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.81 \u00a0%\u00a019.15 %\u00a0\u00a0\nOperating expenses \u00a012.92 \u00a0%\u00a013.38 %\u00a0\u00a0\nOperating income \u00a05.89 \u00a0%\u00a05.77 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n17", "original_text": "\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a02021 \u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$589,033 \u00a0\u00a0\u00a0$563,097 \u00a0\u00a04.6 %\nOther \u00a0123,180 \u00a0\u00a0\u00a0108,260 \u00a0\u00a013.8 %\nIntersegment eliminations \u00a0(5,655 )\u00a0\u00a0328 \u00a0\u00a0\u00a0\nTotal segment operating income \u00a0706,558 \u00a0\u00a0\u00a0671,685 \u00a0\u00a05.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a0\u00a054 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a020,918 \u00a0\u00a0\u00a0(23,853 )\u00a0\u00a0\nPharMEDium shutdown costs \u00a0\u2014 \u00a0\u00a0\u00a0(32,470 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(24,973 )\u00a0\u00a0(26,670 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(78,156 )\u00a0\u00a0(67,732 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0(223,652 )\u00a0\u00a0\nContingent consideration adjustment \u00a0\u2014 \u00a0\u00a0\u00a012,153 \u00a0\u00a0\u00a0\nOperating income \u00a0$624,347 \u00a0\u00a0\u00a0$309,515 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.39 \u00a0%\u00a02.32 %\u00a0\u00a0\nOperating expenses \u00a01.14 \u00a0%\u00a01.08 %\u00a0\u00a0\nOperating income \u00a01.25 \u00a0%\u00a01.24 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a018.81 \u00a0%\u00a019.15 %\u00a0\u00a0\nOperating expenses \u00a012.92 \u00a0%\u00a013.38 %\u00a0\u00a0\nOperating income \u00a05.89 \u00a0%\u00a05.77 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n17", "page_label": "17", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "1207c990-1544-45c3-9819-27f84ccfa8bb": {"node_ids": ["d49302b0-99a8-4234-b8ea-b5053cc69c0a", "443be014-a4cc-4f28-9ec9-149d45c36d9f"], "metadata": {"window": "AmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.12 \u00a0%\u00a02.93 %\u00a0\u00a0\nOperating expenses \u00a01.85 \u00a0%\u00a02.27 %\u00a0\u00a0\nOperating income \u00a01.27 \u00a0%\u00a00.65 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.08 \u00a0%\u00a02.99 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.64 \u00a0%\u00a01.57 %\u00a0\u00a0\nAdjusted operating income \u00a01.44 \u00a0%\u00a01.42 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a02021 \u00a0\u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$97,593,841 \u00a0\u00a0$91,599,498 \u00a0\u00a06.5 %\nOther \u00a04,145,046 \u00a0\u00a03,723,577 \u00a0\u00a011.3 %\nIntersegment eliminations \u00a0(68,160 )(40,694 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nRevenue \u00a0$101,670,727 \u00a0\u00a0$95,282,381 \u00a0\u00a06.7 %\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, \u00a0\nOperating income \u00a02021 \u00a0\u00a02020 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$1,085,100 \u00a0\u00a0$954,791 \u00a0\u00a013.6 %\nOther \u00a0244,827 \u00a0\u00a0212,739 \u00a0\u00a015.1 %\n18", "original_text": "AmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.12 \u00a0%\u00a02.93 %\u00a0\u00a0\nOperating expenses \u00a01.85 \u00a0%\u00a02.27 %\u00a0\u00a0\nOperating income \u00a01.27 \u00a0%\u00a00.65 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.08 \u00a0%\u00a02.99 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.64 \u00a0%\u00a01.57 %\u00a0\u00a0\nAdjusted operating income \u00a01.44 \u00a0%\u00a01.42 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "18", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "cee84c53-8da1-4b2a-9ff8-0c1fec5d5f8d": {"node_ids": ["ce13a88f-f62a-401e-8bd4-0bec83c7a2be"], "metadata": {"window": "Intersegment eliminations \u00a0(6,453 )\u00a0(579 )\u00a0\u00a0\nTotal segment operating income \u00a01,323,474 \u00a0\u00a01,166,951 \u00a0\u00a013.4 %\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a08,546 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a046,645 \u00a0\u00a0(37,134 )\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0\u2014 \u00a0\u00a0(48,635 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(50,007 )\u00a0(60,236 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(148,537 )\u00a0(107,041 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0(361,652 )\u00a0\u00a0\nContingent consideration adjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,171,575 \u00a0\u00a0$572,952 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0 \u00a0\u00a0\nGross profit \u00a02.22 \u00a0%2.13 %\u00a0\u00a0\nOperating expenses \u00a01.11 \u00a0%1.09 %\u00a0\u00a0\nOperating income \u00a01.11 \u00a0%1.04 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0 \u00a0\u00a0\nGross profit \u00a018.84 \u00a0%19.08 %\u00a0\u00a0\nOperating expenses \u00a012.94 \u00a0%13.37 %\u00a0\u00a0\nOperating income \u00a05.91 \u00a0%5.71 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0 \u00a0\u00a0\nGross profit \u00a02.94 \u00a0%2.75 %\u00a0\u00a0\nOperating expenses \u00a01.78 \u00a0%2.15 %\u00a0\u00a0\nOperating income \u00a01.15 \u00a0%0.60 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\n19", "original_text": "Intersegment eliminations \u00a0(6,453 )\u00a0(579 )\u00a0\u00a0\nTotal segment operating income \u00a01,323,474 \u00a0\u00a01,166,951 \u00a0\u00a013.4 %\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a0\u2014 \u00a0\u00a08,546 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a046,645 \u00a0\u00a0(37,134 )\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0\u2014 \u00a0\u00a0(48,635 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(50,007 )\u00a0(60,236 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(148,537 )\u00a0(107,041 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0(361,652 )\u00a0\u00a0\nContingent consideration adjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,171,575 \u00a0\u00a0$572,952 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0 \u00a0\u00a0\nGross profit \u00a02.22 \u00a0%2.13 %\u00a0\u00a0\nOperating expenses \u00a01.11 \u00a0%1.09 %\u00a0\u00a0\nOperating income \u00a01.11 \u00a0%1.04 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0 \u00a0\u00a0\nGross profit \u00a018.84 \u00a0%19.08 %\u00a0\u00a0\nOperating expenses \u00a012.94 \u00a0%13.37 %\u00a0\u00a0\nOperating income \u00a05.91 \u00a0%5.71 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0 \u00a0\u00a0\nGross profit \u00a02.94 \u00a0%2.75 %\u00a0\u00a0\nOperating expenses \u00a01.78 \u00a0%2.15 %\u00a0\u00a0\nOperating income \u00a01.15 \u00a0%0.60 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0 \u00a0\u00a0\n19", "page_label": "19", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "1822fead-8efa-432d-bc81-0cf5b64dd207": {"node_ids": ["01ab6bc0-2ae3-4f5c-b3ee-7917fdf752e0", "6c96a8c8-d247-437a-935a-ba93dcd0f342"], "metadata": {"window": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.89 \u00a0%2.79 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.59 \u00a0%1.57 %\u00a0\u00a0\nAdjusted operating income \u00a01.30 \u00a0%1.22 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0 March 31, \u00a0September 30,\n\u00a0 2021 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $6,641,180 \u00a0\u00a0\u00a0$4,597,746 \u00a0\u00a0\nAccounts receivable, net 14,134,326 \u00a0\u00a0\u00a013,846,301 \u00a0\u00a0\nInventories 12,954,676 \u00a0\u00a0\u00a012,589,278 \u00a0\u00a0\nRight to recover assets 1,217,032 \u00a0\u00a0\u00a01,344,649 \u00a0\u00a0\nIncome tax receivable 331,291 \u00a0\u00a0\u00a0488,428 \u00a0\u00a0\nPrepaid expenses and other 190,644 \u00a0\u00a0\u00a0189,300 \u00a0\u00a0\nTotal current assets 35,469,149 \u00a0\u00a0\u00a033,055,702 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,482,753 \u00a0\u00a0\u00a01,484,808 \u00a0\u00a0\nGoodwill and other intangible assets 8,548,906 \u00a0\u00a0\u00a08,592,826 \u00a0\u00a0\nDeferred income taxes 302,554 \u00a0\u00a0\u00a0361,640 \u00a0\u00a0\nOther long-term assets 1,199,888 \u00a0\u00a0\u00a0779,854 \u00a0\u00a0\n20", "original_text": "AmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.89 \u00a0%2.79 %\u00a0\u00a0\nAdjusted operating expenses \u00a01.59 \u00a0%1.57 %\u00a0\u00a0\nAdjusted operating income \u00a01.30 \u00a0%1.22 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "20", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "0ee094e4-d0dc-4ce6-8296-c8877a54f241": {"node_ids": ["f481639f-3a55-43c3-bb42-8e0c591e47c2"], "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $47,003,250 \u00a0\u00a0\u00a0$44,274,830 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 DEFICIT \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $31,420,390 \u00a0\u00a0\u00a0$31,705,055 \u00a0\u00a0\nOther current liabilities 1,532,171 \u00a0\u00a0\u00a01,646,763 \u00a0\u00a0\nShort-term debt 43,885 \u00a0\u00a0\u00a0501,259 \u00a0\u00a0\nTotal current liabilities 32,996,446 \u00a0\u00a0\u00a033,853,077 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 6,147,112 \u00a0\u00a0\u00a03,618,261 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 273,031 \u00a0\u00a0\u00a0284,845 \u00a0\u00a0\nDeferred income taxes 768,551 \u00a0\u00a0\u00a0686,485 \u00a0\u00a0\nOther long-term liabilities 708,174 \u00a0\u00a0\u00a0472,855 \u00a0\u00a0\nAccrued litigation liability 6,212,718 \u00a0\u00a0\u00a06,198,943 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal deficit (102,782 )\u00a0\u00a0(839,636 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' deficit $47,003,250 \u00a0\u00a0\u00a0$44,274,830 \u00a0\u00a0\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0 Six Months Ended Mar ch 31,\n\u00a0 2021 \u00a02020\nOperating Activities: \u00a0 \u00a0\u00a0\n21", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $47,003,250 \u00a0\u00a0\u00a0$44,274,830 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 DEFICIT \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $31,420,390 \u00a0\u00a0\u00a0$31,705,055 \u00a0\u00a0\nOther current liabilities 1,532,171 \u00a0\u00a0\u00a01,646,763 \u00a0\u00a0\nShort-term debt 43,885 \u00a0\u00a0\u00a0501,259 \u00a0\u00a0\nTotal current liabilities 32,996,446 \u00a0\u00a0\u00a033,853,077 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 6,147,112 \u00a0\u00a0\u00a03,618,261 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 273,031 \u00a0\u00a0\u00a0284,845 \u00a0\u00a0\nDeferred income taxes 768,551 \u00a0\u00a0\u00a0686,485 \u00a0\u00a0\nOther long-term liabilities 708,174 \u00a0\u00a0\u00a0472,855 \u00a0\u00a0\nAccrued litigation liability 6,212,718 \u00a0\u00a0\u00a06,198,943 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal deficit (102,782 )\u00a0\u00a0(839,636 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' deficit $47,003,250 \u00a0\u00a0\u00a0$44,274,830 \u00a0\u00a0\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0 Six Months Ended Mar ch 31,\n\u00a0 2021 \u00a02020\nOperating Activities: \u00a0 \u00a0\u00a0\n21", "page_label": "21", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "d56b4157-8ffb-43b5-8e6b-707f8b385440": {"node_ids": ["2aa8372b-993b-4947-afee-19c7fa4e5600"], "metadata": {"window": "Net income $812,712 \u00a0\u00a0\u00a0$1,157,679 \u00a0\u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1415,159 \u00a0\u00a0\u00a0643,981 \u00a0\u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (193,770 )\u00a0\u00a0(2,052,216 )\u00a0\nInventories (314,294 )\u00a0\u00a0(152,359 )\u00a0\nAccounts payable (292,555 )\u00a0\u00a02,395,847 \u00a0\u00a0\nOther, net 2 21,898 \u00a0\u00a0\u00a0(997,225 )\u00a0\nNet cash provided by operating activities 449,150 \u00a0\u00a0\u00a0995,707 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (151,612 )\u00a0\u00a0(144,382 )\u00a0\nCost of equity investments (162,620 )\u00a0\u00a0(30,580 )\u00a0\nOther, net \u2014 \u00a0\u00a0\u00a07,162 \u00a0\u00a0\nNet cash used in investing activities (314,232 )\u00a0\u00a0(167,800 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings 3 2,069,645 \u00a0\u00a0\u00a0947 \u00a0\u00a0\nPurchases of common stock 4 (82,150 )\u00a0\u00a0(407,152 )\u00a0\nExercises of stock options 130,326 \u00a0\u00a0\u00a076,757 \u00a0\u00a0\nCash dividends on common stock (182,365 )\u00a0\u00a0(170,541 )\u00a0\nOther (26,940 )\u00a0\u00a0(10,174 )\u00a0\nNet cash provided by (used in) financing activities 1,908,516 \u00a0\u00a0\u00a0(510,163 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash and cash equivalents 2,043,434 \u00a0\u00a0\u00a0317,744 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $6,641,180 \u00a0\u00a0\u00a0$3,691,938 \u00a0\u00a0\n________________________________________\n22", "original_text": "Net income $812,712 \u00a0\u00a0\u00a0$1,157,679 \u00a0\u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1415,159 \u00a0\u00a0\u00a0643,981 \u00a0\u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (193,770 )\u00a0\u00a0(2,052,216 )\u00a0\nInventories (314,294 )\u00a0\u00a0(152,359 )\u00a0\nAccounts payable (292,555 )\u00a0\u00a02,395,847 \u00a0\u00a0\nOther, net 2 21,898 \u00a0\u00a0\u00a0(997,225 )\u00a0\nNet cash provided by operating activities 449,150 \u00a0\u00a0\u00a0995,707 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (151,612 )\u00a0\u00a0(144,382 )\u00a0\nCost of equity investments (162,620 )\u00a0\u00a0(30,580 )\u00a0\nOther, net \u2014 \u00a0\u00a0\u00a07,162 \u00a0\u00a0\nNet cash used in investing activities (314,232 )\u00a0\u00a0(167,800 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings 3 2,069,645 \u00a0\u00a0\u00a0947 \u00a0\u00a0\nPurchases of common stock 4 (82,150 )\u00a0\u00a0(407,152 )\u00a0\nExercises of stock options 130,326 \u00a0\u00a0\u00a076,757 \u00a0\u00a0\nCash dividends on common stock (182,365 )\u00a0\u00a0(170,541 )\u00a0\nOther (26,940 )\u00a0\u00a0(10,174 )\u00a0\nNet cash provided by (used in) financing activities 1,908,516 \u00a0\u00a0\u00a0(510,163 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash and cash equivalents 2,043,434 \u00a0\u00a0\u00a0317,744 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $6,641,180 \u00a0\u00a0\u00a0$3,691,938 \u00a0\u00a0\n________________________________________\n22", "page_label": "22", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "9ab178de-7e31-40c8-865d-dfbd67b65b31": {"node_ids": ["fd33ba48-77ff-4319-b9b8-632613bdd9c3", "702e8d60-1094-49b0-b060-55fd1db4b493", "f85a9c9c-b7bc-44e0-a87c-d019e33800f5", "b7df945f-6340-43c3-8292-6656a8d4099d", "6f958a16-e853-43bc-bc81-e20110072bb3", "5ad730c6-6d58-40a2-a815-1d6618c4bc05", "35f0ff08-6e17-4b08-bc85-293731668c1d", "c9652ee9-d68e-4c50-9406-2dd906b3ecf4", "433d9204-fd11-4f66-b0d5-bbd2dc5fc967", "8bc5cf17-41ac-4799-be07-25d26a60f480", "1a2b7b64-dc1e-4a70-b638-ed5bbe4eeeba", "6cdaa795-769d-4690-9235-4fa354351837", "f88b23a0-1ea8-427f-b146-6d351fb0fb8c", "c74e45df-42e4-4f3d-93b0-de59bf5a8de9", "3cdece7e-3876-4512-a0f2-78f328907f4a", "6c4cdb70-1a31-4cd4-b465-cc56ab5aa03d", "2aee4e3a-f83d-486c-90af-9e825702a80b", "8a3088c9-089e-4387-ace4-2f1967e0dd6f", "a4066649-479a-4441-9387-1b99e079abd5", "38e910dc-f2fe-4253-a975-9ac7a4498ba7", "57cf8892-f785-43df-a9ab-420c035bc6a8", "0517d427-a449-41d1-ae28-1faae85f1ac7", "669cb27d-3ddd-4692-b57f-2072ab08ba8f", "79fb7cb8-5279-46eb-88b1-7f3e3be069c4", "40e1f09b-7f9e-4535-9a6e-eb0d047f7f5c", "8de97e96-03b9-4aa0-b0c0-1aafdf63c37f", "aa58eb67-8727-48fe-8e59-2095a2fb2835"], "metadata": {"window": "1Includes a $361.7 million impairment of PharMEDium assets in the six months ended March 31, 2020.\n\u00a0\u00a0\n 2Includes a $693.6 million increase in income tax receivable for the six months ended March 31, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n\u00a0\u00a0\n 3Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes and $1,000 million of 2.700%\nsenior notes that will be used to finance a portion of the acquisition of a majority of WBA's Alliance Healthcare businesses.\n\u00a0\u00a0\n 4Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.\n", "original_text": "1Includes a $361.7 million impairment of PharMEDium assets in the six months ended March 31, 2020.\n\u00a0\u00a0\n", "page_label": "23", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "4fe04d1c-1513-4449-a463-b3501c9148e1": {"node_ids": ["896ae604-b722-4e30-9809-1315986cb6a2", "69872798-c38b-429a-9fe5-259c1404fae0", "3e1846ed-725c-4982-a4e4-036b06e3370d", "9dd86cf3-99b9-492a-aaee-a7d12f7ced66", "ca53759c-6de5-4885-9dee-cfce8df364c6", "4cd5d840-7d27-4a46-a9d2-96aa20159ed3", "c8b001c0-d67b-4a52-a5e4-9e68ded9e93d", "c60416ab-21c6-4647-8298-0827b8f0cdd1", "7b77091d-22d6-43a3-9c71-c7cfe22b5167", "df7a2a6f-14e0-4869-b81d-c4c96b01e0f6", "578314c2-7dac-4b8c-9a2a-d27c4b51c17d", "eb7f3eed-4951-4eed-8dbc-c5942329600d", "b110535c-4abe-41b6-a6f6-ea0bc8e33cba", "cb0d966c-5d29-40e5-8f39-b0e5e83f4d92", "5fc4dafe-c4a8-40e7-9927-bc78f3bfb5ed", "7304958d-7def-4ba2-9cf3-e298eaffcf5f", "3c8ab8e2-049e-49fd-93c6-31df417baff4", "76029f32-88f5-4b60-95dd-e2feb2c1f687", "fdb325b9-23cd-46f9-8b83-b6d8ecd11a8b", "d3ec5e0a-f817-4144-ab80-b4ef2257c053", "b84b4bcd-878f-495b-b364-3caf7b128544", "e84c4117-2e98-4e4a-8182-47defdff8502", "a102aadc-c173-4eb0-ae8e-3406a012b9ef", "5e96638c-178f-486c-a836-85990b3b8dfa", "369eb69f-0486-4722-b985-a0eba6e588ce"], "metadata": {"window": "analysis of our ongoing operational performance.  The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "analysis of our ongoing operational performance. ", "page_label": "24", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "8e7e90b2-727a-4238-a631-ce3709745632": {"node_ids": ["9526277c-8e13-493b-a028-5bd0888eabaf", "6fe1665a-2130-4d5a-b40c-adef252231fe", "f4b3c67e-2ed2-4186-9292-764d64f89415", "0f39df59-a5e5-4431-b004-a2d4aa25ebbc", "85696409-ea3c-4021-b312-c960dc60a1f7", "78ee81ec-0d3d-4c38-ba0b-4a723b378767"], "metadata": {"window": "we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating activities, excluding\nother significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus capital expenditures.\n For the six months ended March 31, 2021 adjusted free cash flow of $297.5 million consisted of net cash provided by operating\nactivities of $449.2 million minus capital expenditures of $151.6 million.  The Company does not provide forward looking guidance\non a GAAP basis for such metrics because certain financial information, the probable significance of which cannot be determined, is\nnot available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation\nor deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "original_text": "we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating activities, excluding\nother significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus capital expenditures.\n", "page_label": "25", "file_name": "CEN-Q2-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 221418, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}}}